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Abstract
Cancer cells express unique carbohydrate signatures on their surfaces known as
tumour-associated carbohydrate antigens (TACAs). These antigens are not typically found
on healthy cells and therefore are promising targets for immunotherapy using adaptive immune response tools. If the immune system could theoretically be “trained” to target this
molecule, then the immune system could be used to help eradicate any cancer cells from
the host. A problem with carbohydrate-based targets is they are not stable in the body because of their inherent acetal functionality: the glycosidic bond. This research aims to remove the unstable acetal functionality in carbohydrates by replacing the exocyclic anomeric oxygen with a methylene group (C-glycoside) to make new N-Fmoc protected acetalfree C-glycoside analogues of the Tn antigen, a TACA found on many tumor cells. Removing the labile functionality should result in a greatly enhanced lifetime and bioavailability relative to the native system with no likely loss in recognition specificity as the exocyclic oxygen is not generally involved in molecular recognition events.
The Thomsen-Friedenreich antigen is another tumour-associated carbohydrate,
which is found on specific types of cancer cells, such as CD34+ T-cells in leukemia and
sarcoma, as well as CD 44+-cells in colon and breast cancers. The application of this antigen confronts the same limitation as to the Tn antigen. In order to be more effective, it has
to be modified to increase its stability and have a higher chance of getting to the target and
inducing the required immune response. The synthesis of a fully acetal-free TF is challenging because of the unique 1,3-β one carbon linkage between the galactose and N-acetyl
galactosamine moieties. Through the removal of both the exocyclic oxygens in the anomeric position and the linkage between the two sugar moieties, and replacing them with
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methylene groups, the stability of this antigen under biological conditions in the body
greatly increases, and as a result, can better activate the immune system. This type of double C-glycoside-amino acid conjugate has never been reported in the literature for any carbohydrate. This thesis will discuss significant progress towards the synthesis of this promising, but challenging, fully acetal-free TF antigen.
The next portion of the thesis expresses the synthesis of two glycolipids isolated
from S. pneumoniae, the leading cause of neonatal sepsis and meningitis. Two main fractions of antigenic S. pneumoniae glycolipids were identified. One contains a monosaccharide, and the second fraction contains a disaccharide. Both the monosaccharide and the
disaccharide appear capable of activating invariant natural killer T cells (iNKT), a subclass
of white blood cells that produce non-specific cytokines whose activation can lead to a
systemic uncontrolled immune response. The total synthesis of both the mono- and the
disaccharide will be discussed in this thesis and the biological activity of these synthesized
saccharides will be measured in order to confirm their structures, which have never been
examined.
The next part of the thesis reports the efforts toward the study of the limitations of
the selective removal of acetates in the presence of long-chain esters. This area of research
remains under development as selective deprotection of the acetyl group, especially in the
pyranose sugar moiety is largely unexplored.
The final section of the thesis outlines the synthesis of an acetylated lactose bearing
free hydroxyl groups at the C-6 and C-6΄ for attachment to conjugated polymers, with applications in electronic devices.
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1 Chapter 1: Introduction
Carbohydrates are complex biomolecules which fill essential roles in cellular communications such as signaling to cell surface receptors and diverse cellular targets.1 A wide
variety of glycans composed of oligosaccharide and monosaccharide residues are linked
via glycosidic linkages to access to very important glycoconjugates, such as glycolipids,
glycoproteins, and glycosylated biologically active molecules. The biosynthesis of those
glycans is conducted by several enzymes, so any modification in the structure of cell-surface glycans empowers them to assist in the release of the information critical for disease
development.2 Therefore, sugar molecules which participate in carbohydrate-mediated
communications, are targets for medicinal therapeutics and remedies for various pathological illnesses. A large portion of materials, which are used for the immunotherapeutic studies are composed of carbohydrates targeting cancers.
Cancer is one of the most common deadly diseases, which takes a lot of lives annually all around the world.3 Scientists have made promising progress in traditional forms
of cancer therapy, including radiation, surgery, and chemotherapy over the past decades.
However, a cure or preventative treatment continues to elude researchers. Consequently, it
is critical to establish other approaches to fight cancer. Immunotherapy using a vaccine
approach is an attractive target as an alternative method for cancer prevention and treatment
as the application of vaccines has proven to be effective against other infectious diseases.
The first efforts towards a vaccine against cancer were reported by William Coley in 1893,
when live or inactivated Streptococcus pyogenes and Serratia marcescens were injected
into tumor tissues. The result indicated the activation of immune system against established
sarcomas.4 In recent years, antitumor monoclonal antibodies (mAbs) has been successfully
applied for the passive immune therapy in clinics around the world.5, 6
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At first, many glycans employed in the cancer diagnostic field were isolated from
natural sources. Nowadays, scientists try to synthesis these compounds rather than isolate
them because of the lengthy isolation procedure, low quantities isolated and low purity of
isolated glycans process from natural sources. These include glycolipids and tumour-associated carbohydrate antigens (TACAs).7 The standard application of vaccines provides prevention and protection against infectious diseases. However, most experimental cancer
vaccines aim to induce an immune response to eliminate the threats, including cancers and
infections.4–7 Vaccines are also applied for metastatic cancers that often occurs after removing the tumour by chemotherapy or surgery. The current cancer vaccines can be classified as dendritic cell vaccines, whole-cell vaccines, DNA vaccines, viral vectors, and
antigen-specific vaccines, the last of which has recently attracted the most attention from
researchers.8
After the discovery of tumour-associated carbohydrate antigens (TACA) development of antigen-specific vaccines has become possible. In recent years, progress has been
made towards vaccines that use these antigens for cancer immunotherapy through controlled activation of the immune system to attack to the cancer cells. However, many challenges are left to be addressed in order to get effective treatments. These challenges include
low stability and immunogenicity of these antigens, both of which are under study in this
thesis, and overcoming these challenges could be the key to eradicating cancer cells.
TACAs are characterized in two categories: Glycoprotein antigens including Tn,
Thomsen−Friendreich (TF), and sialyl-Tn (sTn), which are O-linked to the amino acid serine or threonine and glycolipid antigens, which are carbohydrates O-linked to ceramide
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lipids with fatty chains. The glycolipids can be subclassified into blood group determinants
such as Lewisx, Lewisy, the gangliosides, GD2, GM2, Globo class Globo-H, Gb3.
Although, glycolipid vaccines appeared to not have a significant effect on tumour growth,9
recently, new methodology associated with a better in-depth understanding of glycolipids
properties and interactions paved the path for new immunotherapy development.10 Glycolipids are also widely applied as an adjuvant in cancer immunotherapy.11-14 More recently,
α-Linked glycolipids attracted scientists' interest after the therapeutic potential of α-galactosylceramide KRN7000 showed promising result in treatments of tumours, autoimmune
diseases and microbial infections.15
Despite promising preliminary results to activate the immune system against the
threats, more information is necessary to get this massive response under control as immune response generated by these types of glycolipid antigens contributes to dangerous
effects.16 As a result, research is required in order to synthesize glycolipids analogues with
the ability to activate the immune system in a controlled way against a specific target.
Consequently, carbohydrates in the form of glycoconjugate are essential in the battle
against cancer and serve as the backbone of an immunotherapy. Recent studies have shown
progress towards finding a way to prevent or cure cancer, however, synthesis of more relevant carbohydrates such as modified tumour associated carbohydrates, glycolipids and
glycoproteins, and their application against cancer heavily is still required.17, 18

1.1 Biostable acetal-free Tn and TF antigen-based vaccines as an immunotherapy for cancer
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1.1.1 Cancer and immunotherapy
Cancer has been a major cause of death among humans for a long time and is still
taking lives. Despite an enormous global effort to try and mitigate the effects of this disease, there has not been a major breakthrough in terms of an absolute cure for this category
of disease.19, 20 Traditionally, most of the initiatives were focused on finding innovative
treatments for all kind of cancers. Surgery, radiotherapy, chemotherapy, and newer targeted
drug therapies are all major targets for researchers. A major issue, however, lies in the
endless obstacles that must be overcome. For example: Surgery, followed by chemotherapy, and/or radiation therapy has the potential to effectively terminate tumours. However,
the mutations that are responsible for developing certain cancers may remain hidden in
nearby pre-cancerous tissue, and because of this, the disease can often return. These treatments can work if the disease is diagnosed in an early stage and the tumour is located in
tissue that can be easily sacrificed. Even targeted therapies, which initially show promising
results in the early stages of research, have often led to drug resistance as the long-term
outcome.21
These results have led researchers to try to find a way to activate the immune system
against cancer cells to terminate them when they are introduced into the body.22 Immunologists suggest using a vaccine to activate the immune system. Usually the immune system
responds to foreign proteins, however, proteins that exist in cancer cells can also be found
in healthy cells as well. This means that they are not an appropriate target for a vaccine
therapy. Fortunately, some antigens are unique and are not found in healthy cells. This
class of antigens are normally called tumour-associated carbohydrate antigens (TACAs)
and can be found in different cancers such as ovarian, breast, prostate and lung.23, 24
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1.1.2 TACAs in Cancer
The TACAs are a subclass of mucin-glycopeptides in carcinomas. These mucinglycopeptides usually exist in fetal tissue in the early stages, and are expressed on the surface of carcinomas; however, they are not present in adult healthy cells.25, 26 Carcinomas
include lung, prostate, colon, breast, oral, pancreas, ovarian, and cervical cancers that make
up the surface of an organ. Epithelial cells secrete mucins which are glycosylated proteins
that form a backbone of mucous and other biological lubricants. The mucins often consist
of large, complicated oligosaccharides.27 In the carcinomas, glycosylation and/or glycosidase procedures can undergo misregulation, which leads to truncated carbohydrates, but
scientists are uncertain whether or not this is a cause of carcinoma progression or merely a
common side effect. Regardless, the presence of these carbohydrates has correlated with
the invasion of healthy tissue, metastasis, and more aggressive tumours. Furthermore, this
interaction has been associated with their role in mediating tumour-cell adhesion.28
The TACAs can be classified into three classes: Firstly, the mucin-based glycopeptides, Tn 101, TF 102 and sialyl-Tn 103; the lactosamine-series depicted as both glycoproteins and glycolipids, the sialyl-LewisX 104, LewisX 105, sialyl LewisA 106, LewisY 107
(Figure 1.1). Furthermore, we have the truncated gangliosides which are represented by
not only the Globo-H 108 antigen but the stage-specific embryonic antigens 3, 109, and
ganglioside monosialic 2 (GM2) 110 (Figure 1.1). The first category is the primary focus
of this dissertation which focuses heavily on both the Tn and TF antigens. These antigens
have received the majority of both synthetic and biological attention because of comparable
simplicity and their exclusivity to carcinomas. The second class includes blood-group an-
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tigens. Their structural complexity has limited their use as potential vaccine targets, especially the unnatural multimeric forms. The final ganglioside class shows good potential,
and these TACA glycolipids continue to be reported and they may open up new source of
immunological targets in the future. The remainder of part of this dissertation will focus
exclusively on the Tn and TF antigens.7, 29-34
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Figure 1. 1 Structures of the most common tumour-associated carbohydrate antigens. R
represents either H or CH3 in the case of the mucin antigens, and R2 represents either a
peptide or a lipid
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1.1.3 Synthesis of the natural TACAs, historical overview
1.1.3.1 Synthesis of Tn Antigen
The Tn antigen is comprised of two parts, (2-deoxy-2-acetamido-galactose (GalNHAc))αO-linked to either serine 101a, or threonine 101b through their side chains as depicted in
Figure 1.2.35 It is the simplest possible antigen that exists currently.

Figure 1. 2 Serine-linked 101a and threonine linked 101b forms of the Tn antigen; both
are often co-expressed on the same glycopeptide
The Tn antigen was discovered in 1957 by Moreau as the “T antigene nouvelle” to
differentiate it from the Thomsen-Friedenreich antigen (TF antigen).36 In 1975 Dahr determined the exact structure of the carbohydrate portion of this antigen as GalNHAc using
co-elution in gas-liquid chromatography. Moreover, they also identified the major glycopeptides affected.37 The Tn antigen attracted additional attention when it was correlated
with breast carcinomas by Springer in 1974, where it was shown to be present in over 90%
of cases.38 It has also been identified in ovarian,9 bladder,39 cervical,40, 41 colon,42, 43 lung,44
stomach,45 pancreatic46 and prostate tumours,47 and it usually has been associated with tumour expansion and metastatic behaviour. Its presence in normal healthy fetal tissue may
be consistent with its role in facilitating rapid cell division.48 Tn antigen backbone structure
is generated in the Golgi body (or apparatus) but is always then rapidly glycosylated with
additional residues before ever being introduced on the surface of healthy cells. These further steps often do not happen in many carcinomas.
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The cancer-specificity and simple structure of the Tn antigen has attracted the attention of chemists to synthesis this target. In 1977 Osawa reported the first synthesis of
this antigen.33 A Koenigs-Knorr glycosylation using mercuric cyanide as an activator of
the glycosyl donor was performed (Scheme 1.1). In this synthesis, the C-2 amine 111 was
protected as a 2,4-dinitroanilino group in 112 to prevent any anchimeric assistance.34 The
glycosyl donor 114 was formed through an acetylation to the α-acetate 113, followed by
an acid catalyzed anomeric bromination. The glycosylation was performed between the Ntosyl-L-serine methyl ester 115 and the glycosyl donor 114, to provide the first reported
synthetic TACA glycoconjugate 116. A subsequent global deprotection under basic conditions provided tosylamine 117, followed by a selective protection of the C-2 amine as the
N-acetamide performed to generate Tn antigen 118.

Scheme 1. 1 First synthesis of the Tn antigen reported by Osawa using a 2,4dinitroanilino protecting group approach
The formation of a syn-1,2-relationship between the α-orientation of the respective
amino acid and the 2-acetylamino group in 118 has always been challenging due to neighbouring group participation.
9

Oxocarbenium cations are not useful for generating α-glycosides if the acetamido group is
present and intact. Different approaches have been examined to increase the probability of
making this syn relationship using an appropriate choice of protecting groups for the amine,
including imines, electron-withdrawing amines (Scheme 1.1), azides, nitro and dinitroanilino groups.
Paulsen pioneered using the azide group as a masked NHAc group towards the
synthesis of the TF-glycon.49, 50 Since then, it has used in the vast majority of synthetic
procedures to date. Expanding from this research, Pavia used this approach to generate the
Tn antigen (Scheme 1.2).51 Starting with the introduction of the azide and an anomeric
nitrate to galactal 119 using the oxidative addition, β-glycosyl chloride 121 was formed
through a selective α-anomeric iodide formation, this was subsequently followed by an SN2
inversion, which provided the β-chloride 121 in a 70% overall yield. Compound 121 underwent a mercuric-mediated glycosylation with the serine acceptor derivative 122. The
glycoconjugate 125 was formed via conversion of the azide to the acetamide group followed by a mild deprotection of the acetates. Although this approach has become popular
among chemists, different methods have been applied to modern glycoside donors, including the use of anomeric fluorides and trichloroacetimidates which save a few synthetic
steps. These compounds have been extensively examined as bioconjugates however, this
discussion remains beyond the scope of this dissertation.
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Scheme 1. 2 Pavia synthesis of the Tn antigen using a C-2 azide as an amine masking
group as developed by Paulsen
1.1.3.2 Synthesis of the TF antigen
The first series of TACAs that were identified were both the T or TF antigens,
established by Huebener in 1925, Thomsen in 1926, and further defined by Friedenreich,
and as a result, should be called the HTF antigen on that basis, though Huebener has been
“deleted” by the scientific community.52, 53 The structure was first reported by Kim and
Uhlenbruck in 1966.54 It was represented as the disaccharide, β-D-galactosyl-1,3-linked to
2-deoxy-2-acetamido-galactose (GalNHAc) α-O-linked to either serine or threonine. The
TF antigen, like the Tn antigen, is a cancer biomarker that does not exist in normal healthy
cells. The TF antigen, as with other non-oncogenic markers, interacts selectively with a
protein which is specific for β-galactose residues called galectin-3.55 Galectin-3 is responsible for antimicrobial activity, mediating cell adhesion, apoptosis, and regulating cell cycle checkpoints. However, galectin-3’s precise role in healthy or cancerous cells remains
unclear.55 The TF antigen and galectin-3 co-over-expression is accompanied with the ability of cancer cells to bond better to the extracellular matrix and can result in metastasis.55
The TF antigen is present in several cancers, including ovarian (>99% of cases),
breast (85%), colon cancer (60%) and acute lymphoblastic leukemia (50%).56 Although the
TF antigen has only been presented on adult cancer cells, the disaccharide unit itself,
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(which is referred to as the Core 1 carbohydrate), is used to build simple oligosaccharides
in healthy mucins. As a result, any antibodies produced against the TF antigen should recognize the carbohydrate-protein linkage in addition to the carbohydrates alone.
To save time and reduce more challenges toward the synthesis of the TF antigen,
the majority of the synthetic pathway is quite similar to synthesis of the Tn antigen. The
TF antigen is composed of the C-3 oxygen of the Tn antigen unit which is β-linked to the
anomeric position of galactose. The first synthesis of the TF antigen reported by Kaifu and
Osawa follows directly from the synthesis of the Tn antigen (Scheme 1.3).57 The glycosylation was performed between 126 and 127 to generate a protected disaccharide 128. Global
deprotection in both basic and acidic conditions respectively provided compound 129. This
is a relatively efficient synthesis of 129 from galactosamine 111 in 10 linear steps.

Scheme 1. 3 Osawa and Kaifu’s synthesis of the TF antigen from their previously prepared Tn antigen
Lemieux reported the first synthesis of the glycon alone in 1981 which is depicted
in Scheme 1.4.58Azido-chloride 121 was prepared by Paulsen’s approach and then glyco-
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sylated with a long chain hydroxy-ester. The acetamide was generated by an azide reduction, and subsequent deacetylation afforded triol 130. Hydroxyl groups in C-4 and C-6
were protected with a benzylidene protecting group. The corresponding compound 131
underwent a glycosylation with a 2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl bromide donor 127 to provide compound 132. A global deprotection afforded glycoside 133, which
then applied for inhibition of a T-antigen-specific agglutination. A similar approach was
used by Paulsen to prepare the glycoconjugate with both the serine and threonine analogues
attached.59

Scheme 1. 4 Lemieux’s synthesis of the TF antigen glycon, and its conjugation to a hydrophobic linker

1.1.4 Synthetic TACA antigens as potential immunotherapeutic
TACAs are only present on cancer cells and cannot be found on healthy cells, this
inspires researchers to target these compounds when designing a vaccine to induce the
immune system to target cancer cells. The general mechanism of a vaccine is as follows:
Initially, after being introduced to the serum where the most common enzymes are present,
endocytosis occurs by antigen-presenting cells in a lysozyme. This cellular compartment
is responsible for breaking down the components into fragments. These fragments, using
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the Golgi apparatus, are delivered and bind to the human leukocyte antigen receptor and
placed on the cell surface. Recognition of the antigen-HLA complex by a T-cell receptor
plays an essential role in receiving a robust immune response. T-cell dependent and independent pathways are the two common ways to activate the immune system. The independent T-cell activation is when antigens cannot bind to the T-cell receptor (HLA), and
consequently, T-cells can not recognize them. In this case, the immune system will be activated only through the activation of B-cell via the B-cell receptor (BCR); however, this
activation would be inferior due to the low affinity of Immunoglobulin M (IgM), which is
the first antibody that exists mainly in blood and lymph fluid, produced by the body to fight
against a new infection. The B-cell response is usually more potent when they are activated
via a dependent pathway through activation of T-cell.
T-cell dependent pathway occurs when antigens survive the biological conditions.
This includes the glycosidases that are present in their path and bind to the T-cell receptor
(HLA) and activate T-cells. T-cells release cytokines to activate a cytotoxic T-cell, which
can eliminate damaged cells, cells infected by viruses and can also kill cancer cells. In
addition, these T-cells can cause activation of B-cells. B-cells can release a high affinity of
Immunoglobulin G (IgG), which is the most common antibody present in blood and other
body fluids capable of forming after immunization or infection and fighting against bacterial and viral infections. via plasma cells. Moreover, inducing memory B-cells plays an
essential role in the immunotherapy. These cells remain last longer in the body compared
to the rest of the immune system cells in order to recognize and fight infections or cancer
cells when they return.

14

1.1.4.1 Challenges in TACA vaccine preparation
The first TACA-targeting vaccines were isolated from natural sources. For example, Hakomori’s Tn-dense sialo-ovine submaxillary mucin, which was able to assist inoculated mice in resisting a highly invasive Tn-antigen-overexpressing tumour line.28 However, these are still challenges left to be addressed. The first question is, are antigens capable of activating the immune system? In other words, can they survive through the harsh
biological conditions and activate T-cells? As many of the tumour-associated carbohydrate
antigens are expressed exclusively on cancer cells, the initial postulate was that these systems might be able to act as monomeric vaccines because TACAs are T-cell independent
antigens. For example: the human leukocyte antigen (HLA) receptors on the surface of
antigen-presenting cells cannot recognize sugars instead they interact with approximately
8-12 amino acids of antigenic peptides through their binding grooves.60, 61 As above mentioned, the human leukocyte antigen (HLA) receptors are responsible for binding prospective antigens and displaying them to T-cells. The second question is due to the presence of
the acetal group, which is susceptible to cleavage by biological conditions, mainly through
enzymes cleavage how can we improve the low biostability of TACAs? The third question
is how do we improve the typically low immunogenicity of TACAs?
The new antigen design with the ability to activate T-cells was the first question
that researchers tried to address. Knowing that T-cells are good at binding to peptides,
antigen synthesis was imperative and therefore relied on conjugation to a carrier protein
KLH to activate a T-cell. Dansihefsky developed monomeric TACA antigens and a multivalent vaccine that incorporated all three of the mucin carbohydrates as well as Globo-H
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and GM2 in a genuinely great synthetic campaign (Figure 1.3a).62, 63 The first case indicated limited success in early-phase clinical trials, and for the second case, the clinical trials
are yet to be reported. As an alternative, a monovalent Tn antigen vaccine was provided in
one molecule as a complete package by the Boons group (Figure 1.3b).64

Figure 1. 3a,b Structure of Danishefsky’s multiantigen vaccine candidate and Boons’
self- adjuvating Tn-vaccine system as examples of existing TACA immunotherapeutic
constructs
These approaches express a promising future for the development of vaccines. Unfortunately, despite the significant production of Immunoglobulin-G responses in animal
models, these carbohydrate vaccines remain a work in progress and have yet to be tested
in or delivered to the human population. The reasons for this are partly because of low
16

immunogenicity of carbohydrates and partly the potential lack of specificity of the immune
response for the carbohydrate counterpart of the vaccine rather than the T-helper epitopes
and the development of immunotolerance.25
The low biological half-life of TACAs, which degrade via enzymatic cleavage of
the acetal group, poses another question. The biological half-life of TACAs is usually only
a few hours, and before they can get to the T-cell and activate the immune system, they are
catabolized by the body. The difference between human and mouse immune systems might
explain this failure in translation. Rodents have many α-galactose residues on their cells,
but these are far rarer in humans. This difference is extreme enough that α-galactosidase is
the most common enzyme circulating in human serum, which is precisely the enzyme necessary to cleave these sugars and deactivate the vaccine. This enzyme is also greatly overexpressed and present in the lysozymes of antigen-presenting cells. But they are not common in rodents. This means that vaccines that work well in rodents are much more readily
cleaved in humans; this highlights again the caution needed when translating animal models to human systems.65 Chemists have proposed two ways to remove the acetal group; The
endocyclic oxygen can be removed and replaced with a methylene group, namely a carbasugar or the exocyclic oxygen can be replaced with a methylene group which is called a
C-glycoside.
The synthesis of a C-glycoside attracted more attention among chemists compared
to the synthesis of a carbasugar simply because of a simpler potential synthetic pathway.
Although the instability of TACAs can be addressed through C-glycosides and carbasugars, these compounds are synthesized predominantly to showcase the novel chemistry and
the biological behaviour of these compounds remains mostly neglected. There are only a
17

few reported cases to date using these compounds to explore improvements to the stability
of TACAs.66-68
For the multivalency to overcome low immunogenicity, preliminary preclinical
data suggests that the immunogenicity could be improved by increasing the number of
carbohydrates and, as a result, exponentially increasing the number of carbohydrates
should elicit significantly higher immunogenicity.69 Dendrons are monodisperse, highly
symmetric branched macromolecule synthesized in a stepwise process, which each step
exponentially increases the number of branches.70 This highly symmetric multiple
branches in a single molecule versus polymers, where the presence of many different
lengths is unavoidable, facilitates the precise characterization of the expected co-operativity effects and simplifies any clinical characterization.
Trant, Gillies, Haeryfar and Lecommandoux reported the first application of multivalent antigen-loading, which resulted in higher immunogenicity using acetal-free antigens on dendron support, showing the number of antigens doubled, the immunogenicity
appeared to improve exponentially.71 They synthesized the first acetal-free glycodendron–
lipid hybrids based on glycerides and applied it to activate iNKT cells. The result showed
enhanced activation of iNKT cells using higher generation systems (a single molecule with
16 carbohydrate antigens). This result indicates a direct relationship between antigen multivalency and immunogenic response, however, the designed molecule only produced moderate immunogenic result as it does not closely resemble the natural glycolipid antigen.71
The interleukin-2 was measured by ELISA with introducing 20 ng/mL of samples to mouse
DN32.D3 cells (Figure 1.4).
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Although dendrons can be functionalized with TACAs27 and rarely with AFCs,71
only a few of them biologically evaluated, 71, 45 however, there appears to be no investigation on effect on multiple antigen-loading in a single molecule (antigens on dendron support) with immunogenicity. This multivalency effect could be applied to functionalize a
carrier protein, which would be novel and further increase immunogenicity, and solve the
low immunogenicity of the TACA vaccine candidates.
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Figure 1. 4 Relationship between antigen multivalency and immunogenic response from
Trant et al 2016.71
Hence, the significant challenges of vaccine therapies remain the same regardless
of promising results that have been achieved. Both immunotolerance and immunogenicity
remain problematically low, and the immune response is often specific for the peptide or
carrier protein and produces a minimal response against the carbohydrate component.
These challenges can be attributed to a variety of different reasons. Many of the individual
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carbohydrates exist in the body in diverse forms, which means only a few antibodies exist
in the body against these particular forms. T-cell receptors are not trained nor optimized
for identifying glycopeptides. Lastly, the antigen processing of carbohydrate-bearing materials, (including the enzymatic profile of the liposomes and survival of glycopeptides
through this process) is still poorly understood and currently under exploration.

1.1.5 Acetal-free carbohydrate antigens
The immune system is not designed to target carbohydrates, and this could be an
important reason for the lack of success in this field, despite significant efforts and considerable promise, to generate anti-cancer vaccine candidates. It should be noted, however
that these vaccine candidates have been capable of producing antibodies although the response is not sufficient to target the cancer cells. Three factors could explain the inadequate
immune response generated by vaccines. First, the fact that cancer cells are often resistant
toward carbohydrate antibodies causes problems for carbohydrate based vaccines and this
immunotolerance is a reason for the weak immune response provided by these vaccines.
Second, it is still not clear whether or not the specificity of the antibodies generated from
the antigen vaccine candidate can be congruent towards actual glycopeptides (cancer cells).
The immune system cannot recognize glycopeptides in the presence of peptide support
alone. This is mostly due to the higher immunogenicity of peptides. Third, the lack of stability of the antigen vaccine (mainly in the antigen processing step), could be another factor
contributing to the inadequate immune response. Carbohydrates have a short physiological
half-life in the body, mostly because of the acetal functionality which is susceptible to
cleavage in biological conditions, including acidic, basic, and enzymatic processes. If the
physiological half-life of the antigen is sufficiently short, the carbohydrate antigens may
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not survive antigen processing in the immune system, and before they can fulfill their duty,
they can be decomposed and excreted by the body. As mentioned above, chemists can
theoretically solve this problem by making the acetal-free carbohydrate molecules. This
includes: removing the acetal group by replacing the exo- or endocyclic oxygen with different elements including sulfur (exocyclic oxygen replacement), nitrogen (endocyclic oxygen replacement), and more importantly carbon (both exocyclic C-glycoside and endocyclic oxygen replacement carbasugar). The first two cases, azasugars, and thioglycosides as
well as carbasugars are beyond the scope of this dissertation and have been well-reviewed
elsewhere.72, 73 In this subsection, three general routes toward the synthesis of a C-glycoside is presented: cross-coupling, ring-closing metathesis and allylation reactions. For further detail refer to the review by Sadraei et al.74

Figure 1. 5 Structural comparison between C-glycoside 136, natural acetal-system, 101a,
and carbasugar 137, analogues of the Tn antigen
1.1.5.1 Cross-Coupling
Cross-coupling reactions are potent synthetic methods and have attracted much
interest, particularly relevant is the development of sp3-sp2 couplings in carbohydrate
chemistry. Carbon-carbon bond formation, especially in the anomeric position, has always
been a challenge in carbohydrate chemistry.75 Cross-coupling approaches can be used to
provide novel solutions to this challenge, as an example, both C-glycosides76, 77 and C21

nucleoside analogues78 have been generated from this approach. The cross-coupling reactions are usually catalyzed by transition metal complexes, most commonly based on palladium. Heck, Suzuki and Negishi cross couplings are the most well-known reactions belong
to this group.
The Heck reaction is a palladium-catalyzed cross-coupling under basic conditions
to generate a sp2-sp2 bond between an alkene containing at least one proton and an aryl or
alkenyl halide or triflate. A limitation of this approach is that it has often been used to make
a sp2-sp2 carbon bonds in carbohydrate chemistry, rather than sp2-sp3 or sp3-sp3, the latter
of which is needed for carbohydrate chemistry where we have few modifications. There
are only a few examples of using Heck reactions to make bioconjugated glycosides. In one
of those examples, Yang and co-workers reported benzyl-protected glucal 138 could be
coupled with a variety of different aryl bromides under microwave irradiation to form the
corresponding α-2-deoxy-dihydro-C-aryl glycosides.

Scheme 1. 5 Aryl-Bromide Coupling Under Microwave Conditions by Yang
The Suzuki-Miyarua coupling is another well-known cross-coupling reaction, usually it is catalyzed with either Palladium or Nickel complexes. These catalysts mediate
carbon-carbon bond formations between boronic acids (or boronic esters) and alkyl halides
(or triflates) in what has become a powerful synthetic tool.79, 80
The Suzuki coupling approach has been used in carbohydrate chemistry in two
slightly different ways. In a report by Johnson, the authors were able to formally alkylate
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gluconolactone producing exo-glycals via introducing a 9-BBN functionality through a hydroboration, followed by palladium catalyst mediated Suzuki coupling reaction, which
could be an elegant way to achieve further functionalization including the synthesis of Cglycosides (Scheme 1.6).81
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Scheme 1. 6 9-BBN hydroboration and Suzuki coupling approach for the synthesis of
benzyl C-glycosides
In a second report, C-glycals have been generated by the Tan group using a Suzuki
coupling between olefinic species, which can be in situ borylated using 9-BBN and halogenated glycals (Scheme 1.7). This chemistry is tolerant of Fmoc amino acids and other
differentially-protected carbohydrates producing products in very good isolated yields.82
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Scheme 1. 7 Synthesis of C-glycals by Tan using Suzuki coupling reaction
The Negishi Coupling is a compelling methodology amongst the cross-coupling
reactions because it provides selective and rapid access to α-C-glycosides. In the Negishi
coupling, an organohalide is coupled with an organozinc nucleophile through a catalytic
process using either palladium or nickel complexes. The highly selective and rapid synthesis of α-C-glycosides were reported via the same chemistry using α-glycosyl halides and
alkyl-zinc reagents by Gagné.83
1.1.5.2 Ring-Closing Metathesis
The ring-closing metathesis reaction involves the formation of a cyclic olefin between two sp2-sp2 carbons of an alkene mediated by a ruthenium catalyst. This approach
has widely been used in synthesis and an example of its utility in carbohydrate chemistry
can be seen in the reported synthesis of a complicated acetal-free trisaccharide shown in
Scheme 1.8.84, 85
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Scheme 1. 8 Overview of Postema’s approach to a trisaccharide using a double RCM
1.1.5.3 Allylation and Related Reactions
The anomeric allylation method is an effective and efficient approach to generate a
C-glycoside in the anomeric position. It has been so effective that it dominates the literature, bring used far more than any other methodology. High selectivity and rapid access to
α-allylation, in addition to straight forward manipulation for the attachment of amino acids,
have made this method an outstanding choice for the synthesis of TACA antigens. This
methodology is extremely important in the synthesis of acetal-free analogues of TACAs
when an allyl group is used as a tool to connect the amino acid to the sugar moiety in order
to generate C-glycoside derivatives of the TACA antigens.
Hosomi and co-workers reported the addition of allyl silyl nucleophiles to glycopyranosides using TMSOTf as a Lewis acid obtaining moderate to high yields;86, 87
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Table 1. 1 Allylation of glycopyranosides using allyl silyl nucleophiles and TMSOTf
In 1987, Bennek and Gray reported rapid access to the fully deprotected C-allyl
glycosides.88 For example, (trimethylsilyl)trifluoroacetamide (BSTFA) in situ silylates the
hydroxyl group before allylation which, after aqueous workup, cleavage of the silyl protecting groups afforded the desired C-allyl glycosides (Scheme 1.9).

Scheme 1. 9 Bennek and Gray’s one-pot allylation of unprotected glycosides
Allyltributyltin can be used to allylate acetylated galactose as an alternative for allyl
silyl nucleophiles. Guindon reported allylation with retention of configuration when they
used alkyl halides adjacent to electron-withdrawing functionalities with AIBN or Et3B as
a radical initiator.89
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A large number of C-linked glycoconjugates of antifreeze studies have been carried
out in good selectivity by Ben, Leclere, Trant, and co-workers using an allyltributyltin
toward the formation of anomeric allylation.90-93
Using yet another method, Danishefsky and co-workers94 reported the first FerrierType 1 rearrangement of glycal acetates via a carbon nucleophile, using allyl-TMS, or
TiCl4 as a Lewis acid, to form 2,3-unsaturated glycosides (Table 1.1). Despite an appealing
outcome of high yields and excellent regioselectivity, the reformation of the desired
carbohydrate requires further manipulation.

Table 1. 2 Danishefsky’s allylation of disparate glycals with 1 equiv. of TiCl4 and 1.5
equiv. of allyl TMS at –78 ºC
All of the previously mentioned allylation approaches predominantly afford the αanomer. The β-C-glycoside formation was accomplished by Hanessian using the SmI2mediated Reformatsky type reaction on both aldonolactones and oxocarbeniums generated
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from an anomeric acetate using TiCl4 as a Lewis acid.95 The carbon in oxocarbenium ion
can act as an electrophile for the nucleophilic attack of the organozinc compound produced
by ethyl bromoester and zinc reported by Oguni (Scheme 110).96

Scheme 1. 10 Titanium-mediated Reformatsky-like, β-selective alkylations
The allylation chemistry is the most powerful tool for the synthesis of acetal-free
carbohydrate (C-glycoside), in particular TACAs, however, the synthesis of these compounds has been done only to represent a novel methodology toward the synthesis of these
antigens, and the biological evaluation of these antigens mostly remained unexplored. It is
worth mentioning that, despite only a few other approaches reported as mentioned above,
still more reliable procedures required in order to develop new and elegant synthetic routes,
especially when applying the allylation, would be challenging and involves multiple manipulations.
1.1.5.4 Synthesis of an Acetal-Free Tn antigen
The Tn antigen is a sugar moiety known as N-acetyl galactosamine, where an αlinked amino acid is attached to the sugar. The amino acids are usually either serine or
threonine. The Tn antigen has become the centre of attention in the field of tumourassociated carbohydrate antigens, because this antigen belongs to the simplest branch of
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amino acid-monosaccharide conjugates. As a result, the synthesis of this antigen should be
less challenging compared to the rest of the TACAs. Although there are four possibile
acetal-free Tn antigen analogues, the few attempts carried out to date have focused on the
synthesis of only 136 (Figure 1.6). Despite remarkable progress for the synthesis of the Cglycoside analogue of the Tn antigen (See Section 1.1.5.3), the true acetal-free analogue of
the natural Tn antigen has never been synthesized. In addition, the other three analogues
have yet to be prepared. We will now show the various approaches used towards the
synthesis of 136.

Figure 1. 6 The four possible direct acetal-free Tn analogues; the C-glycoside and
carbasugar derivatives of both the threonine and serine conjugates
Beau and co-workers,97 reported the first synthesis of the C-Glycoside derivative
of the Tn antigen, which is only the second example of the preparation of C-2 aminohexose
C-glycoside in the literature.98 Synthesis of this compound initiated with the formation of
serine- analogue amino acid components, starting from L-aspartic acid 170 (Scheme 1.10).
This compound was selectively protected with a carbamate, cyclized in two steps, and then
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deprotected and replaced with a TBS group. Finally, the terminal alcohol was oxidized to
form the desired compound 173. This report indicates that having a TBS protecting group
is necessary to afford the aldehyde coupling partner 173 with an optimal yield.

Scheme 1. 11 Beau’s synthesis of the amino acid required for samarium-mediated C- glycosylation
After a coupling reaction between the aldehyde 173 and the glycosyl pyridyl sulfone 174, which was prepared using an azido nitration sequence from tri-O-benzyl galactal,
a mixture of diastereomeric alcohols 175 was obtained.99 The hydroxyl group was removed
via a tin hydride reduction after conversion to their respective xanthates. Consequently, the
first reported hydrolytically stable C-glycoside Tn antigen mimics were obtained in the
four additional steps. Lastly, TBS was replaced with a carbamate Boc protecting group,
followed by a ring-opening reaction via cesium carbonate and a subsequent Jones oxidation, generated the desired product 177 (Scheme 1.12).
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Scheme 1. 12 Beau’s synthesis of the Tn antigen
In 2000, Cipolla and co-workers reported100 the synthesis of C-glycoside analogues
of N-acetylgalactosamine through a synthetic strategy based on their previous work with
the mannosamine and glucosamine derivatives.101 The reaction of previously reported allylated C-glycoside, compound 178,102 with iodine affords cyclic iodoether 179 (Scheme
1.13). Compound 179 undergoes a ring opening with Zn in acetic acid followed by selective deprotection of the C-2 hydroxyl to prepare 180. Compound 183 was afforded in a
moderate yield via oxidation followed by oxime formation (compound 182) using
NH2OMe in acidic media, and finally, reduction using LiAlH4. However, the oxime reduction in these systems always proceeded with an associated elimination of the C-4 benzyl
alcohol which would require multiple challenging manipulations to re-install.
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Scheme 1. 13 Cipolla’s Initial approach to an α-C-glycosidic analogue of N- acetylgalactosamine
In a revised approach, Cipolla and co-workers synthesized a Tn building block
starting from simple D-glucose. Although, the starting material is cost-effective, this approach is step-intensive which drives up the overall cost of the synthesis. In the revised
approach the starting material glucosamine hydrochloride was readily converted to C-allylglucoside 178,87 then compound 184 was formed according to the previous report,101 followed by the benzyl deprotection to generate 185 (Scheme 1.14). Hydroxyl groups at the
C-4 and C-6 positions of 186 were protected using trimethyl acetyl chloride (PivCl) in
order to convert glucosamine to galactosamine with the assistance of triflic anhydride, pyridine, and water in two subsequent steps. Finally, the methyl ketone 189 afforded via the
Zemplén deprotection protocol followed by the oxidation of the allyl group using sodium
tetrachloropalladate in water.
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Scheme 1. 14 Cipolla’s revised approach to an α-C-glycosidic analogue of N-acetylgalactosamine
A different approach was applied by Schmidt and co-workers for the synthesis of
the Tn mimic using a Horner-Wadsworth-Emmons olefination instead of using a samarium
coupling as the key conjugation step.103 Although this approach was efficient and effective
with a high degree of stereoselectivity, the ultimate synthesis of the exact analogue of the
natural Tn antigen motif (which involves adding further synthetic steps and applications of
this compound as an anti-cancer vaccine), remains to be explored.
Galactosamine hydrochloride was used as a starting material, which in the first
step was converted to 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranosyl chloride 190 according to the known procedure reported by Jeanloz.104 Aldehyde 92 was
formed after an allylation using AIBN and allyl tributylstannane was then followed by the
ozonolysis process, generating 192. A Horner-Wadsworth-Emmons olefination applied between aldehyde 192 and glycine-derived phosphonate 193 resulted in a mixture of two
diastereomers with good yield (Scheme 1.15). An asymmetric halogenation performed using a chiral Rhodium complex catalyst to afford either the L-195a or D-195b amino acid in
excellent 98:2 ratios depending on the choice of catalyst. It is worth mentioning here that
using an alternative starting material seems be preferable as galactosamine hydrochloride
is not readily available and is very costly. Ben and his group tried to address this problem
using two different starting materials in two separate experiments; with both galactose and
glucosamine hydrochloride investigated as potential galactosamine replacements.105
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Scheme 1. 15 Schmidt’s HWE-mediated approach towards the C-glycosyl analogue of
the Tn antigen
The first route, starting from galactose, did not afford an acceptable yield and turned
out to be an inefficient alternative for previous approaches. As shown in Scheme 1.16, the
nitroso azide 197 was obtained via three sequence steps: acetylation, galactal formation,
followed by azidonitration. Consequently, peracetylated 2-Deoxy-2-acetamido-α-D-galactopyranose was afforded using sodium methoxide and acetic acid. Although the chlorination step was done successfully using HCl gas and acetyl chloride, allylation only provides
a 14% yield regardless of the previous success of Schmidt with this transformation. This
low yield was explained by the presence of minor impurities. A more direct route was then
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applied to examine the viability of this approach. The 2-Acetamido-2-deoxy-D-galactopyranose obtained from selective acetylation of galactosamine hydrochloride and then converted to per-acetylated α-chloro galactoside 190 using the same chlorination protocol in
their previous method. Finally, they tried allylation, which again failed to provide more
than a 14% yield. The result indicated that oxazoline 1100 and a polymer is always favoured over the desired allylated compound. The Bromo-substituted pyranose was examined to improve the yield of this reaction, despite obtaining a slightly better result, the
purification step seemed to be extremely challenging.

Scheme 1. 16 Ben’s initial approach to N-acetyl C-allyl galactosamine 191

35

After those unsuccessful attempts, Ben and Bouvet began with inexpensive D-glucosamine (Scheme 1.17).105 The same acetylation and chlorination protocol were implemented, followed by an allylation resulting in good yields using AIBN and allyl tributyltin
in toluene. The rest of the procedure followed as Cipolla outlined above.100 After deacetylation, the glucosamine was converted to galactosamine 187 using a Pivoyl protecting
group, TF2O, and water, respectively. In the parallel procedure, compound 1106 was obtained in five steps from 185. Subsequent protection of both alcohols at C-4 and C-6 respectively with benzylidene protecting groups were subsequently followed by a protection
of the C-3 hydroxyl group with PivCl, and therefore, afforded compound 1104. Continuing
on, compound 1106 was obtained via a selective benzylidene deprotection, followed by the
conversion of the glucosamine analogue to the respective galactosamine analogue through
the previously reported procedure using TF2O and water.

Scheme 1. 17 Ben’s alternate approach to differentially protected N-acetyl C-allyl galactosamine derivatives 187 and 1106
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Consequently, both intermediates 187 and 1106 may therefore, be synthesized in
8 and 6 steps, respectively: with both high yields and selectivity, using either Beau or
Cipolla chemistry. This represents rapid, efficient, and cost-effective routes for the syntheses of these useful building blocks.
Finally, we will conclude this section by discussing the synthesis of conformationally-restricted acetal-free Tn antigen mimics by Peregrina and co-workers.106 These C-glycoside bicyclic systems are designed to investigate the effect of the carbohydrate component of antigens on the cancer cells; particularly, the interactions between lectins and the
Tn antigen. The lectin-antigen interaction may have a destructive impact on cancer metastasis and therefore, interfering with this process may show some therapeutic effect.106
The bicyclic compounds prepared by Peregrina and co-workers are in a locked conformation which force the carbohydrate into a similar conformation as the energy minima
for the natural Tn antigen. In these compounds, the methyl group is eliminated from the
acetamido group of GalNAc and as a result, the amide is locked into a cis-geometry. Peregrina prepared three structurally relevant bicyclic acetal-free Tn antigen analogues to provide additional information. In those three compounds: 1107 and 1108 in Figure 1.7, the
C-2 amido group and the anomeric positions are attached to the same α-carbon of the amino
acid. The only difference between these compounds pertains to the carboxylic acid carbon
of the amino acid in compound 1108. This is present in the form of an alcohol functionality.
However, in the other two members of the series, a carboxylic acid carbon is removed.
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Figure 1. 7 Peregrina’s targeted conformationally-restricted Tn antigens 1107 and 1108,
compared to the Tn antigen 101
To begin the synthesis, the serine-equivalent C-nucleophile 1110 was prepared
from (S)-N-Boc-serine benzyl ester in mostly a single diastereomeric form then underwent
conjugate addition with a nitrogalactal derivative 1111 as a carbohydrate moiety in the
presence of LHMDS (lithium bis(trimethylsilyl)amide). The functionalized tetracyclic
1113 was obtained via two subsequent steps. Initially, a reduction of the nitro group using
a hydrogenation with platinized Raney nickel and an intramolecular cyclization resulted.
Secondly, the acetal group was hydrolyzed, followed by the acetylation of the alcohols and
finally, the amine-to- amide conversion produces compound 1108 (Scheme 1.18). Consequently, an isomeric mixture of 1107a and 1107b was prepared via oxidation and Tollens
decarbonylation. These conformationally restricted Tn antigen mimics resulted in moderate bioactivity for the lectin-carbohydrate interactions.106
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Scheme 1. 18 Peregrina’s synthesis of conformationally-restricted Tn antigens 1107a and
b, and 1108
In this section, many useful syntheses of acetal-free (C-glycoside) Tn antigen analogues were shown with promising leads for future synthesis. In the next section, we will
focus on previous attempts towards the synthesis of the acetal-free TF antigen, which is
much more challenging than the synthesis of the Tn antigen.
1.1.5.5 Synthesis of Acetal-Free TF Antigens
Another prominent and complex target, the TF antigen, which consists of the Tn
antigen unit 1,3-β-linked to a galactose moiety, is a difficult synthetic target. The construction of a one carbon 1,3-β-linkage between two sugars, removing both the acetal group in
sugar units of TF antigen and the attachment of the amino acid to the sugar moiety in the
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α orientation are the three most critical challenges that chemists currently are trying to
address. The first challenge facing chemists in the synthesis of the acetal-free TF antigen
is to form a one-carbon 1,3-β link between the galactose and the galactosamine moieties.
The previous research suggests that the best biological result would be achieved using acetal-free antigens that are structurally quite similar or exactly resemble the natural antigen
with peptide chain linked to an amino acid moiety.67 Consequently, the construction of a
one carbon linkage with a β orientation between the two sugar moieties is essential. At the
same time, this requirement could present significant challenges to the synthesis of the TF
antigen. The stereoselective formation of the second C-glycoside in the galactosamine moiety is the second obstacle to obtaining a fully acetal-free TF antigen. Due to this challenge
there is no example of a fully acetal-free TF antigen in the literature. Although the third
challenge seems to have been resolved by Beau and Schmidt, which are the only two reported ways to install an α-oriented amino acid onto the sugar moiety in the syntheses of
Tn antigen derivatives, these approaches use samarium iodide chemistry or Horner–
Wadsworth–Emmons chemistry, which require specific synthetically challenging precursors.97, 103 These three challenges are most likely the main reasons why there is no example
of the synthesis of a fully acetal-free TF antigen analogue in the literature to date. The
formation of an aldehyde functionality seems to have attracted the majority of attention
amongst the chemists as both an electrophile, and an essential precursor in the one-carbon
coupling strategy between two sugars. Schmidt reported the first attempt to solve the first
challenge, installing a one-carbon linkage between two sugar moieties, however, this linkage did not have the same connectivity as native TF antigen.107
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Aldehyde 1120 was synthesized from two separate precursors to find optimized
conditions, see Scheme 1.18. The first precursor, 1119, was synthesized through the Wittig
reaction from 1118, which itself was obtained from 1115 in three steps:108 protection, selective deprotection, and oxidation. The compound 1119 was then subjected to a hydroboration to afford a mixture of epimers in a 2:1 ratio of the glucose (not shown)-galactose
1121 diastereomers. These two diastereomers were separated by column chromatography
and oxidized separately. The undesired α-aldehyde (not shown) was epimerized with triethylamine to afford a 2:1 ratio of glucosyl-galactosyl aldehydes. The process could be
subsequently repeated to drive the material towards the desired product. This process was
not an efficient route however, because of a poor yield in the olefination step (Scheme
1.19).
An alternative method was examined using compound 1117, which was converted
to the aldehyde through a cyanation followed by an aldehyde formation. Alcohol 1117 was
treated with triflic anhydride in pyridine, followed by tetrabutylammonium cyanide to replace alcohol with nitrile functionality in an SN2 fashion. A reduction of the nitrile group
with DIBAL-H, followed by epimerization with triethylamine was performed to generate
the desired aldehyde 1120 in good yield. The coupling partner, nucleophile 1124 was
formed from D-galactal 1123 (Scheme 1.19) and was subsequently coupled with aldehyde
1120.
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Scheme 1. 19 First steps for Schmidt’s synthesis of a C-linked N-acetyllactosamine
After synthesis of the vinyl sulfoxides, two epimeric hydroxyl methylene-bridged
C-disaccharides (1126a and 1127b) were obtained through an LDA deprotonation of the
vinyl sulfoxides, followed by nucleophilic attack to the aldehyde. These compounds were
successfully separated in parallel syntheses and subjected to an azide reduction using
Raney nickel to generate a free amine, which, upon in situ acetylation, obtained 1127a,b.
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The alcohol was deprotected via Zemplén deacetylation, then hydroboration was performed to produce compounds 1129a,b. It is worth mentioning that, although the hydroxyl
group in the bridge was not removed in this synthetic step, the corresponding chirality and
differentiation between the two epimers were furnished using O-iso-propylidenation of
1129a,b with 2,2-dimethoxypropane in the presence of acid. The protection of the R isomer
with 2,2-DMP led to the generation of a 6-membered ring with the glucosamide residue,
lying in the equatorial position of a typical chair conformation. On the other hand, the S
isomer could not adapt a chair conformation and therefore rearranged towards a boat conformation to minimize the steric demands (not shown here) (Scheme 1.20).

Scheme 1. 20 Completion of Schmidt’s synthesis of a C-linked N-acetyllactosamine
Vogel was the first chemist to accomplish the synthesis of a β- D-galactosyl-1,3
carbon-linked to 2-deoxy-2-acetamido-galactose using Baylis-Hillman chemistry, which is
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the earliest reported formation of a 1,3-β carbon linkage between galactose and galactosamine components (Scheme 1.21).109, 110 The coupling partner of isolevoglucosenone was
synthesized according to a known procedure by Horton.111 The Compound 1132 was furnished in three subsequent steps, epoxidation, hemiacetal formation, and lactone formation
using manganese dioxide from the anhydro sugar glycal (Scheme 1.21). The second Baylis-Hillman coupling partner was prepared from peracetylated galactose by replacing the
acetyl group at the anomeric position with an allene group using propargyl-TMS and a
superacid consisting of and TMSOTf and BF3•OEt2, followed by replacement of the acetyl
protecting group with a TBS group. Finally, the allene functionality underwent oxidative
cleavage with ozone to afford the β-anomeric aldehyde 1130. The Baylis-Hillman reaction
assisted by diethyl aluminum iodide was exploited to provide the C-glycoside 1137, primarily as one diastereomer, from the coupling components. Compound 1137 was subjected
to Michael addition to introducing the nitrogen source in the C-2 position using N,O-dibenzyl hydroxylamine, and dimethyl aluminum chloride as a Lewis acid catalyst. An undesired
imine functionality accompanied by 1,4 conjugate addition was observed when they used
O-benzylhydroxylamine as a nucleophile. The glycosyl donor 1142 was then successfully
prepared in three steps. First, selective reduction of the ketone was performed with LiBH4
as the rest of the common reducing agents failed to produce the desired absolute galactose
configuration product. Second, a cyclic acetal cleavage with an SPh group and subsequent
C-6 hydroxyl protection with a TMS protecting group was carried out using ZnI2 and
Me3SiSPh. Finally, desialylation of the C-6 position afforded desired product 1142.
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Scheme 1. 21 Synthesis of the disaccharide component in Vogel’s synthesis of a C-linked
N-acetyllactosamine (R= TBS)
A few years later, Vogel reported the second-generation synthesis of a C-linked
disaccharide using the Baylis-Hillman approach. In this research the authors investigated
C-linked disaccharides of the TF antigen as potential anti-cancer vaccine candidates.66 To
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determine the effect of the C-anomeric linkage between the two carbohydrates in the immunogenicity of the antigen, both anomeric α and β disaccharides 1137 and 1137a were
synthesized using the same Baylis-Hillman approach between isolevoglucosenone and
both anomers of TBS-protected C-1 aldehyde 1130 and 1154.
A Michael addition was performed to introduce an amine source in the C-2 position
using O-methyl hydroxybenzylamine. The hydroxyl group in the bridge was then removed
using TFAA and DBU to generate the acyclic enone, which was then reduced by Raney
Nickel, followed by a selective reduction of the ketone to form an axial hydroxyl group at
the C-4 position in a galactose configuration. As a next step, BnNOMe was reduced to an
amine and then converted to the respective azide functionality using a diazo transfer, and
compound 1143 was then formed by acetylation of the hydroxyl group at the C-4 position.
Consequently, the glycoconjugate 1146 was successfully obtained in five steps. A cyclic
acetal cleavage using triethyl silyl triflate/acetic anhydride, followed by bromination of the
anomeric alcohol using titanium (IV) bromide generated the desired glycosyl donor.
Koenigs-Knorr glycosylation was performed using Fmoc-Ser-t-Bu, followed by acetamide
formation and t-butyl carboxyl deprotection, produced compound 1145.
The solid-supported core, compound 1148, was then prepared by loading the glycoconjugate onto a solid support and an amino-functionalized trityl resin. The short tripeptides of repeating glycoconjugate monomers load three antigens per peptide resulting in an
antigen-dense system, 1149, which is prepared via solid-phase peptide synthesis. The diazo
protecting group at the C-terminus of the peptide was installed to simplify the purification
of 1150, and the free glycopeptide was obtained after its cleavage of the resin under standard acidic conditions. The amino terminus was then attached to an acetylthioacetate, 1152,
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using pentafluorophenyl acetylthioacetate. A Zemplén deacetylation was then performed
to generate a conjugate that could be linked to the carrier protein KLH mediated through
an m-maleimidobenzoic acid N-hydroxysuccinimide ester (MBS), providing Antigen 1153
(Scheme 1.22).

Scheme 1. 22 Completion of the synthesis of 1153, an acetal-free TF analogue
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The same synthetic procedure was applied for the α-anomeric aldehyde, with only
a few exceptions; The Itoh-Nozaki coupling procedure yielded the epimeric alcohols rather
than the single major product. A flexible diaminopropane spacer is used to conjugate the
tripeptide to the resin in the synthesis of the TF β-mimic. In this second case, a more rigid
p-xylylenediamine linker was exploited to provide a suitable chromophore to help in HPLC
detection during the purification. The antigen 1156 was then prepared using peptide synthesis, followed by hydrolysis of the resin, and direct protection of the N-terminus as the
acetate and ligation to the KLH-MBS provides the glycopeptide 1156 (Scheme 1.23).

Scheme 1. 23 Completion of the synthesis of 1156, an α-anomer version of the acetalfree TF analogue
Although the first synthesis of a mono C-glycoside disaccharide toward the synthesis of an acetal-free TF antigen was accomplished, many obstacles still remain. For example, the O-glycosylic linkage between the glycan and the peptide remained in the molecule,
which makes the molecule vulnerable towards enzymatic or acidic-mediated hydrolysis in
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vivo. Second, an extended multi-step synthesis is required for the generation of these compounds, and an effort to reduce the step count is necessary. Third, despite the positive biological results of this research, regarding producing a robust immune response, as determined by serum immunoglobulin G concentrations, the specificity of these antigens towards cancer cells has yet to be conducted and biological testing has to be performed on
the corresponding C-glycoside TF antigen analogue and actual natural TF antigen for a
useful comparison.

1.1.6 Biological Conjugation and Biological Evaluation of Acetal-Free Mimics
The immunogenicity of natural TACAs is usually low because the immune system
cannot recognize the sugar, and there are sugars all over the surface of these tumours. As
a result, these antigens cannot activate T-cells, and therefore generate a T-cell-independent
immune response. Consequently, antibodies generated from the immune system will be
weak and will not stay in the body for a long time. The low stability of TACAs is another
major challenge that should be solved to get an adequate response from the immune system
to eliminate these cancer cells. Glycosidases are mostly responsible for the cleavage of the
glycosyl functionalities from peptides as part of the antigen-processing process, which are
present in human serum and the liposomes of antigen-presenting cells.65,112 In this section,
conjugation and biological evaluation of acetal-free mimics will be discussed.
1.1.6.1 Tn Antigen
The C-glycoside derivative of the Tn antigen was prepared by Cipolla for the immunological evaluation, which is described above. Based on a general supposition, an ideal
carbohydrate-based vaccine candidate should express three main features: they should have
the ability to activate B-cells, they should have the ability to activate T-cells to strongly
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activate the immune system, and should include an adjuvant to boost the immune sensitivity to the candidate vaccine.69
In order to meet these features the OVA peptide, a T-cell epitope which is readily
recognized by the immune system of DO11.10 mice, was chosen for this research.113 The
protected hydroxylamine-containing peptide was obtained via solid-phase peptide synthesis using a Fmoc/t-butyl protection approach.68 The linkage was cleaved using standard
cation-scavenging conditions to afford the deprotected peptide that was incubated with the
glycosyl ketone in a pH 4.5 acetate buffer for 90 minutes and monitored by RP-HPLC to
produce a mixture of the syn and anti-oxime isomers. Although the Major histocompatibility complex (MHC) found on the surfaces of cells, which are the class of genes that code
for proteins that assist the immune system in recognizing foreign treats recognizes the isolated neo-glycopeptide to the same degree as the peptide aglycon, the oxime linkage does
not resemble a natural glycopeptide linkage. They mentioned that the vaccine did not require internalization to bind with the MHC receptor, they postulated that it maybe because
of the competitive displacement of the antigen interacting with surface-localized receptors.
The result showed that T-cell activation of both the hydroxylamine aglycon and neo-glycopeptide were reduced compared to the native unmodified peptide. Thus, the unnatural
linkage interferes with either MHC-binding or T-cell receptor (TCR) activation.
A few years later, Cipolla reported the synthesis of mono and divalent neo-glycopeptides with modified peptide fragments,114 as the previous sequence, does not precisely
match the antigenic sequence proposed by the NCBI and is shifted by an additional residue.115, 116 Both neo-glycopeptides are shown in Figure 1.8. The results indicate that the
new peptide could interact with the MHC, and the oxime successfully survives antigen
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processing. The successful survival of antigen processing occurs when the peptide is introduced into an unfixed compared to fixed dendritic cells similar to the aglycons and in turn.
As a result of this interaction the TCR activation was improved.

Figure 1. 8 The structure of the revised neoglycopeptide 1157 based on the OVA peptide, and the divalent analogue 1158
It is worth mentioning that the divalent system showed a more robust TCR activation which may be due to crosslinking of dendritic cell receptors and suggests a multivalency effect may be operative.91, 117-119 However, inter-trial reliability is not particularly
strong, and the effect is only moderate with these types of cellular assays which precludes
confirming the multivalency affect. The result indicated that the antigen with a new peptide
sequence interacts with the MHC and therefore, the oxime successfully survived antigen
processing. This occurs because, when the peptide was introduced into unfixed compare to
fixed dendritic cells similar to the aglycons, the TCR activation was improved. Despite
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exciting preliminary work, some key questions are left unanswered. First, the specificity
of the native antigen towards cancer cells should have been evaluated. Second, as an immunological response is similar in magnitude for both the glycon and peptide alone, it is
essential to determine if the glycon is actually responsible for an immune response or if it
was only courtesy of the peptide alone. As a neo-glycopeptide linkage is different from the
natural Tn antigen linkage, it is beneficial to compare these two antigens to understand the
importance of introducing an oxime linkage rather than a traditional glycosidic linkage.
Lastly, the examination of the effect of this mono-and divalent neo-glycopeptide on tumours in vivo remains an unanswered question.
The bicyclic Tn antigen mimics synthesized by Peregrina, which locks the conformation of the ring have been screened, which as mentioned above, this was examined in a
competitive lectin-binding assay with a Tn-specific lectin and soybean agglutinin lectin.120
Although, the bicyclic systems can interact with the lectin with approximately 80% of the
efficiency of the Tn antigen, the lectin preferred the natural antigen rather than the bicyclic
forms and their enantiomers in competition experiments. Computational simulations rationalized this lower recognition due to the possible hydrogen-bonding interactions between the ligand and the carbohydrate-binding site of the lectin (Figure 1.9). Finally, it
should be mentioned that the Tn antigens synthesized by Ogawa, Beau, Ben, and Schmidt,
as mentioned above, were not examined for their biological activity as Tn antigens.
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Figure 1. 9 The structures of the conformationally restricted Tn antigens examined for
lectin-binding affinity by Peregrina
1.1.6.2 TF Antigen
Not many syntheses of analogues of the natural C-glycoside TF antigen exist to
date. It is noteworthy that there is no reported synthesis of a fully acetal-free analogue of
the TF antigen yet. Partial analogues, the mono C-glycoside TF antigen α-O-linkage to the
serine building block, as mentioned above, was first reported by Vogel and Awad.110 However, even this compound was never examined for biological applications. Seven years
later, they reported the synthesis of the clustered glycopeptide as both linkages between
two sugars, the α (unnatural) and β (natural) anomers with galactose amine α-O-linked to
the serine building block.66
These antigens were constructed with the belief that the TACA would activate the
B-cells, and the KLH would activate the T-cells. This compound was accompanied by the
carbohydrate adjuvant QS21,121, 122 and applied against BALB/c adult mice. This particular
strain of albino mice is frequently chosen for immunological studies because they of their
generally potent immune response.23 The structures of the two vaccines is shown in Figure
1.10. As expected, the α-linkage did not generate significant an immune response, as it is
not the same analogue of natural TF antigen. However, the β-isomer provided a robust
immune response, as determined by serum immunoglobulin G concentrations. The result
indicated that the serum antibodies induced by the β-vaccine were also specific for the βglycopeptide, and it could not recognize the α-glycopeptide.
Despite the response of the immune system towards the KLH carrier protein as
expected, a few antibodies induced by α vaccine, could not recognize either the α or the βglycopeptides. For this reason, the immune response of the α-vaccine was not examined
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against the natural antigen. Finally, this C-glycoside analogue of the TF antigen is not an
entirely acetal-free antigen. In order to reach the maximum potential of this antigen (by
increasing biostability), a synthesis of fully acetal-free TF antigen seems to be necessary.

Figure 1. 10 The structures of the trivalent vaccine TF vaccine candidates investigated by
Vogel
1.1.6.3 sTn Antigen
Synthesis of an acetal-free sTn antigen have attracted the attention of chemists and
biologists because they belong to the TACAs antigen class, which are expressed in many
cancers, including breast, esophageal, gastric, prostate, lung, and colon cancer. In this section, only the biological activity of the C-glycoside analogues of these compounds are discussed because they are the only ones showing a 1:1 comparison to the TACA immunogenicity of a C- and an O-linked carbohydrate antigen. The synthesis of these compounds
is not discussed in this thesis.
Linhardt synthesized the double C-glycoside and mono C-glycoside sTn antigens
and applied them to the same protocol in the one described above by Vogel, for the measurement of the IgM and IgG titres.67 The carbohydrate in the sTn antigen is not part of a
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glycopeptide or neo-glycopeptide as above and makes it an unusual mucin antigen. Although the O,C-disaccharide 1159b (Figure 1.11) showed the highest immune response,
the sugar-amino acid O-linkage remained susceptible to enzymatic cleavage. This is not
surprising as one acetal group is still present in the molecule. The C,C-disaccharide 1160,
which was expected to show better immune activity than O,C-disaccharide, proved to be
less potent immunologically. To explain the lower immune activity of the fully acetal-free
disaccharide compared to the O,C-disaccharide we note that the structure of the C,C-disaccharide was not a direct analogue of the native O,O-antigen. The linkage between the two
sugars is one carbon short. Also, the hydroxyl functionality introduced to the bridge is a
mismatch, which changes the hydrogen bonding and solvation properties of the antigen.
Despite the remarkable results showing a direct comparison of O,C-disaccharide, the sTn
antigen analogue versus the native sTn antigen, and its better immunogenic response, (Table 1.2) the specificity of this antigen towards cancer cells and the antibodies produced by
the immune system remains unclear. Consequently, these issues remain to be addressed
before the application of TACA antigens can be fully realized.

Figure 1. 11 The structures of Linhardt’s differentially linked sTn antigen analogues

55

Table 1. 3 Antibody titres from BALB/c mice immunized thrice with either 1 μg/mouse
of (O,C) or 10 μg/mouse of (C,C or O,O) of the KLH conjugate. After 1 week, mice were
sacrificed and serum IgG and IgM titres were measured through ELISA; error represents
the standard deviation from 5 mice

1.1.7 Conclusions and perspectives
At first, the native antigens were targeted for anti-cancer vaccine applications. Despite remarkable preclinical data results reported by Danishefsky,123 the following reports
for the synthesis and application of clustered Tn and TF mucin candidates showed that the
antibodies generated were specific for the natural antigens. Therefore, these candidates
have not been introduced as commercial vaccines. A few years later the acetal-free carbohydrate, introduced to compensate for the low biostability of the O-linked carbohydrate in
the synthesis of TACAs, showed better immunogenicity by a factor of 6. Although there
are many ways to synthesize the C-glycoside and carbasugar, there are few reports of the
biological application of these compounds. Furthermore, there is not a single example of
immunological studies on carbasugar derivatives of TACAs, despite their potent immune
activity when applied as glycomimetics in other systems.124, 125 This is most likely because
the structural complexity of these antigens makes their synthesis very tempting targets for
chemists to showcase novel synthetic chemistry, rather than for their potential as vaccine
candidates.
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Consequently, there are three main questions in this field that remain to be addressed:
1) What is the reason for enhancing the immunogenicity of acetal-free candidates compared to natural antigens?
2) Are acetal-free analogues capable of inducing an antibody response that is specific for
the glycopeptide conjugate?
3) Does the increased immune response observed for these acetal-free systems have an
impact on tumour growth, and do these materials have potential as anti-cancer vaccines?
All the research done previously in this field has paved the path for the bright future,
however, until research addresses these questions, we cannot realize that future of a real
anti-cancer vaccine.

1.2 Total synthesis of glycolipids as antigens and the biological evaluation of their immunological activity
1.2.1 Invariant natural T killer cells
Invariant natural T killer cells (iNKT) are a subclass of white blood cells that use
their T cell receptors (TCRs) interact with self and foreign lipids and as a result, capable
of inducing immune system via a robust and rapid cytokine release.126 These lipids are
presented by CD1d, a non-polymorphic major histocompatibility complex class I-like antigen-presenting protein.126 It is a member of the lipids antigen family that includes the
CD1a, CD1b, and CD1c molecules.126 Invariant natural killer T cells are conserved between humans and mice. These cells have been shown to be very useful and, at the same
time, destructive in many pathological states, including autoimmune disease,127 allergic
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disease,128 cancer,129 and microbial infection.130, 131 Activation of iNKT cell leads to producing a mixture of cytokines that often work against each other. Many significant efforts
have been expended trying to uncover a better understanding of lipid antigen recognition
by iNKT cell and TCR and interactions between iNKT cells and other leukocytes.
After activation of iNKT cells, cytokines are released, which are the small proteins
responsible for cell signaling in an innate-like manner. Consequently, they engage in the
effector functions, such as NK transactivation, T cell activation and differentiation, B cell
activation. When iNKT cells are activated, cytokines are involved in direct and indirect Bcell activation, cognate, and non-cognate interactions. They are also responsible for dendritic cells activation and cross-presentation activity and macrophage activation. Furthermore, invariant natural killer T cells can regulate and recruit dendritic cells, neutrophils,
and lymphocytes through cytokine release. The multi-functional responses of iNKT cells
have been shown to enhance microbial and tumour immunity as well as promoting tolerance and suppressing autoimmune disease.132 The α-galactosylceramide (α-GalCer,
KRN7000) was reported as the first CD1d presented lipid antigen that can activate iNKT
cells by Natori and coworkers in 1994 (Figure 1.12).133 This antigen was isolated from a
sea sponge off the coast of Okinawa Japan, however, there is still some debate as to whether
this lipid may be isolated from a bacterium present in the sample rather than from the sea
sponge itself.
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Figure 1. 12 Structure of KRN 7000
The lipid antigens capable of activating iNKT cells are classified into two categories: glycerol-based lipids and glycosphingolipids (ceramide-based glycolipids) depicted
in Scheme 1.24. The glycerol-based lipids contain two parts: the sugar moiety in which the
anomeric oxygen is linked to the glycerol moiety bearing two long acyl chains. Conversely
the glycosphingolipids are composed of a sugar and a ceramide. The sphingosine moiety
consists of 18-carbon amino alcohol bearing an unsaturated hydrocarbon chain and fatty
acid.
This α orientation does not exist in the mammalian lipids, and it is unique for the
foreign lipidic antigens. Sphingomonas spp are antigenic glycosphingolipids bearing
α-linked glucuronic or galacturonic acid.134-136 Borrelia burgdorferi137 and Streptococcus
pneumoniae138 are examples of α-linked glucosyl and galactosyl diacylglycerols.

Scheme 1. 24 General structural feature of glycolipids
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A cholesterol ester produced by Helicobacter pylori and lipopeptidophosphoglycans found in Leishmania donovani139 have been proposed to bind to the iNKT cells TCR.
The antigenicity of these lipids is less well understood than the other foreign lipid antigens.
This α orientation may be a structural feature which explains how iNKT cells can be activated during infection; however, to date the direct and actual mechanism of action of these
lipids with this linkage orientation is uncertain.
A study on lipid self-antigens attracted much attention among biologists, when
iNKT cells were activated during viral infections, cancer, and autoimmune diseases, without the presence of a foreign lipid antigen.140-142 Generally, in the absence of an infection,
and as a result any pathogen associated with it, iNKT cells still can be activated by antigenpresenting cells (APCs). This activation happens through Toll-like receptor (TLR) agonists, and therefore, the presence of lipid–CD1d complex signal still seems to be necessary
for the activation of iNKT cells. Consequently, this has led to the isolation and characterization of lipid self-antigens from CD1d with which the glycerol-based phospholipids, glycosphingolipids, and lysophospholipids were identified.143-145 The results showed that
among human-CD1d self-antigen lipids, only single-branched fatty acid lysophospholipids
can activate iNKT cells. Lysophosphatidylcholine (lysoPC) was also found to be antigenic
towards the activation of iNKT cells. This lysoPC results from cleavage of phosphatidylcholine (PC), via a phospholipase A2 (PLA2).146, 147 These self-antigen lipids are capable
of inducing the immune system by releasing granulocyte-macrophage colony-stimulating
factors from iNKT cells. However, these antigens cannot use another cytokine type to
strongly activate iNKT cells. Indeed, there are not many foreign lipid antigens presented
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by CD1d that can strongly activate iNKT cells. Before 2011, the glycolipid α-galactosylceramide, known as KRN7000, was the only glycolipid identified as being capable of
strongly activating this cell.

1.2.2 KRN7000
KRN7000 belongs to ceramide-based glycolipids, which are isolated from a marine
sponge, Agelas Mauritius in Japan.133 This glycolipid, composed of a sugar moiety (Galactose) α-linked to ceramide, is specific for only iNKT cells to activate the immune system. The ligand should be presented by CD1d protein, then the iNKT cell is activated
through the T-cell receptor (TCR). Consequently, iNKT cells release cytokines to provoke
immune system components, and as mentioned above, many defensive cells will be activated to eliminate the foreign antigens. In this process, two types of defence mechanisms
are applied: TH1, for the fight against tumours and antimicrobial functions and TH2,
against autoimmune diseases (Figure 1.13).16 KRN 7000 showed a strong ability to prevent
asthma development148, 149 by suppressing the growth of a variety of tumour cells, such as
liver,150 melanoma,151 hepatitis and lung,152 as well as fighting against inflammation,153
pathogens,154 and autoimmune diseases. Hence, this lipid antigen has become an interesting
therapeutic target for researchers.155

61

Figure 1. 13 KRN 7000 derivatives and their defense mechanisms
A wide range of modifications have been performed on KRN 7000 to increase the
activity of this molecule. These include modifications of the polar sugar portion, the orientation of the linkage, the polar part of ceramide, and the fatty acid chains. Using galactose
showed better iNKT cells activation results than glucose and mannose derivatives.156 Attempts to replace hydroxyl groups with different functionalities resulted in interesting outcomes. Replacement of C-2-hydroxyl groups with methoxide, fluoride- and sulfate showed
no activity at all. However, replacement of C-3 and C-4 with fluoro- and methoxide promoted the production of Interleukin-2 (IL-2), which was is a type of cytokine signaling
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molecule responsible for in protein that blood cell activity adjustment. The amount of production of this cytokine was not compatible with the amount of this protein produced by
KRN7000. 3-O-sulfate substitution resulted in similar iNKT cell activity as KRN7000, this
is probably due to the presence of a strong hydrogen bonding network. The formation of a
disaccharide using different sugars in different positions, as expected, showed the same
activity as KRN7000 in vivo. This is, of course, due to cleavage of the acetal linkage by
glycosidases. However, the C-6 linked disaccharide(s) showed iNKT cell activity. This
result is explained by the unique structure and orientation of this molecule, which can fit
itself in TCR space between the active areas CDR1a and CDR3a. Consequently, researchers have turned their attention to optimize the activity of iNKT cells by changing the C-6
substitution in KRN7000. Various functionalities were introduced, including acid,157 amide, acyl amides,158 biotin,159 methoxyethers160 and aryl ring with electron-withdrawing
group substituted.161 Unfortunately, none of these resulted in stronger activation of the T
cells.
Subsequently, the polar ceramide portion of the KRN 7000 molecule was subjected
to modification looking for enhanced anti-tumour activity. Based on previous research by
Trappeniers, the presence of an amide functionality and 3΄-OH are necessary for TCR
recognition.162 The removal of both hydroxyl groups resulted in complete loss of activity,
and any changes at the 4΄-OH, including any alteration of the conformation or even complete removal of the 4’-OH afforded no notable difference in iNKT cell activity. Although
the replacement of the hydroxyl group with an amide group showed good TCR affinity,
the production of cytokines was reduced.
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Next, alterations to the fatty chains were investigated and analogues with different
chain lengths were synthesized. Unfortunately, these compounds did not produce a consistent trend and showed a wide range of lower and higher activities, none of which were
significantly higher than KRN7000. Finally, the linkage orientation was evaluated and αKRN7000 indicated excellent TCR binding compare to the β linkage. This result showed
better iNKT cell activation, however, using the β-anomer resulted in better CD1d interaction.
Finally, the oxygen at the anomeric position was replaced by sulfur157 and also
CH2.159 The replacement with sulfur showed no iNKT cell activity, possibly, due to lack
of efficiency of hydrogen bonding, and when the exocyclic oxygen was replaced with a
methylene group, a robust TH1 cytokine response was observed in mice. However, this
effect did not translate to humans with the same strength. Consequently, the presence of
oxygen at the anomeric position seems to be necessary for efficient activation of iNKT
cells, particularly in humans. So far, all the modifications on KRN 7000 have not resulted
in significant improvement of iNKT cell activity in humans, and the majority of them
showed no or low activity in comparison to KRN7000 itself.

1.2.3 Bacterial antigens for invariant natural killer T-cells
Five major bacterial antigens, which can activate invariant natural killer T-cells,
have been isolated. The previous studies showed that phospholipids from Mycobacterium
tuberculosis, which was the first reported glycolipid antigen presented by group 1 CD1
protein, are capable of activating any T-lymphocytes.163-165 Careful screening of the bonding between Mycobacterium lipids and CD1d in mammals showed a strong binding between CD1d and phosphatidylinositol tetramannoside. This lipid is isolated from a related
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bacterium, Mycobacterium Bovis bacillus, contains different fatty chains and is responsible
for bovine tuberculosis.166
S. paucimobilis, Sphingomonas capsulate and Sphingomonas yanoikuyae belong to
the Sphingomonas spp family. Among them, Sphingomonas paucimobilis is the most pathogenic bacteria, and in both synthetic and natural forms the glycosphingolipids (GSLs)
from S. paucimoblis showed the ability to activate iNKT cells.136 However, the activity
was weaker than that observed for KRN7000. Glycosphingolipids (GSLs) GSL-1, isolated
from S. yanoikuyae and GSL-1̍, isolated from S. paucimobilis, are highly structurally similar to KRN7000 (Figure 1.14) and are capable of the highest activation of iNKT cells
compared to the rest of the Sphingomonas spp family, however, as mentioned above, none
are as high as αGalCer.

Figure 1. 14 Structure of Gal-GSL 1166 (isolated from Sphingomonas spp.)
Spirochete Borrelia burgdorferi is the only pathogenic member of the Borrelia
burgdorferi family, which can be introduced to humans by Ixodes scapularis (deer tick)
bites. These lipids are composed of a variety of galactosyl diacylglycerols (DAGs), including BbGL-2, which is capable of activating iNKT cells in both natural and synthetic
forms.137 These antigens include a galactose sugar moiety, an α-O-glycosidic bond, and
lipid chains, which are linked with ester bonds to a glycerol moiety bearing saturated or
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unsaturated fatty chains. In the mice study BbGL-2c (Figure 1.15), which contains oleic
acid in the sn-1 and palmitic acid in the sn-2, was identified as the most effective member
of this family in activating iNKT cells.137 The length and degree of saturation of the fatty
acid plays an essential role in the activation of the iNKT cells through TCR recognition of
the sugar component. In this case, sn-1 fatty acid picks A΄ or F΄ pockets of mouse CD1d to
bind, whereas, sn-2, which in this case is oleic acid, picks the A΄ pocket. Simply binding
is insufficient however as the effectiveness of these antigens is related to how strong they
can bind in the pocket. This is very important as the lipid chain binding to the pocket is
directly related to the orientation of the sugar moiety for the TCR recognition. Changing
this orientation could improve the interaction between TCR and the sugar moiety or may
have adverse effects.

Figure 1. 15 Structure of B. burgdorfei, BbGL-2c
Streptococcus pneumonia is a gram-positive bacterium and is the leading
cause of neonatal sepsis and bacterial meningitis, both of which were leading causes of
death among humans before the discovery of antibiotics. The two main fractions of antigenic S. pneumoniae glycolipids were identified, one contains a monosaccharide glucose
sugar α-linked to diacylglycerol (DAG), the second fraction was identical except it had a
disaccharide moiety attached to the DAG.167 The lipid chains were composed of palmitic
acid in the sn-1 and cis-vaccenic acid in the sn-2, which is (C18:1) fatty acid with a C11-
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C12 unsaturated bond present in low concentrations in mammalian cells. The glycolipid
response was dependent on cis-vaccenic acid due to improved TCR recognition caused by
changing the orientation of the sugar moiety, particularly the rearrangement of an axial
hydroxyl group in the C-4 position of glucose.131 These antigens can activate iNKT cells
by releasing IFN-γ, Interferon gamma, a cytokine responsible for activation of macrophages, neutrophils and natural killer cells.

Figure 1. 16 Structure of S. pneumoniae (Glc-DAG) 1168
Helicobacter pylori is a gram-negative helical bacterium and are the leading cause
of duodenal and peptic ulcers, gastritis, gastric cancer, and lymphoma.168 This bacterium
is composed of cholesterol α-linked to a glucoside sugar moiety, and they are capable of
activation of iNKT cells. PI57 (Figure 1.17) is a glycolipid, which belongs to the Helicobacter pylori family and has been used for asthma symptom protection studies.169 This
glycolipid has also been shown to activate iNKT cells in both mice and humans. However,
studies towards biochemical analysis and structural analysis of binding a cholesterol-containing antigen to the CD1d, remain to be explored.
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Figure 1. 17 Structure of H. pylori (PI57) 1169
Aspergillus fumigatus is a fungus, which leads to infections in the lungs and sinuses.170 Among the Aspergillus fumigatus family, a microbial Asperamide B (Figure
1.18) lipid can activate iNKT cells in both synthetic and natural forms. This lipid is composed of the glucose sugar moiety, linked to the ceramide bearing lipid chains via β-Oglycosidic bond. The sn-1 chain contains the 9-methyl-4,8-sphingadienine, which is commonly found in fungi171 and the sn-2 chain is a β-γ unsaturated acyl chain with a hydroxyl
group.172

Figure 1. 18 Structure of Asperamide B (A. fumigatus) 1170
In conclusion, iNKT cell, which are part of the immune system, could be activated
internally (self-antigen) or externally by bacterial and fungal lipids. The lipid antigens presented by the CD1d molecule induce a response from iNKT cells, which leads to the release
of cytokines, both gamma (IFNg) and interleukin-4 responses, which work against each
other. This is the most challenging problem in the application of these antigens for acquiring constructive iNKT cell responses. The study, design, and synthesis of antigens that are
capable of inducing an iNKT cell response by releasing only the strong interleukin-4 or
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robust interferon-gamma (IFNg) drew considerable attention.173 Despite very optimistic
preliminary results, both the control and specificity mechanisms of the iNKT cell response
have yet to be explored.

1.2.4 Background of the synthesis of glycerol-based glycolipids
1.2.4.1 Synthesis of monosaccharide glycerol-based glycolipids
This section only discusses the background of the synthesis of glycerol-based glycolipids, as the synthesis of the rest of the glycolipid family is beyond the scope of this
thesis. The first full synthesis of glycerol-based glycolipids was reported by Wehrli and
Pomeranz.174 They used racemic isopropylidene glycerol with an acetobromogalactose donor in the glycosylation step. This glycosylation afforded a β-oriented product. The hydroxyl groups in the glycerol moiety were deprotected and then esterified with palmitoyl
chloride. Finally, a selective deprotection of the sugar moiety provided the galactosyl diglyceride bearing a racemic long-chain ester 1176 in 25% yield. Although the synthesis of
this compound did not provide a practical biologically active glycolipid, their approach
could be applied for the synthesis of optically active glycolipids with a brief modification
and is shown below in Scheme 1.25.
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Scheme 1. 25 The first full synthesis of glycerol-based glycolipids was reported by
Wehrli and Pomeranz
Four years letter, Evstigneeva reported the first synthesis of optically active versions of both mono- and disaccharide glycolipids bearing a β glycosidic bond using the
orthoester method of 1,2-transglycosylation (Scheme 1.26).175 A 1,2-di-O-palmitoyl-snglycerol 1178 was directly used instead of isopropylidene glycerol as an acceptor in the
glycosylation. Consequently, the acetylated glycolipids were selectively deacetylated using
hydrazine hydrate. In the subsequent attempt, cellobiosyl diglyceride 1185 was prepared
from the orthoester, which itself was synthesized through glycosylation, from the corresponding glycosyl donor and the 1,2-di-O-hexadecanoyl-sn-glycerol acceptor. The desired
glycolipid was then formed using selective deacetylation using hydrazine hydrate.
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Scheme 1. 26 The first synthesis of optically active versions of both mono- and disaccharide glycolipids
Gervay-Hague and coworkers176 reported the first synthesis of the glucosyl analogue of the bacterial antigen BbGL-II. The TMS group was used as a protecting group in
the glycosyl iodide donor to perform a glycosylation with functionalized unprotected acceptors (Scheme 1.27). The fully protected TMS glucose 1186 was employed as a starting
material. α-glycosyl iodide was prepared using TMSI, subsequently, the α-glycosyl iodide
was converted to the β-glycosyl donor using TBAI and DIPEA, which is a more reactive
anomer of the initial glycosyl iodide. Then, the glycosyl donor was subjected to an in situ
glycosylation with the corresponding glycosyl acceptor 1187. Finally, the desired glycoli-
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pid was obtained after removal of the protecting group using Dowex 50WX8-200 ion-exchange resin and methanol in 58% yield. Although this approach provided efficient access
to biologically relevant glycolipids with α-orientation, this approach has not become a popular method. Reasons include the use of a TMS-protected glycoside donor does not afford
acceptable results in terms of both selectivity and yield with specific acceptors. In addition,
conditions could be problematic in some cases due to the sensitivity of the TMS protecting
group towards reaction conditions.

Scheme 1. 27 The first synthesis of the glucosyl analogue of the bacterial antigen BbGLII
In 2013, McConville and Williams reported the biochemical analysis and synthesis
of acyl-isoforms of GlcAGroAc2, which were isolated from C. glutamicum and M. smegmatis, bearing two acylation patterns.177 The first containing (R)-tuberculostearic acid
(C19:0) and palmitic acid (C16:0) and the second containing oleic acid (C18:1) and palmitic acid (C16:0). It is worth mentioning that these glucuronosyl diacylglycerides include
carboxylic acid functionality at the C-6 position of the sugar moiety. The glycosyl donor
1197 was synthesized based on Thiem report.178 Simultaneously, the homochiral glycerol
moiety was bearing two different hydroxyl protecting groups in TIPS and PMB, which
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were synthesized from compound 1189 in 5 steps (Scheme 1.28a). As the third part of the
glycolipids construction, the enantiopure (R)- tuberculostearic acid 1196 was targeted using an Evans’ chiral auxiliary to provide the 10-(R)-methyl stereocenter.179 They applied
N-decanoyloxazolidinone 1193,180 as a starting material for the diastereoselective methylation using NaHMDS and iodomethane. The desired product was obtained by reductive
cleavage of chiral auxiliary using sodium borohydride, followed by oxidation of primary
alcohol to the carboxylic acid via TEMPO, NaOCl and NaClO2 in CH3CN (Scheme 1.28b).

Scheme 1. 28a,b Synthesis of the glycosyl acceptor 1192, a, and (R)-Tuberculostearic
Acid 1196, b
After the preparation of the main components of glycolipids, they tried to link them
together (Scheme 1.29). First, a glycosylation was performed over four days between the
acceptor 1192 and the donor 1197,178 using TBAI and TTBP in dichloromethane. Then,
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the acetyl group at the C-6 position was deprotected and oxidized to the resulting carboxylic acid using TEMPO and PhI(OAc)2 in a biphasic mixture of CH2Cl2/H2O. In the next
step, the TIPS protecting group in sn-1 was first removed, and then subjected to an esterification with the corresponding fatty acid. This was followed by a PMB deprotection in sn2, and finally an esterification with the other fatty acid. The same procedure was repeated
with the rearrangement of fatty acids in the glycerol moiety to provide glycolipids with
different fatty chains. Finally, a global deprotection of 1203 afforded the glycolipids 1204
in 85% yield via hydrogenation using Pd(OH)2.

Scheme 1. 29 Synthesis of acyl-isoforms of GlcAGroAc2
Richardson and Williams reported the total synthesis of an α-glucosyl diglyceride
isolated from Streptococcus pneumonia.181 Different methods for acylation of the glyceride
moiety was examined to investigate the fidelity of acylation, particularly acyl migration.
To this end, a quantitative 13C NMR spectroscopy study was done via carbon labelling at
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the carbonyl carbon of one of the fatty acyl chains and then measuring the abundance of
the 13C label at each position using a paramagnetic relaxation enhancement (PRE) agent.
First, a nonselective acylation of the diol 1205, was performed in the presence of a
1:1 mixture of commercial 1-13C-palmitic acid and 10-methyl decanoic acid (iso-C13:0).
As expected, no regioselectivity was observed. Next, they tried a stepwise esterification of
glycerol using 10-methyl decanoic acid, DMAP and DCC at 0°C. After careful monitoring
of the reaction, the crude was subjected to rapid purification at cold temperature to minimize the acyl migration, then the secondary alcohol was esterified with

13

C-labelled pal-

mitic acid at the same reaction conditions as the primary alcohol acylation. After purification and a carbon NMR study, the result showed the desired regioisomer in R = 92%.

Scheme 1. 30 Synthesis of α-glucosyl diglyceride isolated from Streptococcus pneumonia
In the next experiments the acylation was conducted in a stepwise acylation manner
and was controlled by the appropriate choice of different protecting groups as shown in
Scheme 1.31. First, compound 1208 was acylated using lauroyl chloride, DMAP, and pyridine. The PMB protecting group was then removed via ceric ammonium nitrate in acetonitrile and water and (without purification) was subjected to the second acetylation to
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minimize acyl migration even further. The resulting secondary alcohol was subsequently
treated with

13

C-labelled palmitic acid in the presence of COMU and N, N-Diisopro-

pylethylamine. The result showed R = 97.2% desired regioisomer in the product 1209. In
the next experiment, the primary alcohol was replaced by bromide to eliminate the possibility of having a free primary hydroxyl group as this should decrease the possibility of any
acyl migration. First, the secondary alcohol was esterified using palmitic acid, followed by
the replacement of bromide with 1-13C-palmitic acid through nucleophilic substitution. The
result afforded the product 1211 with a 56:1 ratio of sn-1 and sn-2 carbonyl resonances,
corresponding to an R > 99%.

Scheme 1. 31 Quantitation of acylation fidelity by 13C NMR spectroscopy
The same bromohydrin strategy was applied for the synthesis of the S. pneumoniae
isolate Glc-DAG-s2 and is shown in Scheme 1.32. A glycidol-derived bromohydrin 1210
was prepared based on their previous report using commercial provided allyl α- D-glucopyranoside as a starting material.182 Compound 1212 was treated with mCPBA to generate
an epoxide in 1: 0.95 (20R/20S) mixture of diastereoisomers. A single stereoisomer was
obtained in 48% yield using S,S-C1.OTs in water and THF.182 Finally, compound 1168
76

was prepared after regioselective ring-opening using Li2NiBr4. The first esterification was
performed using vaccinoyl chloride, pyridine, and CH2Cl2. Then a palmitic acid salt, which
was prepared from the reaction of tetrabutylammonium salt, corresponding carboxylic acid
and base, was applied for the nucleophilic substitution of the alkylbromide.
Although this hydrobromin approach provides glycolipids with high regioselectivity in the acylation part, the total synthesis of these compounds starting from common
starting materials such as

D-glucose

and D-galactose requires an extended multi-step syn-

thesis compare to other approaches. In addition, the selectivity and yields of some of the
reactions (especially with regards to the epoxide formation) needs to be improved.

Scheme 1. 32 Synthesis of Streptococcus pneumonia Glc-DAG-s
In 2017, Sodeoka and Hirai reported the synthesis of GlcADG containing polyunsaturated fatty acids (PUFAs), which includes α-linolenic acid (α-Lin, 18:3(n-3)) in sn-1,
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palmitic acid in sn-2 and a carboxylic acid functionality in the sugar moiety.183 This synthesis, shown in Scheme 1.33, represents the first synthesis of GlcADG bearing a PUFA.
They explained that due to the poor stability of the oxocarbenium ion intermediate bearing
an electron-withdrawing ester functionality at the C-6 position, and also weak reactivity of
glycosyl acceptor because of the presence of two acyl electron-withdrawing functionalities,
3,4-dimethoxybenzyl (DMPM) protecting groups were applied to increase the stability of
oxocarbenium ion intermediate and enhance the α-selectivity of the glycosylation.
The commercially available(S)-2,2-dimethyl-1,3-dioxolane-4-methanol was used
for the synthesis of the glycosyl acceptor 1220. The two hydroxyl groups were regioselectively acylated by α-linolenic and palmitic acids. In parallel, the glucuronide donor bearing
the DMPM protecting group was synthesized, starting from compound 1217, which then
was selectively protected by DMTr group using DMTrCl in pyridine, then the rest of hydroxyl groups were protected by DMPMCl in the presence of NaH and TBAI in DMF. The
DMTr were removed by 80% acetic acid in the water and oxidized using TEMPO and
bis(acetoxy)iodobenzene and finally, esterification of carboxylic acid with DMPMOH in
the presence of COMU and DMAP afforded thioglucuronide donor 1219. The glycosyl
acceptor and donor were then subjected to glycosylation reactions in the presence of methyl
triflate as an activator. The result showed poor yield and weak selectivity with a 1.5:1 α:β
ratio, this result expected in glycosylation of a thioglucuronide donor with a less reactive
acceptor bearing two acyl withdrawing groups. As a result, it seems necessary to have a
highly reactive glycosyl acceptor to get high selectivity during the formation of the α-glucuronide product.
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Scheme 1. 33 Synthesis of compound 1221
The authors tried to optimize the reaction by changing the functionality at the anomeric position. They replaced the thioethyl functionality with ortho-alkynylbenzoates in
two subsequent steps: hydrolysis of thioethyl, followed by the installation of ortho-alkynylbenzoates at the anomeric position using ortho-alkynylbenzoic acid, COMU, DMAP,
i-Pr2NEt in CH2Cl2 as shown in Scheme 1.34. In this case the glycosylation between glycosyl acceptor 1220 and glycosyl donor 1224 was performed using Ph3PAuNTf2 as an activator. The result indicated a slightly better yield, and α selectivity improved to a 4:1 α:β
ratio. It is worth mentioning that these two anomers were separated by HPLC. They reported the presence of 1,6-lactone 1225 and 3,6-lactone 1226 as byproducts.
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Scheme 1. 34 Synthesis of compound 1227
The authors postulated that the formation of byproduct 1225 occurs through the
formation of intermediate 1228 in Scheme 1.35. First, the sugar moiety inverts, then, the
carbonyl oxygen in the C-6 position attacks to the cationic carbon at the anomeric position.
Consequently, byproduct 1225 is formed by the release of the DMPM group. In the case
of byproduct 1226, intermediate 1228 was subjected to the nucleophilic attack of the oxygen at the C-3 position to afford intermediate 1229. Then, the DMPM protecting group at
the C-6 position was removed and the nucleophilic attack of O1 to the benzylic carbon of
the DMPM group on the C-3 position provides byproduct 1226.
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Scheme 1. 35 Formation of compounds 1225, 1226 and 1227a through intermediates
1228 and 1229
With the glycosylation complete, the final product 1227 was obtained by removal
of the DMPM groups using TFA and anisole in 67% yield. The glycosyl donor (orthoalkynylbenzoates), protecting group (DMPM), and a gold catalyst for the activation of glycosyl donor (which are not very common in carbohydrate glycosylation chemistry) were
used in this modified synthesis. However, it did not afford efficient results in either productivity or selectivity. This report shows that exploring a more convenient route for the synthesis of these glucuronosyl-diacylglycerol lipids seems to be necessary.
1.2.4.2 Synthesis of disaccharide glycerol-based glycolipids
There are not many syntheses of the diglycosyl diglyceride glycolipids previously
reported in the literature. In 1985 Boom and coworkers reported the first synthesis of 2,1α linked glucose-glucose disaccharide and the second synthesis of diglycosyl diglyceride
glycolipids.184 They prepared phosphatidyl-α-diglucosyl using compound 1180 as glycosyl
acceptor in Scheme 1.36 as a starting material, which was previously synthesized by the
same group.185 The oxygens at the C-4 and C-6 positions were protected via a cyclic silicon
protecting group using TIPSCl, after which selective glycosylation was performed using
bromoglycosyl donor 1231, TBAB and DIPEA. Consequently, disaccharide 1233 was revealed by the removal of the TIPS and benzyl protecting group via tetrabutylammonium
fluoride and hydrogenation, respectively.
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Scheme 1. 36 The first synthesis of 2,1-α linked disaccharide 1233
In 1992, Kusumoto reported the synthesis of the same molecule, 1233, in the synthesis of Streptococcus Pyogenes LTA.186 Their approach is quite lengthy and required further manipulation. They synthesized glycosyl donor 1237 using O-diisopropylidine glucose as the starting material. This compound was benzylated, followed by an allylation at
the anomeric position with allyl alcohol and HCl. This reaction gave the desired product
1235 in a 3:1 α:β ratio. The oxygens at C-6 and C-4 carbons were protected with a benzylidene protecting group and then a hydroxyl group at C-2 position was blocked with an
NPM group using NPMBr and Ag2O. The anomeric allyl group was first removed via an
iridium complex then acetylated, finally, fluorination using HF.Py afforded compound
1233.
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The glucosyl acceptor 1228 was used, bearing allyl groups to prevent acyl migration during the acidic glycosylation. The alcohol was then converted to an OTMS and subjected to the first glycosylation with glycosyl donor 1237 using TMSOTf as an activator to
afford the desired product 1239 in 3 to 1 α:β ratio. The allyl groups in the glycerol moiety
were converted to acyl groups in three subsequent steps. First the allyl groups were isomerized, then hydrolyzed to free alcohols, and finally acylated afforded compound 1240. To
generate glycosyl acceptor 1242, the NPM protecting group was removed via a three-step
procedure. The first nitro group was reduced to an amine using a mixture of zinc and copper
and acylated in the presence of acetylacetone. With the amine functionality acetylated, the
acetamido benzyl protecting group was then removed via oxidative cleavage using DDQ
as shown in Scheme 1.37.

Scheme 1. 37 Synthesis of glycosyl acceptor 1242
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The glycosyl donor 1244 was prepared using compound 1236 as a starting material
as shown in Scheme 1.38. The 2-hydroxyl group was benzylated, then a benzylidine protecting group was selectively removed and the C-6 hydroxyl group was blocked with a
Troc protecting group. The allyl group at the anomeric position was replaced with fluorine
in two subsequent steps. First, hydrolysis of the allyl functionality, then fluorination using
FMPT and triethylamine. The last glycosylation was performed between glycosyl donor
1244 and glycosyl acceptor 1242 to afford desired compound 1245 in a 3 to 1 α:β ratio.
Compound 1245 was then deprotected using zinc in acetic acid to remove the Troc group,
followed by a benzyl deprotection to provide glycolipid diglycosyl diglyceride 1246. However, the result did not show any antitumor activity or any production of cytokines such as
TNF or IL-6.

Scheme 1. 38 Synthesis of Streptococcus Pyogenes LTA
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Recently, Imamura and Ishida reported the synthesis of α-diglycosyl diglyceride
1262 bearing an unsaturated fatty chain in a glyceride moiety using the cyclic silyl protecting group strategy that we discussed previously to achieve the desired selectivity for the
glycosylation procedure.187 This approach is distinct from the previous reported α-diglycosyl diglyceride synthesis. Their synthetic design involves using the isopropylidene protected glyceride moiety as a glycosyl acceptor, and the fatty acid chains are then selectively
added by acylation at the end of the synthesis. Cyclic silyl protecting groups were exploited
to improve α-selectivity of glycosylation.
The first attempt to produce glycosyl acceptor gave a low yield due to the generation of byproduct 1255 (Scheme 1.39). They start by manipulating protecting groups and
finally applying the naphthyl methyl (Nap) group to protect the 2-hydroxyl functionality.
At this point the glycosylation was performed but the result showed the oxocarbenium ion
promotes a Friedel-Crafts reaction with 2-naphthyl methyl functionality resulting in the
formation of byproduct 1255.
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Scheme 1. 39 Synthesis of compound 1254 and byproduct 1255
After the first synthesis was found unacceptable, compound 1258 was prepared
based on known procedure. In this protocol the C-4 and C-6 hydroxyl groups were first
protected by the DTBS protecting group using DTBS(OTf)2 and 2,6-lutidine in DMF. The
3-hydroxyl group was then selectively protected via the benzyl group followed by acetal
formation using n-Bu2SnO in toluene and finally, a benzylation using benzyl bromide and
TBAB in toluene afforded glycosyl donor 1258 in two steps.

Scheme 1. 40 Synthesis of glycosyl acceptor 1258
The second glycosylation was performed using the glycosyl acceptor 1258 and the
known 4,6-O-DTBS–protected glucosyl donor 1259,188 using NIS and TfOH as activators
to obtain the desired disaccharyl glycerol 38 in an 8 to 1 α:β ratio (Scheme 1.41). Due to
complications of removing the benzyl protecting group in the presence of an unsaturated
fatty chain in the last step, they had to replace the benzyl groups with monochloroacetyl
protecting groups. This procedure was done in two stages. First, hydrogenation of the benzyl groups afforded free hydroxyl groups, then monochloroacetylation was performed using monochloroacetic anhydride and DMAP.
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The target compound 1262 was revealed in three steps, initially removal of the isopropylidene protecting group was done using trifluoroacetic acid. Then, selective acylation
of sn-1 with cis-13-octadecenoic acid and the second acylation of sn-2 was performed using palmitic acid, DCC and DMAP. The final α-diglycosyl diglyceride 1262 was obtained
via deprotection using 1-selenocarbamoylpiperidine and tributylamine hydrofluoride to remove the monochloroacetyl and DTBS groups, respectively.

Scheme 1. 41 Synthesis of α-diglycosyl diglyceride 1262
Although, the approach previously discussed above could be a convenient route for
the synthesis of disaccharyl glycerol glycolipids bearing 1-2-O-α-linkage between two
sugar moieties, this is an extended multi-step synthesis, and a reduction in the reduced
number of synthetic steps seemed to be required for this synthetic route to be viable. The
1-2-α-linkage between the two sugar moieties and the presence of an unsaturated acyl chain
makes the synthesis of disaccharyl glycerol glycolipids difficult. This is mainly due to the
excessive manipulation of protecting groups needed in both sugar moieties and two stereoselective glycosylation strategies required, which is one of the most challenging procedures in carbohydrate chemistry.184 Despite the increasing number of isolated disaccharyl
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glycerol glycolipids from natural sources,189, 190 only a few synthetically prepared derivatives of these glycolipids have been synthesized to date. As a result, a general and efficient
methodology for the preparation of synthetic disaccharyl glycerol glycolipids seems to be
required to allow for the biological examination of their properties in activation of immune
system.

1.3 Tertbutyl amine as a mild and effective for the selective deacetylation
There are many approaches for protecting hydroxyl group in organic synthesis.
However, esters have emerged as the preferred option because of the diversity of ester
choices, for example: acetate, benzoate, pivaloate, and also the convenience of installation
and removal under mild conditions.191 Acetate esters in particular are commonly used to
protect hydroxyl groups in organic chemistry due to the availability of simple reactions for
attachment and removal of this protecting group. Many reagents and reaction conditions
can facilitate the removal of this protecting group, allowing chemists to optimize the deprotection of a wide range of organic compounds. During the past decades, more attention was
paid to the selective removal of the acetate functionality than any other protecting group.
This functionality often needs to be deprotected in different steps of a synthesis to prevent
having any conflict in protecting and deprotecting strategies.192 Many attempts have been
made to develop reactions that selectively remove acetate esters in the presence of other
ester functionalities. For example, DBU in benzene has been reported to remove the acetate
group selectively in the presence of a benzoate group. Furthermore, Guanidine193 or magnesium methoxide194 have both been used to deprotect acetate groups in the presence of
benzoates, pivaloates, and acetamides. In addition, ammonia,195 hydrazine,196 and Mg
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metal in methanol are also the reagents found capable of removing acetate groups in the
presence of other esters.197
The selective deprotection of the ester group in the presence of the same type of
esters is the other important subject in carbohydrate chemistry. It has great potential to be
beneficial in complex syntheses by reducing the step counts for the protection processes.
Primary, secondary, and tertiary acetates can be differentiated based on steric and electronic properties and thus can be selectively removed by proper choice of reagent. In carbohydrate chemistry, this process is more complicated because of the unique structure of
carbohydrates, which can contain primary alcohols and a number of distinct secondary alcohols. Other than enzymes,198 which are well known to be selective towards the cleavage
of ester groups, BF3•OEt2199 and Bu3SnOMe200 are chemical reagents that have been used
to selectively remove acetates at the anomeric position in the presence of other acetates.
Aluminum oxide,201potassium carbonate,202 potassium cyanide203and potassium hydroxide204 have all shown the ability to selectively deacetylate primary alcohols.191
Johns and Jerina reported the selective hydrolysis of steroidal acetates in 1963.201
The primary acetate in 1263 was selectively deacetylated in the presence of a secondary
acetate, using alumina in benzene, in moderate yield (Scheme 1.42a). In a second example,
8 years later, Hirata and Yamamura reported the synthesis of Shyobunone and Sesquiterpene derivatives.204 In their report 5% KOH in methanol was applied for the selective
deprotection of a primary acetate in the presence of a secondary acetate and gave a successful result with 88% yield (Scheme 1.42b).
In the synthesis of Eldanolide, Schmidt reported the removal of primary acetates in the
presence of a tertiary acetate.202 Schmidt exploited a methanolic solution of K2CO3 for the
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selective deacetylation of the primary hydroxyl group in excellent yield (Scheme 1.42c).
The selective deprotection of the primary acetyl group in the previous two examples
seemed to garner their selectivity from the steric and electronic effects which make the
primary acetate more reactive than the secondary acetate. In contrast, the relative stability
of the acetate protecting group in carbohydrates are mostly based on the geometry and
acidity of the masked hydroxyl groups.

Scheme 1. 42a,b,c Selective hydrolysis of steroidal acetates, a, selective deprotection of
a primary acetate in the synthesis of Shyobunone, b, and selective removal of primary acetates in the presence of a tertiary acetate, c
In 1979 Ishido and coworkers reported regioselective deacetylation of acetylated Purine and pyrimidine ribonucleosides using hydrazine hydrate.196 This study showed
that hydrazine hydrate reacts first with the 2΄-O-acetyl group, then the acetyl group at the
C-3 position and lastly, the acetyl group at C-5 (Scheme 1. 43a). They rationalized that the
hydroxyl group at the C-2 position, after acetyl deprotection, could interact with the C-3
acetyl group which may explain the rate enhancement of the C-3 compared to the C-5
acetyl deprotection. In order to eliminate this effect, they investigated compound 1272
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without a C-2 substitution (Scheme 1. 43b). The deprotection procedure showed that the
C-3 acetate group is deprotected faster than C-5 with or without C-2 participation. This
result showed presence of C-2 does not affect in rate of deprotection of C-3 versus C-5.

Scheme 1. 43a,b Regioselective deacetylation rate of acetylated compounds 1269 and
1272
In the next experiment, they applied N- 6,2΄,5΄-triacetyl-3΄-O-methyl- 1275 and N6,3΄,5΄-triacetyl-2΄-O-mehtyladenosine 1277 to evaluate the reactivity of 2΄-O-acetyl group
compared to 3΄-O-acetyl group deacetylation (Scheme 1.44). These experiments were performed in the presence of hydrazine hydrate in a mixture of pyridine and acetic acid. The
results indicated that 2΄-O-acetyl group is far more reactive than the 3΄-O-acetyl functionality, as the 2΄-O-acetyl was deprotected with 2.2eq. in 2 days and 74% yield, whereas the
3΄-O-acetyl group was removed with 3.3 eq. of hydrazine in 8 days and 44% yield.
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Scheme 1. 44 Selective deacetylation of N- 6,2΄,5΄-triacetyl-3΄-O-methyl- 1275 and N6,3΄,5΄-triacetyl-2΄-O-mehtyladenosine 1277
Robins tried the selective deacetylation of the 2′- and 3′-O-Acyl groups from
2′,3′,5′-Tri-O-acylribonucleoside derivatives using two separate procedures, both Dowex
(CF3CH2O-) in 2,2,2-trifluoroethanol (TFE) and lithium trifluoroethoxide in TFE (Scheme
1.45).205 The experiments afforded the 5′-O-acyl derivatives in high yields and purity, especially using the latter set of conditions. This research illustrated a mild and rapid procedure for selective deacetylation that can tolerate a fused furan ring in furo[2,3-d]pyrimidin2(3H)-one derivative, an amino group and a double bond in pyrimidines as well as the 6(imidazol-1-yl) group in purines, because of the low nucleophilicity of CF3CH2O ̶ ion.
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Scheme 1. 45 Selective deacetylation of the 2′- and 3′-O-Acyl groups from compound
1279 using two separate procedures
It is important to mention a couple gaps in the literature at this point. First, the
selective deprotection of the acetyl group in pyranosyl carbohydrate moieties are rarely
investigated. Second, a reliable method does not exist for controlling the selective deprotection of acetate protecting group in the presence of alkyl acetates group of different
lengths.

1.4 Non-biomedical application of carbohydrates, as facilitating agent
for green solubility and degradability
This section highlights the potential application of carbohydrates outside of the biomedical applications discussed. It is related to the research reported in Chapter 7. This
technology and the devices created from them have become critical in many aspects of our
lives including healthcare, communications, entertainment, and manufacturing.206 Faster
than ever, electronic products are being updated, upgraded, and replaced as the lifetime of
these devices become shorter and shorter. This planned obsolescence has led to a growing
surplus of electronic waste around the world which has had a substantial environmental
impact.207
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Recycling is a difficult and expensive process, and as a result, most of these toxic
materials are being deposited directly into landfills. The United Nations estimates that 50
million metric tons of electronic waste is discarded worldwide each year.208 Further, the
Environmental Protection Agency estimates that only 15%-20% of electronic waste is recycled.208 The remainder of that waste ends up in traditional landfilling which may result
in leaching of toxic components of electronic waste, such as lead, mercury, and cadmium,
into the ground water.208 It is clear, that there is an imperative to develop more environmentally friendly materials to be used in these products.
Green chemistry offers us the tools needed to build a sustainable industrial process.
In 1997, Paul Anastas and John Warner defined green chemistry as the design of chemical
products and processes that reduce or eliminate the use or generation of hazardous substances.209 Green chemistry has 12 principles which include the following:
prevention;
atom economy;
less hazardous chemical syntheses;
designing safer chemicals;
safer solvents and auxiliaries;
design for energy efficiency;
use of renewable feedstocks;
reduce derivatives;
catalysis;
design for degradation;
real-time analysis for pollution prevention;
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and inherently safer chemistry for accident prevention. 2
The development of economically feasible and ecologically benign alternatives to
traditional synthetic reactions is highly desirable.210 From an industrial perspective, the
interest in a green chemistry approach include the public relations benefits of being labeled
as a “green” company, lower production costs by using fewer materials, lower waste costs
due to less waste being processed and decreased toxicity in the waste streams produced. In
this regard, the application of green chemistry for the development of low-waste and energy efficient synthetic approaches to organic electronic synthesis is advantageous.
To address the environmental issues associated with the ever-growing problem of
electronic waste, degradable, organic electronic materials have been gaining interest for
many low-cost applications.211 Biodegradable electronics, which are electronic devices
manufactured with biocompatible and biodegradable materials, are in high demand due to
their positive financial and environmental aspects.208 They have several advantageous
qualities including their environmental safety, nontoxicity, low cost, which can obtained
in large scale, and ease of disposal compared to traditional silicon-based electronics.208 The
degradability is crucial for eliminating hazardous waste products as well as the associated
health risks and costs associated with recycling operations.208 Additionally, biodegradable
electronics can be used in implantable biomedical applications.208 Their use enables the
electronic devices to be completely or partially absorbed into and excreted from the body
after functioning under physiological conditions.208
Conjugated polymers, which are based on alternating electron donor-acceptor units,
have gained interest in the field of organic electronics.212 Specifically, diketopyrrolopyrole

95

(DPP)-based polymers are good candidates for use in degradable technologies. This polymer is environmentally benign and is known for its favourable charge carrier properties.
Diketopyrrolopyrole (DPP)-based polymers show high charge carrier mobility in organic
field-effect transistors (OFETs).212 This is due to the coplanar nature of the conjugated
backbone, short-contact oxygen-sulfur interactions, and cross-axis dipoles which result in
strong intermolecular pi bonding interactions and therefore long-range order.208 The rigid
polymer backbones, high molecular weights, and strong aggregation properties of conjugated polymers is essential for good charge transport. However, these properties result in
challenges in regard to the dissolution of high-mobility polymers for organic field-effect
transistors (OFETs).213 The conjugated polymers exhibit strong intermolecular interactions, which cause large free volume dissimilarity between polymer and solvent molecules
and the free energy change of solvation is less negative.213 It is therefore clear that improving the solubility properties of (DPP)-based polymers, while maintaining the properties
which make them good charge transporters, is a worthwhile goal that will lead to the creation of polymers which are ideal candidates for use in degradable electronics.
When evaluating the environmental performance of a chemical processes, solvents
have a major impact on cost, safety, and health issues. Furthermore, solvents are a major
input in the synthetic processes and typically comprise the largest fraction of waste generated.210 Traditional solvents account for most of the mass wasted in synthetic and industrial
processes and many common solvents are toxic, flammable, or corrosive.214 Often, the
large volumes of solvents used are not directly responsible for the composition of a reaction
product, nor are they an active component of a formulation.214 Therefore, the use of environmentally damaging solvents, which have no impact on the function or progress of the
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system, seems unnecessary. When possible, even the recovery and reuse of these solvents
is associated with energy-intensive distillation which creates unwanted air emissions and
the safety risks associated with worker exposure.209 The concept of green solvents is intrinsically linked to the principles of green chemistry. Introducing a green solvent to a
chemical process provides a large reduction of the environmental impact of said processes.214 These solvents, which are bio-sourced and non-toxic, are derived from renewable
feedstock and the processing of agricultural crops. To be useful these solvents must be
capable of replacing traditional solvents for use in extractions, separations, formulations,
and reaction chemistry.214 Environmentally preferable solvents can be determined by the
GSK Solvent Selection Guide.215 The greenest option for solvents is, of course, water. The
saccharide-containing backbone with hydroxyl functionality inserted into the modified
conjugated polymers makes them soluble in water.
The ever-increasing need for non-toxic and environmentally friendly electronic devices is evident in our world. The field of green chemistry, including organic electronics
and green solvents, allows us the opportunity to utilize sustainable processes and biosourced materials to minimize the environmental impact at each stage of the product lifecycle.

1.5 Summary
This thesis focuses on the application of novel synthesis for accessing carbohydrates for diverse applications. The focus is entirely on the use of the end-goal carbohydrates, target-oriented synthesis; however, this provides an extremely useful platform for
conducting discovery research as we shall see in the coming chapters. Carbohydrates have
been underexplored in immunoregulation and materials science, and this work aims to help
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the global refocus on these extremely diverse, useful, yet synthetically challenging biomolecules as they offer new solutions to longstanding challenges to society.

98

Reference
1.
Brandley, B. K.; Schnaar, R. L., Cell-surface carbohydrates in cell recognition and
response. J. Leukoc. Biol. 1986, 40, 97-111.
2.
Fernández‐Tejada, A.; Cañada, F. J.; Jiménez‐Barbero, J., Glycans in medicinal
chemistry: An underexploited resource. ChemMedChem 2015, 10, 1291-1295.
3.
Ma, X.; Yu, H., Cancer issue: global burden of cancer. Yale J Biol Med 2006, 79,
85.
4.
Coley, W. B., The treatment of malignant tumors by repeated inoculations of
erysipelas: With a report of ten original cases. 1. Am. J. Med. Sci. 1893, 105, 487.
5.
Dougan, M.; Dranoff, G., Immunotherapy of cancer. In Innate immune regulation
and cancer immunotherapy, R., W., Ed. Springer: New York, NY, 2012; 391-414.
6.
Weiner, L. M.; Surana, R.; Wang, S., Monoclonal antibodies: versatile platforms
for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10, 317-27.
7.
Feng, D.; Shaikh, A. S.; Wang, F., Recent advance in tumor-associated
carbohydrate antigens (TACAs)-based antitumor vaccines. ACS Chem. Biol. 2016, 11,
850-863.
8.
Krüger, C.; Greten, T.; Korangy, F.; histopathology, Immune based therapies in
cancer. J. Med. Histol 2007.
9.
Davidson, B.; Berner, A.; Nesland, J. M.; Risberg, B.; Kristensen, G. B.; Trope,
C. G.; Bryne, M., Carbohydrate antigen expression in primary tumors, metastatic lesions,
and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence
of up-regulated Tn and Sialyl Tn antigen expression in effusions. Hum. Pathol. 2000, 31,
1081-7.
10.
Durrant, L.; Noble, P.; Spendlove, I., Immunology in the clinic review series; focus
on cancer: glycolipids as targets for tumour immunotherapy. Clin Exp Immunol 2012, 167,
206.
11.
Gonzalez-Aseguinolaza, G.; Van Kaer, L.; Bergmann, C. C.; Wilson, J. M.;
Schmieg, J.; Kronenberg, M.; Nakayama, T.; Taniguchi, M.; Koezuka, Y.; Tsuji, M.,
Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity
induced by malaria vaccines. J. Exp. Med. 2002, 195, 617-24.
12.
Kamijuku, H.; Nagata, Y.; Jiang, X.; Ichinohe, T.; Tashiro, T.; Mori, K.;
Taniguchi, M.; Hase, K.; Ohno, H.; Shimaoka, T., Mechanism of NKT cell activation by
intranasal coadministration of α-galactosylceramide, which can induce cross-protection
against influenza viruses. Mucosal Immunol. 2008, 1, 208-218.
13.
Youn, H.-J.; Ko, S.-Y.; Lee, K.-A.; Ko, H.-J.; Lee, Y.-S.; Fujihashi, K.; Boyaka,
P. N.; Kim, S.-H.; Horimoto, T.; Kweon, M.-N., A single intranasal immunization with
inactivated influenza virus and α-galactosylceramide induces long-term protective
immunity without redirecting antigen to the central nervous system. Vaccine 2007, 25,
5189-5198.
14.
Kopecky-Bromberg, S. A.; Fraser, K. A.; Pica, N.; Carnero, E.; Moran, T. M.;
Franck, R. W.; Tsuji, M.; Palese, P., Alpha-C-galactosylceramide as an adjuvant for a live
attenuated influenza virus vaccine. Vaccine 2009, 27, 3766-3774.
15.
Kobayashi, E.; Motoki, K.; Uchida, T.; Fukushima, H.; Koezuka, Y., KRN7000,
a novel immunomodulator, and its antitumor activities. Oncol. Res. 1995, 7, 529-34.
99

16.
Birkholz, A. M.; Kronenberg, M., Antigen specificity of invariant natural killer Tcells. Biomed J 2015, 38, 470-83.
17.
Hanahan, D.; Weinberg, R. A., Hallmarks of cancer: the next generation. Cell 2011,
144, 646-74.
18.
Vogelstein, B.; Papadopoulos, N.; Velculescu, V. E.; Zhou, S.; Diaz, L. A., Jr.;
Kinzler, K. W., Cancer genome landscapes. Science 2013, 339, 1546-58.
19.
American Cancer Society, Society: Cancer Facts and Figures; American Cancer
Society: Atlanta, USA,. 2016.
20.
Canadian Cancer Society's Advisory Committee on Cancer Statistics; Canadian
Cancer Society: Toronto, ON, . 2017.
21.
Mellman, I.; Coukos, G.; Dranoff, G., Cancer immunotherapy comes of age.
Nature 2011, 480, 480-9.
22.
Schumacher, T. N.; Schreiber, R. D., Neoantigens in cancer immunotherapy.
Science 2015, 348, 69-74.
23.
Arteaga, C. L.; Sliwkowski, M. X.; Osborne, C. K.; Perez, E. A.; Puglisi, F.;
Gianni, L., Treatment of HER2-positive breast cancer: current status and future
perspectives. Nat. Rev 2012, 9, 16-32.
24.
Karantanos, T.; Corn, P. G.; Thompson, T. C., Prostate cancer progression after
androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic
approaches. Oncogene 2013, 32, 5501-11.
25.
Feng, D.; Shaikh, A. S.; Wang, F., Recent Advance in Tumor-associated
Carbohydrate Antigens (TACAs)-based Antitumor Vaccines. ACS Chem. Biol. 2016, 11,
850-63.
26.
Liu, C. C.; Ye, X. S., Carbohydrate-based cancer vaccines: target cancer with sugar
bullets. Glycoconj. J. 2012, 29, 259-71.
27.
Laurent, G. J.; Shapiro, S. D., Encyclopedia of respiratory medicine. Academic
Press: 2006; 3.
28.
Singhal, A.; Fohn, M.; Hakomori, S., Induction of alpha-N-acetylgalactosamineO-serine/threonine (Tn) antigen-mediated cellular immune response for active
immunotherapy in mice. Cancer Res. 1991, 51, 1406-11.
29.
Chen, H.-L., Lewis glyco-epitopes: structure, biosynthesis, and functions. In Adv.
Exp. Med. Biol., Wu, A. M., Ed. Springer: New York, 2011; 705, 53-80.
30.
Ritter, G.; Livingston, P. O., Ganglioside antigens expressed by human cancer cells.
Semin. Cancer Biol. 1991, 2, 401-9.
31.
Birklé, S.; Zeng, G.; Gao, L.; Yu, R. K.; Aubry, J., Role of tumor-associated
gangliosides in cancer progression. Biochimie 2003, 85, 455-463.
32.
Hakomori, S.-i., Tumor-associated carbohydrate antigens defining tumor
malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 2001,
491, 369-402.
33.
Kaifu, R.; Osawa, T., Synthesis of O-(2-acetamido-2-deoxy-α-Dgalactopyranosyl)-N-tosyl-L-serine. Carbohydr. Res. 1977, 58, 235-239.
34.
Annison, E. F.; James, A. T.; Morgan, W. T., The separation and identification of
small amounts of mixed amino sugars. Biochem J 1951, 48, 477-82.
35.
Ju, T.; Otto, V. I.; Cummings, R. D., The Tn antigen—Structural simplicity and
biological complexity. Angew. Chem. Int. Ed. 2011, 50, 1770-1791.

100

36.
Paris, S. M. d. H. d., Bulletins et mémoires de la Société médicale des hôpitaux de
Paris. Masson: 1867; 3.
37.
Dahr, W.; Uhlenbruck, G.; Gunson, H. H.; Van Der Hart, M., Molecular basis of
Tn-polyagglutinability. Vox Sang. 1975, 29, 36-50.
38.
Springer, G.; GF, S., Blood group MN specific substances and precursors in normal
and malignant human breast tissues. J. Natl. Cancer Inst. 1975, 54, 335-339.
39.
Costa, C.; Pereira, S.; Lima, L.; Peixoto, A.; Fernandes, E.; Neves, D.; Neves,
M.; Gaiteiro, C.; Tavares, A.; Gil da Costa, R. M.; Cruz, R.; Amaro, T.; Oliveira, P.
A.; Ferreira, J. A.; Santos, L. L., Abnormal Protein Glycosylation and Activated
PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
PLoS One 2015, 10, e0141253.
40.
Hirao, T.; Sakamoto, Y.; Kamada, M.; Hamada, S.; Aono, T., Tn antigen, a marker
of potential for metastasis of uterine cervix cancer cells. Cancer 1993, 72, 154-9.
41.
Terasawa, K.; Furumoto, H.; Kamada, M.; Aono, T., Expression of Tn and sialylTn antigens in the neoplastic transformation of uterine cervical epithelial cells. Cancer Res.
1996, 56, 2229-32.
42.
Itzkowitz, S. H.; Yuan, M.; Montgomery, C. K.; Kjeldsen, T.; Takahashi, H. K.;
Bigbee, W. L.; Kim, Y. S., Expression of Tn, sialosyl-Tn, and T antigens in human colon
cancer. Cancer Res. 1989, 49, 197-204.
43.
Byrd, J. C.; Bresalier, R. S., Mucins and mucin binding proteins in colorectal
cancer. Cancer Metastasis Rev. 2004, 23, 77-99.
44.
Lopez-Ferrer, A.; Barranco, C.; de Bolós, C., Differences in the O-glycosylation
patterns between lung squamous cell carcinoma and adenocarcinoma. Am. J. Clin. Pathol.
2002, 118, 749-755.
45.
Ohshio, G.; Imamura, T.; Imamura, M.; Yamabe, H.; Sakahara, H.; Nakada, H.;
Yamashina, I., Distribution of Tn antigen recognized by an anti-Tn monoclonal antibody
(MLS128) in normal and malignant tissues of the digestive tract. J Cancer Res Clin Oncol
1995, 121, 247-52.
46.
Remmers, N.; Anderson, J. M.; Linde, E. M.; DiMaio, D. J.; Lazenby, A. J.;
Wandall, H. H.; Mandel, U.; Clausen, H.; Yu, F.; Hollingsworth, M. A., Aberrant
expression of mucin core proteins and o-linked glycans associated with progression of
pancreatic cancer. Clin Cancer Res 2013, 19, 1981-93.
47.
Zhang, S.; Zhang, H. S.; Reuter, V. E.; Slovin, S. F.; Scher, H. I.; Livingston, P.
O., Expression of potential target antigens for immunotherapy on primary and metastatic
prostate cancers. Clin Cancer Res 1998, 4, 295-302.
48.
Fu, C.; Zhao, H.; Wang, Y.; Cai, H.; Xiao, Y.; Zeng, Y.; Chen, H., Tumorassociated antigens: Tn antigen, sTn antigen, and T antigen. HLA 2016, 88, 275-286.
49.
Paulsen, H.; Kolar, C.; Stenzel, W., Synthesis of alpha-glycosidically linked
disaccharides of D-galactosamine. Angew Chem Int Ed Engl 1976, 15, 440-1.
50.
Paulsen, H.; Kolář, Č.; Stenzel, W., Synthese α‐glycosidisch verknüpfter
disaccharide des d‐galactosamins. Angew. Chem. 1976, 88, 478-478.
51.
Ferrari, B.; Paviat, A. A., The synthesis of derivatives of 3-O-(2-acetamido-2deoxy-α-d-galacto-pyranosyl)-L-serine and-L-threonine. Carbohydr. Res. 1980, 79, C1C7.

101

52.
Thomsen, O., Ein vermehrungsfähiges agens als veränderer des
isooagglutinotorischen verhaltens der roten blutkörperchen, eine bisher unbekannte quelle
der fehlbestimmung. Z. Immun.-Forsch 1927, 52, 85.
53.
Hübener, G., Untersuchungen über Isoagglutination mit besonderer
berücksichtigung scheinbarer abweichungen vom gruppenschema. Zeitschrift für
Immunitate. Forschung 1926, 45, 223-226.
54.
Kim, Z.; Uhlenbruck, G., [Studies on the T-antigen and T-agglutinin]. Z.
Immunitatsforsch. Allerg. Klin. Immunol. 1966, 130, 88-99.
55.
Newlaczyl, A. U.; Yu, L.-G., Galectin-3–a jack-of-all-trades in cancer. Cancer Lett.
2011, 313, 123-128.
56.
Karsten, U.; Goletz, S. J. B., What controls the expression of the core-1
(Thomsen—Friedenreich) glycotope on tumor cells? J. Biochem 2015, 80, 801-807.
57.
Kaifu, R.; Osawa, T., Syntheses of O-β-D-galactopyranosyl-(1→ 3)-O-(2acetamido-2-deoxy-α (and-β)-d-galactopyranosyl)-N-tosyl-l-serine and their interaction
with d-galactose-binding lectins. Carbohydr. Res. 1979, 69, 79-88.
58.
Ratcliffe, R.; Baker, D.; Lemieux, R., Synthesis of the T-antigenic determinant in
a form useful for the preparation of an effective artificial antigen and the corresponding
immunoabsorbent. Carbohydr. Res. 1981, 93, 35-41.
59.
Paulsen, H.; Hölck, J.-P., Synthese der glycopeptide O-β-d-galactopyranosyl-(1→
3)-O-(2-acetamido-2-desoxy-α-d-galactopyranosyl)-(1→
3)-l-serin
und-l-threonin.
Carbohydrate Res 1982, 109, 89-107.
60.
Apostolopoulos, V.; Chelvanayagam, G.; Xing, P. X.; McKenzie, I. F., AntiMUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA
molecules. J. Immunol. 1998, 161, 767-75.
61.
Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Stern, L. J.; Urban, R. G.;
Strominger, J. L.; Wiley, D. C., Three-dimensional structure of the human class II
histocompatibility antigen HLA-DR1. Nature 1993, 364, 33-9.
62.
Wilson, R. M.; Danishefsky, S. J., A vision for vaccines built from fully synthetic
tumor-associated antigens: from the laboratory to the clinic. J. Am. Chem. Soc. 2013, 135,
14462-72.
63.
Zhu, J.; Wan, Q.; Lee, D.; Yang, G.; Spassova, M. K.; Ouerfelli, O.; Ragupathi,
G.; Damani, P.; Livingston, P. O.; Danishefsky, S. J., From synthesis to biologics:
preclinical data on a chemistry derived anticancer vaccine. J. Am. Chem. Soc. 2009, 131,
9298-303.
64.
Ingale, S.; Wolfert, M. A.; Gaekwad, J.; Buskas, T.; Boons, G. J., Robust immune
responses elicited by a fully synthetic three-component vaccine. Nat. Chem. Biol. 2007, 3,
663-7.
65.
Bonten, E. J.; Annunziata, I.; d'Azzo, A., Lysosomal multienzyme complex: pros
and cons of working together. Cell Mol Life Sci 2014, 71, 2017-32.
66.
Awad, L.; Madani, R.; Gillig, A.; Kolympadi, M.; Philgren, M.; Muhs, A.;
Gérard, C.; Vogel, P., A C‐Linked Disaccharide Analogue of Thomsen–Friedenreich
Epitope Induces a Strong Immune Response in Mice. Chem-Eur J 2012, 18, 8578.
67.
Weïwer, M.; Huang, F.; Chen, C.-C.; Yuan, X.; Tokuzaki, K.; Tomiyama, H.;
Linhardt, R. J., Synthesis and evaluation of anticancer vaccine candidates, c-glycoside
analogs of STn and PSA. ACS Publications: 2008.

102

68.
Peri, F.; Cipolla, L.; Rescigno, M.; La Ferla, B.; Nicotra, F., Synthesis and
biological evaluation of an anticancer vaccine containing the C-glycoside analogue of the
Tn epitope. Bioconjug. Chem. 2001, 12, 325-8.
69.
Astronomo, R. D.; Burton, D. R., Carbohydrate vaccines: developing sweet
solutions to sticky situations? Nat. Rev. Drug Discov. 2010, 9, 308-24.
70.
Tomalia, D. A.; Christensen, J. B.; Boas, U., Dendrimers, dendrons, and dendritic
polymers: discovery, applications, and the future. Cambridge University Press: 2012.
71.
Trant, J. F.; Jain, N.; Mazzuca, D.; McIntosh, J.; Fan, B.; Haeryfar, S. M. M.;
Lecommandoux, S.; Gillies, E. R., Synthesis, self-assembly, and immunological activity
of -galactose-functionalized dendron-lipid amphiphiles. Nanoscale 2016, 8, 1769417704.
72.
Asano, N., Azaglycomimetics: natural occurrence, biological activity, and
application. J glyc 2008, 1887.
73.
Wrodnigg, T., Sulfur Containing Glycomimetics. In Glycoscience: Chemistry and
Chemical Biology, 2nd ed.; Springer: Heidelberg, 2008; 3243-3265.
74.
Sadraei, S. I.; Reynolds, M. R.; Trant, J. F., The synthesis and biological
characterization of acetal-free mimics of the tumor-associated carbohydrate antigens. In
Advances in Carbohydrate Chemistry and Biochemistry, Elsevier: 2017; 74, 137-237.
75.
Brahmachari, G., Design for carbon–carbon bond forming reactions under ambient
conditions. RSC adv 2016, 6, 64676-64725.
76.
Levy, D. E.; Fügedi, P., The organic chemistry of sugars. CRC Press: 2005.
77.
Zou, W., C-glycosides and aza-C-glycosides as potential glycosidase and
glycosyltransferase inhibitors. Curr. Top. Med. Chem. 2005, 5, 1363-1391.
78.
Hocek, M., C-nucleosides: Synthetic strategies and biological applications. Chem.
Rev 2009, 109, 6729-6764.
79.
Taillefumier, C.; Chapleur, Y., Synthesis and Uses of exo-Glycals. Chem Rev 2004,
104, 263-92.
80.
Chapleura, Y.; Approaches, B., Exo-glycals as useful tools for anomeric
functionalization of sugars. J. Carbohydr. Chem 2014, 40, 99-117.
81.
Johnson, C. R.; Johns, B. A., Suzuki cross-coupling of carbohydrates: synthesis of
β-arylmethyl-C-glycosides and aryl-scaffolded trisaccharide mimics. Synlett 1997, 12,
1406-1408.
82.
Potuzak, J. S.; Tan, D. S., Synthesis of C1-alkyl- and acylglycals from glycals using
a B-alkyl Suzuki–Miyaura cross coupling approach. Tetrahedron Lett. 2004, 45, 17971801.
83.
Gong, H.; Sinisi, R.; Gagne, M. R., A room temperature negishi cross-coupling
approach to C-alkyl glycosides. J. Am. Chem. Soc. 2007, 129, 1908-9.
84.
Postema, M. H.; Piper, J. L.; Betts, R. L., Synthesis of stable carbohydrate
mimetics as potential glycotherapeutics. Synlett 2005, 2005, 1345-1358.
85.
Postema, M. H.; Piper, J. L.; Komanduri, V.; Liu, L., A double ring-closing
metathesis approach for the synthesis of beta-C-trisaccharides. Angew Chem Int Ed Engl
2004, 43, 2915-8.
86.
Hosomi, A.; Sakata, Y.; Sakurai, H., Highly stereoselective C-allylation of
glycopyranosides with allylsilanes catalyzed by silyl triflate or iodosilane. Tetrahedron
Lett. 1984, 25, 2383-2386.

103

87.
Hosomi, A.; Sakata, Y.; Sakurai, H., Stereoselective synthesis of 3-(Dglycopyranosyl) propenes by use of allylsilanes. Carbohydrate res 1987, 171, 223-232.
88.
Bennek, J. A.; Gray, G. R., An efficient synthesis of anhydroalditols and allylicglycosides. J. Org. Chem. 1987, 52, 892-897.
89.
Guindon, Y.; Lavallée, J.-F.; Boisvert, L.; Chabot, C.; Delorme, D.; Yoakim,
C.; Hall, D.; Lemieux, R.; Simoneau, B., Stereoselective rardical-mediated reduction and
alkylation of α-halo esters. Tetrahedron Lett. 1991, 32, 27-30.
90.
Leclere, M.; Kwok, B. K.; Wu, L. K.; Allan, D. S.; Ben, R. N., C-linked antifreeze
glycoprotein (C-AFGP) analogues as novel cryoprotectants. Bioconjugate Chem. 2011, 22,
1804-1810.
91.
Trant, J. F.; Jain, N.; Mazzuca, D. M.; McIntosh, J. T.; Fan, B.; Haeryfar, S. M.;
Lecommandoux, S.; Gillies, E. R., Synthesis, self-assembly, and immunological activity
of alpha-galactose-functionalized dendron-lipid amphiphiles. Nanoscale 2016, 8, 1769417704.
92.
Trant, J. F.; Biggs, R. A.; Capicciotti, C. J.; Ben, R. N., Developing highly active
small molecule ice recrystallization inhibitors based upon C-linked antifreeze glycoprotein
analogues. RSC adv 2013, 3, 26005-26009.
93.
Capicciotti, C. J.; Trant, J. F.; Leclere, M.; Ben, R. N., Synthesis of C-linked
triazole-containing AFGP analogues and their ability to inhibit ice recrystallization.
Bioconjugate Chem. 2011, 22, 605-616.
94.
Danishefsky, S.; Kerwin Jr, J. F., On the addition of allyltrimethylsilane to glycal
acetates. J. Org. Chem. 1982, 47, 3803-3805.
95.
Hanessian, S.; Girard, C., Facile access to 3-ulosonic acids via a SmI2-Mediated
Reformatsky reaction on aldonolactones. Synlett 1994, 1994, 865-867.
96.
Hayashi, M.; Sugiyama, M.; Toba, T.; Oguni, N., Deacyloxy-alkylation of 2acyloxy-tetrahydrofurans and -tetrahydropyrans by Reformatsky reagents. J. Am. Chem.
Soc, Chemical Comm 1990, 1990, 767-768.
97.
Urban, D.; Skrydstrup, T.; Beau, J.-M., First synthesis of a C-glycoside anologue
of a tumor-associated carbohydrate antigen employing samarium diiodide promoted Cglycosylation. Chem. Commun. 1998, 955-956.
98.
Burkhart, F.; Hoffmann, M.; Kessler, H., Stereoselective Synthesis of a CGlycosidic Analog of N‐Glucoasparagine. Angew. Chem. Int. Ed. Engl. 1997, 36, 11911192.
99.
Urban, D.; Skrydstrup, T.; Riche, C.; Chiaroni, A.; Beau, J.-M., Stereocontrolled
synthesis of α-C-galactosamine derivatives promoted by samarium diiodide: an example
of chelation controlled C-glycosylation. Chem. Commun. 1996, 1883-1884.
100. Cipolla, L.; La Ferla, B.; Lay, L.; Peri, F.; Nicotra, F., Stereoselective synthesis
of α-C-glycosides of N-acetylgalactosamine. Tetrahedron: Asymmetry 2000, 11, 295-303.
101. Cipolla, L.; Lay, L.; Nicotra, F., New and easy access to C-glycosides of
glucosamine and mannosamine. J. Org. Chem. 1997, 62, 6678-6681.
102. Giannis, A.; Sandhoff, K., Stereoselective synthesis of α- C-allylglycopyranosides. Tetrahedron Lett. 1985, 26, 1479-1482.
103. Röhrig, C. H.; Takhi, M.; Schmidt, R. R., Synthesis of a C-Glycoside Analog of
the Tumor-Associated Tn Antigen. Synlett 2001, 2001, 1170-1172.
104. Tarasiejska, Z.; Jeanloz, R. W., Acetohalogeno Derivatives and Glycosides of DGalactosamine1. J Am Cheml Soc 1958, 80, 6325-6327.
104

105. Bouvet, V. R.; Ben, R. N., A short and economical synthesis of orthogonally
protected C-linked 2-deoxy-2-acetamido-alpha-D-galactopyranose derivatives. J. Org.
Chem. 2006, 71, 3619-22.
106. Aydillo, C.; Navo, C. D.; Busto, J. H.; Corzana, F.; Zurbano, M. M.; Avenoza,
A.; Peregrina, J. M., A double diastereoselective Michael-type addition as an entry to
conformationally restricted Tn antigen mimics. J. Org. Chem. 2013, 78, 10968-10977.
107. Eisele, T.; Ishida, H.; Hummel, G.; Schmidt, R. R., Synthesis of carbon‐bridged
N‐acetyl‐c‐lactosamine and derivatives. Liebigs Ann. Recl. 1995, 1995, 2113-2121.
108. Kobertz, W. R.; Bertozzi, C. R.; Bednarski, M. D., An efficient method for the
synthesis of α-and β-C-glycosyl aldehydes. Tetrahedron Lett. 1992, 33, 737-740.
109. Zhu, Y.-H.; Vogel, P., Synthesis of a C-disaccharide analog of the ThomsenFriedenreich (T) epitope. Synlett 2001, 2001, 0079-0081.
110. Awad, L.; Riedner, J.; Vogel, P., C-linked disaccharide analogue of the ThomsenFriedenreich (T)-epitope alpha-O-conjugated to L-serine. Chemistry (Easton) 2005, 11,
3565-73.
111. Horton, D.; Roski, J. P.; Norris, P., Cycloaddition of Cyclopentadiene to 3-Deoxy1,2:5,6-di-O-isopropylidene-alpha-D-erythro-hex-3-enofuranose.
Synthesis
and
Representative Chemistry of 1,6-Anhydro-2,3-dideoxy-beta-D-glycero-hex-2-enopyran-4ulose ("Isolevoglucosenone"). J. Org. Chem. 1996, 61, 3783-3793.
112. Winchester, B. G., Lysosomal metabolism of glycoconjugates. In Biology of the
Lysosome, Lloyd J.B.; Mason, R. W., Eds. Springer: Boston, MA, 1996; 191-238.
113. Murphy, K. M.; Heimberger, A. B.; Loh, D. Y., Induction by antigen of intrathymic
apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 1990, 250, 1720-3.
114. Cipolla, L.; Rescigno, M.; Leone, A.; Peri, F.; La Ferla, B.; Nicotra, F., Novel
Tn antigen-containing neoglycopeptides: synthesis and evaluation as anti tumor vaccines.
Bioorg. Med. Chem. 2002, 10, 1639-1646.
115. Ishioka, G. Y.; Lamont, A. G.; Thomson, D.; Bulbow, N.; Gaeta, F. C.; Sette,
A.; Grey, H. M., MHC interaction and T cell recognition of carbohydrates and
glycopeptides. J. Immunol. 1992, 148, 2446-2451.
116. Shimonkevitz, R.; Colon, S.; Kappler, J. W.; Marrack, P.; Grey, H. M., Antigen
recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for
processed antigen. J. Immunol. 1984, 133, 2067-2074.
117. Serre, K.; Machy, P.; Grivel, J.-C.; Jolly, G.; Brun, N.; Barbet, J.; Leserman, L.,
Efficient presentation of multivalent antigens targeted to various cell surface molecules of
dendritic cells and surface Ig of antigen-specific B cells. J. Immunol. 1998, 161, 60596067.
118. Richichi, B.; Thomas, B.; Fiore, M.; Bosco, R.; Qureshi, H.; Nativi, C.;
Renaudet, O.; BenMohamed, L., A cancer therapeutic vaccine based on clustered Tnantigen mimetics induces strong antibody-mediated protective immunity. Angew Chem Int
Ed Engl 2014, 53, 11917-20.
119. Mascaraque, A.; Kowalczyk, W.; Fernández, T.; Palomares, F.; Mayorga, C.;
Andreu, D.; Rojo, J., Glycodendropeptides stimulate dendritic cell maturation and T cell
proliferation: a potential influenza A virus immunotherapy. MedChemComm 2015, 6,
1755-1760.
120. Dam, T. K.; Gerken, T. A.; Cavada, B. S.; Nascimento, K. S.; Moura, T. R.;
Brewer, C. F., Binding studies of alpha-GalNAc-specific lectins to the alpha-GalNAc (Tn105

antigen) form of porcine submaxillary mucin and its smaller fragments. J. Biol. Chem.
2007, 282, 28256-63.
121. Kensil, C. R.; Kammer, R., QS-21: a water-soluble triterpene glycoside adjuvant.
Expert Opin Investig Drugs 1998, 7, 1475-82.
122. Singh, M.; O'Hagan, D., Advances in vaccine adjuvants. Nat. Biotechnol. 1999, 17,
1075-81.
123. Kuduk, S. D.; Schwarz, J. B.; Chen, X.-T.; Glunz, P. W.; Sames, D.; Ragupathi,
G.; Livingston, P. O.; Danishefsky, S. J., Synthetic and immunological studies on clustered
modes of mucin-related Tn and TF O-linked antigens: the preparation of a glycopeptidebased vaccine for clinical trials against prostate cancer. J Am Chem Soc 1998, 120, 1247412485.
124. Tashiro, T.; Nakagawa, R.; Hirokawa, T.; Inoue, S.; Watarai, H.; Taniguchi, M.;
Mori, K., RCAI-37, 56, 59, 60, 92, 101, and 102, cyclitol and carbasugar analogs of
KRN7000: Their synthesis and bioactivity for mouse lymphocytes to produce Th1-biased
cytokines. Biorg. Med. Chem. 2009, 17, 6360-6373.
125. Tashiro, T.; Nakagawa, R.; Hirokawa, T.; Inoue, S.; Watarai, H.; Taniguchi, M.;
Mori, K., RCAI-56, a carbocyclic analogue of KRN7000: its synthesis and potent activity
for natural killer (NK) T cells to preferentially produce interferon-γ. Tetrahedron Lett.
2007, 48, 3343-3347.
126. Tefit, J. N.; Davies, G.; Serra, V., NKT cell responses to glycolipid activation. In
Vaccine Adjuvants, Springer: 2010; 149-167.
127. Novak, J.; Lehuen, A., Mechanism of regulation of autoimmunity by iNKT cells.
Cytokine 2011, 53, 263-70.
128. Meyer, E.; DeKruyff, R.; Umetsu, D., iNKT cells in allergic disease. In T Cell
Activation by CD1 and Lipid Antigens, Springer: 2007; 269-291.
129. Vivier, E.; Ugolini, S.; Blaise, D.; Chabannon, C.; Brossay, L., Targeting natural
killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 2012, 12, 239-52.
130. Brigl, M.; Brenner, M. B. In How invariant natural killer T cells respond to
infection by recognizing microbial or endogenous lipid antigens, Semin. Immunol.,
Elsevier: 2010; 79-86.
131. Tupin, E.; Kinjo, Y.; Kronenberg, M., The unique role of natural killer T cells in
the response to microorganisms. Nat. Rev. Microbiol. 2007, 5, 405-17.
132. Terabe, M.; Berzofsky, J. A., The role of NKT cells in tumor immunity. Adv.
Cancer Res. 2008, 101, 277-348.
133. Natori, T.; Morita, M.; Akimoto, K.; Koezuka, Y., Agelasphins, novel antitumor
and immunostimulatory cerebrosides from the marine sponge Agelas mauritianus.
Tetrahedron 1994, 50, 2771-2784.
134. Kinjo, Y.; Wu, D.; Kim, G.; Xing, G. W.; Poles, M. A.; Ho, D. D.; Tsuji, M.;
Kawahara, K.; Wong, C. H.; Kronenberg, M., Recognition of bacterial glycosphingolipids
by natural killer T cells. Nature 2005, 434, 520-5.
135. Mattner, J.; DeBord, K. L.; Ismail, N.; Goff, R. D.; Cantu, C.; Zhou, D.; SaintMezard, P.; Wang, V.; Gao, Y.; Yin, N.; Hoebe, K.; Schneewind, O.; Walker, D.;
Beutler, B.; Teyton, L.; Savage, P. B.; Bendelac, A., Exogenous and endogenous
glycolipid antigens activate NKT cells during microbial infections. Nature 2005, 434, 525529.

106

136. Sriram, V.; Du, W.; Gervay-Hague, J.; Brutkiewicz, R. R., Cell wall
glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT
cells. Eur. J. Immunol. 2005, 35, 1692-701.
137. Kinjo, Y.; Tupin, E.; Wu, D.; Fujio, M.; Garcia-Navarro, R.; Benhnia, M. R.;
Zajonc, D. M.; Ben-Menachem, G.; Ainge, G. D.; Painter, G. F.; Khurana, A.; Hoebe,
K.; Behar, S. M.; Beutler, B.; Wilson, I. A.; Tsuji, M.; Sellati, T. J.; Wong, C. H.;
Kronenberg, M., Natural killer T cells recognize diacylglycerol antigens from pathogenic
bacteria. Nat. Immunol. 2006, 7, 978-86.
138. Kinjo, Y.; Illarionov, P.; Vela, J. L.; Pei, B.; Girardi, E.; Li, X.; Li, Y.; Imamura,
M.; Kaneko, Y.; Okawara, A.; Miyazaki, Y.; Gomez-Velasco, A.; Rogers, P.; Dahesh,
S.; Uchiyama, S.; Khurana, A.; Kawahara, K.; Yesilkaya, H.; Andrew, P. W.; Wong,
C. H.; Kawakami, K.; Nizet, V.; Besra, G. S.; Tsuji, M.; Zajonc, D. M.; Kronenberg,
M., Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive
bacteria. Nat. Immunol. 2011, 12, 966-74.
139. Amprey, J. L.; Im, J. S.; Turco, S. J.; Murray, H. W.; Illarionov, P. A.; Besra,
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2 Chapter 2: Goals and Objectives
2.1 Synthesis of biostable N-Fmoc protected acetal-free exact analogue of Tn
antigen
The first objective of this research, discussed in Chapter 3, is to accomplish the synthesis
of the exact C-glycoside analogue of the Tn antigen. This molecule depicted in Figure 2.1 has not
been synthesized to date. In particular, a N-Fmoc protected acetal-free analogue of the Tn antigen
is targeted in order to enhance the stability of this antigen. The Fmoc protecting group is already
attached to the amino acid moiety so that solid phase peptide synthesis can be conducted resolving
the T-cell recognition problem discussed in Chapter 1. Once synthesized a secondary goal will be
to attach compound 201 to a short peptide chain and send it for biological examination. Both acetal-free and native Tn antigens will be evaluated together to see if the difference in immune response between the two antigens. We want to determine whether an immune response is generated
from our acetal-free Tn antigen, specifically to see if these antigens can trigger the immune system
to attack cancer cells.

Figure 2. 1 Structure of acetal-free Tn antigen 201

2.2 Toward the synthesis of biostable acetal-free TF antigen
To date, only one reported TF antigen analogue has been synthesized and evaluated in
immunological studies. This analogue was prepared and examined by Vogel in 2012 and it shown
in Scheme 2.1.1 This was the first synthesis of the single C-glycoside version of the TF antigen,
which was synthesized in more than 40 steps, however, some questions remain unanswered. Is the
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vaccine candidate prepared by Vogel specific for cancer cells? Or, is this activity only observed
because of the peptide chain, as it is independently capable of activating T-cells. Moreover, this
C-glycoside antigen was never examined against the natural TF antigen to show whether the generated immune response is also specific for the native antigen.
The second objective of this research, discussed in Chapter 4, is to remove the unstable
acetal functionality in the TF antigen by replacing the exocyclic anomeric oxygen with a methylene group (C-glycoside), thus creating the first fully-acetal-free C-glycoside analogues of the TF
antigen. We will attempt to design this synthesis with a reasonable overall step count, and ultimately try to attach a peptide chain to this antigen for biological evaluation. Removing the labile
functionality should result in enhanced biostability relative to the native system, likely, with no
loss in recognition specificity as the exocyclic oxygen is not generally involved in molecular
recognition events.

2.3 Total Synthesis of glycolipids from S. pneumoniae and the biological reevaluation
The third objective for this thesis is the synthesis of mono- and disaccharide glycolipids
(Figure 2.2), which are isolated from pneumonia, for the purpose of biological evaluation. Despite
a few reported syntheses of the monosaccharide glycolipid, to date, no biological examination has
been performed on these synthetic analogues. Kinjo, in 2011, reported for the first-time isolation
and identification of these glycolipids and showed their ability to activate iNKT cells.2 However,
these tests were carried out using minimal amounts of the isolated glycolipids in questionable purity.2 As a result, it is impossible to ascertain whether the activity observed was due to these glycolipids or due to some minor impurity. Also, there remains some questions about the unusual
structures of the glycolipids due to insufficient structural evidence in the 2011 report to confirm
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the proposed structures conclusively. Synthesis of this type of glycoside diglycerides, which includes either the same or different fatty acid residues, requires significant effort to manipulate the
protecting groups in both sugar and glyceride parts in order to get the desired selectivity and avoid
any conflict in protecting and deprotecting strategies. These approaches commonly suffer from
lack of high efficiency, flexibility and stereopurity.3-5 On the other hand, synthetic procedures using the starting material with well-established stereopure glycoside associated with an appropriate
protecting group is costly.5, 6 Here, an efficient, total synthesis of both S. pneumonia glycolipids is
reported, and our surprising re-evaluation of their immunological activity will be discussed.

Figure 2. 2 Structure of mono- and disaccharide glycolipids 1168 and 202. Synthetic targets for
Chapter 5

2.4 t-Butylamine as a mild and selective deacetylation agent
The selective hydrolysis of esters has always been an exciting subject among carbohydrate
chemists, especially when the result is saving a few synthetic steps which can become essential for
an efficient synthesis. In particular, the selective removal of acetates in the presence of longer
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chain esters remains a significant challenge in carbohydrate chemistry. In the synthesis of the
disaccharide glycolipids project discussed in Chapter 5, the acetyl protecting group had to remove
selectively in the presence of glycerol ester chains. The only reagent reported in the literature
suitable for this transformation was not able to selectively deprotect acetyl groups without also
degrading the disaccharide glycolipid. All listed chemical methods in Green and Wutz either failed
to provide selectivity or degraded the complex carbohydrate. To address this challenge, we had
turned to methoxyacetates as an alternative protecting group. Standard conditions for their
cleavage involve the use of tert-butylamine, although the precise mechanism of action remains
unclear. Furthermore, this reagent has never been used for the deacetylation of carbohydrates.
A fourth objective of this thesis, discussed in Chapter 6, is to study the mechanism and
evaluate the steric and electronic effects of t-butyl amine as a mild, selective, and inexpensive
reagent for the selective deprotection of the acetyl group in the presence of different ester functionalities. The potential application for the selective hydrolysis of acetates in protected carbohydrates, as well as our explorations into the chemoselectivity, kinetic profile, and scope of this reaction will be discussed.

Scheme 2. 1 Selective acetyl deprotection in the presence of different esters at C-6 position using
t-BuNH2

2.5 Conjugated polymer backbone modifications for greener solubility and degradability
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The final goal of this research is to utilize the hydrogen bonding inherent in saccharides to
improve the solubility of conjugated polymers in greener solvents and introduce a degradable component to the polymer backbone. The objectives of the project include developing a series of saccharide-containing backbone modified conjugated polymers for electronic devices (shown in red
in Figure 2.3); achieve solubility in greener solvents for eco-friendly device processing; and introduce the possibility of enzyme-catalyzed degradability to the polymer backbone through ester
linkages for waste reduction. Saccharides have several characteristics that make them an advantageous choice for organic electronics: low cost, bio-sourced, inherent degradability, and are already
found to improve aqueous solubility in pharmaceuticals. In this thesis the acetylated lactose bearing free hydroxyl groups at the C-6 and C-6΄ is targeted. This target molecule will then be sent to
our collaborator for polymerization and evaluation of the resulting properties.

Figure 2. 3 Proposed oligosaccharides conjugation-breaking polymer units 205

117

Reference
1.
Awad, L.; Madani, R.; Gillig, A.; Kolympadi, M.; Philgren, M.; Muhs, A.; Gérard, C.;
Vogel, P., A C‐Linked Disaccharide Analogue of Thomsen–Friedenreich Epitope Induces a Strong
Immune Response in Mice. Chem-Eur J 2012, 18, 8578.
2.
Kinjo, Y.; Illarionov, P.; Vela, J. L.; Pei, B.; Girardi, E.; Li, X.; Li, Y.; Imamura, M.;
Kaneko, Y.; Okawara, A.; Miyazaki, Y.; Gomez-Velasco, A.; Rogers, P.; Dahesh, S.;
Uchiyama, S.; Khurana, A.; Kawahara, K.; Yesilkaya, H.; Andrew, P. W.; Wong, C.-H.;
Kawakami, K.; Nizet, V.; Besra, G. S.; Tsuji, M.; Zajonc, D. M.; Kronenberg, M., Invariant
natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat. Immunol.
2011, 12, 966-974.
3.
Takato, K.; Kurita, M.; Yagami, N.; Tanaka, H. N.; Ando, H.; Imamura, A.; Ishida, H.,
Chemical synthesis of diglucosyl diacylglycerols utilizing glycosyl donors with stereodirecting
cyclic silyl protective groups. Carbohydr. Res. 2019, 483, 107748.
4.
Van Boeckel, C.; Van Boom, J., Synthesis of streptococci phosphatidyl-αdiglucosyldiglyceride and related glycolipids: Application of the tetraisopropyldisiloxane-1, 3-diyl
(TIPS) protecting group in sugar chemistry. Part V. Tetrahedron 1985, 41, 4567-4575.
5.
Richardson, M. B.; Smith, D. G.; Williams, S. J., Quantitation in the regioselectivity of
acylation of glycosyl diglycerides: total synthesis of a Streptococcus pneumoniae alpha-glucosyl
diglyceride. Chem. Commun. (Camb.) 2017, 53, 1100-1103.
6.
Shah, S.; Nagata, M.; Yamasaki, S.; Williams, S. J., Total synthesis of a cyclopropanefatty acid α-glucosyl diglyceride from Lactobacillus plantarum and identification of its ability to
signal through Mincle. Chem. Commun. 2016, 52, 10902-10905.

118

3 Chapter 3. Synthesis of an N-Fmoc protected, biostable acetal-free analogue of the Tn antigen
3.1 Synthesis of the C-glycoside acetylated glucosamine
The synthesis of the N-Fmoc protected acetal-free Tn antigen, 201, has attracted chemists'
attention as a way to increase the biostability compared to the native antigen. Even with this attention, there is no synthetic analogue of this antigen linked to the peptide reported, compound 301
in Figure 3.1, and no biological examination has been performed to date.1 Only two attempts have
been made towards the synthesis of the exact analogue of the native Tn antigen, 101a (Figure 3.1).
Although these two reports were valuable contributions, both required modifications to the synthetic route in order to be completed, and as a result, the ultimate target was never synthesized,
and the biological activity never examined.

Figure 3. 1 Structure of the Acetal-free Tn antigen target 301 and native Tn antigen 101a
As mentioned in the introduction, the first attempted synthesis of a C-Glycoside analogue
of the Tn antigen was reported by Beau and coworkers in 1998 using a samarium iodide strategy.2
This synthesis was performed in 24 steps to generate a C-glycoside analogue of the Tn antigen;
however, the sugar moiety was left protected with the benzyl group, and the Boc amino protecting
group remained in the amino acid moiety (Scheme 3.1). Deprotection of the benzyl group and
replacement of the Boc group with an Fmoc protecting group, necessary for most modern solid
phase peptide synthesis, are still required in order to achieve the desired acetal-free Tn antigen;
this represents a minimum of three additional steps.
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Scheme 3. 1 The first synthesis of the C-Glycoside Analogue of Tn antigen reported by Beau
Three years later, Schmidt reported a relatively short synthesis of the acetal-free analogue
of the Tn antigen.3 This compound, however, was never biologically evaluated, as it was never
integrated into a peptide. This synthesis was performed in 14 steps, however, the synthetic approach saved multiple steps by using galactosamine hydrochloride as a starting material (Scheme
3.2). This starting material is very costly (~$328/g, Sigma Aldrich). Moreover, both the acetyl
protecting group in the sugar moiety and the methyl ester need to be removed, and more importantly, the free amine needs to be protected with an Fmoc functionality for the peptide synthesis.
This synthesis was clearly never intended to provide a building block. Consequently, a more
streamlined synthetic strategy which uses a more readily available starting material and allows for
complete deprotection of the sugar and attachment of an Fmoc groups to the amino acid is required.

Scheme 3. 2 Short synthesis of the acetal-free analogue of the Tn antigen by Schmidt
To begin the synthesis of 301, the glucosamine hydrochloride was used as a starting material, as commercial galactosamine hydrochloride is not economically available, and we planned to
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convert to galactosamine moiety in further steps, allylation of the galactosamine is also more challenging than of glucosamine from experience.4 The very first step, acetylation of glucosamine
hydrochloride, which was supposed to be an easy step, failed to give the right β-anomer as αanomer is usually inactive towards the glycosylation reactions, because α-anomer is more stable
due to anomeric effect. Despite trying multiple published protocols, which reportedly would provide the β anomer from acetic anhydride, including catalysis with zinc chloride5 and pyridine,6 all
exclusively afforded the α-acetyl anomer. Finally, fully acetylated glucosamine was synthesized
based on the Zhang’s 4 step procedure, which seems to be the only way to synthesize the β-anomer
of acetylated glucosamine.7 This is yet another example of the lack of reproducibility in the carbohydrate literature.
In this procedure, shown in Scheme 3.3, the amine group of 305 was protected using anisaldehyde and a 1M solution of NaOH, then pyridine and acetic anhydride were applied for acetylation of the hydroxyl groups. In this reaction, the large steric bulk of the imine functionality pushes
an anomeric acetyl group to re-orient to the β-anomer. The imine functionality was then hydrolyzed via 5M HCl in acetone. Finally, the acetamide functionality was generated using Et3N and
acetic anhydride. It is worth mentioning that, although this procedure seems to be lengthy, this
procedure can be performed on a large-scale without chromatographic purification at any step of
the preparation of 309, and the p-methoxyanisaldehyde can be easily recovered to make it quite
economical.
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Scheme 3. 3 Synthesis of acetylated glucosamine 309
The next steps involved the synthesis of C-glycoside glucosamine starting from acetylated
glucosamine based on a report by Cipolla (Scheme 3.4).8 The allyl group was chosen because it
can be exploited in the construction of the amino acid linkage later in the synthesis. First, the
anomeric acetyl group was replaced with chlorine using thionyl chloride and acetic acid with a
75% yield. The allylic C-glycoside compound 1103 must be prepared carefully as this reaction is
sensitive to any moisture or air. A solution of compound 1102 in distilled benzene, AIBN and allyl
tributylstannane was degassed for 45 minutes by bubbling N2 through the solution. The reaction
mixture was then heated to reflux to afford the desired allylic compound 1103 in moderate yield.
It should be mentioned that there is a limitation for using this protocol on larger scales; AIBN must
be added portionwise to maintain acceptable yields.
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Scheme 3. 4 Synthesis of compound 1103

3.2 Synthesis of galactosamine aldehyde 317
The glucosamine moiety was converted to galactosamine using four subsequent steps
shown in Scheme 3.5. First, the initial acetyl groups were removed via a solution of sodium methoxide in methanol. Hydroxyl groups in C-3 and C-6 were then selectively protected with the Piv
group using pivaloyl chloride in pyridine and dichloromethane. The galactose derivative was subsequently achieved by successful inversion of the C-4 hydroxyl group via SN2 substitution using
Tf2O in pyridine and dichloromethane and subsequent hydrolyzed with the addition of water.

Scheme 3. 5 Conversion of glucosamine to galactosamine 187
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The mechanism of this procedure was well explained by Ben and is shown below. 9 First
the carbonyl oxygen of C-2 removes the triflate, followed by carbocation hydrolysis from the opposite side of the tert-butyl orientated face. The intermediate 313 (Scheme 3.6) is generated after
a proton transfer to the oxygen at the C-3 position. The galactose moiety with having a pivaloyl
ester protecting group at C-4 and C-6 positions 187 forms with the oxygen atom's assistance and
deprotonation. However, compound 314 is not observed for two reasons, first, intermediate 312 is
less favourable due to steric complication between the tert-butyl and sugar moieties. Second, better
stability of protonated oxygen at the equatorial position in compound 313 compares to protonated
oxygen at the axial position in compound 312.

Scheme 3. 6 The proposed mechanism for the formation of galactosamine 187
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The pivaloyl-protected galactosamine was subjected to a Zemplén reaction to remove the
protecting group, then hydroxyl groups were protected with an acetyl group using pyridine and
acetic anhydride, which is necessary for asymmetric hydrogenation in later steps.10 To attach the
amino acid to the sugar moiety through an allyl functionality, the allyl group had to be converted
to an aldehyde, which can be linked to the amino acid fragment using the Horner-WadsworthEmmons olefination reaction.

The production of Aldehyde 192 was expected without difficulties, as reported by
Schmidt.3 However, this reaction did not afford acceptable product usable for the next step. The
presence of an equilibrium of a five- and/or seven-membered cyclic forms of aldehyde were expected;11, 12 however, an attempt to purify and apply the mixture for the next step did not result in
the desired product.

Scheme 3. 7 Attempt to the formation of aldehyde 192
In order to eliminate the equilibrium forms of the aldehyde, the nitrogen in the acetamide
functionality was inactivated by protection with the Boc group. A mixture of Boc2O, DMAP and
pyridine was treated with compound 191 to afford 316 (Scheme 3.8). Next, the ozonolysis was
performed at –78°C and dimethyl sulfide was used to generate the aldehyde. Although this reaction
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gave pure desired aldehyde after purification, the yield was low, and surprisingly the trioxolane
intermediate was stable enough to be isolated. The exact structure of a mono-or disaccharide trioxolane intermediates could not be determined using standard NMR techniques and mass spectrometry. X- ray diffraction studies will have to be performed to determine the exact structure of
this intermediate. Regardless, the result showed clearly that the generation of the aldehyde from
the trioxolane is a slow process, presumably due to the low reactivity of dimethyl sulfide.

Scheme 3. 8 Synthesis of aldehyde 317 accompanied by intermediates 318 and 319
Two sets of reaction conditions, (Scheme 3.9), were set up to optimize the yield of this
reaction. First, the ozonolysis was performed, and dimethyl sulfide was added, and the mixture
stirred for 16 h at room temperature. The second approach used the same initial ozonolysis, but
this time triphenylphosphine was used to open the trioxolane intermediate. The result of the first
reaction indicated the presence of an intermediate by TLC. Increasing the reaction time did lead
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to a slightly improved yield but was not ideal when compared to the PPh3 reaction. The second
reaction was completed in 6 hours with a 90% yield indicating that PPh3 is far more reactive compared to dimethyl sulfide in this specific reaction. As the reader is aware, these are the two standard
agents for resolving ozonides, and the relative merits of each are beyond the scope of this thesis.

Scheme 3. 9 Optimization of aldehyde formation through ozonolysis procedure

3.3 Synthesis of biostable acetal-free Tn antigen bearing N- Fmoc protected
amino acid
With aldehyde 317 in hand, attachment of the amino acid appeared to be straight forward.
First, the synthesis of phosphonate 323 can be performed as shown in Scheme 3.10 and subsequently linked to the sugar fragment by a Horner-Wadsworth-Emmons olefination reaction that
will result in the serine amino acid addition.13 Synthesis of phosphonate 323 started from glyoxylic
acid monohydrate and benzyl carbamate, which reacted in diethyl ether to produce α-Hydroxy-Nbenzyloxycarbonylglycine in moderate yield.14 The concentrated H2SO4 and EtOH were added to
320a to generate the ethyl ester and protect the alcohol functionality.13 Compound 321 then underwent a reaction with phosphorus trichloride and triethyl phosphite to produce the phosphonate.
The CBz protecting group was converted to Fmoc in two sequential steps. The CBz group was
first removed using Pearlman’s catalyst and TFA in ethyl acetate, then Fmoc was applied for the
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protection of the amine using fluorenylmethyloxycarbonyl chloride and NaHCO3 in dioxane and
water. This reaction afforded the desired Fmoc protected Serine amino acid derivative ready for
olefination in the next step.

Scheme 3. 10 Synthesis of N-Fmoc protected amino acid 323
Gratifyingly, aldehyde 317 and amino acid 323 underwent a Horner-Wadsworth-Emmons
reaction in the presence of LDA to give the desired product in good yield. The sugar moiety was
successfully linked to the amino acid counterpart through the alkene functionality to generate the
first Tn antigen backbone containing the N-Fmoc protecting group 324 (Scheme 3.11). The Boc
protecting group in the sugar moiety was then successfully removed using TFA in 77% yield. The
olefin group was asymmetrically reduced using a chiral rhodium complex in a hydrogen atmosphere at 200 Psi.10, 15-19 The result gave a 90% yield of compound 326, ready to use for the last
step, final deprotection.
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Scheme 3. 11 Synthesis of compound 326
The 1HNMR spectrum of 326 showed broad peaks, which was most likely caused by the
restricted rotation between Fmoc rotamers depicted in Figure 3.2. This phenomenon is well known
as the Fmoc protection group is widely utilized in solid-phase peptide synthesis.20 The high barrier
for rotation around the C–N bond usually leads to a broadening or in some cases even increasing
and decreasing the intensities of some of the peaks due to the durability of the two major rotamers.
In order to prove that restricted rotation was the cause of the atypical NMR spectrum VT-NMR
spectroscopy was performed. The sample was heated at three temperature points 22°C (room temperature), 35°C and 50°C and spectrum were recorded to observe any changes to the molecule`s
NMR signals. As was expected, changing the temperature changed the intensities of some of the
peaks associated with the Fmoc protecting group, which supports the idea of restricted Fmoc rotation around the C–N bond (see supplementary data page 344).
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Figure 3. 2 Fmoc rotation in an equilibrium
The final step, selective hydrolyzation of the acetate group and the ethyl ester functionality
appeared to be challenging because under basic conditions all the carbamate and ester functionalities are usually removed and selective hydrolyzation of ester groups in the presence of carbamates
is extremely challenging. Three reaction procedures were examined to selectively remove two different ester groups in the presence of an Fmoc group. In the beginning, two sets of acidic conditions
were applied for the selective deprotection of both acetyl and ethyl ester groups. First, concentrated
HCl with acetic acid and second, anhydrous HCl in dioxane were applied. Both reactions started
at room temperature and were then heated to reflux. Both reactions did not afford the desired
product, but instead gave a mixture of partially deprotected compounds containing some remaining
acetyl group. Finally, the acetal-free Tn antigen analogue 201 was obtained in moderate yield using
a 0.8 molar solution of CaCl2 and NaOH in the solution of isopropyl alcohol and water.21

Scheme 3. 12 Synthesis of C-glycoside Tn antigen 201
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4 Chapter 4: Synthesis of biostable acetal-free TF antigen
As mentioned in Chapter 1, carbohydrate-based antigens have great potential as cancer
vaccines. In particular, the TF antigen, which is responsible for many carcinomas, attracted scientist’s attention for the cancer vaccine application, however, these attempts ultimately did not lead
to the desired vaccine, mainly due to the low stability of this antigen. On the other hand, these
results led to the idea of attempting to synthesize the acetal-free TF antigen in order to address the
low stability of this antigen. Despite several promising attempts, still, synthesis of fully acetal-free
TF antigen remained under exploration. In order to improve the stability of the TF antigen an
acetal-free TF-antigen was selected as a synthetic target. The Tn antigen serves as the core of both
the TF antigen (Figure 4.1). One underlying problem of how to link an amino acid to a carbohydrate conjugate needs to be solved to synthesize the target molecule. Conveniently, solutions to
this problem were explored in the synthesis of the Tn antigen (Chapter 3) and can be applied here.
The two carbon linker between the amino acid and the carbohydrate brings a certain degree of
flexibility to the potential synthetic solutions. A more challenging obstacle is the synthesis of an
anomeric carbon-carbon bond using the one-carbon linkage required for the preparation of the
inter-glycosidic bond. This is an exceptionally challenging problem, and there are only a few existing solutions for this challenge. In many aspects, this is more challenging for the TF antigen
than the sTn antigen. In particular, the glycosidic linkage in the sTn antigen is formed through the
primary C-6 OH of the sugar, which provides an extra carbon allowing for a bit more synthetic
flexibility.
The first challenge involves the attachment of the N-Fmoc protected amino acid to the
galactosamine moiety was already solved in the synthesis of the Tn antigen. The most challenging
part is the formation of a carbon-carbon bond between an anomeric carbon of galactose and the C-
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3 position of the galactosamine moieties using a one-carbon linkage. Although Vogel solved this
problem using Baylis Hillman reaction, his synthetic route is quite lengthy. It contains over 40
steps and did not end in the fully acetal-free TF antigen. Thus, completing his synthesis towards
an actual fully acetal-free analogue of TF antigen would not be practical.

Figure 4. 1 Fully acetal-free TF antigen target 401
The aldehyde functional group, either in the galactose or the galactosamine component,
seems to be the key in the synthesis of acetal-free TF antigen. This aldehyde moiety can be converted into other useful functionalities or participate directly in nucleophilic or radical substitution
approaches. In this research the two main synthetic approaches, were attempted. The first involves
the synthesis of aldehyde 402 in the galactosamine moiety and using samarium iodide chemistry
as the key step to attach the aldehyde to the second monomer bearing the sulfone functionality
(Scheme 4.1a). The second is the synthesis of aldehyde 405 in the galactose moiety, which can be
linked to the enone monomer, 406, which already has an allyl group attached to the anomeric
position to form double C-glycoside, through a Baylis-Hillman reaction as the key step.1 Both
routes would then require further transformation to achieve the desired acetal-free TF antigen
(Scheme 4.2b). In addition to those main approaches, a few side approaches were attempted as
well, which will be discussed in this chapter.
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Scheme 4. 1a,b Two different proposed synthesis of acetyl free TF antigen, a and b
Although the installation of the aldehyde functionality initially seems easier in a galactose
sugar due to the lack of a nitrogen source at the C-2 position, the proposed synthesis of this molecule would require a longer synthesis than the galactosamine derivatives, because after forming
the linkage between two sugars, more manipulation must be done in order to achieve the final
product, including; introducing nitrogen at the C-2 position, dihydroxylation, selective reduction
of ketone and lastly, attachment of amino acid to the galactosamine sugar part (Figure 4.2).
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Figure 4. 2 Highlighted challenges towards the synthesis of 401 from 407
On the other hand, the formation of the aldehyde at the C-3 position in the galactosamine
moiety is extremely challenging because of the presence of nitrogen source at the C-2 position
close to the aldehyde. There are no reports of such an aldehyde in the literature. It is evident that
both routes will require significant synthetic innovation to generate the required aldehydes. In this
chapter, the synthesis of acetal-free TF antigen via samarium iodide chemistry through synthesis
of aldehyde 402, followed by investigation of some related side reactions, and lastly, the synthesis
of acetal-free TF antigen via Baylis Hillman reaction are discussed.

4.1 Attempt to synthesis of acetal-free TF antigen via samarium iodide chemistry
4.1.1 Synthesis of the first monomer aldehyde 413 through the synthesis of aldehyde
410 precursor
The aldehyde in the galactosamine is the key component of the first approach. It is required
to react with the sulfone galactose derivative as a coupling partner. Coupling using the samarium
iodide method is proposed to take advantage of a single electron transfer to connect aldehyde to
the anomeric position of galactose moiety. The proposed synthesis of aldehyde 413 is shown in
Scheme 4.2 and has been designed so as to go through compound 410, reported by Seshadri.2 As
shown in the retrosynthesis of the aldehyde, there are two key steps in this proposed approach. The
first aldehyde, 410, generated from the Claisen rearrangement is one carbon longer than the target
aldehyde, 413, and attaches to the sugar moiety with the wrong stereoselectivity. However, we
proposed to convert compound 410 to aldehyde 413 through trimethylsilyl vinyl ether formation,
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followed by oxidative cleavage via ozonolysis. The epimerization of the α aldehyde can correct
the stereoselectivity to the more stable β oriented aldehyde. The second key feature in this method
is the formation of a galactal moiety bearing a nitrogen source at the C-2 position and installing an
R group at the anomeric position in order to transform it to the C-Glycoside linked to amino acid
(Serine). The aziridine formation approach was chosen to simultaneously introduce the nitrogen
source and R group at the C-2 and anomeric positions, respectively.

Scheme 4. 2 Retrosynthesis of the first monomer aldehyde 413 via aldehyde 410 formation
The aldehyde 410 was prepared starting from galactose which was acetylated via sodium
acetate and acetic anhydride. Acetylated galactal was prepared in two steps (Scheme 4.3). First,
a bromination of the anomeric position of acetylated galactose via HBr in acetic acid, then galactal formed using zinc and ammonium chloride.
A Ferrier rearrangement3 was performed between acetylated galactal 119 and 2-(phenylselenyl)ethanol using BF3•OEt2 to generate compound 415. The oxidation was done via sodium periodate and sodium bicarbonate to establish selenone glycoside. An allyl vinyl ether was then generated through a base-mediated thermal fragmentation with the assistance of DIPA in benzene.
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The desired product was finally achieved by a Claisen [3,3]-sigmatropic rearrangement4 at high
temperature using N,N-dimethylaniline and nitrobenzene (Scheme 4.3).

Scheme 4. 3 Synthesis of aldehyde 410
Next, we attempted to introduce a nitrogen source into the molecule. First, the aldehyde
was treated with ethylene glycol in the presence of p-TsOH to protect aldehyde 410; however, the
presence of an olefin was problematic. Consequently, the protection of the aldehyde failed and
produced a complex mixture.
Not being able to protect the aldehyde we hypothesized that aziridine formation on compound 410 could be accomplished using (saltmen)Mn(N) as a reagent to deliver nitrogen to the
alkene forming the aziridine ring. (saltmen)Mn(N)5 was freshly prepared based on a published
procedure reported by Carrieira,6 via reaction of salicylaldehyde with diamine 418. This diamine
was synthesized in two steps (Scheme 4.4).7 2-nitropropane was converted to the dinitro compound 417 via iodine and KOH, and then the nitro group was reduced to the diamine functionality
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using tin and concentrated HCl. The sialic aldehyde was treated with diamine compound 418 to
form imine 420, which then reacted with Mn(OAc)2.4H2O to afford the desired (saltmen)Mn(N)
complex.

Scheme 4. 4 Synthesis of (saltmen)Mn(N) 421 as nitrogen donor
Unfortunately, the aziridine formation using (saltmen)Mn(N) and TFAA failed. This reaction afforded a complex mixture in which no useful information could be obtained from the crude
produc(s) using NMR techniques. This result may be explained by the high reactivity of the aldehyde and/or acetyl protecting group, which could destructively interfere with Saltmen’s reagent.
It is worth mentioning again that the attempt to protect the aldehyde functionality using ethylene
glycol and p-TsOH failed to generate an acetal group and afforded a complex mixture, the conditions for both reactions are shown in Scheme 4.5.
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Scheme 4. 5 Attempts to aziridination and protect aldehyde 410
To investigate the applicability of this procedure, a peracetylated galactal was used for
aziridine formation; however, this reaction gave no conversion whatsoever, which eliminated the
possibility of acetyl protecting group interference. The galactal 119 seems to have inherently low
reactivity towards the Saltmen complex for aziridine formation.
The second method chosen to introduce a nitrogen source to 410 was the azidonitration
strategy.8 The plan was to attach the azide functionality via azidonitration using ceric ammonium
nitrate (CAN) and NaN3, followed by adding the SPh group to the anomeric position. The mechanism of azidonitration has been studied by Lemieux and Ratcliffe and is depicted in Scheme 4.6.8
First, Ceric ammonium nitrate is reduced to generate an azide radical, then the radical azide attacks
to the C-2 position of galactal. The anomeric radical then changes to an oxocarbenium ion through
a one-electron transfer to the ceric ammonium nitrate ion, and finally the nitrate ion attacks the
anomeric position to form a mixture of nitro galactosamine derivatives.
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Scheme 4. 6 Azido nitration mechanism of galactal 119
Although this reaction works fine based on TLC and HNMR technique as previous report
mentioned,8 the next step was extremely challenging. In our first attempt, the thiophenyl applied
directly to replace with the nitro group using thiophenol and sodium hydride (Scheme 4.7). This
reaction afforded a complex mixture, which could not be used for the next step.
To solve this problem, we tried to install the SPh functional group at the anomeric position
through chlorination. Based on TLC and crude NMR the reaction proceeded to completion; however, this compound was not stable at room temperature for more than half an hour and also attempt
for the purification was impossible due to lack of stability. In a final attempt, azidonitration and
chlorination were performed, but this time the chlorinated compound was used in situ after work
up. After successful chlorination, based on a crude NMR spectrum, this compound was treated
with thiophenol and sodium hydride. This compound again decomposed in about half an hour
indicating an overall stability issue with compound 124 (Scheme 4.7). Synthesis of aldehyde 413
seems to be more challenging than expected. Protection of aldehyde 410 through a simple protection and deprotection strategy such as using TBS group to mask aldehyde could be a solution in
order to convert aldehyde 410 to 413, however, taking this approach would be lengthy.
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Scheme 4. 7 Attempt to synthesis of aldehyde 425 via azidochlorination procedure
As an alternative, an azido phenylselenylation was attempted with the hope that the
phenylselenide could be an appropriate replacement for the SPh group.9 Moreover, the one pot
synthesis eliminates the need for chlorination and thus the possibility of the formation of an unstable intermediate. A proposed mechanism for this transformation is shown in Scheme 4.8 based on
the mechanism proposed by Tingoli.9 The azide radical is first generated via iodosobenzene diacetate, which reacts with the alkene of the radical to produce radical intermediate 422. The radical
422 is trapped with diphenyl diselenide to form the desired compound 426 accompanied by iodobenzene and sodium acetate. Unfortunately, this procedure produced a complex mixture again.
Clearly, these methods, which readily work with acetylated galactal, do not work in the presence
of an aldehyde and our attempts to regioselectively introduce the nitrogen group at the C-2 position
failed to produce the galactosamine moiety.
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Scheme 4. 8 Mechanism of compound 426 formation

4.1.2 Attempt toward the synthesis of aldehyde at C-3 position through a cyanation
procedure
Introducing a nitrogen source to compound 410 failed and as a result the desired aldehyde
413 could not be produced. As an alternative strategy, glucosamine 187 was chosen for the synthesis of the aldehyde at C-3 position, which already has an amine functionality attached to the C2 position. Although this molecule saves some synthetic steps, the presence of an amine group
made the synthesis of the aldehyde far more challenging. We initially attempted to install the aldehyde on the glucosamine residue via cyanation, and those attempts are discussed below.
Initially we attempted direct cyanation of 187 (Scheme 4.9), this reaction was performed
in two steps. First, the alcohol 187 was turned into a triflate leaving group which was then substituted through an SN2 substitution using tetrabutylammonium cyanide. This procedure afforded a
complex mixture from which product could not be isolated. It was assumed that the Piv protecting
group is labile in this reaction. To solve this problem, the Piv groups were replaced with a benzylidene group in two sequential steps. A Zemplén rection to remove the Piv groups, followed by the
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protection of alcohol groups at the C-4 and C-6 positions with a benzylidene group using benzaldehyde dimethyl acetal and p-TsOH, to produce compound 187 (Scheme 4.9). Hoping that we had
reduced the reactivity of the protecting group towards nucleophilic substitution, the cyanation was
repeated, this time using compound 427. Unfortunately, a complex intractable mixture was again
obtained. The result suggests that the Piv protecting the group were not an issue in the original
cyanation of 187. Therefore, the main problem with the cyanation is most likely the presence of
the acetamido group. Consequently, the only option left was to try and remove the acetamide group
from the molecule and replace it with another source of nitrogen.

Scheme 4. 9 Attempt to cyanation of alcohol
An azide functionality was targeted to replace the acetamido group, which was thought to
be slightly less reactive and can be easily converted to the acetamido group in later steps. The
galactal 119 was subjected to azidochlorination using FeCl3.6H2O, NaN3 and H2O2, followed by
an SN2 substitution of chlorine with SPh functionality. We are hoping to be able to convert the SPh
group to an allyl group in later steps for the eventual attachment of amino acid to the sugar moiety.
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There is no exact known mechanism using this approach, however, we proposed a mixture of an
ionic pathway accompanied by a radical addition/atom transfer sequence (Scheme 4.10).
We proposed that the nucleophilic attack of NaN3 to FeCl3 happens first, followed by
HOO- formation in order to convert to HOO and azide radicals using FeCl2N3. The azide radical
attacks the C-2 position of galactal to produce intermediate 422. This radical intermediate reacts
with Cl radical, prepared from the reaction between HOO radical and HCl to form compound 428.

Scheme 4. 10 Proposed azidochlorination mechanism using FeCl3.6H2O and H2O2
The one pot azidochlorination and nucleophilic substitution successfully afforded the desired product 429. The acetyl protecting group were then replaced with more inert benzylidene
group in good yield. Finally, to convert the alcohol to a cyano group, compound 430 was treated
with TF2O, followed by the addition of tert-butyl ammonium cyanide based on the same procedure
as above, however, the result of the reaction is again a highly complex mixture. This appears to be
a nearly intractable problem.
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Scheme 4. 11 Attempt to cyanation of alcohol 430

4.1.3 Attempt to the synthesis of aldehyde at C-3 position via an olefination procedure
As the cyanation strategy had failed to provide adequate results, we turned our attention to
the Wittig reaction. Compound 432 was prepared as a Wittig reagent so that it once the Wittig
reaction was complete the resulting compound could be converted directly to the aldehyde through
a hydrolyzation process. This reagent was synthesized using diethyl hydroxymethyl phosphonate,
dihydropyran and phosphorus oxychloride in moderate yield (Scheme 4.12). The other Wittig
counterpart was formed upon oxidation of alcohols 427 and 430 to the ketone using Dess-Martin
periodinane10 in good yields. Compound 432, treated with base and then exposed to ketones 427a
and 433 separately, underwent a Wittig reaction in THF. No matter what type of base was applied,
compounds 427a and 433 did not show any conversion to the desired compound.
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Scheme 4. 12 Attempt to the synthesis of aldehyde through a Wittig reaction
With ketone 433 in hand, we attempted to form the olefin using other synthetic techniques.
The olefin was targeted as the key compound for eventual aldehyde formation through hydroboration, followed by oxidation. The olefination was attempted using two separate methods (Scheme
4.13). First, the Tebbe reagent was used to convert the ketone to the alkene functionality;11 however, this reaction did not afford the desired product and produced a complex mixture. Again, a
Wittig reaction was performed, this time in the presence of methyl triphenylphosphonium bromide
to achieve the alkene functionality. The phosphonium ylides were attempted to be generated using
n-BuLi, but a complex mixture was obtained, and no desired product was observed.
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Scheme 4. 13 Attempt to olefination of compound 433
Based on the previous research done by Heras using a Wittig strategy to form a C-C bond
between a stabilized ylide reagent and C-3 of the glucosamine derivative 334 (Scheme 4.14a), it
is clear that having a less hindered stabilized ylide is necessary for the C-C bond formation.12 We
proposed that aldehyde 436 could be accessible through the following procedures: Wittig reaction,
reduction of ester, hydroboration of alkene and an oxidative cleavage. The retrosynthetic analysis
is shown in Scheme 4.14b. The first step in this procedure is a Wittig reaction using ethoxycarbonylmethyl and triphenylphosphine as a stabilized ylide reagent.
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Scheme 4. 14a,b An example of Wittig reaction on C-3 ketone 434, a, retrosynthesis of aldehyde
436 via a Wittig reaction, b
To this end, the ylide regent was synthesized in two steps. First, ethyl bromoacetate was
treated with triphenylphosphine, followed by ylide formation using NaOH. This reagent was then
used for a Wittig reaction with ketone 433. The reaction afforded the desired α,β-unsaturated system with a 3:1 ratio of E to in 67% yield. The E and Z isomers then successfully were separated,
and E isomer subjected to the next step. This result was promising as we thought C-C bond formation would be the most challenging part of the synthesis. The ester group was subsequently
reduced to the alcohol via DIBAL-H to generate the allylic alcohol 444 in 74% yield.
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Scheme 4. 15 Synthesis of allyl alcohol 444
With alcohol 444 in hand, hydroboration was then attempted to form the dihydroxyl groups
and remove the alkene functionality; however, this reaction did not work, despite several trials
with various borane sources such as BH3, BH3.SMe2 and 9-BBN. Regardless of the conditions
employed the result did not afford the desired product (Scheme 4.16). To avoid the problematic
hydroboration, epoxidation was attempted in order to generate the alcohol functionality through a
selective epoxide ring-opening using mCPBA and NaHCO3. Unfortunately, the result showed no
conversion of starting material. Although this approach failed to produce aldehyde 436, Ketone
433 seemed to be reactive for small and stabilized Wittig reagents which inspired us to apply this
strategy for other similar nucleophiles to generate an sp3-sp3 carbon bond, which will be discussed
later in the following section.
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Scheme 4. 16 Attempt to synthesis of aldehyde 436 through hydroboration and epoxide formation

4.1.4 Attempt to synthesize aldehyde 436 using Grignard chemistry
As mentioned, the reactivity of ketone 433 towards small nucleophiles inspired us to attempt a final approach to the aldehyde using Grignard chemistry. In particular, the use of Grignard
chemistry to introduce the vinyl group at the C-3 position as the key intermediate towards the
synthesis of aldehyde 436. This approach is proposed to require 4 steps and the retrosynthetic
analysis is presented in Scheme 4.17.

151

Scheme 4. 17 Retro synthesis of aldehyde 436 via Grignard reaction
Compound 433 was treated with vinyl magnesium bromide in THF at –78°C. The results
indicated the vinyl group was attached to the C-3 position, which was a promising result for further
transformations; however, this reaction afforded exclusively an axially oriented vinyl group with
a hydroxyl group in the equatorial position, which is not the desired orientation for aldehyde 436
(Scheme 4.18). This orientation of the substituents may be explained by the structure of sugar 433
which makes the bottom face less sterically encumbered. A hydroxyl group elimination was attempted using TMSOTF and BF3•OEt2 in the presence of Et3SiH in two separate experiments.
However, we failed to dehydroxylate compound 436 and instead obtained a complex mixture of
benzylidene deprotected product accompanied with an isomerized alkene group (Scheme 4.18) .13,
14
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Scheme 4. 18 Synthesis of allylic alcohol 448 via Grignard reaction and Attempt to dehydroxylate compound 448
With the carbon-carbon bond formed, albeit in the wrong orientation, we decided to continue the synthesis, hoping to fix this problem after the attachment of the two sugar moieties. The
hydroxyl group in compound 448 was protected using acetic anhydride and pyridine under reflux,
as expected protection of a tertiary alcohol, especially in carbohydrates, require harsh reaction
conditions. After acetylation of the alcohol, the ozonolysis process was performed and aldehyde
449 (Scheme 4.19a) was formed in 60% yield, bearing an acetyl group at the β position. An initial
attempt to couple the sugar moieties, mediated by samarium iodide, was performed between aldehyde 449 and sulfone 450 (The synthesis of sulfone 450 will be discussed in section 4.1.5). The
coupling was unsuccessful, and the sulfone 450 was recovered, surprisingly, the aldehyde 449 was
converted to our desired aldehyde 436 in 25% yield (Scheme 4.19b). It seems SmI2 first reacted
with aldehyde 449 and, through radical reaction, eliminated the acetyl group and epimerized the
aldehyde to the most favoured equatorial orientated position.
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Scheme 4. 19a,b Synthesis of compound 449, a, and aldehyde 436 using SmI2, b
A mechanism for this transformation is proposed in Scheme 4.20. First the samarium transfers one electron to the carbonyl oxygen of the ester to generate a radical at the C-3 position, then,
samarium transfers another single electron to generate minus charge, which then shares electron
with oxygen to release an acetate group and form enolate. The enolate convert to the more stable,
β-oriented aldehyde 436; however, this reaction appeared not to be scalable as we were not able to
repeat the reaction when we scaled up (it is perfectly reproducible on small scale).
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Scheme 4. 20 Proposed mechanism of SmI2 mediated aldehyde formation
In order to optimize this reaction, compound 449 alone was subjected to the same reduction
procedure using SmI2. The result showed a slight improvement in the yield, by 5% (Scheme 4.21).
In the following reaction, methanol was applied to the mixture of aldehyde 449 and samarium
iodide and compound 436 was afforded in excellent yield. However, scaling up this reaction failed
to provide the desired product and afforded a complex mixture, consequently, this result, lead us
to set up multiple small scale synthesis in order to achieve enough material for our next step synthesis. It is worth mentioning that, despite a few reported syntheses of aldehyde at the C-4 and C6 positions of a sugar bearing a nitrogen source at the C-2 position, compound 436 is the first
reported synthesis of an aldehyde at the C-3 position of a sugar moiety in the presence of any
nitrogen source at the C-2 position.15, 16

Scheme 4. 21 Attempt to optimize aldehyde synthesis 436

4.1.5 Attempt toward the sp3-sp3 one carbon coupling formation via samarium iodide
chemistry
After a successfully synthesis of the more challenging aldehyde 436, we turned our attention to the synthesis of the second sugar partner and the coupling reaction between them. When
we began synthesis of the second monomer, we decided to target both the 2-mercaptopyridine and
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phenyl sulfone galactose derivatives which were prepared in the same reaction conditions (Scheme
4.22). Initially, the galactose was acetylated and then the acetyl group at the anomeric position was
replaced with SPh or SPy using BF3•OEt2. The acetyl groups were removed via the Zemplén procedure and replaced with a more stable isopropylidene protecting group using 2-Methoxypropene
and p-TsOH in DMF. Then, potassium permanganate and copper sulfate were applied for the oxidation of sulfur to form the desired sulfone compounds 450 and 457 in good yields.

Scheme 4. 22 Synthesis of the second monomer 450 and 457
Having both coupling partners in hand, the first coupling reaction was performed between
aldehyde 436 and sulfone 450 with the assistance of SmI2. The SmI2 was prepared freshly based
on the known procedure by Procter,17 and the SmI2 was titrated prior to use in the reaction.18 Using
the reaction conditions shown in Scheme 4.23 did not show any consumption of either aldehyde
436 or sulfone 450 even when heated to reflux. SmI2 usually reacts readily with common sulfones
derivatives which may suggest that isopropylidene groups of sulfones 450 were sterically or electronically preventing the samarium from fulfilling its role in this reaction. The more reactive
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pyridyl sulfone 457 was then used for the radical reaction with aldehyde 436 mediated by SmI2;
however, the result was the same, and no conversion was observed.

Scheme 4. 23 Attempt to form 1,3-β one carbon link between first and second monomers
The isopropylidene had to be replaced by other protecting groups, but we knew that using
common protecting groups such as acetyl and benzyl would increase the possibility of producing
a 1,2-elimination byproduct. Therefore, we attempted to remove substitution at the C-2 position in
order to reduce the chance of producing the 1,2-elimination byproduct mediated by SmI2, 2-pyridyl
2-deoxy-sulfone moiety was then prepared using peracetylated galactal 119 as a starting material.
The acetylated galactal 119 underwent a 1,2-addition reaction using anhydrous p-TsOH and 2mercaptopyridine in the reflux condition. The compound 458 then oxidized to form sulfone via
KMnO4 and CuSO4 (Scheme 4.24). Surprisingly, even after removing the substituent on the C-2
position the coupling reaction between deoxy sulfone 459 and aldehyde 436 afforded acetylated
galactal, the 1,2-elimination product (Scheme 4.24).
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Scheme 4. 24 Synthesis of 2-pyridyl 2-deoxy-sulfone 459 and its reaction with aldehyde 436
This result shows that aldehyde 436 reacts slowly, which gives time for the 1,2-elimination
to proceed. This is most likely due to the structural conformation of aldehyde and its sugar backbone. In the case of isopropylidine protected sulfones, the recovery of starting material proved the
low reactivity of aldehyde 436 and sulfones towards the samarium activated sugar, which may be
cause by steric hinderance and/or low reactivity due to electronic effects of the sugar moiety. 16
Usually samarium mediated coupling reactions fails for two reasons: either because of steric hindrance from the sugar ketone or aldehyde coupling partner, or due to the highly reactive intermediate generated from reaction of the sulfone with samarium iodide undergoing a premature intramolecular transformation, often, an elimination reaction. It seems having an electron-withdrawing
group in the same carbon as sulfone to stabilized carbon radical and removing any C-2 substitution
to reduce the chance of the side reaction are necessary, and the generation of an intermediate samarium enolate, which assumes to facilitate the coupling reaction between samarium enolate and
the aldehyde and suppress the elimination reaction is required.16 The synthesis of acetal-free TF
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antigen failed via samarium iodide chemistry; however, we were able to synthesize an aldehyde,
436, that could be used as an electrophile for the nucleophilic reactions, which led us to try one
more additional attempt.

4.2 Attempt toward the sp2-sp3 one carbon coupling formation between aldehyde 436 and sulfoxides 1124 and 1125
In order to further investigate the reactivity of aldehyde 436, the sulfoxides 1124 and 1125
were prepared, which was previously shown to act as a nucleophile capable of attacking an aldehyde at the axial position C-4 position of a galactose moiety bearing an azide group at the C-2
position.15 The sulfoxides 1124 and 1125 were prepared by replacement of the acetyl protecting
group of galactal by benzyl group in two steps, followed by the addition of phenyl sulfenyl chloride
and subsequent hydrogen chloride elimination using DBU (Scheme 4.25). The acetyl group was
then removed via Zemplén deacetylation and the hydroxyl groups were benzylated using NaH and
benzyl bromide. The phenyl sulfenyl chloride, freshly prepared from N-Chlorosuccinimide, was
used directly for addition to the benzylated galactal. After the addition reaction, hydrogen chloride
was eliminated with DBU,19, 20 and upon oxidation using mCPBA, a diastereomeric mixture of
sulfoxide 1124 and 1125 was obtained.21
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Scheme 4. 25 Synthesis of sulfoxide 1124 and 1125
The nucleophilic addition of both sulfoxide 1124 and 1125 with the aldehyde were performed in the presence of strong bases, however, the result did not show the desired product. Using
different bases including LDA, n-BuLi and t-BuLi accompanied by HMPA to enhance the nucleophilicity of the nucleophile did not improve matters. Using LDA and n-BuLi gave no conversion
of aldehyde 436 and using t-BuLi indicated the decomposition of both the nucleophile and electrophile.
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Scheme 4. 26 Nucleophilic addition reaction between sulfoxide 1224,1225 and aldehyde 436
Consequently, the synthesis of aldehyde at the C-3 position through Claisen rearrangement,
olefination, and Wittig reaction as the key step, did not afford the desired result, however using
Grignard reaction, followed by samarium iodide chemistry resulted in desired aldehyde 436.
Although our attempts did not lead us to the final product, after trying multiple approaches,
we were able to synthesis novel aldehyde 436, which seems necessary for the construction of a
single sp3-sp3 carbon linkage between two sugar moieties in reasonable steps counts.

4.3 Alternative meanderings: Attempt to synthesize acetal-free TF antigen
As our previous research showed, (Section 4.1.3) using Wittig reactions for the synthesis
of aldehyde 436, ketone 433 could behave as an electrophile if small stabilized ylide reagents were
used. However, we did not know how small the ylide should be to be effective. We then targeted
Wittig and Horner–Wadsworth–Emmons reactions to build one carbon linkages between two sugar
moieties (Scheme 4.27). First, we introduced β-aldehyde functionality to the anomeric position of
a galactose moiety to be converted to and unstabilized ylide. Compound 464 could then react with
ketone 433 via ylide formation to form one carbon linkage between sugars. Elimination of water
would afford compound 466 bearing an alkene group in the bridge, which upon selective reduction
would provide the desired compound 467.
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Scheme 4. 27 Proposed synthesis of fully C-glycoside disaccharide 468 via a Wittig reaction
The triphenylphosphonium iodide 464 was prepared in three steps as shown in Scheme
4.28. Aldehyde 1131 (Synthesis of aldehyde 1131 will be discussed in section 4.4) was readily
reduced to alcohol 468 using NaBH4, then the alcohol was replaced with an Iodide via PPh3, I2 and
imidazole. The desired salt 464 was prepared using neat PPh3 and heated at 120°C for 2 hours.
Then n-BuLi was used to convert compound 464 to the triphenyl phosphonium ylide for the Wittig
reaction with ketone 433. Unfortunately, the Wittig reaction gave a complex mixture from which
no product could be observed.
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Scheme 4. 28 Synthesis of compound 464 and a Wittig reaction
Next, we tried to use a slightly more activated ylide for the Wittig reaction, specifically
compound 472, which was synthesized starting from lactone 470 (Synthesis of aldehyde 470 will
be discussed in section 4.4). In the first step, a nucleophilic attack of dimethyl methyl phosphonate
ion, generated by n-BuLi to the lactone 470, afforded compound 471, which after dihydroxylation
with trimethylsilyl triflate and triethylsilane converted to the desired compound 472. A Horner–
Wadsworth–Emmons reaction between compound 472 and ketone 433 was attempted through an
in situ ylide formation using n-BuLi, however, this reaction did not proceed and trying to push the
reaction forward with heating to the reflux resulted in a complex and intractable mixture (Scheme
4.29).
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Scheme 4. 29 A Wittig reagent attempt between ketone 433 and compound 472
After two failed attempts at using Wittig chemistry to link the two sugar moieties together,
the next step was to design a stabilized ylide for use in the Horner–Wadsworth–Emmons reaction.
The synthesis of compound 473 was initiated using compound 471 as a starting material (Scheme
4.30). This compound was synthesized using NaH to form an open chain and trapped the hydroxyl
group with TIPSCl. This compound was used for a Horner–Wadsworth–Emmons reaction with
ketone 433. We attempted to generate the corresponding ylide in situ using n-BuLi, but the desired
product never formed, and the reaction gave a complex mixture. This result may be explained by
too much combined steric hinderance on both the ylide and the electrophile, ketone 433.

Scheme 4. 30 Synthesis of compound 473 and a Horner–Wadsworth–Emmons attempt between
compound 473 and 433
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Our next proposed approach was built based on the recent application of cyclic sulfamidates, derived from serine, to activate the β-position to nucleophilic attack.22, 23 A Julia-Lythgoe
olefination would then allow us to make our target, and this inspired us to combine these methods
for the synthesis of TF antigen. This approach, (Scheme 4.31), involves a thiol functionality in the
galactose moiety that would β attack a cyclic sulfamidate 475 in glucosamine sugar to connect two
sugar moieties together. Sulfur was oxidized to form the sulfone, which upon Ramberg-Bäcklund
Reaction would generate the bridge-bearing alkene group. This olefin then could be selectively
reduced to build a one-carbon bridge with a β orientation.

Scheme 4. 31 Proposed synthesis of acetal TF antigen through a cyclic sulfamidate 475 formation as the key step
To begin our synthesis, compound 474 was synthesized from compound 469, which is to
be used as a nucleophile in an SN2 reaction to attack a cyclic sulfamidate 475 and open the cyclic
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ring. The nucleophile synthesis was straight forward with a simple nucleophilic substitution between thioacetate and iodide afforded the compound 474 in 73% yield, (Scheme 4.32a) which
then could easily convert to the resulting thiol using sodium methoxide.
The synthesis of the galactosamine moiety was more challenging. The nucleophilic substitution between glucose bearing thiol directly attaching to the anomeric position and compound
475 was already reported by Fernández-Mayoralas,24 however, in our case, -CH2SH is attached to
the anomeric position of galactose and electrophile has to be galactosamine moiety. First, we tried
to investigate whether we could successfully perform an SN2 reaction between compound 474 and
compound 475 bearing glucosamine moiety, hoping to convert to galactosamine in later steps.
Synthesis of compound 475 began based on known procedure reported by Withers25 using
compound 1102 as the starting material (Scheme 4.32b). 4-nitrophenol was applied as a glycosyl
acceptor to react with the glycosyl chloride donor in the presence of K2CO3 to generate compound
480. The acetyl group was then deprotected, and the hydroxyl group at C-6 and C-4 were blocked
by a benzylidene protecting group using benzaldehyde dimethyl acetal and p-TsOH. The equatorial hydroxyl group was then converted to the axial orientation through another SN2 reaction. A
mesylation of the hydroxyl group using MsCl and pyridine followed by nucleophilic substitution
with water yielded the axially oriented hydroxyl group on compound 482. Despite the known procedure for sulfonation using 1,1΄-sulfonyldiimidazole, we were not able to obtain the same result.
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Scheme 4. 32a,b Synthesis of the first monomer 474, a, and Attempt to synthesis of the second
monomer, b
Unfortunately, none of these routes toward the synthesis of acetal-free TF antigen resulted
in the desired product, and we had to move on the next approach, the synthesis of acetal-free TF
antigen via Baylis-Hillman reaction, which will be discussed in the next section.

4.4 Attempt to synthesis of acetal-free TF antigen via Baylis-Hillman reaction
This synthetic route was inspired by Vogel’s synthesis of the mono C-glycoside analogue
of the TF antigen.26 We tried to modify the synthesis with two goals in mind. First, we are targeting
the fully acetal-free analogue of the TF antigen. Second, we are trying to build a more efficient
route for the synthesis antigen. In particular, we concluded that starting from the synthesis of the
mono C-glycoside, reported by Vogel which itself was performed in more than 40 steps, to access
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a fully acetal-free version would not be practical if it were to be actually used in a glycopeptide as
we intend.26
Our first proposed synthesis of a β-oriented anomeric aldehyde of a galactose moiety goes
through a cyanation procedure and the results are shown in Scheme 4.33. TMSCN was used as the
cyanide source that replaced the acetyl group at the anomeric position via a Lewis acid assisted
nucleophilic substitution using BF3•OEt2. Next, the rest of the acetyl groups were removed via a
Zemplén deacetylation. Although the cyanation and acetyl deprotection procedures worked
smoothly the next step, protection of the hydroxyl group, was problematic. First, compound 485
was subjected to the standard benzylation procedure using NaH, BnBr in DMF, which did not
result in the desired product. It may be explained by the electron-withdrawing nature of the cyanide
group, which makes the proton at the anomeric position more acidic and using a strong base such
as NaH drives the reaction towards an elimination product.
As an alternative, the TBS protecting group was then applied to protect the hydroxyl group
in two separate reactions. First TBSCl was used with Et3N, DMAP and imidazole. This reaction
afforded a mixture of multi-substituted products resulting from incomplete protection. Forcing the
reaction toward completion by heating and increasing the amount of each reagent still did not
provide the desired outcome. TBSOTf was then applied as a TBS source accompanied by DMAP
and pyridine; however, no desired product was observed. Despite using a milder base and a
stronger electrophilic TBS source, the steric effect and decreased reactivity of the alcohols toward
the electrophile results in the same incomplete protection.
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Scheme 4. 33 Synthesis of aldehyde 483 via cyanation procedure
Next, we turned our attention to the use of a furan substituent at the anomeric position
which we could convert to the aldehyde in three steps. The proposed synthetic analysis is presented
in Scheme 4.34. First, oxidative cleavage of furan, reduction of the carboxylic acid and then subsequent oxidation of the alcohol would form the aldehyde. A solvent assisted procedure was proposed to push the furan to attack from the equatorial site of the anomeric position.
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Scheme 4. 34 Proposed synthesis of aldehyde 1135 through furan oxidative cleavage
The first glycosyl donor was synthesized from fully acetylated galactose. First, SPh was
installed at the anomeric position, then the acetyl protecting groups were replaced with non-participating benzyl groups to facilitate glycosylation. Glycosyl donor 486 was then activated by NIS
and TfOH to form the oxocarbenium ion. In order to get a β-oriented furan at the anomeric position,
acetonitrile is employed as a solvent for glycosylation to take advantage of a solvent assisted procedure reported by Schmidt.27 This was successful, producing the furyl glycoside in 80% yield.
The mechanism originally proposed by Schmidt is shown in Scheme 4.35. After formation of the
oxocarbenium ion, acetonitrile then could attack to the C-1 position to build a network. This network encumbered the axial face and nucleophile, furan, in this case, can occupy β position. However, the presence of this network and solvent assistance in general is under debate and are currently under investigation in the Trant group.
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Scheme 4. 35 Proposed solvent effect of acetonitrile for β-glycosylation through an axial network by Schmidt
Oxidative cleavage of the furan substituted galactose 487 based on the standard Sharpless
procedure was performed successfully using RuCl3, NaIO4;28 however, the carboxylic acid produced was unstable and decomposed in one hour. This is not a very useful reaction.

Scheme 4. 36 Attempt to synthesis of aldehyde 1131 via oxidative cleavage of furan
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The final approach, which successfully produced the desired aldehyde 1131 was designed
with a Grignard reaction as the key step (Scheme 4.37). First, lactone 470 was prepared from
compound 486, which was previously synthesized for the previous furan glycosylation approach.
This molecule underwent hydrolyzation of the SPh group using NBS and water, and then the hydroxyl group was oxidized using Dess-Martin Periodinane to generate lactone 470 in 81% yield.
The lactone 470 was subjected to a Grignard reaction using a vinyl magnesium bromide solution
in THF. Subsequent dihydroxylation of the anomeric alcohol using triethylsilane and BF3•OEt2
afforded the desired β-vinylic compound 495 in moderate yield in two steps from 470. Having a
vinyl group in the β orientation at the anomeric position in hand, we tried the ozonolysis process
to obtain aldehyde 1131. The ozonolysis was performed, and subsequently dimethyl sulfide was
used to cleave an O-O bond of the trioxolane intermediate produced from ozonolysis. This reaction
gave the desired aldehyde in good yield. With aldehyde 1131 in hand, we turned our attention to
the second component necessary for the Baylis-Hillman reaction, the enone 499, and finally to
linking the two sugar moieties and forming the first double C-glycoside disaccharide.

Scheme 4. 37 Synthesis of aldehyde 1131 through a Grignard reaction as the key step
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In order to save some steps, an allyl group was introduced to the second monomer at the
anomeric position, which was intended to be used to convert to the galactosamine moiety in later
steps. The installation of an allyl group before a Baylis-Hillman reaction allows the formation of
the first double C-glycoside of a disaccharide in fewer steps and provides the tools for the attachment of an amino acid to the allylic functionality.
The Ferrier rearrangement29, 30 was performed to install the allyl group at the anomeric
position in the presence of BF3•OEt2 in acetonitrile. As expected, an absolute α oriented allylated
product was obtained, then acetyl groups were removed via NaOMe, MeOH. The hydroxyl group
at the C-6 position was then selectively protected by the TBS group using Et3N and DMAP,31
which upon oxidation using PCC, formed the desired enone 499 in good yield (Scheme 4.38a).
Finally, the Baylis-Hillman reaction was carried out using Et2AlI to couple enone 499 and aldehyde 1131. This reaction afforded the first disaccharide bearing double C-glycoside 4401 in low
yield (Scheme 4.38b).
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Scheme 4. 38a,b Synthesis of the second monomer 499, a, and Synthesis the first double C-glycoside of disaccharide via a Baylis-Hillman reaction, b
A mechanism for this reaction is proposed in Scheme 4.39. Initially, the aldehyde 1131 is
activated by the Lewis acidic aluminum species. Iodide ion then attacks in Michael 1,4-addition
fashion to the enone, which upon collapse of the enolate establishes the C-C bond formation. The
enolate again forms by removing an ethanol molecule, which upon the nucleophilic attack of iodide
ion to the aluminum, regenerates the Et2AlI and the enone. The desired product 4401 obtained
after work up via hydrolysis.

Scheme 4. 39 Mechanism of a Baylis-Hillman reaction between aldehyde 1131 and enone 499
With the linkage of the sugars complete and the double C-glycoside in hand, we set up a
plan to get to the target TF antigen analogue. Our proposed strategy includes, first, introducing
nitrogen source to the C-2 position of the enone, dihydroxylation of the bridge, a selective reduction of ketone followed by linking the amino acid to the galactosamine moiety, the sites of these
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manipulation are highlighted in Figure 4.3. At first glance this approach seems lengthy, however,
if the plan works it would still be less than 40 steps and would be a more efficient route for the
synthesis of a very important biological relevant and completely acetal-free TF antigen analogue.

Figure 4. 3 Manipulation sites of C-glycoside disaccharide towards synthesis of acetal-free TF
antigen 401
We first tried to introduce a nitrogen source at the C-2 position. First, we tried using neat
MeONHBn, which is a known reagent to do conjugate addition with isolevoglucosenone reported
by Vogel.32 Unfortunately, this reagent did not work with our α,β-unsaturated system, and the
starting material was recovered. NaN3 and MeONHBn were then used with a wide range of acidic
and basic conditions to push the reaction forward which are summarized in Scheme 4.40. Acetic
acid, HCl and alumina were used for the azidation reactions; however, none of them showed any
conversion. Introducing a nitrogen source using MeONHBn was then again examined, this time
via basic, using Et3N and acidic, using FeCl3, conditions. Again, no conversion was observed. The
results suggest low reactivity of the nitrogen sources or, more likely, the α,β-unsaturated system
500.
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Scheme 4. 40 Michael addition procedures of enone 500
Two main challenges have to be addressed in order to move forward using this approach.
First, the key step in the yield and scalability of the Baylis-Hillman reaction must be optimized as
a lengthy synthesis remains in order to get to the target TF anitgen.26 Second, Identification of a
more reactive nitrogen source with higher nucleophilicity is required. Depending on the identity
of this reagent, further manipulation may be required in order to convert it to the acetamide group
with the correct stereochemistry. Once these two issues are solved, the selective reduction of the
ketone could be accomplished using LiBH4, as previously published by Vogel.26 Finally introducing an amino acid to the sugar moiety has already been solved in the synthesis of the Tn antigen
in Chapter 3 and similar methodology could be applied here.
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5 Chapter 5: Total synthesis of glycolipids from S. pneumoniae and the
biological re-evaluation of their immunological activity
5.1 Synthesis of mono- and disaccharide glycolipids
Glycosphingolipids are very important in biological compounds. Invariant natural T killer
cells are a subclass of white blood cells, which activate the immune system through releasing cytokines. These cells are activated with glycolipid antigens. Once activated, they engage in many
effector functions. They can activate T cell, B cell, dendritic cells, and macrophages. Also, they
can be involved in the cross-presentation activity and NK transactivation. This means we can expect a robust immune response from the activation of iNKT cells. Unfortunately, there is no known
mechanism up to date to control this massive immune response. However, this type of robust immune response could be applied as the last line of defense against cancers, or pathogenic infections.
iNKT cells recognize lipid antigens presented by CD1d, a non-polymorphic major histocompatibility complex class I-like antigen-presenting molecule. These cells are conserved between
humans and mice, specifically the glycolipid antigens. KRN 7000 was the first glycolipid antigen
known to have the ability to activate iNKT cells, this antigen was isolated from sea sponge in
japan. KRN 7000 was isolated as a result of structure-activity studies on glycolipid cell extracts of
sea sponge. KRN 7000 acts as an antigen causing a systemic immune response in mammalian
cells, by the release of signaling molecules called cytokines, and has potential as immunotherapy
of last resort. However, it is still unclear how the mammalian immune system responds to the
glycolipid antigen isolated from a sea sponge.
Two main fractions of antigenic S. pneumoniae glycolipids, which were isolated from S. pneumoniae, have been identified; one contains a monosaccharide glucose sugar α-linked to diacylglycerol (DAG), the second was identical except it had a galactose moiety attached to the DAG
shown in Figure 2.2. Both the monosaccharide and the disaccharide appear capable of activating
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iNKT cells, however, the exact biological properties of these two glycolipids remained uncertain.
Despite a few reported synthesis of the monosaccharide, biological evaluation of this antigen remained incomplete, and synthesis of disaccharide glycolipids has yet to be reported. Here an efficient and well manipulated total synthesis of both S. pneumoniae glycolipids and our re-evaluation
of their immunological activity are discussed.

5.1.1 Synthesis of monosaccharide glycolipid 1168
The synthesis of 1168 was initiated using glucose as a starting material (Scheme 5.1). Glucose was acetylated using the standard acetylation protocol, then the acetyl group at the anomeric
position was replaced with an SPh functionality. The acetyl protecting groups were replaced with
non-participating benzyl protecting groups to prevent the anchimeric assistance of the acetyl group
for the glycosylation step. Zemplén deacetylation, followed by benzylation using BnBr and NaH
in DMF afforded compound 502.1 Finally, the glycosyl chloride donor was prepared for use in the
glycosylation reaction. This compound was synthesized by hydrolyzing SPh in compound 502
using NBS and H2O,2 then chlorination of the anomeric position via oxalyl chloride afforded glycosyl donor 503 in 38% yield (Scheme 5.1).3

Scheme 5. 1 Synthesis of compound 502 and chlorination of the anomeric position
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The diglycerides acceptor was synthesized based on Trivedi’s reported procedure as shown
in Scheme 5.2.4

D-mannitol

was protected with zinc chloride and acetone to form mannitol di-

acetonide. An oxidative cleavage followed by reduction afforded the glycosyl acceptor 1253. it is
worth mentioning that the oxidative cleavage step of mannitol di-acetonide, was done using lead
IV acetate as sodium periodate did not work according to Trivedi’s report.4

Scheme 5. 2 Synthesis of glycosyl acceptor 1253
The first glycosylation reaction between glycosyl donor 5033 and glycosyl acceptor 1253
was performed based on the Pozsgay approach using AgOTf and 2,6-di-tert-butylpyrimidine.5 The
result showed exclusively β oriented glycosylic bond against our expectation based on Pozsgay's
outcome (Scheme 5.3a).5 The next glycosylation procedure was done using the glycosylation procedure reported by Sugawara with the exact glycosyl donor and acceptor using Bu4NCl and DIPEA.6 However, despite numerous attempts, we were not able to reproduce the same yield or selectively reported by Sugawara. In our hands, it instead afforded a mixture of products in a 2:1 α:β
ratio with low yield. We then pivoted to a solvent assistant strategy using glycosyl donor 502 and
glycosyl acceptor 1253 (Scheme 5.3b).7 This resulted in a 90% yield with slightly better selectivity
toward the α anomeric oriented product in a 3:1 α:β ratio. However, the standard purification procedure was not successful, and a mixture of both anomers was used for the next step planning to
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separate them in later synthetic steps. Next, the benzyl protecting group was replaced with an
acetyl group (Scheme 5.3c) to prevent complications at the last deprotection step as the cis-vaccenic acid fatty chain contains an alkene functionality, which is prone to reduction in the hydrogenation step. Pd/C was used under a H2 atmosphere to remove the benzyl groups, then the resulting hydroxyl groups were acetylated via Ac2O and pyridine in a 67% overall yield.

Scheme 5. 3 Glycosylation procedures a,b and c
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The isopropylidene group was removed using zinc nitrate to form free hydroxyl groups
ready for acylation.8 The first selective esterification of the primary alcohol was performed by
controlling the temperature at 0°C in the presence of Palmitic acid, EDC and DMAP (Scheme
5.4a). The cis-vaccenic acid was freshly prepared as shown in Scheme 5.4b and applied for the
second esterification. The synthesis of cis-vaccenic acid followed the protocol published by Duffy
in two steps.9 First, a triphenylphosphonium fatty acid was formed via reaction of 11-bromodecanoic acid with PPh3. Then an ylide, generated using KHMDS, was able to attack heptanal through
a Wittig reaction resulting in cis-vaccenic acid. Then cis-vaccenic acid was successfully used in
the esterification of the secondary alcohol in the presence of EDC and DMAP. Fortunately, at this
stage the mixture of α and β anomers were easily separated using column chromatography.

Scheme 5. 4 Synthesis of compound 510 and 511, a, and cis-vaccenic acid 514, b
The final deprotection was carried out using N2H4 at 40°C, which is the only reported reagent capable of deprotecting acetyl group in the presence of long acyl chains.10 This reaction afforded both α and β anomers of glycolipids in 55% and 53%, respectively.
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Scheme 5. 5 Synthesis of both α and β glycosylic bond of monosaccharide glycolipids, 1168,
and 512.
The monosaccharide glycolipid 1168 was synthesized successfully starting from glucose in eleven
steps, and ready to be sent for the further biological evaluation. In the next section, the synthesis
of disaccharide glycolipid 202 will be discussed.

5.1.2 Synthesis of disaccharide glycolipid
Our proposed approach for the synthesis of disaccharide glycolipid 202 was designed to
link glucose to the galactose moieties through a glycosylation procedure, then the second glycosylation between disaccharide and (S)-(+)-Solketal would generate the backbone of the disaccharide glycolipid. The fatty acid chains could then be introduced to the glycerol moiety in the same
manner as described in Section 5.1.1 to afford disaccharide glycolipid antigen 202.
First, the glycosyl acceptor 516 was targeted and synthesized, based on a known procedure
reported by Ensley, in 5 steps starting from glucose (Scheme 5.6).11 The acetylation of glucose
was performed based on the standard protocol and then the acetyl group at the anomeric position
was replaced with a SEt functionality using ZrCl4 in 93% yield. The acetyl protecting groups were
then removed via Zemplén deacetylation procedure. The hydroxyl groups at C-4 and C-6 positions
were blocked with the benzylidene functionality via benzaldehyde dimethyl acetal and p-TsOH at
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50°C, and the rest of the hydroxyl group protected by acetyl group using Ac2O and pyridine. In
order to get a free hydroxyl group at the C-2 position, (which is necessary for the glycosylation),
an acetal migration assisted by NBS and TMSOTf has been done to afford glycosyl acceptor 516
in 40% yield.

Scheme 5. 6 Synthesis of glycosyl acceptor 516
This acetal migration is rationalized by the mechanism depicted in Scheme 5.7. First, the
activation of the glycosyl donor bearing the SEt group at the anomeric position via NBS and
TMSOTf to make an oxocarbenium 517. The oxocarbenium then undergoes a nucleophilic attack
by the carbonyl oxygen of the acetyl group at the C-2 position, which upon addition of water, the
acetyl group migrated to the C-1 and the free hydroxyl group is formed to make acceptor 516.
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Scheme 5. 7 Mechanism of acetyl migration to the anomeric position
With the glycosyl acceptors in hand, the glycosyl donors 519 and 520 were prepared for
the glycosylation in two separate procedures starting from compound 408 (Scheme 5.8).12 After
hydrolyzation of SPh using NBS and H2O compound 487 treated with trichloroacetonitrile and
K2CO3 to produce β oriented glycosyl donor 519. The attempts to provide α oriented glycosyl
donor did not afford exclusively α anomer. The treatment of compound 487 with trichloroacetonitrile in the presence of DBU gave a mixture of anomeric glycosyl donor 519 and 520 in 82% yield.
It is worth mentioning that these glycoside donors needed to be used for glycosylation directly
after synthesis due to their instability.
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Scheme 5. 8 Synthesis of glycosyl donors 519 and 520
In order to optimize the glycosylation reaction a set of experiments were examined under
anhydrous conditions using various reaction conditions in order to achieve the highest yield and
selectivity. BF3•OEt2 and TMSOTf were used as activators accompanied by α or β glycosyl donors
in the glycosylation reaction (Scheme 5.9). The results showed that TMSOTf was not an appropriate activator, and importantly, the β glycosyl donor was utterly inactive in glycosylation. The
mixture of glycosyl donors was exploited for glycosylation in order to use the α glycosyl donor,
as this donor could not be separated through standard purification procedures. This glycosyl donor
was activated via BF3•OEt2 for the glycosyl acceptors attack and the product was achieved exclusively in the desired α orientation. The overall yield of this reaction indicates full conversion of
the α glycosyl donor.
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Scheme 5. 9 Glycosylation procedures between glycosyl acceptor 516 and glycosyl donors 519
and 520
Based on Savage’s procedure, a regioselective deacetylation at the anomeric position was
performed using a mixture of ethylenediamine and acetic acid (Scheme 5.10).13 After successful
deacetylation, the second glycosylation was examined. First, diphenyl sulfoxide, TF2O and 2,4,6tri-tert-butylpyrimidine were applied to acceptor 1253;13 However, this reaction did not afford the
desired product. Finally, 2,4,6- tri-tert-butylpyrimidine replaced with 2-chlropyridine to afford
compound 523 in 46% yield with absolute α configuration.14
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Scheme 5. 10 Synthesis of compound 150 through the second glycosylation
A proposed mechanism for this glycosylation is shown in Scheme 5.11. First, attack of
sulfoxide oxygen to TF2O forms the active diphenyl sulfide bis(trifluoromethanesulfonate) specious, which upon nucleophilic substitution release triflic acid and form the oxosulfonium trifluoromethanesulfonate 524. The oxocarbenium trifluoromethanesulfonate 525 then forms by regeneration of diphenyl sulfoxide and finally the oxocarbenium ion reacts with the glycosyl acceptor
1253 to obtain compound 523.
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Scheme 5. 11 Mechanism of the second glycosylation
After this step, the same protocol was applied to add the long chain ester functionality as
was used in the synthesis of the monosaccharide (Scheme 5.12). First, the benzylidine and benzyl
protecting groups were removed at the same time via hydrogenation, and then the hydroxyls were
reprotected with acetyl groups. The isopropylidene group was then removed using zinc nitrate and
primary and secondary alcohols in diglycerides part esterified with palmitic acid and cis-vaccenic
acid, respectively.
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Scheme 5. 12 Synthesis of compound 527
The final step, the chemoselective removal of the acetyl group, which was well
accomplished in the previous examples, did not work out for the disaccharide 527. The
disaccharide 527 fragmented upon using hydrazine hydrate at standard conditions, however
cooling down the temperature did not show any product formation. Evidently, hydrazine hydrate
was too reactive to deprotect disaccharide glycolipid and disaccharide 527 decomposed to its
monosaccharides and the glyceride in both room temperature and at 0°C.
In order to get the final product, we had to try another protecting group, which requires a
milder condition for the deprotection. We found methoxyacetyl (MeOAc) can be used as an
alternative for the acetyl protecting group, which can be selectively removed via t-BuNH2, a milder
nucleophile than hydrazine hydrate (Scheme 5.13a).15, 16 Switching acetyl protecting groups to the
MeOAc involved adding one extra deprotection step in our proposed approach. The full
deprotection of compound 523 was performed in two separate steps. First, The acetyl group was
removed with sodium methoxide, and then both benzylidine and benzyl protecting groups were
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deprotected with palladium on carbon in methanol in 73% yield. This time, methoxyacetyl groups
were applied as a protecting group.15, 16 The full deprotected of compound 523 was treated with
methoxyacetyl chloride and pyridine to generate fully methoxyacetylated disaccharide 530
(Scheme 5.13b).

Scheme 5. 13a,b. A t-BuNH2 as deprotecting agent for methoxyacetyl protecting group,a, and
synthesis of compound 530, b
The same protocol was successfully applied via isopropylidene removal, followed by
stepwise esterification using palmitic and cis-vaccenic acids. The final product was obtained by
selective deprotection of methoxyacetyl groups using tert-butyl amine in 82% yield (Scheme
5.14).

192

Scheme 5. 14 Synthesis of disaccharide glycolipid target 202
Although t-BuNH2 is a milder and cheaper reagent than hydrazine hydrate and capable of
deprotecting of methoxyacetyl groups, there is no reported application of t-BuNH2 for the selective
removal of acetyl groups in the synthesis of glycolipids. This discovery led us to consider another
project, a selective deacetylation procedure using t-Butylamine, which will be discussed in the
next chapter.

5.2 The First preliminary biological result
With the glycolipid antigens in hand, we proceeded to evaluate their biological activity.
We employed mouse hydridoma models using two different cell lines: DN32.D3, and N38.3C3
with bone marrow-derived dendritic cells from a DR4 transgenic mouse, expressing human HLADRA-IEα and DRB1*0401-IEβ, on a B6 background, lacking any endogenous type II MHC receptors. The DN32.D3 hydridoma line is especially well designed for this experiment as it possesses both the CD1d receptor for these antigenic glycolipids and the unique conserved, invariant
Natural Killer T-cell receptor. The N38.3C3 does not express the Cd1d receptor. Consequently, it
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does require more additional antigen presenting cells to display the glycolipid antigen. These two
cell lines have been applied in the past to measure iNKT response expressed by interleukin-2 (IL2, other cytokines produce similar results).17-19 IL-2 is secreted when KRN7000 binds to the CD1d
receptor; making KRN7000 a great positive control. Several other glycolipid formulations have
also been demonstrated to induce an immune response from these cell types, including bacterial
superantigens (SAgs),11 a series of glycolipids from pathogenic bacteria,13 including the antigens
synthesized here,5 and also a multivalent acetal-free,13 dendron-supported carbohydrate previously
presented by this team.12c Kinjo and co-workers examined the immunogenicity of their isolated
glycolipids using a similar system to the one applied by our team: mouse Vα14iNKT cell hybridomas were applied. Kinjo isolated glycolipids showed good elicitation of IL-2 from Vα14iNKT+
cells, but no activation in the absence of Vα14iNKT+, then the monosaccharide synthesized and
evaluated the immunogenicity of that system (while also confirming the structure and regiochemistry of the ester groups) and demonstrated the similar activity to the isolated monosaccharide,
however, our result was different. We observed very poor activity in Vα14iNKT cells using our
synthesized glycolipids at any concentration from 1 ng/mL to 1 mg/mL. α-GalCer (KRN7000)
shows its typical potent activity, but the glycolipids show a very low affinity to interact with the
CD1d receptor. The difference between the cell lines used by our research group and that of the
Kronenberg group is that our cells, and mice, have had the murine MHC receptors eliminated,
leaving on CD1d. The Kronenberg group’s cells still have other receptors present. Glycolipids do
not generally bind with other MHC receptors, but the possibility remains that this could explain
this discrepancy. The authors comment on this themselves showing that some of the CD1d-dependent in vivo activation of the iNKT cells could be related to self-antigens presented by CD1d
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and finish their description by stating that the isolated antigens likely “make a contribution to the
production of cytokines by Vα14iNKT cells”5

Figure 5. 1 Elicited IL-2 levels obtained from exposing cells to the synthesized glycosphingolipids
Although this preliminary result disagrees with the Kinjo result, it is worth mentioning that
the Kinjo results regarding iNKT activation was obtained with in vivo biological examination,
however our biological evaluation performed using two different cell lines in vitro. Therefore, it
is not a completely fair comparison nor can any valid conclusions regarding low iNKT cell activity
be drawn. The biological evaluation in vivo is currently under study by our collaborator at the
University of Windsor and will be reported soon. With this in vivo study and our preliminary biological data, the extremely low activity of these glycolipids antigen in vitro obtained by our collaborators, it will result in two possibilities. First, if our in vivo study confirms the Kinjo result, it
implies that in vitro results are not an appropriate tool for measuring the biological activity of
iNKT activators without an accompanying in vivo study. Second, if our results disagree with the
Kinjo result, and no activity is observed in vivo, it may mean that the biological results noted by
Kinjo may have resulted from the presence of impurities in their isolated samples, and possibly in
the synthetic batches as full synthetic characterization was not provided for their monosaccharide.
There are currently more than 300 publications that have cited the Kinjo paper, and this figure is
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expected to grow in the future. It would be problematic if these studies have been based on an
inaccurate result or a poorly characterized compound. This study highlights the need for resynthesize and the importance of careful isolation and characterization of natural products from complex
biological matrices.
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6 Chapter 6. t-Butylamine as a mild and selective deacetylation agent
6.1 Synthesis of starting materials for the deprotection procedure using t-Butylamine
Based on our previous challenge, the deacetylation of a disaccharide glycolipid in the presence of longer ester chains in the glyceride moiety, we were inspired to study the use of t-BuNH2
as a deacetylation reagent. If successful, this compound could be an excellent alternative to traditional deprotection conditions because it is a milder nucleophile and more inexpensive than the
reagents typically employed. However, an essential requirement is the deprotection of acetyl protecting group must be selective for acetyl groups in the presence of other esters.
Although primary esters are typically more prone to hydrolysis than secondary or tertiary
ones, mainly due to steric effects, in carbohydrates this is not always the case. The primary alcohol
in pyranose carbohydrates has lower acidity1 and it seems that the steric effects do not play as
important a role, especially when using small bases and/or nucleophiles for the ester hydrolyzation.
However, due to the lack of adequate research in the carbohydrate field, more detailed studies
evaluating the reactivity of acetate protecting groups at different positions of the pyranosyl form
are required: is it possible to selectively remove some acetates/esters in the presence of others?
The regioselectivity of the deacetylation of nucleosides are well studied;2, 3 however, it is
difficult to extend these results to pyranoses due to a lack of sufficient data. Selective deacetylations have been accomplished when a small base/nucleophile is used for the deprotection; Furthermore, the reactivity order of nucleophilic sites remains to be explored. The steric effects of the
deprotecting reagent are important as, in some cases, these effects work against the electronic
preferences in carbohydrates. The higher acidity of secondary acetyl protecting groups makes it
more susceptible to deprotection than the primary acetate group, however, steric effects in the
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more sterically hindered reagent suggests primary alcohol should deprotect faster than secondary
acetates.
The focus of this study will be examining the potential selectivity of the t-BuNH2 deprotecting agent and its limitations. In particular, tert-butyl amine is studied as a sterically hindered
reagent for the selective deprotection of acetyl groups in the presence of different ester chains
synthesized from propionyl chloride, iso-butyryl chloride, iso-pentanoyl chloride, benzoyl chloride, pivaloyl chloride and palmitoyl chloride. Before examining the selectivity, we needed to confirm that t-BuNH2 can deprotect acetyl groups. This was successful as galactose was acetylated,
then deprotected via t-BuNH2 in the presence of MeOH and CHCl3 in an 84% yield (Scheme 6.1a).
Next, the acetyl group at the anomeric position was replaced with the SPh group, and the
rest of the acetyl groups were removed using NaOMe and MeOH.4 The alcohol at C-6 was selectively protected with a TBS group using TBSCl, imidazole, and DMAP in DMF, then the rest of
hydroxyl groups protected with acetic anhydride and pyridine in 74% yield. The TBS protecting
group was removed (Scheme 6.1b) using TBAF in THF to generate a free C-6 hydroxyl group
ready to be esterified with different ester chains.
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Scheme 6. 1 Deprotection of acetyl group using t-BuNH2, a, and synthesis of compound 604, b
Esterification of the hydroxyl group at the C-6 position was then performed using different
acyl chlorides, the esterification of propionyl chloride, iso-butyl chloride and iso-pentyl chloride
were done using DMAP and pyridine in 80%, 97% and 56% yield, respectively. Those reactions,
shown in Scheme 6.2 were done in DCE at 85°C as performing the reaction in dichloromethane
at ambient temperature did not afford full conversion. The benzoyl chloride reacted with primary
alcohol in the presence of DMAP and pyridine to form the desired product in 80% yield. The
alcohol 604 was subjected to esterification using palmitic acid with EDC, DMAP in CH2Cl2, to
afford compound 609 in 74% yield.
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Scheme 6. 2 Esterification of alcohol 604 with different acyl chlorides
The PivCl was introduced selectively at the C-6 alcohol of fully deprotected compound
601 directly through the acylation. The synthesis provided the product as per the crude NMR, but
due to the COVID-19 situation, we were not able to purify this compound (Scheme 6.3).

Scheme 6. 3 Synthesis of compounds 610
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6.2 Selective acetyl deprotection of compound 605-609 using t-BuNH2
First, deprotection was carried out in parallel on compound 606 and 609 and was allowed
to proceed until the full consumption of starting material was observed by TLC (Scheme 6.4). The
t-butylamine was used in a 1:1 ratio with the starting materials. The solvent and reagent were added
at 0°C, and the reaction was stirred for 16 hours and allowed to warm to ambient temperature (2023°C). The iso-butyl substituted compound 606 was treated with t-BuNH2, MeOH and CHCl3
starting at 0°C then left it to reach ambient temperature. The result showed the starting material
was fully deprotected. However, when the same reaction conditions were applied to the palmitoyl
substituted compound 609 the result indicated the desired selective deprotected product was produced but contaminated with the fully deprotected ester. This result demonstrated that the steric
demand of ester chains at the C-6 position may play an important role in the selective acetyl deprotection in the presence of t-BuNH2 providing a form of substrate control. The outcome of this
reaction could surely be improved by controlling the rate of deprotection via temperature adjustment.

Scheme 6.4 Deprotecting reactions of compounds 606 and 609 at 0°C to room temperature
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In the next step, we tried to control the progress of this reaction by optimizing the reaction
conditions. A, 1:1.5 ratio of iso-butyl substituted compound 606 to t-butylamine was examined
starting at 0°C, however in order to slow down the rate, the reaction mixture was kept at 0°C
throughout the reaction (Scheme 6.5). In 30 to 45-minute intervals, TLCs of the reaction showed
the formation of the desired product; however, after 1.5 hours, the fully deprotected acetyl group
compound began to form. After 9 hours, the reaction was stopped, and the compounds purified.
The result showed a 27% yield of the desired product accompanied by fully deprotected compound
601 in 21% yield along with starting material.

Scheme 6.5. Deprotecting reactions of compound 606 at 0°C
For our next attempt, we decided to keep the temperature at 0°C and stop it when the undesired fully deprotected compound begins to form, these reactions are shown in Scheme 6.6. This
time the same reaction set up at 0°C with 3:1 reagent to starting material ratio was monitored
closely via TLC techniques. After 6 hours, the intensity of the product grew stronger, judged by
TLC, and then the second spot began to produce a shadow. At this point, the reaction was stopped
and purified. The result showed a 51% yield of the desired product with the mass balance being
recovered starting material. In a second reaction, starting material 607 was added to 3 equivalents
of t-butylamine at 0°C. The TLC observations after 4 hours indicated the desired product spot had
become stronger and minimal amount of fully deprotected compound start to form. The reaction
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was stopped and purified to generate compound 613 in a 45% yield, again with the recovery of
starting material and trace fully deprotected material.

Scheme 6. 6 Deprotecting reactions of compounds 606 and 607 at 0°C
In the next stage, we decided to determine the minimum temperature that the reaction can
progress at and stop it when the undesired fully deprotected compound begins to form. A series of
experiments were set up in parallel with a lower starting temperature, –20°C. This temperature
was raised or maintained depending on the progress of the reaction for specific substrates. Compound 606 was treated with tert-butyl amine in a 1:3 ratio, at –20°C and monitored closely via
TLC. After 3 hours, when no conversion was observed, the temperature was increased to –10°C.
The desired product began to form after 1 hour. The product spot became stronger after one more
hour, and a very faint, fully deprotected compound appeared. The reaction was stopped, and the
mixture was stored at –78°C in a freezer. Due to the sudden lab shutdown, purification of this
compound was not completed. However, it is predicted that this yield would be the highest of the
reactions attempted based on the TLC and crude HNMR.
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In a similar protocol, the isopentyl group 607 was subjected to the deprotection at –20°C.
Similarly, no reaction was observed after 3.5 hours. The temperature increased to –10°C, and after
1 hour, the product started to appear. The reaction continued for one more hour and stopped when
the byproduct began to form. The mixture was stored at –78°C freezer. Due to the sudden lab
shutdown, purification of this compound was not completed. However, the crude 1H NMR indicates the product 613 is present in the reaction mixture.

Scheme 6. 7 Deprotecting reactions of compounds 606 and 607 at –20°C to –10°C
The last deprotection was done on propionyl substituted compound 605, as a challenging
substituted because of size similarity with the acetyl group. The starting material 605 was treated
with tert-butyl amine in a 1:3 ratio at –20°C, the temperature was increased after 3.5 hours when
no reaction was observed. Like the other esters, the product spot reached maximum intensity after
one hour. The reaction stopped, and like the rest of the reactions that have been done in parallel,
the mixture was stored at –78°C freezer. Due to the sudden lab shutdown, purification of this
compound was also not completed.
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Scheme 6. 8 Deprotecting reactions of compound 605 at –20°C to –10°C
This research forced to be stopped due to the COVID-19 pandemic situation. Once allowed
back in the lab, in future work we will complete the purification of the esters investigated during
the first phase. Then we will investigate selective deprotection of acetyl group in the presence of
longer chains in different position of galactose as well as glucose and glucosamine.
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7 Chapter 7: Synthesis of oligosaccharides conjugation-breaking units in
semiconducting polymers
Organic electronics are often processed with halogenated solvents.1, 2 In order to replace
these harmful halogenated solvents with greener ones, we need polymers that are soluble in
greener, generally protic solvents. Carbohydrates seem to be a good candidate to be added to the
polymer to increase the solubility due to their high hydrogen-bonding ability. In this section we
discuss the synthesis of a carbohydrate insulating spacer that can be integrated into conductive
polymers. An additional advantage of using carbohydrates in the backbone is the introduction of a
biodegradable component into the polymer framework. This project will be done in two phases;
the first one, which is discussed in this section, is the synthesis of protected disaccharide bearing
the free hydroxyl group at the C-6 positions, the second phase involves further manipulation and
polymerization. The second phase of this research is currently underway and is being performed
in the research group of our collaborator, Professor Rondeau-Gagné at the University of Windsor.

Scheme 7. 1 Synthesis of disaccharide 702 from lactose
We needed a divalent scaffold to allow for polymerization from both “ends” of the molecule, while also ensuring the presence of an enzymatically/chemically labile linker. A disaccharide,
like lactose, satisfies these conditions. The interglycosidic bond is highly sensitive to omnipresent
lactosidases while also being sensitive to less specific endoglycosidases and mild aqueous acid. At
the same time, it clearly provides two similar sites for polymerization, the sterically unencumbered
C-6 hydroxyls. This target 702 also has a clear and simple strategy available for its synthesis.
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Surprisingly, it is a new compound (Scheme 7.1). The project was initiated by acetylation of lactose; however, the reported acetylation of lactose using I2 and acetic anhydride3 failed to produce
β oriented acetyl at the anomeric position and results showed the production of the α acetylated
product exclusively (Scheme 7.2). As the readers will know, this is not a new problem encountered
in this thesis: many supposedly selective glycosylations have proven to be irreproducible. Acetobromination employing AcBr and AcOH also did not give the desired outcome and afforded a
mixture of undesired products with only a small amount of the desired product.4, 5 Finally, the β
anomeric conformer of peracetylated lactose 704 was obtained using our normal β-selective acetylation system: sodium acetate and acetic anhydride at elevated temperatures with a yield of 76%
after recrystallization.

Scheme 7. 2 Lactose acetylation procedures
Next, the acetate at the anomeric position was replaced with the SPh group using thiophenol and BF3•OEt2. This reaction afforded the desired product in a 73% yield. The acetyl protecting
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groups were then deprotected via the Zemplén deacetylation procedure and the C-6 primary hydroxyl groups selectively protected by the TBS group using imidazole, DMAP and TBDSCl. The
result showed 61% of the desired product, which upon acetyl protection based on standard acetylation procedure using pyridine and acetic anhydride converted to the compound 708 with a quantitative yield (Scheme 7.3). The final step, TBS deprotection, was successfully done via one molar
TBAF solution in THF at 0°C for 4 h. Although this reaction worked smoothly, the result was not
great, due to acetyl migration, and a 38% yield was obtained (Scheme 7.3). This compound was
sent out to our collaborator, Rondeau-Gagné group, at the University of Windsor for further transformation toward polymerization.

Scheme 7. 3 Synthesis of compound 702
If the disaccharide polymer shows a promising result, then we can work on yield optimization for future work. The final step, especially, might benefit from buffering with acetic acid to
avoid undesirable side reactions involving general base/nucleophile catalysis that can occur in the
presence of F ̶.
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8 Chapter 8. Conclusions, synthesis, and future work
8.1 The synthesis of the Tn antigen
The primary objective for Chapter 3 was completed, which was the synthesis of an acetalfree, N-Fmoc protected Tn antigen. The acetal-free Tn antigen bearing N-Fmoc protecting group
was targeted in this research to facilitate solid-phase synthesis for peptide attachment to the antigen. This antigen was synthesized in order to investigate whether it can activate T-cells and to
investigate the immune response produced by this vaccine. Specifically, there are questions regarding whether the immune response is specific for the whole antigen unit or the response comes
from only peptide chain.
For future work, the acetal-free Tn antigen 301 should be integrated into longer peptides
using solid-phase peptide synthesis to link the peptide chain to the Tn antigen unit for the T-cell
activation study (Figure 8.1). After preparation of antigen 801, this compound will be sent to our
collaborator at Laval University for biological examinations, these tests will be performed against
the natural antigen, which is currently under preparation in our group. Our ultimate goal is to use
T-cell activation approach developed by Boons and Danishefsky1-3 by conjugating highly immunogenic T-cell dependent peptides to short B-cell peptide sequences incorporating the acetal-free
Tn antigen, or using a rod-shaped viral nanoparticle comprised of the coat protein (CP) of papaya
mosaic virus (PapMV), which is self-assembled around a single-stranded RNA, developed by our
collaborator Dr. Denis Leclerc at Laval University.4-6 The single-stranded RNA determines the
length of the nanorod (PMVN).
Papaya mosaic virus nanoparticles (PMVN), act as a toll-like receptor 7/8 agonist. These
have been applied to improve the immunogenicity of a peptide antigen fused to the nanoparticle
framework as a vaccine platform technology.7-10 PMVN nanoparticles are used to trigger innate
immunity and increase the immune response against cancer.
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The way that the PMVN nanoparticle vaccine platform works is, after self-assembly around
a ssRNA, Sortase, which is a bacterial enzyme responsible for attachment of specific proteins to
the cell wall of Gram-positive bacteria, ligates our glycopeptide (acetal-free Tn antigen attached
to a peptide chain with the sortase-specific GGG amino acid sequence at the C terminus) to the
surface. Consequently, an immunogenic cylinder can be readily prepared to act as a promising
vaccine candidate. This cylinder could be converted to the multivalent antigen cylinder for further
immunogenicity enhancement.
This biological evaluation includes: the measurement of quantity and quality of the antibodies production and specificity of these antibodies toward the cancer cells. In addition, a second
set of experiments will be done to determine if the T-cells are activated by antigen 801 or only by
the peptide chain alone thus determining the specificity of the immune response activated by Tcells towards antigen 801.

Figure 8. 1 Future work, peptide attachment to the antigen 301
Based on previous results expressing multivalency increases immunogenicity,11-13 which
was also discussed in both sections 1.1.4.2,14 and 1.1.6.1,15 this effect could be applied in the next
step of this research to solve low immunogenicity of TACAS vaccine candidates. If the biological
evaluation of 801 shows promising results then, as an ultimate goal, the acetal-free Tn antigen
could be converted to a dendron, (Figure 8.2) in order to increase the immunogenicity of the antigen taking advantage of the multivalent effect.
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Figure 8. 2 Proposed dendron 802

8.2 The synthesis of the TF antigen
In the synthesis of the acetal-free TF antigen discussed in Chapter 4, the main objective
was the synthesis of a fully C-glycoside version of the TF antigen in a reasonable number of synthetic steps such that we can integrate it into vaccine candidates. This overarching objective was
not met, although progress was made towards it. However, we have been able to solve several key
synthetic challenges including the first synthesis of a sugar bearing an aldehyde at the C-3 position
and a nitrogen source at the C-2 position. In addition, the synthesis resulted in the first ever example of a double C-glycoside disaccharide. With these two lead compounds in hand, the synthesis
will be completed in future work by a different lab member. We have learnt a lot in this endeavour,
it was the majority of the thesis work, and several steps will need to be addressed to move forward:
first, optimization of the double C-glycoside disaccharide formation must be performed. This will
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likely involve modifying the protecting groups and functionalities on the two partners used in the
Baylis-Hillman Reaction in addition to standard reaction optimization screens (Scheme 8.1). For
example, the TBS protecting group could be used instead of a Bn protecting group in the galactose
moiety. Vogel reported a better yield using the TBS group rather than using a Bn protecting group,
which may be valid for our research as well.16 Second, a different, smaller, protecting group in the
enone moiety such as an electron withdrawing C-6 acetate could be tried to achieve a better result.

Scheme 8. 1 Proposed Baylis-Hillman Reaction between aldehyde 1130 and enones 499 and 803
Once the disaccharide formation has been optimized, a more reactive amine, such as
BnNHOBn, could be used for the conjugate addition to enone 806 as shown in Scheme 8.2. As an
alternative plan, aldehyde 436 could be converted to the olefin using the Tebbe reagent or
CH3PPh3Br through a Wittig reaction, followed by olefin metathesis with olefin 809 mediated by
a Grubbs 2nd generation catalyst. An asymmetric olefin reduction should provide access to disaccharide 810, which after a few manipulations, should be easily converted to the target 401 as
shown in Scheme 8.3. This is a challenging target, but it should be attainable.
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Scheme 8. 2 Proposed synthesis of compound 401 through a conjugate addition reaction

Scheme 8. 3 Proposed synthesis of compound 401 via a Grubbs 2nd generation catalyst

8.3 Synthesis of an immunogenic glycolipids target 1168 and 202
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The main objectives of Chapter 5, the synthesis of a glycolipidic antigen, were fully met.
However, the biological evaluation has yet to be completed. These evaluations are required in
order to form conclusions regarding the activity of these antigens towards iNKT cell activation.
Our result was totally different from the Kinjo report, but as mentioned before, a similar system,
mouse Vα14iNKT cell hybridomas were applied. Glycolipids do not generally interact with other
MHC receptors; however, this could be the reason for discrepancy between the Kinjo result and
ours. Moreover, as they mentioned,17 some of the CD1d-dependent in vivo activation of the iNKT
cells could be obtained from self-antigens presented by CD1d. Consequently, further biological
examination remained for the future using the exact same conditions in vivo as the Kronenberg
group applied to have valid conclusions. Either; these antigens are capable of activating the iNKT
cell, which means the biological result produced in vitro cannot be extended to the in vivo result
meaning further biological evaluation in vivo to validate in vitro results are always necessary, or
there is no significant activation meaning this type of so-called antigen are not actual antigens and
the study and synthesis towards these molecules based on the previous reports are not useful and
should be stopped.

8.4 tert-butylamine as a mild deacetylation agent
The application of t-BuNH2 as a selective deacetylation agent mostly remains to be explored in the future because of the pandemic situation. We had identified this reaction in early
2019 and were pursuing it as a side project in the current academic year; under normal circumstances we would be further ahead, but the pandemic intervened. Before the shutdown, the selective deacetylation of the C-2, C-3, and C-4 in the presence of other esters chain at the C-6 position
was accomplished by controlling the temperature and closely monitoring the progress of the reactions. Still a few reactions remained to be performed to complete this part of the research. As an
ultimate goal, in the future, the location of the esters chain and acetyl group should be changed to
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further investigate the utility of using t-BuNH2 in the selective deacetylation of acyl groups in
different locations, in the presence of varying ester chains. This research also could be extended
by using different sugar moieties, such as glucose, glucosamine and galactosamine. Some proposed target molecules are shown below in Figure 8.3. We want to ensure that this is a general
reaction and it is robust. As noted throughout the thesis, when we applied published protocols to
our systems, they often failed to provide the reported product which does lead to doubts as to the
validity of the original research. We want to ensure that, when we publish these results and share
them with the community, that we can highlight the advantages and limitations. Acetates are likely
the most flexible protecting group in carbohydrate chemistry. It would be a very great benefit if
they could be used freely in the presence of other esters as the designer would have confidence
that they could be selectively removed in reasonable yield from most any system. We are confident
that the data suggests this is likely, but we want to be very confident. One of the methods we will
be employing is to repeat the reaction with different chemists conducting the study. We want to
ensure that these reactions are robust and usable.

Figure 8. 3 The proposed structure of future targets

8.5 Lactose as an insulator in conductive polymers
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The objective of the final chapter of this thesis, Chapter 7, was met in full: the synthesis of
acetylated lactose bearing free hydroxyl group at the C-6 and C-6΄positions. This compound was
synthesized successfully and will be sent in the future to our collaborator for polymerization
through an esterification reaction. This will result in a polymer which hopefully is more soluble in
greener, protic solvents and, which will introduce enzyme-catalyzed degradability to the polymer
backbone through the ester linkages. A depiction of a targeted block co-polymer is shown in Figure 8.4.

Figure 8. 4 Proposed conjugated polymers for greener solubility and degradability

8.6 Synthesis of the thesis
This thesis, and my PhD work more broadly, focused on the interface of carbohydrate
and organic chemistry. In many ways, these have historically been treated as two separate subdisciplines, with the carbohydrate community using its own conventions and approaches to solve
problems that have solutions in the synthetic organic chemistry space. My interest was in applying the tools of synthetic organic chemistry to make unusual carbohydrates, and to integrate them
into biomedically or material-science relevant molecules.
The synthesis of these molecules is challenging. This thesis shows our effort to solve these
challenges using organic chemistry approaches and trying to explore fast, efficient and cost-effec-
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tive ways to overcome these obstacles. Applying the tools of synthetic organic chemistry in carbohydrate research could be used for the deprotection of acetyl group in the presence of other ester
functionality, which may practically save a significant number of steps in carbohydrate synthesis
or can be used for providing carbohydrate-based vaccines that may save lives. Both could be
aligned in the same direction for the bigger picture. This thesis and my PhD work focused on using
this approach especially for applications in immunology. Carbohydrates play important roles in
the pathogenicity of many diseases and could also help provide the solution. However, the immune
system has a complicated relationship with recognizing carbohydrates, and this is further complicated by the inherent physiological instability of glycosides; consequently, my main goal was to
induce specific immune responses by synthesizing specific carbohydrates, including acetal-free
Tn and TF antigens and also glycolipids. This has required new chemistry.
Synthesizing these carbohydrates is challenging, and scientists spend a lot of time and resources making these biomedically relevant molecules, however, despite much effort, including
my own, much more research is required to improve our understanding of the role of carbohydrates
in immunology; our tools could prove very helpful.
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9 Experimental protocols and characterization data
9.1 General methods and materials for chemical reactions
Solvents were purchased from Caledon Labs (Caledon, Ontario), Sigma-Aldrich (Oakville,
Ontario) or VWR Canada (Mississauga, Ontario). Other chemicals were purchased from SigmaAldrich, AK Scientific, Oakwood Chemicals, Alfa Aesar or Acros Chemicals and were used without further purification unless otherwise noted. Anhydrous toluene, tetrahydrofuran (THF), diethyl
ether and N,N-dimethylformamide (DMF) were obtained from an Innovative Technology (Newburyport, USA) solvent purification system based on aluminium oxide columns. CH2Cl2, pyridine,
acetonitrile, N,N-diisopropylethylamine (DIPEA) and NEt3 were freshly distilled from CaH2 prior
to use. Purified water was obtained from a Millipore deionization system. All heated reactions
were conducted using oil baths on IKA RET Basic stir plates equipped with a P1000 temperature
probe. Thin layer chromatography was performed using EMD aluminum-backed silica 60 F254coated plates and were visualized using either UV-light (254 nm), KMnO4, vanillin, Hanessian’s
stain, Dragendorff or phosphomolybdic Acid (PMA)’s stain. Preparative TLC was done using
glass-backed silica plates (Silicycle) of either 250, 500, 1000 or 2000 μm thickness depending on
application. Column chromatography was carried out using standard flash technique with silica
(Siliaflash-P60, 230-400 mesh Silicycle) under compressed air pressure. Standard work-up procedure for all reactions undergoing an aqueous wash involved back extraction of every aqueous
phase, a drying of the combined organic phases with anhydrous magnesium sulphate, filtration
either using vacuum and a sintered-glass frit or through a glass-wool plug using gravity, and concentration under reduced pressure on a rotary evaporator (Buchi or Synthware). 1H NMR spectra
were obtained at 300 MHz or 500 MHz, and 13C NMR spectra were obtained at 75 or 125 MHz
on Bruker instruments. NMR chemical shifts (δ) are reported in ppm and are calibrated against
residual solvent signals of CHCl3 (δ 7.26), DMSO-d5 (δ 2.50), acetone-d5 (δ 2.05), or methanol224

d3 (δ 3.31). HRMS were conducted on a Waters XEVO G2-XS TOF instrument with an ASAP
probe in CI mode.

9.2 Procedure for the preparation of SmI2 from “Inactive” Samarium metal
(Chapter 4)
A 100 mL three neck Schlenk flask equipped with a Teflon-coated magnetic stir bar and a
septum was flame-dried under vacuum. The flask to cool to room temperature and evacuated/backfilled with argon three times, then (3.30 g, 22.0 mmol) of “inactive” samarium metal was added,
the flask was sealed with a septum and subjected to three evacuation/backfilling cycles, then Sm
metal was stirred in the high speed under nitrogen atmosphere for 24 h. The samarium metal was
dissolved in THF (90 mL) and then a solution of iodine (2.80 g, 11 mmol) in THF (20 mL) was
added. The reaction flask was sealed with Parafilm and heated at 60°C for 18 h, then stirring was
turned off and the solution of SmI2 settled for 2 h before cannulating to the Serum Bottle.1

9.3 General deprotection protocol using t-BuNH2 (Chapter 6)
The deprotection of the acetyl protecting groups in the presence of the ester groups followed a general protocol adapted by literature.2 The adaptation was based on using t-BuNH2 as the
deprotecting agent for O-methoxy acetates in the presence of esters. The galactose molecule with
thiophenol on the anomeric carbon, the ester groups on C-6, and the acetyl protecting groups on
C-2, C-3, C-4 was subjected to deprotection with CHCl3 and MeOH as the solvents in every reaction. The temperature and ratio of t-BuNH2 were both varied. All reactions were done in a sealed
tube. After the reaction is done, there is no work-up, and the reaction mixtures concentrated under
reduced pressure.
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9.4 Experimental protocols for Chapter 1
(2R,3R)-2-(acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate 119
The glycopyranosyl bromide 127 (354 mg, 0.86 mmol) was dissolved in CH3CN
(10 mL), and then zinc dust (422 mg, 6.46 mmol) and ammonium chloride (354
mg, 6.46 mmol) were added, and stirred for 4 h at 60°C. Inorganic salts and
excessive zinc dust were removed by filtration. The filtrate was concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (9:1) and passed through a silica
gel column to produce 119, the title compound, as a colourless liquid (141 mg, 60% yield). On
replication, yields varied between 53% and 60% for scales between 100 mg and 50.0 g. Rf = 0.25.
9:1 hexanes/EtOAc. 1H NMR (500 MHz, CDCl3) ppm 6.47 (dd, J = 6.28, 1.70 Hz, 1H), 5.62-5.50
(m, 1H), 5.49-5.36 (m, 1H), 4.73 (ddd, J = 6.29, 2.62, 1.46 Hz, 1H), 4.34-4.19 (m, 3H), 2.14 (s,
3H), 2.09 (s, 1H), 2.03 (s, 3H). Consistent with the literature.3
((2R,3S,4R,5S,6R)-6-allyl-3-hydroxy-5-methyl-4-(pivaloyloxy)tetrahydro-2H-pyran-2yl)methyl pivalate 186
Compound 1103 (5.50 g, 14.8 mmol) was dissolved in methanol (100 mL) then
NaOMe solution was added until a pH of 12 was reached. Upon stirring for 1
h, Dowex 50WX8 was added to neutralize the solution. The solution was filtered and concentrated under reduced pressure. The residue (3.45 g, 14.1 mmol) was dissolved in
a 2:1 mixture of dry pyridine/CH2Cl2 (72 mL), and the solution was cooled to –20°C. Pivaloyl
chloride (6.90 mL, 56.3 mmol) was added in portions and the reaction mixture was allowed to
warm to 0°C. After 7 h, CH2Cl2 (50 mL) was added and the organic phase was washed sequentially
with 5% aqueous HCl (2 x 50 mL) and water (2 x 50 mL). The organic phase was dried, filtered,
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and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce 186, the title compound, as a white
solid (3.70 g, 64% yield). On replication, yields varied between 52% and 64% for scales between
100 mg and 5.00 g. Rf = 0.45. 1:1 EtOAc/hexanes. 1H NMR (300 MHz, CDCl3): δppm 6.12 (d, J =
8.2 Hz, 1H), 5.85–5.71 (m, 1H), 5.00-5.16 (m, 3H), 4.49 (dd, J=12.0, 5.8 Hz, 1H), 4.25–4.13 (m,
3H), 3.77 (ddd, J=8.1, 6.0, 2.8 Hz), 3.53 (t, J = 7.7 Hz, 1H), 3.14 (bs, 1H), 2.51–2.40 (m, 1H),
2.25-2.32 (m, 1H), 1.93 (s, 3H), 1.23–1.19 (m, 18H). Consistent with the literature.4
(2R,3R,4R,5R,6R)-6-allyl-4-hydroxy-5-methyl-2-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3-yl pivalate 187
Compound 186 (3.70 g, 8.95 mmol) was dissolved in a 2:1 pyridine/CH2Cl2
mixture (63 mL) and the solution was cooled to 0°C. Triflic anhydride (3.9 mL,
23.3 mmol) was added in portions until complete consumption of the starting
material. Water (9.3 mL) was then added, and the reaction mixture was allowed to stir overnight
at room temperature. The reaction was diluted with CH2Cl2 (200 mL) and the organic phase was
washed sequentially with 5% aqueous HCl (2 x 100 mL) and water (2 x 100 mL). The organic
phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (1:1, EtOAc/hexanes +0.2% EtOH) and passed through a silica gel
column to produce 187, the title compound, as a yellowish oil (1.10 g, 30% yield). On replication,
yields varied between 24% and 30% for scales between 150 mg and 5.00 g. Rf = 0.25. 1:1
EtOAc/hexanes +0.2% EtOH. 1H NMR (300 MHz, CDCl3): δppm 5.83–5.74 (m, 1H), 5.17-5.07 (m,
3H), 4.62 (bt, J = 9.7 Hz, 1H), 4.37 (ddd, J=8.9, 5.0, 3.3 Hz, 1H), 4.20 (dt, J=7.7, 3.3 Hz, 1H),
4.16-4.01 (m, 3H), 2.34–2.18 (m, 2H), 2.03 (s, 3H), 1.29–1.19 (m, 18H). Consistent with the literature.4
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(2R,3R,4R,5R,6R)-6-allyl-2-(hydroxymethyl)-5-methyltetrahydro-2H-pyran-3,4-diol 187a
Compound 187 (1.10 g, 2.66 mmol) was dissolved in methanol (100 mL) then
NaOMe solution was added until a pH of 12 was reached. Upon stirring for 1
h, Dowex 50WX8 was added to neutralize the solution. The solution was filtered and concentrated under reduced pressure to produce 187a, title compound as a colourless
jelly liquid (600 mg, 92%). On replication, yields varied between 82% and 92% for scales between
500 mg and 5.00 g. Rf = 0.3. 9:1 EtOAc/MeOH. 1H NMR (300 MHz, D2O): δ ppm 5.88–5.66 (m,
1H), 5.00 (dd, J=17.1, 2.3 Hz, 1H), 4.95 (dd, J=9.1, 2.3 Hz, 1H), 4.17–4.03 (m, 2H), 3.83 (bs, 1H),
3.72–3.57 (m, 4H), 2.43–2.32 (m, 1H), 2.05–2.14 (m, 1H), 1.89 (s, 3H). Consistent with the literature.4
(2R,3R,4R,5S,6R)-2-(acetoxymethyl)-6-allyl-5-methyltetrahydro-2H-pyran-3,4-diyl

diace-

tate 191
To a solution of compound 187a (600 mg, 2.45 mmol) in pyridine (50 mL),
Ac2O (25 mL) was added. The reaction mixture was then stirred for 3 h, and
then CH2Cl2 (100 mL) was added and the mixture was washed with 10% HCl
(2 x 50 mL), water (2 x 50 mL) and brine (1 x 50 mL). The organic phase was
dried, filtered, and concentrated under reduced pressure to produce 191, title compound as a colourless liquid (680 mg, 75% yield). On replication, yields varied between 58% and 75% for scales
between 100 mg and 5.00 g. Rf = 0.33. 2:1 EtOAc/hexanes. 1H NMR (300 MHz, CDCl3) δ

ppm

5.89-5.66 (m, 2H), 5.32 (t, J = 3.02, 3.02 Hz, 1H), 5.21-5.04 (m, 3H), 4.48 (dt, J = 8.98, 8.87, 4.88
Hz, 1H), 4.32 (td, J = 9.87, 4.88, 4.88 Hz, 1H), 4.22 (d, J = 8.03 Hz, 1H), 4.15-4.01 (m, 2H), 2.502.31 (m, 1H), 2.32-2.24 (m, 1H), 2.11 (s, 3), 2.06 (s, 3H), 2.04 (s, 3H), 1.97 (s, 3H). Consistent
with the literature.5
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(2R,3S,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-chlorotetrahydro-2H-pyran-3,4-diyl
diacetate 1102
To a solution of 309 (57.0 g, 0.15 mol) in CH2Cl2 (500 mL) at 0°C, thionyl
chloride (170 mL) and acetic acid (28.5 mL) were added. The mixture was
stirred at ambient temperature for 4 h then concentrated in vacuo. The residue
was recrystallized from Et2O to produce 1102, title compound as a brown solid
(40.2 g, 75%). On replication, yields varied between 70% and 75% for scales between 100 mg and
100 g. Rf = 0.3. 2:1 EtOAc/hexanes. 1H NMR (300 MHz, CDCl3): δ ppm 6.20 (d, J = 3.7 Hz, 1H),
5.83 (d, J = 8.6 Hz, 1H), 5.35–5.28 (m, 1H), 5.22 (t, J = 9.7 Hz, 1H), 4.54 (ddd, J = 12.4, 8.7, 3.8
Hz, 1H), 4.32–4.25 (m, 2H), 4.16–4.12 (m, 1H), 2.11 (s, 3H), 2.06 (s, 6H), 1.99 (s, 3H). Consistent
with the literature.6
(2R,3S,4R,5S,6R)-2-(acetoxymethyl)-6-allyl-5-methyltetrahydro-2H-pyran-3,4-diyl

diace-

tate 1103
In a flame dried round bottom flask, compound 1102 (10.0 g, 27.4 mmol)
was dissolved in anhydrous benzene under nitrogen. Allyltributyltin (8.50
mL, 27.4 mmol) and AIBN (680 mg, 4.10 mmol) then were added to the
mixture and the reaction mixture was degassed for 30 minutes by bubbeling nitrogen through the mixture. The reaction mixture then was heated to reflux at 85oC and
strred for 8 h. The solution was cooled to room temperature and concentrated under reduced pressure. The remaining residue was partitioned between CH3CN (200 mL) and hexanes (400 mL).
The CH3CN phase was extracted with additional hexanes (3 x 400 mL) to remove the remaining
organotin compounds and then concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (1:1) and passed through a silica gel column to produce 1103, the
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title compound, as a waxy solid (7.50 g, 74% yield). On replication, yields varied between 52%
and 74% for scales between 100 mg and 18.0 g. Rf = 0.33. 2:1 EtOAc/hexanes. 1H NMR (300
MHz, CDCl3): δppm 5.90-5.66 (m, 2H), 5.21-5.00 (m, 3H), 4.95 (t, J = 6.83, 6.83 Hz, 1H), 4.364.15 (m, 3H), 4.10 (dd, J = 11.99, 3.64 Hz, 1H), 3.88 (dt, J = 6.57, 6.53, 3.75 Hz, 1H), 2.52-2.33
(m, 1H), 2.33-2.19 (m, 1H), 2.09 (s, 3H), 2.07 (s, 6H), 1.97 (s, 3H). Consistent with the literature.5
(2R,3R,4R)-3,4-bis(benzyloxy)-2-((benzyloxy)methyl)-3,4-dihydro-2H-pyran 1123
Compound 119 (4.02 g, 14.8 mmol) was dissolved in methanol (100 mL) then
NaOMe solution was added until pH of 12 was reached. The reaction was stirred
at room temperature for 1 h to produce a faint yellow coloured solution.
DOWEX 50W X8 ion exchange resin was added to the reaction mixture until a pH of 7 was
reached. The solution was filtered and concentrated under reduced pressure. The crude was dissolved in DMF (9 mL) and was cooled to 0°C. It was then subsequently treated with sodium hydride (2.20 g, 55 mmol, 60% suspension in mineral oil) and benzyl bromide (6.4 mL, 53.7 mmol)
and stirred for 12 h. Methanol (10 mL) was then added slowly, diluted with ethyl acetate (250 mL),
and washed with water (150 mL). The organic phase was dried, filtered, and concentrated under
reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (1:9) and passed
through a silica gel column to produce 1123, the title compound, as a colourless liquid (1.80 g,
30% yield). On replication, yields varied between 22% and 30% for scales between 100 mg and
5.00 g. Rf = 0.32. 9:1 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.61-7.26 (m, 15H), 6.36
(dd, J = 6.21, 1.41 Hz, 1H), 4.91-4.83 (m, 2H), 4.63 (dd, J = 8.09, 3.80 Hz, 2H), 4.46 (q, J =
11.91, 11.91, 11.86 Hz, 2H), 4.24-4.13 (m, 2H), 4.00-3.89 (m, 1H), 3.78 (dd, J = 10.08, 7.26 Hz,
1H), 3.64 (dd, J = 10.10, 5.10 Hz, 1H). Consistent with the literature.7
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(2R,3S)-3,4-bis(benzyloxy)-2-((benzyloxy)methyl)-5-((S)-phenylsulfinyl)-3,4-dihydro-2Hpyran 1124
Compound 463 (200 mg, 0.38 mmol) in CH2Cl2 (5 mL) was treated with
mCPBA (126 mg, 0.40 mmol) and stirred for 2 h at –20°C. The reaction mixture was filtere and diluted with a saturated aqueous NaHCO3 solution (5 mL)
and extracted with CH2C12 (2 x 5 mL). The organic phase was dried, filtered,
and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (8:2) and passed through a silica gel column to produce ratio l : l 1124 and 1125, the title
compounds, as colourless liquid (195 mg, 95% total yield). 1125: Rf = 0.52 and 1125: Rf = 30.
1:1 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 1H NMR (300 MHz, CDCl3) ppm 7.57-7.37
(m, 2H), 7.36-7.21 (m, 11H), 7.21-7.08 (m, 6H), 6.77-6.66 (m, 2H), 4.63 (d, J = 11.73 Hz, 1H),
4.53-4.40 (m, 6H), 3.89 (t, J = 3.80, 3.80 Hz, 1H), 3.82 (dd, J = 11.40, 8.28 Hz, 2H), 3.68 (dd, J
= 11.32, 3.18 Hz, 1H).8
(2R,3S)-3,4-bis(benzyloxy)-2-((benzyloxy)methyl)-5-((R)-phenylsulfinyl)-3,4-dihydro-2Hpyran 1125
1125: 7.57-7.48 (m, 2H), 7.42 (dd, J = 5.23, 1.79 Hz, 3H), 7.38-7.14 (m, 13H),
7.05 (dd, J = 4.50, 1.29 Hz, 2H), 7.02 (s, 1H), 4.69 (d, J = 11.58 Hz, 1H),
4.52 (d, J = 11.30 Hz, 2H), 4.45 (d, J = 4.05 Hz, 2H), 4.42-4.37 (m, 1H), 4.26
(d, J = 11.95 Hz, 1H), 4.18-4.03 (m, 1H), 4.05-3.74 (m, 3H), 3.63 (t, J = 3.91,
3.91 Hz, 1H).8
(2R,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2carbaldehyde 1131
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A solution of 495 (3.50 g, 6.36 mmol) in CH2Cl2 (50 mL) was cooled to
–78°C. Ozone was then bubbled through the solution under vigorous
stirring. Upon a notable colour change to a stable deep blue colour, dimethylsulfide (1.2 mL, 16.0 mmol) was added and the solution was allowed to warm up to room
temperature while stirring was continued overnight. The clear solution was concentrated under
reduced pressure, then water (50 mL) was added and extracted with EtOAc (3 x 40 mL), and the
combined organics were washed with water (20 mL) and brine (20 mL). The organic phase was
dried, filtered, and concentrated under reduced pressure to produce 1131, the title compound as a
colourless liquid (2.80 g, 80% yield). On replication, yields varied between 72% and 80% for
scales between 110 mg and 3.50 g. Rf = 0.3. 7:3 hexanes/EtOAc. 1H NMR (500 MHz, CDCl3)
ppm 9.65 (d, J = 1.33 Hz, 1H), 7.43-7.23 (m, 20H), 4.91 (dd, J = 19.16, 11.02 Hz, 2H), 4.80-4.57
(m, 4H), 4.46 (q, J = 11.97, 11.84, 11.84 Hz, 2H), 4.15-3.92 (m, 2H), 3.83-3.47 (m, 5H). Consistent
with the literature.9
N-benzyl-O-methylhydroxylamine 1138a
To the O-methylhydroxylamine hydrochloride (10.0 g, 0.20 mol) was
added CH2Cl2 (120 mL) and pyridine (16 mL) then benzaldehyde (8.7
mL, 0.09 mol) was added and the mixture was stirred for 16 h at room
temperature. The reaction mixture was diluted with CH2Cl2 (100 mL) and the mixture was washed
with 1M HCl (100 mL), and brine (100 mL). The organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in acetic acid (60 mL), then
NaBH3CN (12.6 g, 0.20 mol) was added and stirred for 1 h at room temperature. Acetic acid was
removed, then 0.05M HCl (100 mL) was added and the mixture was washed with CH2Cl2 (3 x 50
mL). The aqueous phase basified with saturated aqueous Na2CO3, then extracted with CH2Cl2 (4
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x 50 mL). The organic phase was dried, filtered, and concentrated under reduced pressure to produce 1138a, the title compound, as a colourless liquid (3.50 g, 20% yield, note: yield is sensitive
regarding large scale synthesis, and it will be lower). Rf = 0.27. 7:3 hexanes/EtOAc. 1H NMR (500
MHz, CDCl3) ppm 7.40-7.26 (m, 5H), 5.80-5.63 (m, 1H), 4.05 (s, 2H), 3.51 (d, J = 0.43 Hz, 3H).
Consistent with the literature.10
1-O-hexadecanoyl-2-O-cis-Octadec-12-enoyl-3-O-(-D-glucopyranosyl)-sn-glycerol 1168
Compound 510 (0.11 g, 0.12 mmol) was dissolved in EtOH (2.5
mL) and N2H4.H2O 35% (0.3 mL) was added and refluxed at 40°C
for 4.5 h. EtOH was then evaporated under reduced pressure and
(50 mL) of H2O (20 mL) was added. The aqueouse phase was
extracted with CH2Cl2 (4 x 20 mL) and organic phase was washed with brine (40 mL). The organic
phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in ethyl acetate and passed through a silica gel column to produce 1168, title compound as
a colourless liquid (0.05 g, 55% yield). Rf = 0.28. 98:2 EtOAc/MeOH. 1H NMR (500 MHz,
MeOD) ppm 5.37 (t, J = 5.10, 2H), 5.28 (m, 1H), 4.8 (t, J = 3.15, 1H), 4.45 (m, 1H), 4.2 (m, 1H),
3.87 (dd, J = 10.78, 5.79, 1H), 3.79 (ddd, J = 2.46, 5.25, 11.83, 1H), 3.51-3.72 (m, 4H), 3.39 (m,
1H), 3.31, (m, 1H), 2.33 (m, 4H), 2.04 (m, 4H), 1.62 (m, 4H), 1.32 (s, 44H), 0.91 (td, J = 1.95,
6.82, 6H). 1H NMR (500 MHz d6-Me2SO-CDCl3 (5:1, v/v) ppm 5.37-5.20 (m, 2H), 5.18-5.07 (m,
1H), 4.90-4.81 (m, 1H), 4.81-4.73 (m, 1H), 4.70-4.58 (m, 2H), 4.44-4.35 (m, 1H), 4.35-4.26 (m,
1H), 4.18-4.08 (m, 1H), 3.77-3.65 (m, 1H), 3.63-3.55 (m, 1H), 3.53-3.43 (m, 2H), 3.43-3.33 (m,
2H), 3.22-3.16 (m, 1H), 3.13-3.06 (m, 1H), 2.28-2.22 (m, 4H), 2.00-1.93 (m, 4H), 1.55-1.45 (m,
4H), 1.32-1.15 (m, 44H), 0.85 (dd, J = 7.38, 6.65 Hz, 1H). Consistent with the literature.11, 12

233

(2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-(ethylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate
1217
To a solution of compound 513 (30.0 g, 76.9 mmol) in CH2Cl2 (150 mL)
at 0°C and ethanethiol (7.2 mL, 99.9 mmol) and BF3.OEt2 (27 mL, 220
mmol) were added, and stirred for 12 h at room temperature. The reaction
mixture was diluted with CH2Cl2 (100 mL) and washed with 2M NaOH (3 x 100 mL), water (100
mL) and brine (100 mL). The organic phase was dried, filtered, and concentrated under reduced
pressure. The crude product was dissolved in hexanes/ethyl acetate (8:2) and passed through a
silica gel column to produce 1217, the title compound, as a colourless liquid (28.0 g, 93% yield).
On replication, yields varied between 85% and 93% for scales between 100 mg and 30.0 g. Rf =
0.32. 3:7 EtOAc/hexanes. 1H NMR (300 MHz, CDCl3) ppm 5.69 (d, J = 5.79 Hz, 1H), 5.37 (t, J =
9.78, 9.78 Hz, 1H), 5.13-4.98 (m, 2H), 4.57-4.39 (m, 1H), 5.47-5.30 (m, 1H), 4.31 (dd, J = 12.32,
4.59 Hz, 1H), 4.08 (dd, J = 12.33, 2.15 Hz, 1H), 2.66-2.48 (m, 2H), 2.09 (s, 3H), 2.07 (s, 3H), 2.04
(s, 3H), 2.02 (s, 3H), 1.28 (t, J = 7.42, 7.42 Hz, 3H). Consistent with the literature.13
(S)-(+)-1,2-isopropylideneglycerol or (S)-(+)-Solketal 1253
Compound 505 (10.0 g, 38.1 mmol) was dissolved in THF (150 ml) and lead
(IV) acetate (16.8 g, 38.1 mmol) was added. The reaction was stirred for 30 min
at 0°C and 1 h at room temperature. The reaction mixture was filtered and
NaBH4 (2.88 g, 76.2 mmol) was added in 4% NaOH (aq) to the filtrate. The reaction mixture was
stirred at 0°C for 30 minutes and then 2 h at room temperature. The reaction mixture was quenched
with NH4Cl, concentrated under reduced pressure, and diluted with CH2Cl2 (250 mL). The aqueous
phase was extracted with CH2Cl2 (3 x 150 mL) and the organic phase was dried, filtered, and
concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate
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(3:1) and passed through a silica gel column to produce 1253, title compound as a colourless liquid
(2.80 g 55% yield). On replication, yields varied between 48% and 55% for scales between 50 mg
and 10.0 g. Rf = 0.4. 3:7 EtOAc/hexanes. 1H NMR (300 MHz, CDCl3) ppm 4.20-4.27 (m, 1H),
4.05 (t, 1H J = 8.28), 3.81 (dd, 1H J = 6.53, 8.17 ), 3.71 (d, 1H J = 3.81), 3.60 (dd, 1H J = 4.79,
11.70), 1.43 (s, 3H), 1.37 (s, 3H). Consistent with the literature.14
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9.5 Experimental protocols for Chapter 2
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((2R,3R,4R,5R,6R)-3-acetamido-4,5dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)butanoic acid 201
To solution of 326 (20.0 mg, 0.03 mmol) in isopropyl alcohol (3 mL) and
water (1.5 mL), solution of 0.8M calcium chloride (0.3 mL) was added
and stirred for 2 h at room temperature, then ethyl acetate (10 mL) was
added and organic phase was washed with 1M HCl (3 mL). The crude
product was dissolved in hexanes/ethyl acetate (9.5:0.5) and passed
through a silica gel column to produce (L)-201, the title compound as a colourless liquid (10.2 mg,
44% yield). On replication, yields varied between 30% and 44% for scales between 20.0 mg and
965 mg. Rf = 0.29. 9.5:0.5 hexanes/EtOAc. 1H NMR (500 MHz, MeOD) ppm 7.86-7.75 (m, 2H),
7.74-7.62 (m, 2H), 7.46-7.25 (m, 4H), 4.47-4.31 (m, 2H), 4.31-4.08 (m, 5H), 3.94-3.83 (m, 1H),
3.83-3.74 (m, 1H), 3.74-3.60 (m, 3H), 1.93 (s, 3H), 1.32-1.20 (m, 4H).

13

C NMR (125 MHz,

CDCl3) ppm 174.1, 173.6, 158.7, 145.2, 142.6, 128.8, 128.1, 126.1, 120.9, 74.6, 69.5, 62.3, 55.6,
51.8, 40.1, 31.6, 30.1, 24.9, 24.0, 22.6, 14.5. EI-MS m/z was not collected.
(Z)-(S)-1-(((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2R,3R,4S,5R,6R)-3,4,5trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2yl)oxy)-3-(palmitoyloxy)propan-2-yl octadec-6-enoate 202
Compound 531 (6.60 mg, 0.005 mmol) was dissolved in t-butylamine (0.05 mL, 0.43 mmol), CHCl3 (0.09 mL) and MeOH (0.30
mL), and stirred at 0°C for 10 min. The reaction mixture then
warmed to room temperature and stirred for 2 h. The solvents were
evaporated under high vacuum. The crude product was dissolved in
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methanol/ethyl acetate (1:9) and passed through a silica gel column to produce 202, title compound
as a colourless liquid (3.50 mg, 82% yield). Rf = 0.2. 1:9 EtOAc/MeOH.1H NMR (500 MHz,
MeOD) ppm 5.39-5.31 (m, 2H), 5.29-5.20 (m, 1H), 5.04 (dd, J = 16.54, 3.66 Hz, 2H), 4.58 (s,
1H), 4.49 (dd, J = 12.20, 2.89 Hz, 1H), 4.26-4.20 (m, 1H), 4.13-4.07 (m, 1H), 3.94-3.85 (m, 2H),
3.83-3.61 (m, 8H), 3.61-3.56 (m, 2H) , 3.40-3.33 (m, 1H), 2.34 (td, J = 14.23, 7.24, 7.24 Hz, 4H),
2.09-2.00 (m, 4H), 1.67-1.55 (m, 4H), 1.36-1.26 (m, 44H), 0.93-0.87 (m, 6H) 13C NMR (125 MHz,
MeOD) ppm 174.7, 174.0, 101.2, 100.6, 98.2, 97.7, 77.7, 73.8, 73.5, 73.3, 72.6, 71.7, 71.7, 71.5 x
2, 71.4, 71.2, 71.1, 71.0, 70.3, 70.3, 70.2, 67.0, 63.9, 62.8, 62.5, 35.1, 35.0, 34.9, 33.1, 31.6, 30.8
x 4, 30.6 x 2, 30.5, 30.3, 30.2, 30.0, 28.1, 26.0, 23.7, 14.4. (Three peaks are under solvent peak)
EI-MS m/z calcd for C49H90O15 [M+Na]+ : 941.61. Found: 941.62.
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9.6 Experimental protocols for Chapter 3
(2S,3R,4R,5S,6R)-6-(acetoxymethyl)-3-((4-methoxybenzylidene)amino)tetrahydro-2Hpyran-2,4,5-triyl triacetate 307
Ac2O (250 mL) was added slowly to pyridine at 0oC (550 mL) and 306 (80.0
g, 271 mmol) was added. The reaction mixture then warmed to room
temperature whie stirring overnight. The reaction was poured into a beaker
containing crushed ice (2.15 L) under stirring conditions and precipitate was
formed after 2 h. The precipitate was filtered and washed with ice cold water
to produce 307, title compound as a white solid (93.2 g, 75% yield). On
replication, yields varied between 62% and 75% for scales between 5.00 g and 80.0 g. 1H NMR
(500 MHz, CDCl3) ppm 8.14 (s, 1H), 7.64 (d, J = 8.77 Hz, 2H), 6.90 (d, J = 8.76 Hz, 2H), 5.93
(d, J = 8.29 Hz, 1H), 5.42 (t, J = 9.60, 9.60 Hz, 1H), 5.13 (t, J = 9.75, 9.75 Hz, 1H), 4.37 (dd, J =
12.47, 4.50 Hz, 1H), 4.12 (dd, J = 12.44, 2.00 Hz, 1H), 3.96 (ddd, J = 10.11, 4.45, 2.07 Hz, 1H),
3.83 (s, 3H), 3.44 (dd, J = 9.62, 8.39 Hz, 1H), 2.09 (s, 3H), 2.03 (s, 3H), 2.01 (s, 3H), 1.87 (s, 3H).
Consistent with the literature1
(2S,3R,4R,5S,6R)-6-(acetoxymethyl)-3-aminotetrahydro-2H-pyran-2,4,5-triyl triacetate hydrochloride 308
To a solution of compound 307 (93.0 g, 0.20 mol) in acetone (600 mL),
hydrochloric acid (51 mL, 5 N aqueous solution) was added dropwise.
The reaction mixture was stirred for 1 h at 0oC until precipitate formed.
The precipitate was removed by filtration and washed with Et2O (200
mL). It was then dried to produce 308, title compound as a white solid (73.0 g, 93% yield). On
replication, yields varied between 85% and 93% for scales between 820 mg and 93.0 g. Rf = 0.3.
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EtOAc. 1H NMR (300 MHz, CDCl3): δppm 5.70 (d, J = 8.78 Hz, 1H), 5.50 (d, J = 9.48 Hz, 1H),
5.29-4.94 (m, 2H), 4.39-4.21 (m, 2H), 4.13 (dd, J = 12.49, 2.21 Hz, 1H), 3.88-3.72 (m, 1H), 2.13
(s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H). Consistent with the literature1
(2S,3R,4R,5S,6R)-3-acetamido-6-(acetoxymethyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate
309
Et3N (82.2 mL, 0.575 mol) was added dropwise to a solution of 308 (73.5
g, 0.19 mol) in CH2Cl2 (500 mL) under rapid stirring conditions. Ac2O
(233 mL, 2.46 mol) was then added and the mixture was stirred for an
additional 4 h. The reaction mixture quenched with methanol (28 mL) and organic phase was
washed with 1M HCl (2 x 250 mL), saturated aqueous NaHCO3 (2 x 250 mL), water (250 mL) and
brine (250 mL). The organic phase was dried, filtered, and concentrated under reduced pressure to
obtain the desired product 309 (65.0 g, 87% yield). On replication, yields varied between 77% and
87% for scales between 12.0 g and 73.5 g. 1H NMR (300 MHz, CDCl3): δppm 5.70 (d, J = 8.8 Hz,
1H), 5.65 (d, J = 9.6 Hz, 1H), 5.19–5.10 (m, 2H), 4.35–4.24 (m, 2H), 4.13 (dd, J = 12.5, 2.1 Hz,
1H), 3.84–3.75 (m, 1H), 2.15 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 1.94 (s, 3H). Consistent with the literature.2
(2R,3R,4R,5S,6R)-2-(acetoxymethyl)-6-allyl-5-methyltetrahydro-2H-pyran-3,4-diyl

diace-

tate 316
To a solution of compound 191 (200 mg, 0.54 mL) in THF (5 mL), Boc2O
(1.20 g, 5.43 mmol) and DMAP (27.0 mg, 0.22 mmol) were added and
stirred at 80°C for 2 h. The reaction mixture was then concentrated under
reduced pressure. The crude product was dissolved in hexanes/ethyl acetate
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(8:2) and passed through a silica gel column to produce 316 the title compound, as a white solid
(210 mg, 83% yield). Rf = 0.31. 8:2 hexanes/EtOAc. On replication, yields varied between 76%
and 83% for scales between 200 mg and 3.50 g. 1H NMR (500 MHz, CDCl3) ppm 5.97-5.57 (m,
2H), 5.51 (d, J = 2.05 Hz, 1H), 5.15-5.01 (m, 2H), 4.28-4.15 (m, 1H), 4.13-3.98 (m, 4H), 2.702.52 (m, 1H), 2.37 (s, 3H), 2.28-2.14 (m, 1H), 2.12 (s, 3H), 2.01 (s, 3H), 1.93 (s, 1H), 1.51 (s, 9H).
C NMR (125 MHz, CDCl3) ppm 173.4, 170.8, 170.6, 170.0, 153.0, 134.4, 117.5, 84.9, 77.5, 68.4,

13

68.1, 67.7, 62.4, 32.2, 32.0, 30.0, 30.0, 29.7, 28.1, 23.0, 21.0, 14.4. EI-MS m/z calcd for
C22H33NO10: 471.21. Found: [M+Na]+ 494.20.
(2R,3R,4R,5S,6R)-2-(acetoxymethyl)-5-(N-(tert-butoxycarbonyl)acetamido)-6-(2-oxoethyl)tetrahydro-2H-pyran-3,4-diyl diacetate 317
A solution of 316 (200 mg, 0.42 mmol) in CH2Cl2 (50 mL) was cooled to
–78°C and ozone was bubbled through the solution under vigorous stirring. Upon a notable colour change to a stable deep blue colour, triphenylphosphine (330 mg, 1.26 mmol) was added and the solution was
allowed to warm up to room temperature while stirring was continued overnight. The clear solution
was concentrated under reduced pressure, then water (50 mL) was added and extracted with EtOAc
(3 x 40 mL), and then organic phase washed with water and brine, dried, filtered, and concentrated
under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (7:3) and passed
through a silica gel column to produce 317, the title compound, as a white solid (180 mg, 90%
yield). On replication, yields varied between 84% and 90% for scales between 200 mg and 2.50 g
Rf = 0.28. Rf = 0.28. 7:3 hexanes/EtOAc. 1H NMR (500 MHz, CDCl3) ppm 9.69 (d, J = 1.24 Hz,
1H), 5.85-5.65 (m, 1H), 5.57-5.48 (m, 1H), 4.84 (dd, J = 12.94, 6.56 Hz, 1H), 4.33-3.80 (m, 4H),
3.11-2.93 (m, 1H), 2.93-2.72 (m, 1H), 2.37 (s, 3H), 2.15 (s, 3H), 2.04 (s, 3H), 1.96 (s, 3H), 1.51
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(s, 9H). 13C NMR (125 MHz, CDCl3) ppm 198.9, 172.9, 170.4, 170.2, 169.9, 169.5, 152.5, 84.8,
77.6, 77.1, 76.7, 68.9, 68.8, 67.7, 66.7, 61.8, 42.9, 27.7, 27.5, 26.8, 20.8, 20.6. EI-MS m/z calcd
for C21H31NO11: 473.19. Found: [M+Na]+ 496.18.
α-Hydroxy-N-benzyloxycarbonylglycine 320a
A mixture of benzyl carbamate (15.0 g, 99.2 mmol) and glyoxylic acid
monohydrate (10.0 g, 109 mmol) in anhydrous ether (100 mL) was stirred
overnight. The crystalline product was filtered and washed with ether to
produce 320a, title compound as a white solid (13.7 g, 65%). 1H NMR (300 MHz, DMSO-d6):
δppm 1H NMR (500 MHz, CDCl3) ppm 8.14 (d, J = 8.50 Hz, 1H), 7.39-7.23 (m, 5H), 5.21 (d, J =
8.91 Hz, 1H), 5.05 (s, 2H). Consistent with the literature.3
N-Carbobenzoxy-α-ethoxyglycine ethyl ester 321
Compound 320a (7.50 g, 33.3 mmol) was dissolved in EtOH (90 mL), to
which conc. H2SO4 (1.65 mL) was added at 0°C. After stirring for 3 days
at room temperature, the reaction mixture was cooled to 0oC and 8.5 M
NaOH was added dropwise until pH 7. The mixture was extracted with
EtOAc and the organic phase was washed with 0.5 M NaHCO3 (2 x 50 mL), 0.5 M HC1(2 x 50
mL), and brine (2 x 50 mL). The organic phase was dried, filtered, and concentrated under reduced
pressure to produce 321, title compound as a white solid (7.10 g, 76% yield). 1H NMR (300 MHz,
CDCl3) ppm 5.42 (t, J = 12.42 Hz, 1H), 5.26-5.02 (m, 2H), 4.36-4.19 (m, 1H), 4.13 (q, J = 7.15
Hz, 1H), 3.92-3.51 (m, 2H), 1.38-1.27 (m, 3H), 1.27-1.20 (m, 3H). Consistent with the literature.4
Ethyl2-(Benzyloxycarbonylamino)-2-(diethoxyphosphoryl)acetate 322
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Compound 321 (7.10 g, 25.2 mmol) was dissolved in toluene (45 mL) at
50°C under nitrogen gas. The solution was cooled to room temperature and
PCl3 (3.27 mL, 37.8 mmol) was added. The solution was stirred for 18 h at
70°C, and then cooled to room temperature, (EtO)3P (5.34 mL, 31.1 mmol)
was added and heated to 70°C for 3 h. The mixture was concentrated under reduced pressure and
the residue was partitioned between Et2O (50 mL) and saturated aqueous NaHCO3 (50 mL). The
organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was
dissolved in hexanes/ethyl acetate (1:2) and passed through a silica gel column to produce 322 the
title compound, as a white solid (5.82 g, 62% yield) as a white waxy solid. Rf = 0.35. 2:1,
EtOAc/hexanes. 1H NMR (300 MHz, CDCl3) ppm 7.41-7.30 (m, 5H), 5.61 (d, J = 7.40 Hz, 1H),
5.27-5.02 (m, 2H), 4.87 (dd, J = 22.19, 9.22 Hz, 1H), 4.41-3.95 (m, 6H), 1.42-1.11 (m, 9H). Consistent with the literature.5
Ethyl 2-(tert-butoxycarbonylamino)-2-(diethoxyphosphoryl) acetate 323
Compound 322 (200 mg, 0.54 mmol) was dissolved in EtOAc (25 mL). To
this solution was subsequently added TFA (54 µL, 0.67 mmol), water (0.2
mL) and Pearlman’s catalyst Pd(OH)2/C (60 mg). The mixture was treated
with hydrogen gas for 24 h at ambient pressure and room temperature. Thereafter, the black suspension was filtered through a pad of Celite and concentrated under reduced
pressure. The residue was diluted with water (10 mL) and dioxane (10 mL), then NaHCO3 (135
mg, 1.61 mmol) and FmocCl (288 mg, 1.11 mmol) were added and stirred for 16 h at room temperature. The reaction mixture diluted with EtOAc (50 mL) and aqeouse phase extracted with
EtOAc (10 mL). The combined organic phase washed with water (50 mL). The organic phase was
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dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (1:1) and passed through a silica gel column to produce 323, the title compounds
as white solid (200 mg, 80% yield). On replication, yields varied between 75% and 80% for scales
between 200 mg and 3.50 g. Rf = 0.27. 1:1 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.78
(d, J = 7.40 Hz, 2H), 7.61 (dd, J = 6.92, 3.27 Hz, 2H), 7.42 (t, J = 7.47, 7.47 Hz, 2H), 7.36-7.29
(m, 2H), 5.78-5.56 (m, 1H), 4.90 (dd, J = 22.32, 9.32 Hz, 1H), 4.42 (d, J = 7.28 Hz, 2H), 4.39-3.92
(m, 6H), 1.40-1.30 (m, 9H). 13C NMR (125 MHz, CDCl3) ppm 166.6, 155.6, 155.4, 143.4, 141.0,
127.5, 126.9, 124.9, 124.8, 119.8, 67.5, 63.6, 63.5, 62.3, 53.4, 51.5, 46.8, 16.2, 16.1, 13.8. EI-MS
m/z was not collected.
(2R,3R,4R,5S,6R)-6-((Z)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-ethoxy-4-oxobut-2-en-1-yl)-2-(acetoxymethyl)-5-(N-(tert-butoxycarbonyl)acetamido)tetrahydro-2H-pyran-3,4-diyl diacetate 324
To 0.85 M LDA (0.13 mL, 0.11 mmol) was added anhydrous THF (2
mL), and cooled to –40°C and stirring for 20 min. amino acid 323 (50.0
mg, 0.11 mmol) was dissolved in anhydrous THF (1 mL) and added to
the mixture. Within 20 min, the solution was allowed to warm to ̶ 10°C,
then the solution was cooled to ̶ 60 °C and 317 (36.0 mg, 0.08 mmol)
was dissolved in anhydrous THF (1 mL), and was added to the solution. The reaction mixture
warmed up to room temperature, and then was quenched with saturated aqueous NH4Cl (30 mL),
and then Et2O (30 mL) was added. The aqueous phase was then extracted with Et2O (3 x 30 mL),
the combined organic phase was washed with water (50 mL) and brine (50 mL). The organic phase
dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce (E,Z)- 324, the title
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compound, as a colourless liquid (46.0 mg, 80% yield). On replication, yields varied between 72%
and 80% for scales between 36.0 mg and 1.30 g. Rf = 0.29. 7:3 hexanes/EtOAc. 1H NMR (500
MHz, CDCl3) ppm 7.76 (d, J = 7.25 Hz, 2H), 7.57 (d, J = 7.14 Hz, 2H), 7.40 (t, J = 7.79, 7.79 Hz,
2H), 7.35-7.26 (m, 2H), 7.00-6.70 (m, 1H), 6.68-6.48 (m, 1H), 6.02-5.67 (m, 1H), 5.52 (s, 1H),
5.38-5.00 (m, 1H), 4.56-3.94 (m, 9H), 3.27 (ddd, J = 16.29, 10.98, 8.49 Hz, 1H), 2.88-2.57 (m,
1H), 2.40 (s, 3H), 2.13 (s, 3H), 1.99 (s, 3H), 1.95 (s, 3H), 1.52 (s, 9H), 0.87-0.82 (m, 3H).
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C

NMR (125 MHz, CDCl3) ppm 173.1, 170.5, 170.3, 170.3, 170.2, 169.6, 164.1, 163.5, 154.1, 153.5,
152.6, 152.6, 143.6, 141.2, 127.7, 127.0, 124.9, 119.9, 84.8, 84.6, 68.0, 67.9, 67.2, 67.0, 62.4, 62.1,
61.9, 61.5, 47.0, 31.5, 29.0, 28.2, 27.7, 27.6, 26.8, 26.5, 26.3, 22.6, 20.6, 20.5, 20.3, 14.1, 14.0.
EI-MS m/z calcd for C40H48N2O14: 780.31. Found: [M+Na]+ 803.33.
(2R,3R,4R,5S,6R)-6-((Z)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-ethoxy-4-oxobut-2-en-1-yl)-5-acetamido-2-(acetoxymethyl)tetrahydro-2H-pyran-3,4-diyl diacetate 325
To a solution of 324 (120 mg, 0.16 mmol) in CH2Cl2 (3 mL) at room
temperature, TFA (2 mL) was added and stirred for 2 h. The solution
concentrated under reduced pressure. The crude product was dissolved
in hexanes/ethyl acetate (1:2) and passed through a silica gel column to
produce (E,Z)-325, the title compound, as a colourless liquid (88.0 mg,
77% yield). On replication, yields varied between 70% and 77% for scales between 120 mg and
1.50 g. Rf = 0.29. 1:1 hexanes/EtOAc. 1H NMR (500 MHz, CDCl3) ppm 7.76 (d, J = 7.36 Hz, 2H),
7.72-7.52 (m, 2H), 7.47-7.36 (m, 2H), 7.37-7.28 (m, 2H), 6.97-6.76 (m, 1H), 6.76-6.59 (m, 1H),
6.16 (d, J = 8.50 Hz, 1H), 5.41-5.26 (m, 1H), 5.27-5.10 (m, 1H), 4.65-3.94 (m, 10H), 3.07-2.70
(m, 1H), 2.58-2.28 (m, 1H), 2.11 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.96 (s, 3H), 1.41-1.24 (m,
3H).
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C NMR (125 MHz, CDCl3) ppm 170.6, 170.1, 164.1, 163.6, 155.0, 153.6, 143.6, 141.2,
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134.4, 127.7, 127.0, 126.2, 124.9, 124.9, 120.0, 68.2, 67.7, 67.6, 67.1, 66.9, 62.0, 61.4, 48.7, 46.9,
23.0, 22.9, 20.6, 20.6, 14.1. EI-MS m/z calcd for C35H40N2O12: 680.26. Found: [M]+ 681.26.
(2R,3R,4R,5S,6R)-6-((S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-ethoxy-4-oxobutyl)-5-acetamido-2-(acetoxymethyl)tetrahydro-2H-pyran-3,4-diyl diacetate 326
[(COD)Rh-((R,R)-Et-DuPHOS)]+OTf − catalyst precursor (10.0 mg, 0.01
mmol) and (E,Z)-325 (75.0 mg, 0.11 mmol) were dissolved in deoxygenated anhydrous THF (10 mL) in a 100 mL reactor. The reactor was vacuumed and refilled with H2 three times, and finally was pressurized with 9
atm of H2 and stirred at 40°C for 48 h. The reactor was then depressurized, and the solvent was
removed in vacuo. The crude product was dissolved in hexanes/ethyl acetate (1:1) and passed
through a silica gel column to produce (L)-326, the title compound as a colourless liquid (68.0 mg,
90% yield). On replication, yields varied between 84% and 90% for scales between 75.0 mg and
1.20 g. Rf = 0.31. 1:1 hexanes/EtOAc. 1H NMR (500 MHz, CDCl3) ppm 7.77 (d, J = 7.38 Hz, 2H),
7.69-7.52 (m, 2H), 7.41 (t, J = 7.29, 7.29 Hz, 2H), 7.32 (t, J = 7.27, 7.27 Hz, 2H), 6.91-6.37 (m,
1H), 5.77 (dd, J = 27.00, 8.45 Hz, 1H), 5.50 (dd, J = 16.42, 8.08 Hz, 1H), 5.44-5.25 (m, 1H), 4.793.47 (m, 13H), 2.96-2.19 (m, 1H), 2.11 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H), 1.95 (s, 3H), 1.32-1.25
(m, 3H). 13C NMR (125 MHz, CDCl3) ppm 172.1, 170.8, 170.7, 170.6, 170.5, 170.3, 170.2, 170.1,
169.8, 169.8, 169.7, 169.6, 169.5, 169.3, 164.1, 156.0, 155.0, 155.0, 143.8, 143.7, 143.6, 143.5,
141.3, 134.6, 127.8, 127.1, 125.0, 120.0, 68.9, 68.2, 68.1, 67.7, 67.1, 67.0, 66.9, 66.8, 61.9, 61.7,
61.3, 53.8, 48.9, 47.1, 29.7, 28.8, 27.9, 27.9, 23.2, 20.9, 20.7, 14.2. EI-MS m/z calcd for
C35H42N2O12: 682.27. Found: [M]+ 683.28.
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9.7 Experimental protocols for Chapter 4
((2R,3R,6S)-3-acetoxy-6-(vinyloxy)-3,6-dihydro-2H-pyran-2-yl)methyl acetate 409
The crude selenoxide 415a (190 mg, 0.48 mmol) was dissolved in benzene
(5 mL), diisopropylamine (0.4 mL, 2.41 mmol), was added, and the mixture
was heated at reflux for 1 h. The reaction mixture was concentrated under
reduced pressure, and the crude product was dissolved in hexanes/ethyl acetate (8:2) and passed through a silica gel column to produce 409, the title compounds, as colourless liquid (50.0 mg, 41% yield). On replication, yields varied between 35% and 41% for scales
between 50.0 mg and 10.0 g. Rf = 0.28. 8:2 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm
6.45 (dd, J = 14.00, 6.49 Hz, 1H), 6.18 (ddd, J = 10.00, 5.47, 0.82 Hz, 1H), 6.05 (dd, J = 10.01,
3.03 Hz, 1H), 5.36 (d, J = 2.87 Hz, 1H), 5.04 (dd, J = 5.47, 2.44 Hz, 1H), 4.55 (dd, J = 14.00,
1.65 Hz, 1H), 4.37-4.26 (m, 1H), 4.23-4.18 (m, 3H), 2.06 (s, 3H), 2.03 (s, 3H).1
((2R,3R,4S)-3-acetoxy-4-(2-oxoethyl)-3,4-dihydro-2H-pyran-2-yl)methyl acetate 410
Compound 409 (50.0 mg, 0.19 mmol) in nitrobenzene (3 mL) was treated with
N,N‐dimethylaniline (2 mL), and the mixture was heated at 160°C for 3 h, then
crude was subjected to column chromatography using hexanes/ethyl acetate (9:1)
to remove nitro benzene then (1:1) to obtain 410, the title compounds as colourless
liquid (27.0 mg, 54% yield). On replication, yields varied between 50% and 54%
for scales between 50.0 mg and 10.0 g. Rf = 0.25. 7:3 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3)
ppm 9.88 (t, J = 1.42, 1.42 Hz, 1H), 6.51 (dd, J = 6.18, 1.52 Hz, 1H), 4.99-4.89 (m, 1H), 4.89-4.82
(m, 1H), 4.31 (d, J = 5.84 Hz, 2H), 4.21-4.14 (m, 1H), 2.91-2.76 (m, 1H), 2.76-2.52 (m, 2H), 2.19
(s, 3H), 2.19-2.18 (m, 3H).1
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((2R,3R,6S)-3-acetoxy-6-(2-(phenylthio)ethoxy)-3,6-dihydro-2H-pyran-2-yl)methyl acetate
415
The solution of acetylated galactal 119 (375 mg, 1.38 mmol) and compound 414 (277 mg, 1.38 mmol) in benzene (5 mL) at 0°C was treated with
BF3.OEt2 (0.05 mL, 0.4 mmol), then stirred for 30 min and quenched with
Et3N (1 mL). The reaction mixture concentrated under reduced pressure,
then dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce
415, the title compound, as a colourless liquid (200 mg, 40% yield). On replication, yields varied
between 36% and 40% for scales between 30.0 mg and 15.0 g. Rf = 0.28. 9:1 hexanes/EtOAc. 1H
NMR (300 MHz, CDCl3) ppm 7.61-7.38 (m, 2H), 7.27-7.23 (m, 3H), 6.19-6.08 (m, 1H), 6.01 (dd,
J = 9.81, 3.05 Hz, 1H), 5.10 (d, J = 2.95 Hz, 1H), 5.02 (dd, J = 5.47, 2.60 Hz, 1H), 4.42-4.30 (m,
1H), 4.21 (dd, J = 6.33, 3.00 Hz, 2H), 4.07-3.93 (m, 1H), 3.89-3.77 (m, 1H), 3.26-3.01 (m, 2H),
2.09 (s, 3H), 2.03 (s, 3H).1
((2R,3R,6S)-3-acetoxy-6-(2-(phenylsulfonyl)ethoxy)-3,6-dihydro-2H-pyran-2-yl)methyl acetate 415a
Compound 415 (200 mg, 0.48 mmol) in methanol (6 mL) and water (1 mL)
was treated with sodium periodate (155 mg, 0.78 mmol) and NaHCO3
(44.0 mg, 0.53 mmol). The reaction mixture was filtered through a pad of
Celite, and the filtrate was concentrated under reduced pressure. The crude
was dissolved in ethyl acetate (20 mL) and the mixture was washed with water (10 mL), and the
organic phase was concentrated under reduced pressure and used without purification for next
step.1
2,3-dimethylbutane-2,3-diamine 418
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2-nitropropane (2.00 g, 22.5 mmol) and KOH (1.25 g, 22.5 mmol) in methanol
(7 mL) was treated with a solution of iodine (2.82 g, 22.5 mmol) in methanol
(20 mL) and heated to reflux. The solution was cooled and concentrated under
reduced pressure and used without purification. The crude compound (2.20 g, 12.5 mmol) was
dissolved in concentrated HCl (19 mL) and Sn (2.37 g, 79.0 mmol) was added and heated at 80°C
for 1h. The reaction mixture was then cooled to room temperature and washed with diethyl ether
(100 mL). Sodium hydroxide (7.90 g) was added to the aqueous phase and passed through a pad
of Celite, then extracted with CH2Cl2 (2 x 100 mL). The organic phase was dried, filtered, and
concentrated under reduced pressure to produce 418, the title compound as a colourless liquid (470
mg, 33% yield). 1H NMR (300 MHz, CDCl3) ppm 1.31 (s, 4H), 1.12 (s, 12H). Consistent with the
literature.2
2,2'-((1E,1'E)-((2,3-dimethylbutane-2,3-diyl)bis(azanylylidene))bis(methanylylidene))diphenol 420
To a solution of salicylaldehyde 419 (700 mg, 5.73 mmol) in ethanol (10 mL), diamine 418 (320 mg, 2.78 mmol) was added and
heated to reflux for 15 h, then water (2.5 mL)was added and heated
to reflux for 10 min. The reaction mixture was cooled to –20°C and
kept for 16 h to which the solid was filtered and dried to produce 420, the title compound as a
yellow solid (525 mg, 58% yield). 1H NMR (300 MHz, CDCl3) ppm 14.09 (s, 2H), 8.38 (s, 2H),
7.34-7.22 (m, 4H), 6.95 (dd, J = 8.25, 0.45 Hz, 2H), 6.87 (dt, J = 7.67, 7.65, 1.07 Hz, 2H), 1.40 (s,
12H). Consistent with the literature.3

250

(saltmen)Mn(N) 421
Compound 420 (420 mg, 1.30 mmol) in methanol (5 mL), heated
to 60°C for 10 min then the Mn(OAc)2 .4H2O (335 mg, 1.37 mmol)
was added and refluxed for 1 h. The reaction mixture was cooled
to room temperature and NH4OH (1.5 mL, 19.5 mmol) was added followed by addition of Clorox
bleach (NaOC1, 12 mL, 7.8 mmol) over 40 min. The reaction mixture was cooled to room temperature and diluted with CH2Cl2 (100 mL). The combined organics were washed with water (4 x
50 mL) and the organic phase was dried, filtered, and concentrated under reduced pressure. The
crude was dissolved in CH2Cl2 (200 mL) passed through a pad of Celite. The organic phase was
dried, filtered, and concentrated under reduced pressure to produce 421, the title compound as a
green solid (460 mg, 90% total yield). 1H NMR (300 MHz, CDCl3) ppm 8.08 (s, 2H), 7.38 (ddd, J
= 8.64, 6.93, 1.81 Hz, 2H), 7.22 (dd, J = 7.86, 1.70 Hz, 2H), 7.16 (d, J = 8.39 Hz, 2H), 6.74-6.65
(m, 2H), 5.31 (s, 2H), 1.49 (s, 12H). Consistent with the literature.4
N-((2S,4aR,6R,7R,8R,8aR)-6-allyl-8-hydroxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxin7-yl)acetamide 427
Compound 188 (60.0 mg, 0.24 mmol) was dissolved in acetonitrile (4 mL),
then benzaldehyde dimethyl acetal (0.05 mL, 0.30 mmol) and p-TsOH (9.00
mg, 0.05 mmol) were added and stirred for 3 h at 50°C temperature. The
saturated aqueous NaHCO3 (10 mL) was added to the reaction mixture and
extracted with Et2O (4 x 10 mL). The organic phase was washed with water (20 mL). The organic
phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (1:3) and passed through a silica gel column to produce 427, the
title compound, as a white solid (36.0 mg, 45% yield). On replication, yields varied between 40%
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and 45% for scales between 40.0 mg and 500 mg. Rf = 0.29. 1:2 hexanes/EtOAc. 1H NMR (300
MHz, CDCl3) ppm 7.52 (dd, J = 6.55, 3.07 Hz, 2H), 7.44-7.34 (m, 3H), 5.96-5.72 (m, 1H), 5.605.57 (m, 1H), 5.56 (s, 1H), 5.20-5.04 (m, 2H), 4.61 (td, J = 10.47, 5.37, 5.37 Hz, 1H), 4.51-4.37
(m, 1H), 4.24 (dd, J = 12.01, 1.79 Hz, 2H), 4.04 (dd, J = 12.53, 1.66 Hz, 1H), 3.80 (dt, J = 11.15,
11.11, 3.59 Hz, 1H), 3.55 (s, 1H), 2.55 (d, J = 11.25 Hz, 1H), 2.47-2.26 (m, 2H), 2.01 (s, 3H). 13C
NMR (75 MHz, CDCl3) ppm 171.23, 134.58, 129.10, 128.56, 127.09, 126.71, 117.45, 101.73,
96.83, 75.57, 73.66, 72.92, 70.12, 68.96, 68.00, 64.55, 64.02, 63.36, 51.57, 23.69. EI-MS m/z
calcd for C18H23NO5: 333.16. Found: [M]+ 334.16.
N-((2S,4aR,6R,7S,8aS)-6-allyl-8-oxo-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl)acetamide 427a
Compound 427 (50.0 mg, 0.15 mmol) was dissolved in CH2Cl2 (3 mL) and
Dess–Martin periodinane (95.3 mg, 0.22 mmol) was added and stirred at
room temperature for 4 h. The mixture was diluted with CH2Cl2 (20 mL) and
the mixture was washed with sat. Na2S2O3 (10 mL), sat. NaHCO3 (10 mL),
water (10 mL), and brine (10 mL). The organic phase was dried, filtered, and
concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate
(1:2) and passed through a silica gel column to produce 427a, the title compound, as a white solid
40.0 mg, 80% yield). On replication, yields varied between 72% and 80% for scales between 50.0
mg and 200 mg. Rf = 0.31. 1:1 hexanes/EtOAc. 1H NMR (75 MHz, CDCl3) ppm 7.58-7.43 (m,
2H), 7.43-7.32 (m, 3H), 6.39-6.20 (m, 1H), 5.87-5.62 (m, 1H), 5.59 (s, 1H), 5.15-4.93 (m, 3H),
4.51 (d, J = 1.28 Hz, 1H), 4.34 (dd, J = 12.74, 1.41 Hz, 1H), 4.10 (dd, J = 12.76, 1.74 Hz, 1H),
3.72 (d, J = 1.41 Hz, 1H), 2.29-2.12 (m, 1H), 2.12-2.02 (m, 1H), 2.01 (s, 3H).13C NMR (75 MHz,
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CDCl3) ppm 200.19, 169.88, 137.00, 133.14, 129.57, 128.47, 126.41, 117.70, 100.99, 81.08, 69.34,
65.80, 58.14, 30.22, 29.83, 23.18. EI-MS m/z calcd for C18H21NO5: 331.14. Found: [M]+ 332.15.
(2R,3R,4R,5R,6S)-2-(acetoxymethyl)-5-azido-6-(phenylthio)tetrahydro-2H-pyran-3,4-diyl
diacetate 429
To a stirring solution of 3,4,6-Tri-O-acetyl- D-galactal 119 (30.0 g, 110
mmol) in acetonitrile (430 mL), ferric chloride hexahydrate (24.7 g, 91.5
mmol), sodium azide (8.10 g, 121 mmol) (portionwise) and hydrogen
peroxide (20 mL, 121 mmol 33% aq. solution) were added subsequently and the solution was
stirred at ̶ 20 °C for 5 h until the starting material was consumed. The mixture was diluted with
diethyl ether (500 mL) and washed with water (4 x 250 mL), saturated aqueous NaHCO3 (250
mL), and brine (250 mL) until the organic phase was colorless. The crude product was used without further purification. The crude mixture was dissolved in ethyl acetate (830 mL) to which 1M
Na2CO3 (830 mL) was added, followed by addition of both Bu4NHSO4 (46.0 g, 138 mmol) and
thiophenol (40 mL, 392 mmol) and stirred for 16 h. The two phases were separated, and the organic
phase was washed with water (4 x 400 mL), sat. NaHCO3 (400 mL), and brine (400 mL). The
organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was
dissolved in hexanes/ethyl acetate (7:3) and taken up through a silica gel column to produce 429,
the title compound, as a colourless liquid (17.0 g, 37% yield in two steps). On replication, yields
varied between 32% and 37% for scales between 100 mg and 30.0 g. Rf = 0.28. 7:3 hexanes/EtOAc. 1H NMR (500 MHz, CDCl3) ppm 7.75-7.54 (m, 2H), 7.42-7.31 (m, 3H), 5.39-5.34
(m, 1H), 4.87 (dd, J = 10.25, 3.18 Hz, 1H), 4.53 (d, J = 10.09 Hz, 1H), 4.13 (dd, J = 6.71, 2.10
Hz, 2H), 3.93-3.86 (m, 1H), 3.66 (t, J = 10.19, 10.19 Hz, 1H), 2.10 (s, 3H), 2.05 (s, 3H), 2.05 (s,
3H).5
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(4aR,6S,7R,8R,8aR)-7-azido-2-phenyl-6-(phenylthio)hexahydropyrano[3,2-d][1,3]dioxin-8ol 430
Compound 429 (280 mg, 0.66 mmol) was dissolved in methanol (45 mL)
and NaOMe (10 mL) was added until a pH of 11 was reached. Upon stirring for 16 h, Dowex 50WX8 was added to neutralize the solution. The
mixture was filtered and concentrated under reduced pressure to afford
the crude product which was used in next step without purification. The
crude product (150 mg, 0.50 mmol) was then dissolved in acetonitrile (8 mL), to which benzaldehyde dimethyl acetal (0.13 mL, 0.85 mmol) and p-TsOH (14.0 mg, 0.08 mmol) were added and
stirred for 3 h at room temperature. The crude product was dissolved in hexanes/ethyl acetate (7:3)
and passed through a silica gel column to produce 430, the colorless liquid compound (150 mg,
78% yield). On replication, yields varied between 70% and 78% for scales between 100 mg and
10.0 g. Rf = 0.34. 7:3 hexanes/EtOAc. 1H NMR (500 MHz, CDCl3) ppm 7.96-7.58 (m, 2H), 7.557.30 (m, 8H), 5.55 (s, 1H), 4.49-4.36 (m, 2H), 4.26-4.17 (m, 1H), 4.05 (dd, J = 12.52, 1.68 Hz,
1H), 3.73-3.61 (m, 1H), 3.61-3.49 (m, 2H), 2.74-2.19 (m, 1H). Consistent with the literature.6
diethyl (((tetrahydro-2H-pyran-2-yl)oxy)methyl)phosphonate 432
Diethyl hydroxymethylphosphonate 431 (5.00 g, 29.7 mmol) was dissolved in diethyl ether (20 mL) and treated with dihydropyran (4.1 mL,
44.6 mmol) and cooled to 0°C. Phosphorus oxychloride (4.1 mL, 44.6
mmol) was then added and stirred for 3 h at room temperature. After the reaction mixture was
diluted with diethyl ether (50 mL), the combined organics were washed with saturated aqueous
NaHCO3 (30 mL) water (30 mL), and brine (30 mL). The organic phase was dried, filtered, and
concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate
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(7:3) and taken up through a silica gel column to produce 432, the title compound as a light-yellow
liquid (3.60 g, 48% yield). Rf = 0.30. 7:3 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 4.70
(t, J = 3.04, 3.04 Hz, 1H), 4.29-4.10 (m, 4H), 4.02 (dd, J = 13.90, 9.17 Hz, 1H), 3.89-3.67 (m, 2H),
3.61-3.48 (m, 1H), 1.94-1.43 (m, 6H), 1.35 (dt, J = 7.07, 7.06, 1.59 Hz, 6H)s. Consistent with the
literature.7
(4aR,6S,7R,8aS)-7-azido-2-phenyl-6-(phenylthio)tetrahydropyrano[3,2-d][1,3]dioxin8(8aH)-one 433
To a stirring solution of compound 430 (50.0 mg, 0.13 mmol) in CH2Cl2 (3
mL) was added Dess–Martin periodinane (100 mg, 0.26 mmol) and the solution was stirred at room temperature for 3 h. The mixture was diluted with
CH2Cl2 (20 mL) and washed with sat. Na2S2O3 (10 mL), sat. NaHCO3 (10
mL), water (10 mL), and brine (10 mL). The organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl
acetate (1:1) and taken up through a silica gel column to produce 433, the title compound, as a
colourless liquid (41.0 mg, 84% yield in two steps). On replication, yields varied between 78%
and 84% for scales between 50.0 mg and 11.0 g. Rf = 0.29. 1:1 hexanes/EtOAc.1H NMR (500
MHz, CDCl3) ppm 7.89-7.80 (m, 2H), 7.48-7.41 (m, 8H), 5.63 (s, 1H), 4.74 (d, J = 10.17 Hz, 1H),
4.59-4.54 (m, 2H), 4.49 (d, J = 10.17 Hz, 1H), 4.17 (dd, J = 12.66, 1.50 Hz, 1H), 3.74 (d, J = 1.24
Hz, 1H). 13C NMR (75 MHz, CDCl3) ppm 196.9, 136.9, 139.2, 129.8, 129.3, 129.3, 129.1, 128.5,
126.5, 101.0, 87.0, 80.7, 71.2, 68.8, 65.2. EI-MS m/z calcd for C19H17N3O4S: 383.09. Found:
[M+K]+ 424.09 note: One of the carbon oxygen bond in the benzylidene protecting group is
cleaved.
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(2S,4aR,6S,7R,8R,8aR)-7-azido-2-phenyl-6-(phenylthio)hexahydropyrano[3,2-d][1,3]dioxine-8-carbaldehyde 436
To the compound 449 (83.0 mg, 0.18 mmol) was added methanol (64
μL) then excess amount of freshly prepared 0.08 M SmL2 (24 mL, 1.92
mmol) was added and stirred for 6 h at room temperature. The reaction
mixture was diluted with ethyl acetate (100 mL) and the mixture was
washed with saturated aqueous NaHCO3 (70 mL), water (70 mL) and
brine (70 mL). The organic phase was dried, filtered, and concentrated under reduced pressure.
The crude product was dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel
column to produce 436, the title compound, as a colourless liquid (65.0 mg, 91% yield). Note:
yield is sensitive regarding large scale synthesis, and it will be lower). On replication, yields varied
between 85% and 91% for scales between 15.0 mg and 85.0 mg. Rf = 0.27. 7:3 hexanes/EtOAc.
1

H NMR (500 MHz, CDCl3) ppm 9.75 (d, J = 1.76 Hz, 1H), 7.82-7.67 (m, 2H), 7.52-7.29 (m, 8H),

5.55 (s, 1H), 4.86 (d, J = 10.32 Hz, 1H), 4.42 (dd, J = 12.58, 1.57 Hz, 1H), 4.08-3.98 (m, 2H),
3.92 (d, J = 1.04 Hz, 1H), 3.61 (dd, J = 10.31, 1.71 Hz, 1H), 3.40 (s, 1H). 13C NMR (125 MHz,
CDCl3) ppm 202.4, 137.0, 134.7, 129.8, 129.7, 129.1, 128.7, 128.4, 126.5, 101.9, 82.8, 78.0, 73.9,
69.1, 68.5, 65.0. EI-MS m/z calcd for C20H19N3O4S: 397.11. Found: [M+NH4]+ 309.07-benzylidine protecting group.
(2-ethoxy-2-oxoethyl)triphenylphosphonium bromide 441
Triphenylphosphine (39.0 g, 149 mmol) was dissolved in toluene and
cooled to 0°C. Ethyl bromoacetate (16.6 mL, 65.8 mmol) was added and
the mixture was stirred for 18 h. Upon which it the mixture was allowed to
stand and settle for 2 h to which the product was filtered and dried to produce compound 441, the
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title compound as a white solid (25.1 mg, 89% yield). On replication, yields varied between 75%
and 89% for scales between 1.00 g and 39.0 g. Rf = 0.32. 1:9 hexanes/EtOAc. 1H NMR (300 MHz,
CDCl3) ppm 8.01-7.83 (m, 6H), 7.84-7.74 (m, 3H), 7.73-7.63 (m, 6H), 5.55 (d, J = 13.75 Hz, 2H),
4.04 (q, J = 7.13, 7.13, 7.12 Hz, 2H), 1.07 (t, J = 7.14, 7.14 Hz, 3H). Consistent with the literature.8
ethyl 2-(triphenylphosphoranylidene)acetate 442
Sodium hydroxide (868 mg) was dissolved in H2O (36 mL) and added to
a solution of salt 441 (62 g, 145 mmol) in H2O (435 mL) and CH2Cl2 (435
mL) and stirred for 1 h. The organic phase was separated from aqueous
phase and washed with water (300 mL) and brine (300 mL). The organic phase was dried, filtered,
and concentrated under reduced pressure to produce 442, the title compound as a white solid (46.5
g, 93% yield). On replication, yields varied between 87% and 93% for scales between 800 mg and
8.00 g. Rf = 0.32. 4:1 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 8.10-7.50 (m, 15H), 5.61
(bs, 1H), 4.00 (q, J = 7.12, 7.12, 7.10 Hz, 2H), 1.04 (t, J = 7.10, 7.10 Hz, 3H). Consistent with the
literature.8
Ethyl 2-((4aR,6S,7R,8aR)-7-azido-2-phenyl-6-(phenylthio)tetrahydropyrano[3,2-d][1,3]dioxin-8(8aH)-ylidene)acetate 443
The ylide 442 (16.8 g, 48.2 mmol) and ketone 433 (7.70 g, 20.1 mmol)
were dissolved in toluene (700 mL) and heated for 1 h, then the reaction
mixture was concentrated under reduced pressure and diluted with
CH2Cl2 (400 mL). The organic phase was washed with water (200 mL)
and brine (200 mL) and the combined organics were dried, filtered, and
concentrated under reduced pressure. The crude product was dissolved in
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hexanes/ethyl acetate (7:3) and taken up through a silica gel column to produce 443, the title compound as a light-yellow liquid (6.10 g, 67% yield). On replication, yields varied between 51% and
67% for scales between 100 mg and 8.00 g. Rf = 0.28. 7:3 hexanes/EtOAc. 1H NMR (300 MHz,
CDCl3) ppm 7.84-7.77 (m, 2H), 7.43 (dd, J = 6.80, 3.00 Hz, 2H), 7.40-7.34 (m, 3H), 7.34-7.28 (m,
1H), 7.28-7.21 (m, 2H), 6.27 (d, J = 1.43 Hz, 1H), 6.11 (d, J = 1.09 Hz, 1H), 5.66 (s, 1H), 4.534.46 (m, 2H), 4.41 (dd, J = 12.44, 1.59 Hz, 1H), 4.19 (dq, J = 7.12, 7.09, 7.09, 0.92 Hz, 2H), 4.14
(dd, J = 12.46, 1.60 Hz, 1H), 3.53 (d, J = 1.34 Hz, 1H), 1.30 (t, J = 7.13, 7.13 Hz, 3H). 13C NMR
(125 MHz, CDCl3) ppm 165.4, 149.1, 137.7, 134.3, 129.2, 128.4, 126.5, 118.7, 101.3, 88.7, 71.8,
70.7, 69.4, 60.9, 60.4, 14.2. EI-MS m/z calcd for C23H23N3O5S: 453.14. Found: [M+ Na]+ 476.12.
2-((4aR,6S,7R,8aR)-7-azido-2-phenyl-6-(phenylthio)tetrahydropyrano[3,2-d][1,3]dioxin8(8aH)-ylidene)ethanol 444
To a solution of compound 443 (2.70 g, 5.96 mmol) in CH2Cl2 (55 mL) at
0°C was added (1M) DIBAL-H (12.0 mL, 12.0 mmol) and the mixture was
stirred for 2 h. The reaction mixture was diluted with CH2Cl2 (40 mL) and
3M HCl (40 mL) was added. The organic phase was washed with water (40
mL) and brine (40 mL) and the combined organics were dried, filtered, and
concentrated under reduced pressure. The crude product was dissolved in
hexanes/ethyl acetate (1:1) and taken up through a silica gel column to produce 444, the title compound as a light-yellow liquid (1.82 g, 74% yield). On replication, yields varied between 68% and
74% for scales between 100 mg and 3.00 g. Rf = 0.28. 7:3 hexanes/EtOAc. 1H NMR (300 MHz,
CDCl3) ppm 7.62 (dd, J = 8.17, 1.10 Hz, 2H), 7.49-7.44 (m, 2H), 7.44-7.39 (m, 3H), 7.19-7.06 (m,
1H), 6.95 (t, J = 7.76, 7.76 Hz, 2H), 5.99 (d, J = 1.29 Hz, 1H), 5.68-5.64 (m, 1H), 5.63 (s, 1H),
4.50 (dd, J = 12.74, 1.11 Hz, 1H), 4.35 (t, J = 1.43, 1.43 Hz, 1H), 4.20 (dd, J = 12.75, 2.09 Hz,
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1H), 3.98 (t, J = 6.88, 6.88 Hz, 1H), 3.58-3.52 (m, 1H), 3.38 (t, J = 6.47, 6.47 Hz, 2H). 13C NMR
(75 MHz, CDCl3) ppm 137.6, 134.6, 134.5, 133.1, 130.5, 129.3, 128.5, 128.4, 128.4, 126.0, 100.7,
80.7, 70.0, 69.1, 67.3, 66.7, 63.0. EI-MS m/z calcd for C21H21N3O4S: 411.13. Found: [M+ NH4]+
429.16.
(2S,4aR,6S,7R,8R,8aS)-7-azido-2-phenyl-6-(phenylthio)-8-vinylhexahydropyrano[3,2d][1,3]dioxin-8-ol 448
To a solution of ketone 433 (6.70 g, 17.5 mmol) in THF (160 mL) at ̶ 78
°C was added a vinylmagnesium bromide solution 1.0 M in THF (21 mL,
21.0 mmol). The reaction mixture was stirred for 2 h and then allowed to
warm to 0°C. The reaction was then quenched with sat. NH4Cl (100 mL)
and extracted four times with ethyl acetate (70 mL), and then organic phase
was washed once with brine (150 mL). The organic phase was dried, filtered, and concentrated
under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (9:1) and passed
through a silica gel column to produce 448, the title compound, as a colourless liquid (4.20 g, 58%
yield). On replication, yields varied between 52% and 58% for scales between 40.0 mg and 7.00
g. Rf = 0.27. 9:1 hexanes/EtOAc. 1H NMR (500 MHz, CDCl3) ppm 7.88-7.75 (m, 3H), 7.58-7.48
(m, 2H), 7.45-7.25 (m, 5H), 6.10 (dd, J = 16.95, 10.90 Hz, 1H), 5.85 (dd, J = 16.95, 1.29 Hz, 1H),
5.63-5.51 (m, 2H), 4.70 (d, J = 10.35 Hz, 1H), 4.45 (dd, J = 12.47, 1.61 Hz, 1H), 4.03 (dd, J =
12.48, 1.61 Hz, 1H), 3.88 (d, J = 0.54 Hz, 1H), 3.75 (d, J = 1.01 Hz, 1H), 3.70 (d, J = 10.35 Hz,
1H), 3.15 (s, 1H).

13

C NMR (125 MHz, CDCl3) ppm 137.3, 134.7, 132.4, 130.2, 129.7, 129.1,

128.6, 128.4, 126.6, 120.6, 101.6, 83.9, 79.1, 75.5, 69.4, 68.5, 64.6. EI-MS m/z calcd for
C21H21N3O4S: 411.12. Found: [M+Na]+ 434.11.
(2S,4aR,6S,7R,8R,8aS)-7-azido-2-phenyl-6-(phenylthio)-8-vinylhexahydropyrano[3,2d][1,3]dioxin-8-yl acetate 448a
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To a solution of compound 448 (3.50 g, 8.51 mmol) in pyridine (36 mL),
acetic anhydride (18 mL, 190 mmol) was added and stirred at 115°C for
16 h. The reaction mixture was cooled to room temperature and diluted
with CH2Cl2 (150 mL), washed with 10% HCl (2 x 70 mL), water (70 mL)
and brine (150 mL). The organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (9:1) and
passed through a silica gel column to produce 448a, the title compound, as a colourless liquid (3.40
g, 88% yield). On replication, yields varied between 78% and 88% for scales between 240 mg and
3.50 g. Rf = 0.27. 9:1 hexanes/EtOAc. 1H NMR 1H NMR (500 MHz, CDCl3) ppm 7.64-7.52 (m,
2H), 7.31-7.22 (m, 5H), 7.21-7.08 (m, 1H), 5.88 (dd, J = 17.42, 11.55 Hz, 1H), 5.53-5.50 (m, 1H),
5.49 (d, J = 7.61 Hz, 1H), 5.39 (s, 1H), 4.96-4.95 (m, 1H), 4.41 (d, J = 10.52 Hz, 1H), 4.26 (dd, J
= 12.43, 1.65 Hz, 1H), 3.91 (dd, J = 12.45, 1.69 Hz, 1H), 3.82 (d, J = 10.51 Hz, 1H), 3.63-3.58
(m, 1H), 1.85 (s, 1H). 13C NMR (125 MHz, CDCl3) ppm 169.0, 137.7, 134.2, 130.2, 129.0, 128.9,
128.4, 128.1, 126.1, 122.5, 100.8, 83.4, 82.4, 73.9, 69.4, 68.7, 62.6, 21.7. EI-MS m/z calcd for
C23H23N3O5S: 453.14. Found: [M+NH4]+ 471.14.
(2S,4aR,6S,7R,8R,8aS)-7-azido-8-formyl-2-phenyl-6-(phenylthio)hexahydropyrano[3,2d][1,3]dioxin-8-yl acetate 449
To a solution of compound 448a (50.0 mg, 0.11 mmol) in CH2Cl2 (10 mL),
was bubbled ozone through the solution. Upon a notable colour change to
a stable deep blue colour, dimethylsulfide (0.02 mL, 0.29 mmol) was added
to which the solution was left to warm up to room temperature. After 2 h,
CH2Cl2 was removed and water (10 mL) was added and extracted with
ethyl acetate (3 x 10 mL). The organic phase was then washed with brine (20 mL). The organic
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phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (9:1) and passed through a silica gel column to produce 449, the
title compound, as a colourless liquid (30.0 mg, 60% yield). On replication, yields varied between
55% and 60% for scales between 50.0 mg and 1.20 g. Rf = 0.31. 9:1 hexanes/EtOAc. 1H NMR
(500 MHz, CDCl3) ppm 9.62 (d, J = 1.17 Hz, 1H), 7.82-7.59 (m, 2H), 7.39 (s, 5H), 7.36-7.24 (m,
3H), 5.50 (s, 1H), 4.71 (dd, J = 5.74, 4.69 Hz, 2H), 4.39 (dd, J = 12.60, 1.58 Hz, 1H), 4.26-4.19
(m, 1H), 4.06 (dd, J = 12.61, 1.67 Hz, 1H), 4.01 (dd, J = 10.43, 0.97 Hz, 1H), 2.15 (s, 3H). 13C
NMR (125 MHz, CDCl3) ppm 198.5, 170.8, 137.6, 134.1, 130.0, 129.2, 129.1, 128.6, 128.3, 126.1,
100.9, 83.1, 72.0, 69.8, 61.7, 20.7. EI-MS m/z calcd for C22H21N3O6S: 454.11. Found: [M+NH4]+
473.15.
(3aR,4S,9bS)-2,2,8,8-tetramethyl-4-(phenylsulfonyl)hexahydro-[1,3]dioxolo[4',5':4,5]pyrano[3,2-d][1,3]dioxine 450
To the compound 455 (200 mg, 0.57 mmol) in acetonitrile (4.7 mL) and
water (0.9 mL), KMnO4 (360 mg, 2.30 mmol) and CuSO4.5H2O (122
mg, 1.50 mmol) were added and stirred for 2 h at room temperature. Then
solvent was removed and CH2Cl2 (50 mL) was added. The organic phase
was washed water (30 mL) and brine (30 mL). The organic phase was
dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (6:4) and passed through a silica gel column to produce 450, the title compound,
as a colourless liquid (180 mg, 82% yield). Rf = 0.29. 6:4 hexanes/EtOAc. 1H NMR (500 MHz,
CDCl3) ppm 8.02 (d, J = 7.35 Hz, 2H), 7.68 (t, J = 7.46, 7.46 Hz, 1H), 7.57 (t, J = 7.77, 7.77 Hz,
2H), 4.55 (d, J = 8.98 Hz, 1H), 4.36 (s, 1H), 3.98 (dq, J = 13.14, 13.14, 13.12, 1.61 Hz, 2H), 3.66-
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3.56 (m, 2H), 3.43 (s, 1H), 1.47 (s, 3H), 1.38 (s, 3H), 1.36 (s, 3H), 1.09 (s, 3H). Consistent with
the literature.9
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(phenylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 454a
To a solution of compound 196 (30.0 g, 77.0 mmol) in CH2Cl2 (600 mL)
at 0°C, thiophenol (20 mL, 0.20 mol) and BF3.OEt2 (25 mL, 0.20 mol)
were added, and stirred for 12 h at room temperature. The reaction mixture
was diluted with CH2Cl2 (100 mL) and the mixture was washed with 2M NaOH (3 x 200 mL),
water (400 mL) and brine (400 mL). The organic phase was dried, filtered, and concentrated under
reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (8:2) and passed
through a silica gel column to produce 454a, the title compound, as a colourless liquid (30.0 g,
90% yield). On replication, yields varied between 76% and 90% for scales between 100 mg and
30.0 g. 1H NMR (500 MHz, CDCl3) ppm 7.71-7.38 (m, 2H), 7.39-7.27 (m, 3H), 5.42 (dd, J = 3.29,
0.85 Hz, 1H), 5.25 (t, J = 9.96, 9.96 Hz, 1H), 5.05 (dd, J = 9.95, 3.34 Hz, 1H), 4.72 (d, J = 9.96
Hz, 1H), 4.16 (ddd, J = 17.49, 11.34, 6.69 Hz, 2H), 4.02-3.87 (m, 1H), 3.49 (s, 1H), 2.13 (s, 3H),
2.10 (s, 3H), 2.05 (s, 3H), 1.98 (s, 3H). Consistent with the literature.10
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(pyridin-2-ylthio)tetrahydro-2H-pyran-3,4,5-triyl
triacetate 454b
Peracetylated galactose compound 196 (2.00 g, 5.13 mmol) was dissolved in CH2Cl2 (40 mL) and treated with 2-mercaptopyridine (1.14 g,
10.2 mmol) and ZrCl4 (2.40 mg, 10.2 mmol) and heated to 60°C for 16
h. The reaction mixture was cooled to room temperature and diluted with CH2Cl2 (150 mL). The
reaction mixture was washed with sat NaHCO3 (100 mL). and the combined organics were dried,
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filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (8:2) and passed through a silica gel column to produce 454b, the title compound, as a colourless liquid (1.75 g, 77% yield). Rf = 0.32. 8:2 hexanes/EtOAc. 1H NMR (300
MHz, CDCl3) ppm 8.55-8.35 (m, 1H), 7.53 (dt, J = 7.92, 7.89, 1.85 Hz, 1H), 7.26-7.16 (m, 1H),
7.07 (ddd, J = 7.34, 4.90, 0.94 Hz, 1H), 5.79 (d, J = 10.39 Hz, 1H), 5.52-5.43 (m, 1H), 5.41 (t, J =
10.16, 10.16 Hz, 1H), 5.18 (dd, J = 9.92, 3.41 Hz, 1H), 4.23-4.00 (m, 4H), 2.16 (s, 3H), 2.03 (3s,
9H).11
(3aR,4S,9bS)-2,2,8,8-tetramethyl-4-(phenylthio)hexahydro-[1,3]dioxolo[4',5':4,5]pyrano[3,2-d][1,3]dioxine 455
Compound 454a (165 mg, 0.37 mmol) was dissolved in methanol (50 mL)
then NaOMe solution was added till pH 12. The reaction was stirred at room
temperature for 1 h to produce a faint yellow colour solution. DOWEX 50W
X8 ion exchange resin was added to the reaction mixture until pH 7 was
reached. The solution was filtered and concentrated under reduced pressure,
then the crude was dissolved in DMF (5 mL), then 2-methoxy propane (0.16 mL, 1.92 mmol), and
p-TsOH (6.00 mg, 0.03 mmol) were added and the reaction mixture was stirred for 1 h at room
temperature. Saturated aqueous NaHCO3 (10 mL) was added to the reaction mixture and extracted
with Et2O (4 x 10 mL). The organic phase was washed with water (20 mL). The organic phase was
dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce 455, the title compound,
as a colourless liquid (58.5 mg, 48% yield). On replication, yields varied between 35% and 48%
for scales between 200 mg and 10.0 g. Rf = 0.31. 7:3 hexanes/EtOAc. 1H NMR (500 MHz, CDCl3)
ppm 7.65 (dd, J = 6.62, 2.96 Hz, 2H), 7.47-7.14 (m, 3H), 4.80 (d, J = 9.56 Hz, 1H), 4.44 (d, J =
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1.38 Hz, 1H), 4.08 (dq, J = 12.97, 12.97, 12.95, 1.76 Hz, 2H), 3.86 (t, J = 9.39, 9.39 Hz, 1H), 3.57
(dd, J = 9.21, 2.74 Hz, 1H), 3.38 (d, J = 1.14 Hz, 1H), 1.46 (s, 6H), 1.39 (s, 3H), 1.38 (s, 3H).
Consistent with the literature.12
2-(((3aR,4S,9bS)-2,2,8,8-tetramethylhexahydro-[1,3]dioxolo[4',5':4,5]pyrano[3,2-d][1,3]dioxin-4-yl)thio)pyridine 456
Compound 454b (165 mg, 0.37 mmol) was dissolved in methanol (50 mL)
and a NaOMe solution was added until a pH of 12 was reached. The reaction was stirred at room temperature for 1 h to produce a faint yellow coloured solution. DOWEX 50W X8 ion exchange resin was added to the reaction mixture until a pH of 7 was reached. The solution was filtered and concentrated under reduced pressure. The crude was then dissolved in DMF (5 mL) and 2-methoxy propane (0.16 mL,
1.92 mmol), to which p-TsOH (6.00 mg, 0.03 mmol) was added and stirred for 1 h at room temperature. The saturated aqueous NaHCO3 (10 mL) was added to the reaction mixture and extracted
with Et2O (4 x 10 mL). The organic phase was washed with water (20 mL) and the combined
organics were dried, filtered, and concentrated under reduced pressure. The crude product was
dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce 456, the
title compound, as a colourless liquid (65.0 mg, 46% yield). Rf = 0.29. 7:3 hexanes/EtOAc. 1H
NMR (300 MHz, CDCl3) ppm 8.40 (d, J = 4.26 Hz, 1H), 7.57-7.41 (m, 1H), 7.29-7.22 (m, 1H),
7.04-6.96 (m, 1H), 5.80 (d, J = 10.06 Hz, 1H), 4.50 (s, 1H), 4.28-4.01 (m, 2H), 3.94 (d, J = 13.02
Hz, 1H), 3.82-3.60 (m, 2H), 3.49 (s, 1H), 1.47 (s, 3H), 1.46 (s, 3H), 1.44 (s, 3H), 1.43 (s, 3H). 13C
NMR and EI-MS m/z were not collected.
2-(((3aR,4S,9bS)-2,2,8,8-tetramethylhexahydro-[1,3]dioxolo[4',5':4,5]pyrano[3,2-d][1,3]dioxin-4-yl)sulfonyl)pyridine 457
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Compound 456 (50.0 mg, 0.14 mmol) in acetonitrile (1.2 mL) and water
(0.25 mL) was treated with KMnO4 (90.0 mg, 0.56 mmol) and CuSO4.5H2O
(62.0 mg, 0.39 mmol) and stirred for 2 h. The reaction mixture was then
mixture concentrated under reduced pressure and diluted with CH2Cl2 (20
mL). The organic phase was washed with water (10 mL) and brine (10 mL)
and the combined organic phase was dried, filtered, and concentrated under reduced pressure. The
crude product was dissolved in hexanes/ethyl acetate (4:1) and passed through a silica gel column
to produce 457, the title compounds, as colourless liquid (30.0 mg, 55% yield). Rf = 0.32. 4:1
hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 8.76 (ddd, J = 4.68, 1.60, 0.82 Hz, 1H), 8.178.12 (m, 1H), 7.95 (dt, J = 7.78, 7.77, 1.70 Hz, 1H), 7.55 (ddd, J = 7.67, 4.69, 1.10 Hz, 1H), 4.97
(d, J = 9.61 Hz, 1H), 4.42-4.40 (m, 1H), 4.28-4.18 (m, 2H), 3.95 (dd, J = 13.13, 2.23 Hz, 1H),
3.73 (dd, J = 13.17, 1.50 Hz, 1H), 3.63 (dd, J = 9.24, 2.62 Hz, 1H), 3.37 (d, J = 1.31 Hz, 1H),
1.48 (s, 3H), 1.24 (s, 3H), 1.45 (s, 3H), 1.38 (s, 3H) 13C NMR and EI-MS m/z were not collected.
(2R,3R,4R)-2-(acetoxymethyl)-6-(pyridin-2-ylthio)tetrahydro-2H-pyran-3,4-diyl

diacetate

458
Compound 119 (2.00 g, 7.36 mmol) in CH2Cl2 (40 mL) was treated with
2-mercaptopyridine (1.06 mL, 9.56 mmol) and anhydrous p-TsOH (800
mg, 4.80 mmol) and the mixture was heated under reflux for 30 min. The
rection mixture was cooled and poured into water (20 mL), and the organic phase was washed with aqueous 2% KOH (20 mL) and water (20 mL). The organic phase
was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in
hexanes/ethyl acetate (2:1) and passed through a silica gel column to produce 458, the title compound, as colourless liquid (1.75 g, 62% yield). Rf = 0.31. 2:1 hexanes/EtOAc. Mixtures of α and
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β anomers: 1H NMR (300 MHz, CDCl3) ppm 8.48 (dd, J = 10.49, 4.86 Hz, 1H), 7.56 (dt, J = 7.85,
7.71, 1.78 Hz, 1H), 7.40-7.28 (m, 1H), 7.08 (ddd, J = 7.36, 4.91, 1.01 Hz, 1H), 6.52 (d, J = 5.67
Hz, 1H), 5.36 (dd, J = 12.77, 2.89 Hz, 1H), 5.26 (ddd, J = 12.58, 4.81, 3.06 Hz, 1H), 4.54 (t, J =
6.74, 6.74 Hz, 1H), 4.18-3.95 (m, 3H), 2.60 (dt, J = 13.01, 12.97, 5.87 Hz, 1H), 2.14 (s, 3H), 2.122.05 (m, 1H), 2.01 (s, 3H), 1.91 (s, 3H). Consistent with the literature.13
(2R,3R,4R)-2-(acetoxymethyl)-6-(pyridin-2-ylsulfonyl)tetrahydro-2H-pyran-3,4-diyl diacetate 459
Compound 458 (170 mg, 0.44 mmol) in acetonitrile (3.7 mL) and water
(0.75 mL) was treated with KMnO4 (282 mg, 1.78 mmol) and
CuSO4.5H2O (190 mg, 1.20 mmol) and stirred for 2 h then the reaction
mixture was concentrated under reduced pressure and diluted with CH2Cl2 (20 mL). The combined
organic phase was washed with water (10 mL) and brine (10 mL), dried, filtered, and concentrated
under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (3:1) and passed
through a silica gel column to produce 459, the title compounds, as colourless liquid (120 mg, 65%
yield). Rf = 0.29. 3:1 hexanes/EtOAc. Mixtures of α and β anomers: 1H NMR (300 MHz, CDCl3)
ppm 8.84-8.63 (m, 1H), 8.18-8.02 (m, 1H), 8.03-7.89 (m, 1H), 7.61-7.50 (m, 1H), 5.57 (ddd, J =
12.43, 5.38, 2.88 Hz, 1H), 5.51 (d, J = 7.36 Hz, 1H), 5.37 (s, 1H), 5.23 (d, J = 2.36 Hz, 0.5H),
5.11-5.01 (m, 1H), 4.80 (t, J = 6.30, 6.30 Hz, 1H), 3.95-3.81 (m, 3H), 3.82-3.68 (m, 0.5H), 2.66
(dd, J = 14.53, 5.48 Hz, 1H), 2.48-2.28 (m, 2H), 2.05 (s, 3H), 1.96 (s, 3H), 1.84 (s, 3H) . 13C NMR
(75 MHz, CDCl3) ppm 169.9, 169.7, 169.6, 169.4, 155.1, 154.4, 150.4, 150.1, 137.8, 127.5, 124.6,
123.9, 85.6, 85.4, 75.2, 71.1, 68.2, 65.5, 65.2, 65.1, 62.0, 61.1, 22.9, 21.2, 20.5, 20.4, 20.2. EI-MS
m/z was not collected.
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Benzenesulfenyl Chloride (Phenyl hypochlorothioite) 461
NCS (2.67 g, 0.02 mmol) in CH2Cl2 (30 mL), thiophenol (1.85 g, 0.02 mmol)
was added slowly and stirred for 30 min and used directly without any purification. Consistent with the literature.14
(2R,3S)-3,4-bis(benzyloxy)-2-((benzyloxy)methyl)-5-(phenylthio)-3,4-dihydro-2H-pyran 463
To a stirring solution of compound 1123 (470 mg, 1.13 mmol) in CCl4 (3 mL),
phenylsulfenyl chloride (0.5 mL, 1.80 mmol) was added and heated for 5 h at
reflux. 70% of the CCl4 is then evaporated, and DBU (0.25 mL, 1.68 mmol)
was added. This mixture was stirred for 16 h at 50°C for 14 h. The mixture was
cooled to room temperature and diluted with a saturated aqueous NH4CI solution (10 mL) and
extracted with CH2Cl2 (2 x 10 mL). The organic phase was dried, filtered, and concentrated under
reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (7:1) and taken up
through a silica gel column to produce 463, the title compound, as a colourless liquid (335 mg,
55% yield). Rf = 0.29. 7:1 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.39-7.27 (m, 10H),
7.24-7.03 (m, 10H), 4.77 (d, J = 11.68 Hz, 1H), 4.70-4.35 (m, 7H), 4.13 (d, J = 3.62 Hz, 1H), 3.983.63 (m, 3H). Consistent with the literature.15
Triphenyl(((2R,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2Hpyran-2-yl)methyl)phosphonium iodide 464
Compound 469 (265 mg, 0.40 mmol) in toluene (5 mL) was treated
with triphenylphosphine (215 mg, 0.80 mmol), and heated at 120°C
for 2 h. The reaction mixture was cooled and concentrated under
reduced pressure. The crude was triturated with Et2O (10 mL) three
times to produce crude salt 464, the title compound, as white solid (320 mg, 86% yield). Rf = 0.32
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10:1 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.37-7.27 (m, 35H), 5.08-4.87 (m, 6H),
4.79-4.68 (m, 3H), 4.56 (d, J = 12.36 Hz, 2H), 4.23-4.06 (m, 2H), 3.96-3.75 (m, 1H), 3.49 (d, J =
6.92 Hz, 1H), 3.18-3.09 (m, 1H), 3.07-3.00 (m, 1H). Consistent with the literature.16
((2S,3S,4R,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2yl)methanol 468
Compound 1131 (460 mg, 0.83 mmol) in methanol (4 mL) and diethylether (2 mL) was treated with sodium borohydride (35.0 mg, 0.93
mmol) and stirred for 30 min at 0°C. Water (10 mL) was added and
then the reaction mixture was concentrated under reduced pressure to remove methanol. The aqueous phase was extracted with ethyl acetate (2 x 10 mL) and then washed with brine (10 mL). The
organic phase phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (9:1) and passed through a silica gel column to produce
468, the title compounds, as colourless liquid (280 mg, 61% total yield). Rf = 0.26. 9:1 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.43-7.23 (m, 20H), 4.95 (dd, J = 11.20, 6.24 Hz,
1H), 4.83-4.56 (m, 3H), 4.46 (q, J = 11.85, 11.85, 11.82 Hz, 2H), 4.02-3.78 (m, 3H), 3.77-3.50 (m,
5H), 3.42-3.30 (m, 1H). Consistent with the literature.16
(2R,3S,4S,5R,6R)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-6-(iodomethyl)tetrahydro2H-pyran 469
Compound 468 (280 mg, 0.5 mmol) in toluene (5 mL) was treated with
triphenylphosphine (398 mg, 1.50 mmol), imidazole (104 mg, 1.50
mmol) and iodine (256 mg, 1 mmol). The reaction mixture then was
heated at 110°C and stirred for 2 h. The reaction mixture was cooled and
diluted with Et2O (10 mL), washed with 5% aqueous Na2S2O3 (2 x 20 mL), and concentrated under
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reduced pressure. The crude was triturated with Et2O (10 mL) and filtered through a pad of Celite
to remove most of the triphenylphosphine oxide. The organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (9:1)
and passed through a silica gel column to produce 469, the title compounds, as colourless liquid
(265 mg, 80% yield). Rf = 0.32. 10:1 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.46-7.25
(m, 20H), 4.98 (dd, J = 11.24, 5.74 Hz, 2H), 4.84-4.39 (m, 6H), 4.01 (d, J = 2.58 Hz, 1H), 3.80 (t,
J = 9.20, 9.20 Hz, 1H), 3.68-3.60 (m, 3H), 3.54 (dd, J = 10.43, 2.25 Hz, 1H), 3.37-3.24 (m, 1H),
3.24-3.15 (m, 1H), 2.37-2.30 (m, 1H). Consistent with the literature.16
(3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-one 470
Compound 494 (11.4 g, 20.6 mmol) was dissolved in CH2Cl2 (175 mL) then
Dess-Martin Periodinane (9.30 g, 21.6 mmol) was added at room temperature.
The reaction was stirred at room temperature for 2 h and then filtered through
a pad of Celite. The organic phase was dried, filtered, and concentrated under reduced pressure.
The crude product was dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel
column to produce 470, the title compound, as a colourless liquid (8.92 g, 81% yield). On replication, yields varied between 77% and 81% for scales between 100 mg and 12.0 g. Rf = 0.30. 7:3
hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.49-7.40 (m, 2H), 7.39-7.34 (m, 6H), 7.327.22 (m, 12H), 5.20 (d, J = 11.00 Hz, 1H), 4.95 (d, J = 11.29 Hz, 1H), 4.72 (ddd, J = 35.63, 17.38,
8.75 Hz, 4H), 4.56-4.41 (m, 3H), 4.39-4.31 (m, 1H), 4.18 (t, J = 1.81, 1.81 Hz, 1H), 3.90 (dd, J =
9.57, 2.15 Hz, 1H), 3.80-3.61 (m, 2H). Consistent with the literature.17
dimethyl

(((2R,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)-2-hydroxytetra-

hydro-2H-pyran-2-yl)methyl)phosphonate 471
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Lactone 470 (1.35 g, 2.50 mmol) in THF (7.5 mL) was cooled to
–78°C and 1M n-BuLi (3.75 mL, 3.75 mmol) was added and the
mixture was stirred for 20 min. It was then treated slowly with solution of CH3P(O)(OMe)2 (0.46 mL, 3.75 mmol) in THF (5 mL)
and left to reach –40°C. The reaction mixture was diluted with saturated aqueous NH4Cl (20 mL)
and extracted with CH2Cl2 (2 x 20 mL). The organic phase was dried, filtered, and concentrated
under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (1:1) and passed
through a silica gel column to produce 471, the title compound, as a colourless liquid (1.10 g, 68%
yield). Rf = 0.33. 1:1 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.48-7.06 (m, 20H), 4.95
(dd, J = 11.08, 10.36 Hz, 2H), 4.84-4.51 (m, 4H), 4.42 (q, J = 11.65, 11.65, 11.65 Hz, 2H), 3.99
(d, J = 1.78 Hz, 1H), 3.72-3.48 (m, 12H), 2.32 (ddd, J = 20.06, 15.50, 1.46 Hz, 1H), 1.92 (ddd, J
= 16.34, 12.96, 9.39 Hz, 1H). Consistent with the literature.18
dimethyl

(((2R,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-

pyran-2-yl)methyl)phosphonate 472
Compound 471 (1.10 g, 1.66 mmol) in CH2Cl2 (2 mL) was treated
with triethylsilane (2.7 mL, 16.6 mmol) and trimethylsilyl triflate
(0.3 mL, 1.66 mmol). The mixture was stirred at room temperature
for 45 min, then diluted with Et3N (1 mL). The crude concentrated under reduced pressure and
product was dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to
produce 472, the title compounds, as colourless liquid (860 mg, 80% yield). Rf = 0.29. 7:3 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.45-7.05 (m, 20H), 4.95 (dd, J = 11.08, 10.36 Hz,
2H), 4.74 (d, J = 11.64 Hz, 1H), 4.64 (dd, J = 18.62, 7.82 Hz, 3H), 4.42 (q, J = 11.65, 11.65, 11.65
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Hz, 2H), 4.03-3.95 (m, 1H), 3.87-3.24 (m, 12H), 2.32 (ddd, J = 20.06, 15.50, 1.35 Hz, 1H), 1.92
(dt, J = 15.87, 15.54, 9.67 Hz, 1H). Consistent with the literature.18
dimethyl((3S,4S,5R)-3,4,5,7-tetrakis(benzyloxy)-2-oxo-6-((triisopropylsilyl)oxy)heptyl)phosphonate 473
To a solution of compound 471 (100 mg, 0.15 mmol) in THF (5
mL) at 0°C was added NaH (11.0 mg, 1.18 mmol) portionwise
and stirred for 30 min. TIPSCl (0.06 mL, 0.30 mmol) was then
added and stirred for 18 h at room temperature. The reaction
mixture was quenched slowly with water (10 mL) and extracted with ethyl acetate (3 x 10 mL).
The organic phase washed with water (20 mL) and brine (20 mL) and the organic phase was dried,
filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (1:1) and passed through a silica gel column to produce 473, the title compound,
as a colourless liquid (142 mg, 77% yield). Rf = 0.31. 1:1 hexanes/EtOAc. 1H NMR (300 MHz,
CDCl3) ppm 7.56-7.00 (m, 20H), 4.73 (dd, J = 11.52, 4.69 Hz, 2H), 4.60 (d, J = 14.73 Hz, 3H),
4.51 (d, J = 11.98 Hz, 1H), 4.46-4.40 (m, 2H), 4.39-4.28 (m, 2H), 4.17-4.08 (m, 1H), 4.06 (t, J =
5.22, 5.22 Hz, 1H), 3.72-3.48 (m, 8H), 3.36 (dd, J = 22.02, 14.54 Hz, 1H), 2.98 (dd, J = 21.12,
14.52 Hz, 1H), 1.05 (s, 21H).13C NMR (75 MHz, CDCl3) ppm 200.6, 200.5, 138.8, 138.2, 138.1,
137.9, 128.4, 128.2, 128.0, 127.9, 127.7, 127.2, 84.2, 80.1, 79.6, 77.5, 77.1, 76.7, 74.8, 73.3, 72.7,
72.2, 72.0, 71.9, 52.8, 52.8, 38.9, 37.2, 18.3, 18.2, 13.1. EI-MS m/z calcd for C46H63O9PSi: 818.40.
Found: [M]+ 819.41.
S-(((2R,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2yl)methyl) ethanethioate 474
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Compound 469 (200 mg, 0.32 mmol) was dissolved in THF (13 mL)
and treated with KSAc (75.0 mg, 0.66 mmol). The reaction mixture
then was heated at 60°C and stirred for 16 h. The reaction mixture was
cooled to room temperature and concentrated under reduced pressure.
EtOAc (50 mL) was added and washed with saturated NaHCO3 (30 mL), water (30 mL) and brine
(30 mL). The combined organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (8:2) and taken up through a silica
gel column to produce 474, the title compound, as a colourless liquid (95.0 mg, 73% yield). Rf =
0.32. 8:2 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.43-7.27 (m, 20H), 4.94 (dd, J =
11.25, 2.53 Hz, 2H), 4.68 (td, J = 17.73, 11.77, 11.77 Hz, 4H), 4.45 (q, J = 11.83, 11.78, 11.78 Hz,
2H), 3.97 (d, J = 2.70 Hz, 1H), 3.76 (t, J = 9.30, 9.30 Hz, 1H), 3.63-3.50 (m, 5H), 3.44-3.32 (m,
1H), 2.99 (dd, J = 13.56, 7.97 Hz, 1H), 2.31 (s, 3H). 13C NMR (75 MHz, CDCl3) ppm 195.2, 138.6,
138.1, 138.0, 137.8, 128.3, 128.3, 128.2, 128.1, 127.9, 127.8, 127.6, 127.6, 127.4, 84.4, 78.5, 77.7,
77.1, 76.5, 75.3, 74.3, 73.6, 73.4, 72.2, 68.7, 31.3, 30.4. EI-MS m/z was not collected.
(2R,3S,4R,5R,6S)-5-acetamido-2-(acetoxymethyl)-6-(4-nitrophenoxy)tetrahydro-2H-pyran3,4-diyl diacetate 480
Compound 1102 (2.08 g, 5.47 mmol) in acetone (150 mL,
HPLC-grade) was treated with p-nitrophenol (1.8 g, 12.5
mmol) and K2CO3 (2.07 g, 15 mmol) and the suspension
was stirred for 1 h at 50 °C. The reaction mixture was concentrated under reduced pressure and
diluted with CH2Cl2 (150 mL) and the mixture was washed with saturated aqueous NaHCO3 (100
mL) and brine (100 mL). The organic phase was dried, filtered, and concentrated under reduced
pressure. The crude product was recrystallized from MeOH to produce 480, the title compounds,
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as brown solid (2.00 g, 78% yield). On replication, yields varied between 74% and 78% for scales
between 2.00 g and 5.00 g. Rf = 0.26. 1:1 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 8.24
(d, J = 9.26 Hz, 2H), 7.11 (d, J = 9.27 Hz, 2H), 5.65 (d, J = 8.24 Hz, 1H), 5.55-5.44 (m, 2H), 5.18
(t, J = 9.52, 9.52 Hz, 1H), 4.32 (dd, J = 12.33, 5.54 Hz, 1H), 4.26-4.07 (m, 2H), 3.97 (ddd, J =
9.69, 5.51, 2.48 Hz, 1H), 2.12 (s, 6H), 2.10 (s, 3H), 2.00 (s, 3H). Consistent with the literature.19
N-((4aR,6S,7R,8R,8aS)-8-hydroxy-6-(4-nitrophenoxy)-2-phenylhexahydropyrano[3,2d][1,3]dioxin-7-yl)acetamide 481
Compound 480 (2.33 g, 4.97 mmol) was dissolved in
methanol (100 mL) and then NaOMe solution was
added until a pH of 12 was reached. The reaction was
stirred at room temperature for 5 h. DOWEX 50W X8 ion exchange resin was added to the reaction
mixture until a pH of 7 was reached. The solution was filtered and concentrated under reduced
pressure. The crude was dissolved in anhydrous DMF (50 mL), and treated with benzaldehyde
dimethyl acetal (0.9 mL, 5.4 mmol) and p-TsOH (136 mg, 0.78 mmol) and heated at 50°C. The
reaction mixture was cooled and concentrated under reduced pressure. The saturated aqueous NaHCO3 (100 mL) was added and stirred for 0.5 h at room temperature. The dark brown precipitate
was filtered and washed with water (50 mL) and diethyl ether (50 mL) to produce 481, the title
compounds, as brown solid (1.00 g, 47% yield). On replication, yields varied between 35% and
47% for scales between 1.70 g and 4.70 g. Rf = 0.42. 1:9 hexanes/EtOAc. 1H NMR (300 MHz,
CDCl3) ppm 8.20 (d, J = 9.26 Hz, 2H), 7.98 (d, J = 8.40 Hz, 1H), 7.50-7.42 (m, 2H), 7.43-7.35 (m,
4H), 7.24 (d, J = 9.28 Hz, 2H), 5.64 (s, 1H), 5.50 (s, 1H), 5.40 (d, J = 8.08 Hz, 1H), 4.24 (d, J =
5.20 Hz, 1H), 3.93-3.65 (m, 3H), 3.56 (t, J = 8.75, 8.75 Hz, 1H), 1.82 (s, 3H). Consistent with the
literature.19
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N-((4aR,6S,7R,8S,8aS)-8-hydroxy-6-(4-nitrophenoxy)-2-phenylhexahydropyrano[3,2d][1,3]dioxin-7-yl)acetamide 482
Compound 481 (1.00 g, 2.50 mmol) in CH2Cl2 (10
mL) and pyridine (10 mL) was treated with MsCl
(0.56 mL, 7.20 mmol). The reaction mixture was
stirred for 16 h at room temperature, quenched with MeOH (1 mL) and concentrated under reduced
pressure. The crude was dissolved in MeOH (20 mL) and stirred for 30 min at room temperature.
The precipitate was filtered and washed with MeOH to give the mesylate as a solid, which was
dissolved in 2-methoxyethanol (25 mL) and water (2.5 mL), and then reacted with sodium acetate
(1.15 g, 14.0 mmol ) at 130°C for 8 h. The mixture was cooled to room temperature, and the
solvents were concentrated under reduced pressure and distilled water (150 mL) was added, and
the mixture was stirred for an additional 30 min at room temperature. The dark brown precipitate
was filtered and washed with water and diethyl ether to produce 482, the title compound, as a
brown solid (0.58 g, 46% yield). On replication, yields varied between 35% and 46% for scales
between 1.00 g and 4.80 g. Rf = 0.4, EtOAc. 1H NMR (300 MHz, acetone-d6) ppm 8.27-8.17 (m,
1H), 8.16-8.10 (m, 1H), 7.56-7.44 (m, 2H), 7.43-7.31 (m, 3H), 7.32-7.22 (m, 1H), 7.06-6.92 (m,
1H), 5.70 (s, 1H), 5.55 (dd, J = 8.53, 1.00 Hz, 1H), 4.45-4.14 (m, 3H), 3.81 (dd, J = 19.68, 9.47
Hz, 2H), 3.66-3.51 (m, 1H), 3.43-3.34 (m, 1H), 3.30-3.25 (m, 1H), 1.93 (s, 3H). Consistent with
the literature.19
(2R,3S,4R,5S,6S)-2-(acetoxymethyl)-6-cyanotetrahydro-2H-pyran-3,4,5-triyl triacetate 484
Compound 196 (5.00 g, 29.70 mmol) was dissolved in nitro methane
(20 mL) and trimethylsilyl cyanide was added and the mixture was
cooled to 0°C. The solution was then treated with BF3.OEt2 (4.1 mL,
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44.6 mmol) and stirred at room temperature for 2 h. The reaction mixture was quenched with Et3N
and concentrated under reduced pressure. The crude was dissolved in acetyl acetate and washed
with a saturated aqueous NaHCO3 solution (50 mL), H2O (50 mL), and brine (50 mL) and stirred
for 3 h at room temperature. The organic phase was dried, filtered, and concentrated under reduced
pressure. The crude product was recrystallized with ethyl acetate to produce 484, the title compound as an orange solid (3.60 g, 48% yield). Rf = 0.31. 9:1 hexanes/EtOAc. 1H NMR (300 MHz,
CDCl3) ppm 5.52 (t, J = 10.18, 10.18 Hz, 1H), 5.42 (dd, J = 3.25, 0.92 Hz, 1H), 4.99 (dd, J =
10.15, 3.30 Hz, 1H), 4.28 (d, J = 10.21 Hz, 1H), 4.10 (d, J = 6.34 Hz, 2H), 4.00-3.88 (m, 1H),
2.17 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H), 1.99 (s, 3H). Consistent with the literature.20
(2R,3S,4S,5R,6R)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-6-(furan-2-yl)tetrahydro2H-pyran 487
Compound 486 (2.60 g, 4.11 mmol) was dissolved in distilled acetonitrile (35 mL) over activated power 4Å molecular sieves and
stirred for 30 min. The flask was cooled to –25°C and distilled furan
was added and stirred for 30 min, then NIS (1.85 g, 8.22 mmol) and TfOH (0.73 mL, 8.22 mmol)
were added and stirred for 2 h. The reaction mixture warmed to room temperature and diluted with
CH2Cl2 (50 mL) then passed through a pad of Celite. The solution was washed with saturated
NaHCO3 (50 mL), water (50 mL) and brine (50 mL). The organic phase was dried, filtered, and
concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate
(9:1) and passed through a silica gel column to produce 486, the title compounds, as colourless
liquid (1.95 g, 80% yield). On replication, yields varied between 52% and 80% for scales between
50.0 mg and 2.60 g. Rf = 0.32. 9:1 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.48-7.28
(m, 15H), 7.26-7.18 (m, 5H), 7.06-7.00 (m, 2H), 6.44 (dd, J = 3.22, 0.67 Hz, 1H), 6.39 (dd, J =
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3.22, 1.84 Hz, 1H), 5.00 (d, J = 11.72 Hz, 1H), 4.76 (s, 2H), 4.65 (dd, J = 19.42, 11.02 Hz, 2H),
4.42 (q, J = 11.79, 11.79, 11.79 Hz, 2H), 4.35-4.26 (m, 2H), 4.18-4.07 (m, 2H), 4.04 (d, J = 2.45
Hz, 1H), 3.72-3.62 (m, 2H), 3.63-3.55 (m, 2H). Consistent with the literature.21
(3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-ol 494
N-Bromosuccinimide (700 mg, 4.72 mmol) was added to a stirred solution
of 486 (700 mg, 1.11 mmol) in 9:1 acetone/water (16 mL) and the reaction
mixture was stirred for 5 min at room temperature, then NaHCO3 (5.00 g)
was added and the solvent concentrated under reduced pressure. The residue was dissolved in
EtOAc (100 mL) and water (50 mL) and the organic phase was separated and the mixture was
washed with saturated aqueous NaHCO3 (2 x 50 mL), water (50 mL), and brine (50 mL). The
organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was
dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce 494, the
title compound, as a colourless liquid (550 mg, 92% yield). On replication, yields varied between
85% and 92% for scales between 100 mg and 11.0 g. Rf = 0.28. 7:3 hexanes/EtOAc. 1H NMR
(300 MHz, CDCl3) ppm 7.47-7.18 (m, 20H), 5.34-5.26 (m, 1H), 5.00-4.88 (m, 1H), 4.88-4.80 (m,
1H), 4.79-4.72 (m, 3H), 4.71-4.55 (m, 1H), 4.45 (q, J = 11.92, 11.90, 11.90 Hz, 2H), 4.17 (t, J =
6.64, 6.64 Hz, 1H), 4.09-4.01 (m, 1H), 4.01-3.95 (m, 1H), 3.95-3.87 (m, 1H), 3.84-3.70 (m, 1H),
3.66-3.45 (m, 3H). Consistent with the literature.22
(2R,3S,4R,5S,6S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-6-vinyltetrahydro-2H-pyran
495
To a solution of lactone 470 (8.90 g, 0.57 mmol) in THF (160 mL) at ̶
78°C was added allylmagnesium bromide solution 1.0 M in THF (20 mL,
20.0 mmol). The reaction mixture was stirred for 2 h and then allowed to
warm to 0°C. The reaction was then quenched with saturated aqueous NH4Cl (50 mL) water and
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extracted with ethyl acetate (4 x 50 mL). The combined organic phases were washed with brine
(150 mL), dried, filtered, and concentrated under reduced pressure. The crude was immediately
dissolved in CH2Cl2 (100 mL) and cooled to –40 °C. Triethylsilane (16 mL, 99.4 mmol) and then
BF3.Et2O (8.2 mL, 66.4 mmol) were added and the reaction mixture stirred for 1 h. The reaction
was then allowed to warm to room temperature. The reaction was quenched by Et3N (8 mL) and
was washed with water (30 mL) and brine (30 mL). The organic phase was dried, filtered, and
concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate
(10:1) and passed through a silica gel column to produce 495, the title compound, as a colourless
liquid (4.00 g, 45% yield). On replication, yields varied between 40% and 45% for scales between
150 mg and 9.00 g. Rf = 0.29. 10:1 hexanes/EtOAc. 1H NMR (500 MHz, CDCl3) ppm 7.40-7.14
(m, 20H), 6.06-5.82 (m, 1H), 5.38 (dd, J = 17.30, 1.47 Hz, 1H), 5.23 (dd, J = 10.50, 1.67 Hz, 1H),
4.91 (d, J = 11.68 Hz, 1H), 4.78 (d, J = 10.53 Hz, 1H), 4.69 (d, J = 2.44 Hz, 2H), 4.61 (d, J =
2.05 Hz, 1H), 4.58 (s, 1H), 4.40 (d, J = 4.96 Hz, 2H), 3.95 (d, J = 2.72 Hz, 1H), 3.79-3.61 (m,
2H), 3.62-3.46 (m, 4H). Consistent with the literature.23
((2R,3R,6R)-3-acetoxy-6-allyl-3,6-dihydro-2H-pyran-2-yl)methyl acetate 496
A solution of 119 (4.10 g, 15.0 mmol) and allyltrimethylsilane (1.5 mL,
18.0 mmol) in CH2Cl2 (50 mL) was cooled to –30°C and BF3.OEt2 (1.9
mL, 15 mmol) was added. The reaction mixture was quenched by the
addition of saturated aqueous NaHCO3 (50 mL) and EtOAc (100 mL)
was added. The phases were separated, and the organic phase was washed with water (50 mL) and
brine (50 mL). The organic phase was dried, filtered, and concentrated under reduced pressure.
The crude product was dissolved in hexanes/ethyl acetate (8:2) and passed through a silica gel
column to produce 496, the title compound, as a colourless liquid (3.45 g, 91% yield). On replication, yields varied between 85% and 91% for scales between 50 mg and 4.00 g. Rf = 0.32. 8:2
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hexanes/EtOAc. 1H NMR (500 MHz, CDCl3) ppm 6.06 (dd, J = 10.33, 2.83 Hz, 1H), 5.99 (ddd, J
= 10.26, 4.90, 1.83 Hz, 1H), 5.94-5.75 (m, 1H), 5.20-5.04 (m, 3H), 4.44-4.31 (m, 1H), 4.27-4.17
(m, 2H), 4.17-4.10 (m, 1H), 2.53-2.37 (m, 1H), 2.36-2.23 (m, 1H), 2.09 (s, 3H), 2.07 (s, 3H).
Consistent with the literature.24
(2R,3R,6R)-6-allyl-2-(((tert-butyldimethylsilyl)oxy)methyl)-3,6-dihydro-2H-pyran-3-ol 498
Compound 496 (525 mg, 2.20 mmol) was dissolved in methanol (100 mL)
then NaOMe solution was added till pH 12. The reaction was stirred at
room temperature for 1 h to produce a faint yellow colour solution.
DOWEX 50W X8 ion exchange resin was added to the reaction mixture
until pH 7 was reached. The solution was filtered and concentrated under reduced pressure, then
the crude was dissolved in CH2Cl2 (25 mL) and cooled to 0°C and Et3N (0.42 mL, 3.00 mmol),
DMAP (30.0 mg, 0.24 mmol) and TBSCl (430 mg, 2.86 mmol) were added and stirred 4 h. The
reaction mixture was washed with water (50 mL) and brine (50 mL). The organic phase was dried,
filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (10:1) and passed through a silica gel column to produce 498, the title compound, as a colourless liquid (480 mg, 76% yield). On replication, yields varied between 69% and
76% for scales between 50.0 mg and 2.00 g. Rf = 0.33. 10:1 hexanes/EtOAc. 1H NMR (500 MHz,
CDCl3) ppm 5.99-5.77 (m, 2H), 5.20-5.03 (m, 2H), 4.27 (ddd, J = 10.83, 5.39, 2.53 Hz, 1H), 4.003.90 (m, 1H), 3.89-3.73 (m, 3H), 2.53-2.34 (m, 1H), 2.35-2.19 (m, 1H), 1.98 (d, J = 8.71 Hz, 1H),
0.91 (s, 9H), 0.09 (s, 6H). Consistent with the literature.24
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(2R,6R)-6-allyl-2-(((tert-butyldimethylsilyl)oxy)methyl)-2H-pyran-3(6H)-one 499
Compound 498 (190 mg, 0.54 mmol) was dissolved in CH2Cl2 (3 mL)
and treated with PCC (240 mg, 1.09 mmol) and silica (240 mg), The reaction mixture was stirred for 4 h, diluted with CH2Cl2 (30 mL) and then
pass through Celite. The solution was washed with saturated aqueous NaHCO3 (50 mL), water (50
mL) and brine (50 mL). The organic phase was dried, filtered, and concentrated under reduced
pressure. The crude product was dissolved in hexanes/ethyl acetate (90:1) and passed through a
silica gel column to produce 499, the title compound, as a colourless liquid (110 mg, 72% yield).
On replication, yields varied between 65% and 72% for scales between 50.0 mg and 1.00 g. Rf =
0.28. 90:1 hexanes/EtOAc. 1H NMR (500 MHz, CDCl3) ppm 6.97 (dd, J = 10.52, 2.02 Hz, 1H),
6.13 (dd, J = 10.52, 2.20 Hz, 1H), 5.96-5.79 (m, 1H), 5.27-5.09 (m, 2H), 4.93-4.72 (m, 1H), 4.23
(dd, J = 4.27, 2.71 Hz, 1H), 4.02 (dq, J = 11.14, 11.13, 11.13, 3.49 Hz, 2H), 2.60-2.47 (m, 1H),
2.47-2.39 (m, 1H), 0.85 (s, 9H), 0.05 (s, 3H), 0.01 (s, 3H).

13

C NMR (125 MHz, CDCl3) ppm

195.4, 151.0, 133.3, 126.8, 118.1, 79.6, 71.1, 64.9, 38.7, 25.7, 18.1, -5.5, -5.6. EI-MS m/z calcd
for C15H26O3Si: 282.16. Found: [M]+ 283.18.
(2R,6R)-6-allyl-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-(hydroxy((2S,3R,4S,5S,6R)-3,4,5tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)methyl)-2H-pyran-3(6H)one 4401
A mixture of aldehyde 1131 (70.0 mg, 0.13 mmol) and
compound 499 (65.0 mg, 0.23 mmol) in CH2Cl2 (2 mL)
was cooled to –78°C and treated with solution of 1 M
Et2AlI (0.13 mL, 0.13 mmol) in toluene for 2 h. The reaction mixture was diluted with Et2O (20
mL) and then 2M HCl (10 mL) was added. The aqueous phase was extracted with Et2O (2 x 10
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mL), and the combined organic phases was washed with water (20 mL), and brine (20 mL). The
organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was
dissolved in hexanes/ethyl acetate (9:1) and passed through a silica gel column to produce 500, the
title compounds, as colourless liquid (25.0 mg, 22% yield). On replication, yields varied between
6% and 22% for scales between 20.0 mg and 1.60 g. Rf = 0.33. 9:1 hexanes/EtOAc. 1H NMR (300
MHz, CDCl3) ppm 7.52-7.17 (m, 20H), 7.12-6.86 (m, 1H), 6.01-5.72 (m, 1H), 5.26-5.08 (m, 1H),
5.02 (dd, J = 11.24, 2.54 Hz, 2H), 4.97-4.88 (m, 1H), 4.84 (d, J = 11.30 Hz, 2H), 4.81-4.70 (m,
3H), 4.62 (d, J = 11.56 Hz, 1H), 4.56-4.38 (m, 3H), 4.29-4.12 (m, 2H), 4.09-3.94 (m, 3H), 3.743.63 (m, 1H), 3.63-3.52 (m, 2H), 3.52-3.41 (m, 2H), 2.76-2.22 (m, 2H), 0.88 (s, 9H), 0.07 (s, 3H),
0.05 (s, 3H). 13C NMR (125 MHz, CDCl3) ppm 195.0, 146.5, 138.9, 138.8, 138.7, 138.5, 138.5,
138.4, 138.3, 138.2, 138.1, 138.0, 136.5, 133.7, 128.6, 128.5, 128.5, 128.3, 128.0, 127.9, 127.7,
127.6, 127.3, 127.2, 127.1, 118.0, 84.7, 79.7, 78.8, 77.6, 77.3, 76.9, 75.3, 74.9, 74.6, 73.9, 73.6,
72.5, 71.6, 68.7, 66.0, 64.2, 38.3, 31.0, 26.0, 18.3, -5.2, -5.3. EI-MS m/z calcd for C50H62O9Si:
834.42. Found: [M+ NH4]+ 852.45.
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9.8 Experimental protocols for Chapter 5
2,3,4,6-tetra-O-benzyl-α- D-glucopyranosyl Chloride 503
2,3,4,6-tetra-O-benzyl- D-glucopyranose 502 (820 mg, 1.52 mmol) and DMF (128 uL)
were dissolved in CH2Cl2 (12 mL). Oxalyl chloride (0.13 mL) was added dropwise at
0°C and the reaction was stirred for 30 min at 0°C, then for 1 h at room temperature.
The crude product was concentrated under reduced pressure, dissolved in hexanes, and
passed through a silica gel column to to produce 503, title compound as a colourless liquid (320 mg,
38% yield). On replication, yields varied between 32% and 38% for scales between 50.0 mg and

820 mg. Rf = 0.31. 3:7 EtOAc/hexanes. 1H NMR (300 MHz, CDCl3) ppm 7.53-7.30 (m, 18H),
7.29-7.20 (m, 2H), 6.16 (d, J = 3.69 Hz, 1H), 5.07 (d, J = 10.81 Hz, 1H), 4.93 (dd, J = 10.79, 5.15
Hz, 2H), 4.81 (d, J = 1.66 Hz, 2H), 4.73-4.50 (m, 3H), 4.28-4.04 (m, 2H), 3.92-3.78 (m, 3H), 3.74
(dd, J = 10.91, 1.86 Hz, 1H). Consistent with the literature.1
1,2,5,6-di-O-isopropyliidene-D-mannitol 505
Acetone (50 ml) was saturated with anhydrous ZnCl2 (10.0 g, 76.8 mmol)
and the milky solution was allowed to settle down. Solution was cannulated under nitrogen to a round bottom flask containing D-mannitol (5.00
g, 27.4 mmol). The reaction mixture was stirred for 2.5 h at room temperature and saturated K2CO3 (40 mL) was then added. The reaction mixture was stirred at room
temperature for 0.5 h before being filtered. The filtrate and the residue extracted with CH2Cl2 (3 x
50 mL) and the organic phase was dried, filtered, and concentrated under reduced pressure. The
crude product was recrystallized from 9:1 hexanes/CH2Cl2 to produce 505, title compound as a
white solid (6.00 g, 90% yield). On replication, yields varied between 84% and 90% for scales
between 2.50 g and 5.00 g. Rf = 0.37. 1:7 EtOAc/hexanes. 1H NMR (300 MHz, CDCl3) ppm 4.19
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(q, 2H J = 6.03), 4.13 (t, 2H, J = 8.33), 4.0 (d, 1H J = 5.58), 3.97 (d, 1H J = 5.6), 3.76 (t, 2H J =
6.17), 2.72 (d, 2H J = 6.66), (s, 6H), 1.35 (s, 6H). Consistent with the literature.2
(2R)-1-O-(2,3,4,6-Tetra-O-benzyl--D-glucopyranosyl)-2,3-O-isopropylideneglycerol 507
Compound 503 (160 mg, 0.28 mmol), 2-6-di-tert-butylpyrimidine
(180 mg, 0.95 mmol), molecular sieves and (S)-(+)-Solketal 1253
(50 mg, 0.378 mmol) were stirred in anhydrous CH2Cl2 (2 mL) under nitrogen. AgOTf (160 mg, 0.60 mmol) was added to the reaction mixture. After the disappearance of starting material, Bu4NBr (120 mg) and saturated aqueous NaHCO3 (10 mL) were added,
and the mixture was filtered through a pad of Celite, diluted with CH2Cl2 (30 mL) and the mixture
was washed with water (30 x 2 mL), and the organic phase was dried, filtered, and concentrated
under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (3:1) and passed
through a silica gel column to produce 507, title compound as a colourless liquid (100 mg, 54%
yield). 1H NMR (300 MHz, CDCl3) ppm 7.29 (m, 18H), 7.18 (m, 2H), 5.02-4.25 (m, 10H), 4.09
(m, 2H), 3.84 (dd, J = 5.99, 8.28, 1H), 3.71 (m, 2H), 3.62 (m, 3H), 3.46 (t, J = 7.93, 2H), 1.42 (s,
3H), 1.37 (s, 3H). Consistent with the literature.3
(2R)-1-O-(2,3,4,6-Tetra-O-benzyl--D-glucopyranosyl)-2,3-O-isopropylideneglycerol 508
Compound 502 (4.80 g, 7.60 mmol), (S)-(+)-Solketal 1253
(1.00 g, 7.60 mmol) and activated 5Å MS stirred in Et2O (100
ml) for 0.5 h and cooled to –40°C then TfOH (0.14 mL, 16.2
mmol), and NIS (1.71 g, 7.60 mmol) were added. The reaction mixture was then stirred for 2 h
and then passed through Celite upon completion. The reaction was diluted with CH2Cl2 (100 mL)
and the organic phase was washed with Na2S2O3 (100 mL), saturated aqueous NaHCO3 (100 mL)
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and brine (100 mL), then concentrated. The crude product was dissolved in toluene/ethyl acetate
(9:1) and passed through a silica gel column to produce 508, the title compound as a colorless
liquid (4.50 g, 90% yield). On replication, yields varied between 84% and 90% for scales between
50.0 mg and 4.80 g. Rf = 0.29. 3:7 EtOAc/hexanes. Mixtures of α and β anomer : 1H NMR (300
MHz, CDCl3) ppm 7.41-7.27 (m, 14H), 7.25-7.08 (m, 6H), 5.05-4.90 (m, 1H), 4.90-4.71 (m, 3H),
4.71-4.62 (m, 1H), 4.62-4.55 (m, 1H), 4.48 (d, J = 11.64 Hz, 2H), 4.40-4.28 (m, 1H), 4.12-4.03
(m, 1H), 4.03-3.86 (m, 1H), 3.84-3.35 (m, 8H), 1.43 (s, 3H), 1.37 (s, 3H). Consistent with the
literature.3, 4
(2R)-1-O-(-D-glucopyranosyl)-2,3-O-isopropylideneglycerol 508a
To a solution of compound 508 (3.50 g, 5.32 mmol) MeOH
(200 mL), Pd/C (21.0 g, 99.0 mmol) and ammonium formate
(6.40 g, 102 mmol) were added and refluxed at 70°C for 5 h.
After cooling to room temperature, the reaction mixture was passed through a pad of Celite and
washed with MeOH (100 mL). The solvent was evaporated and then co-evaporated with chloroform to produce 508a, the title compound as a colourless liquid (1.40 g, 89% yield). On replication,
yields varied between 80% and 89% for scales between 50.0 mg and 3.50 g. Rf = 0.25. 95:5
EtOAc/MeOH. Mixtures of alpha and beta: 1H NMR (300 MHz, MeOD) ppm 4.80-478 (m, 1H),
4.32-4.28 (m, 1H), 4.05-3.98 (m, 1H), 3.91-3.48 (m, 6H), 3.47-3.04 (m, 4H), 1.36 (s, 3H), 1.29 (s,
4H). Consistent with the literature.4, 5
(2R)-1-O-(-D-2,3,4,6-tetra-O-acetyl-glucopyranosyl)-2,3-O-isopropylideneglycerol 509
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Compound 508a (1.80 g, 6.12 mmol) was added to pyridine
(13 mL) and Acetic Anhydride (7 mL) at 0°C, under nitrogen. The reaction was stirred overnight for 12 h and then
poured into a beaker containing ice water (100 mL), and then CH2Cl2 (100 mL) was added and the
aqueous and organic phase were separated. The organic phase was washed once with CuSO4 aq (2
x 50 mL), saturated aqueous NaHCO3 (50 mL) and water CH2Cl2 (50 mL). The organic phase was
dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce 509, the colourless liquid
compound (1.90 g, 67% yield). On replication, yields varied between 58% and 67% for scales
between 50.0 mg and 1.80 g. Rf = 0.45. 3:7 EtOAc/hexanes. Mixtures of α and β: 1H NMR (300
MHz, CDCl3) ppm 5.49 (t, J = 9.83, 1H), 5.26-4.95 (m, 2H), 4.89-4.81 (m, 1H), 4.27 -4.22 (m,
2H), 4.19-3.98 (m, 3H), 3.82- 3.61 (m, 2H), 3.52-3.44 (m, 1H), 2.06 (acetate singlets, 12H), 1.42
(s, 3H), 1.37 (s, 3H). Consistent with the literature.6
3-O-(-D-2,3,4,6-tetra-O-acetyl-glucopyranosyl)-sn-glycerol 509a
To a solution of compound 509 (1.80 g, 3.90 mmol) in acetonitrile (18 mL), Zn(NO3)2.6H2O (5.80 g, 19.5 mmol) was
added. The mixture was stirred for 6 h at 50°C, and the solvent was then evaporated under reduced pressure. The reaction mixture diluted with CH2Cl2 (150
mL) and water (100 mL) added, and the organic phase was washed with water (2 x 100 mL) and
brine (100 mL). The organic phase was dried, filtered, and concentrated under reduced pressure.
The crude product was dissolved in hexanes/ethyl acetate (5:1) and passed through a silica gel
column to produce 509a, the colourless liquid compound (1.20 g, 70% yield). On replication,
yields varied between 58% and 70% for scales between 50.0 mg and 1.80 g. Rf = 0.3. EtOAc.
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Mixtures of α and β: 1H NMR (500 MHz, CDCl3) ppm 5.55-5.40 (m, 1H), 5.15-5.00 (m, 2H), 5.004.87 (m, 1H), 4.32-4.17 (m, 1H), 4.17-4.04 (m, 2H), 4.01-3.59 (m, 6H), 2.63-2.54 (m, 1H), 2.11
(s, 3H), 2.08 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H). Consistent with the literature.7
1-O-hexadecanoyl-3-O-(-D-2,3,4,6-tetra-O-acetyl-glucopyranosyl)-sn-glycerol 509b
To a solution of compound 509a (1.20 g, 2.76 mmol) in
anhydrous CH2Cl2 (50 mL) under nitrogen, palmitic acid
(0.72 g, 2.76 mmol), EDC (0.53 g, 2.76 mmol), and DMAP
(0.33 g, 0.28 mmol) were added under nitrogen at 0°C and
the reaction was stirred 0°C for 6 h. The reaction mixture diluted with CH2Cl2 (150 mL) and water
(100 mL) added, and the organic phase was washed with water (2 x 100 mL) and with brine (100
mL). The organic phase was dried, filtered, and concentrated under reduced pressure. The crude
product was dissolved in hexanes/ethyl acetate (2:1) and passed through a silica gel column to
produce 509b, the title compound as a colourless liquid (0.90 mg, 50% yield). Rf = 0.22. 3:7
EtOAc/hexanes. Mixtures of α and β: 1H NMR (300 MHz, CDCl3) ppm 5.47 (t, J = 9.94, 1H), 5.32
(t, J = 5.65, 1H), 5.12-4.98 (m, 2H), 4.9 (d, J = 10.05, 1H), 4.05-4.3 (m, 5H), 3.89 -3.63 (m, 2H),
3.54-3.50 (m, 1H), 2.52 (dd, J = 20.46, 4.95 Hz, 1H), 2.35-2.29 (m, 2H), 2.11 (s, 3H), 2.08 (s, 3H),
2.04 (s, 3H), 2.03(s, 3H), 1.61 (m, 2H), 1.31 (s, 24H), 0.91 (t, J = 6.96, 3H). 13C NMR was not
collected.
1-O-hexadecanoyl-2-O-cis-Octadec-12-enoyl-3-O-(-D-2,3,4,6-tetra-O-acetyl-glucopyranosyl)-sn-glycerol 510 and 1-O-hexadecanoyl-2-O-cis-Octadec-12-enoyl-3-O-(β-D-2,3,4,6tetra-O-acetyl-glucopyranosyl)-sn-glycerol 511
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To a solution of compound 509b
(0.85 g, 1.29 mmol) in anhydrous
CH2Cl2 (30 mL), cis-vaccenic acid
(0.43 g, 1.52 mmol), EDC (0.30 g,
1.52 mmol), and DMAP (6 pinches) were added under nitrogen at 0°C and the reaction was stirred
for 16 h at room temperature. CH2Cl2 (50 mL) and water (50 mL) were added to the reaction
mixture and the organic phase was washed with water (2 x 40 mL) and brine (40 mL). The organic
phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (2:1) and passed through a silica gel column to produce α-compound 510, the title compound as a colourless liquid (0.70 g, 58% yield). Rf = 0.33 (30% EtOAc,
70% Hexane). 1H NMR (500 MHz, CDCl3) ppm 5.44 (t, J = 9.87, 1H), 5.34-5.25 (m, 2H), 5.205.11 (m, 1H), 5.09-5.06 (m, 1H), 5.05 (d, J = 9.80, 1H) 4.85 (dd, J = 3.79, 10.27, 1H), 4.32 (td, J
= 4.27, 11.70, 1H), 4.24 (dt, J = 3.69, 12.37, 1H), 4.14-4.10 (m, 1H), 4.09-4.03 (m, 1H), 4.01 (t, J
= 9.82, 1H), 3.81 (dd, J = 4.76, 11.17, 1H), 3.62-3.51 (m, 1H), 2.32-2.28 (m, 4H), 2.09-2.01(acetate
singlets plus H2CCH=CHCH2, m, 16H), 1.62 (t, J = 6.87, 4H), 1.29 (s, 44H), 0.88 (td, J = 1.65,
6.83, 6H).

13

C NMR (500 MHz, CDCl3) ppm 173.3, 172.9, 170.6, 170.2, 170.1, 169.6, 130.1,

130.0, 129.9, 129.8, 96.3, 77.6, 77.2, 76.8, 70.7, 70.1, 70.0, 69.8, 69.8, 68.4, 67.6, 67.6, 66.7, 66.3,
62.2, 62.1, 61.8, 34.3, 34.2, 34.1, 32.0, 31.9, 29.8, 29.6, 29.6, 29.4, 29.4, 29.2, 29.1, 27.3, 24.9,
22.7, 20.7, 20.6, 14.2 and β-compound 511 (0.48 g, 40% yield). Rf = 0.31 (30% EtOAc, 70%
Hexane). 1H NMR (500 MHz, CDCl3) ppm 5.32 (t, J = 4.73, 4.73 Hz, 2H), 5.24-5.12 (m, 2H),
5.11-5.02 (m, 1H), 5.01-4.92 (m, 1H), 4.51 (dd, J = 7.86, 4.03 Hz, 1H), 4.39-4.17 (m, 2H), 4.183.99 (m, 2H), 3.93 (dd, J = 10.95, 4.87 Hz, 1H), 3.75-3.55 (m, 2H), 2.39-2.16 (m, 4H), 2.10-1.89

288

(m, 16H), 1.68-1.50 (m, 4H), 1.36-1.18 (m, 44H), 0.86 (t, J = 6.10, 6.10 Hz, 6H). 13C NMR was
not collected.
1-O-hexadecanoyl-2-O-cis-Octadec-12-enoyl-3-O-(β-D-glucopyranosyl)-sn-glycerol 512
Compound 511 (85 mg, 0.09 mmol) was dissolved in EtOH
(2.5 mL) and N2H4.H2O 35% (0.3 mL) was added and refluxed
at 40°C for 2.5 h. EtOH was then evaporated under reduced
pressure and H2O (20 mL) was added. The aqueous phase was
extracted with CH2Cl2 (4 x 20 mL) and organic phase was washed with brine (40 mL). The organic
phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in ethyl acetate and passed through a silica gel column to produce 512, title compound as a
colourless liquid (48 mg, 53% yield). Rf = 0.29 (98% EtOAc, 2% MeOH). 1H NMR (500 MHz,
CDCl3) ppm 5.49-5.30 (m, 1H), 5.30-5.21 (m, 1H), 4.94 (ddd, J = 26.58, 19.21, 1.34 Hz, 1H), 4.744.47 (m, 1H), 4.44-4.34 (m, 2H), 4.31 (d, J = 7.43 Hz, 2H), 4.16 (ddd, J = 18.57, 12.05, 6.57 Hz,
1H), 3.97-3.86 (m, 1H), 3.83 (s, 2H), 3.75-3.65 (m, 1H), 3.63-3.47 (m, 3H), 3.37 (t, J = 7.97, 7.97
Hz, 1H), 3.30 (d, J = 5.75 Hz, 1H), 2.38-2.20 (m, 4H), 2.04-1.96 (m, 4H), 1.66-1.51 (m, 4H), 1.371.13 (m, 44H), 0.87 (t, J = 6.91, 6.91 Hz, 6H). Consistent with the literature.8, 9
(10-Carboxydecyl)triphenylphosphonium bromide 513

11-bromodecanoic acid 512 (10.0 g, 37.5 mmol) and PPh3 (10.9 g, 41.2
mmol) in toluene (60 mL) were stirred at reflux temperature under nitrogen for 24 h. After cooling to room temperature two phases were apparent
and the upper phase was decanted. CH2Cl2 was added to the viscous residue before the solvent
was rotovaped off, and the resultant solid was washed with boiling ethyl acetate 3 times. A white
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solid was collected via filtration and dried under reduced pressure to produce the title compound
513 (16 g, 81% yield).10
cis-Octadec-12-enoic acid (cis-vaccenic acid) 514

(10-Carboxydecyl)triphenylphosphonium bromide 513 (2.00 g, 3.80
mmol) in THF (25 mL) was cooled to –78°C under nitrogen. KHMDS
0.5M solution in toluene (20 mL) was added and the reaction was
warmed to room temperature over 2 h. The solution was recooled to –78°C before heptanal (0.54
mL, 3.80 mmol) was added dropwise. The reaction was then warmed to room temperature and
stirred for 12 h. EtOAc (50 ml) and 1M HCl (50 ml) were added to the reaction mixture and the
aqueous phase was extracted with ethyl acetate (2 x 50 ml). The organic phase was dried, filtered,
and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (6:1) and taken up through a silica gel column to produce the title compound (640 mg, 60%)
1

H NMR (300 MHz, CDCl3) ppm 5.48-5.27 (m, 2H), 2.45-2.31 (m, 2H), 2.10-1.95 (m, 4H), 1.74-

1.56 (m, 2H), 1.40-1.25 (m, 20H), 0.90 (t, J = 5.70, 5.70 Hz, 3H). Consistent with the literature.10
(2R,4aR,6S,7R,8R,8aS)-6-(ethylthio)-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-7,8-diol
514a
Compound 1217 (3.67 g, 9.03 mmol) was dissolved in methanol (100
mL) then NaOMe solution was added until a pH of 12 was reached.
The reaction was stirred at room temperature for 5 h. DOWEX 50W
X8 ion exchange resin was added to the reaction mixture to neutralize the solution. The solution
was filtered and concentrated under reduced pressure. The crude was dissolved in anhydrous DMF
(18 mL), and treated with benzaldehyde dimethyl acetal (1.6 mL, 10.8 mmol) and p-TsOH (70 mg,
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0.36 mmol) and heated at 50°C for 18 h. The reaction mixture diluted with ethyl acetate (200 mL)
and washed with saturated aqueous NaHCO3 (100 mL) water (100 mL), and brine (100 mL). The
organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was
dissolved in hexanes/ethyl acetate (1:1) and passed through a silica gel column to produce 514a,
the title compounds, as colourless liquid (1.35 g, 48% yield). On replication, yields varied between
42% and 48% for scales between 100 mg and 3.70 g. Rf = 0.30. 1:1 hexanes/EtOAc. 1H NMR
(300 MHz, CDCl3) ppm 7.57-7.44 (m, 2H), 7.46-7.30 (m, 3H), 5.55 (s, 1H), 4.48 (d, J = 9.78 Hz,
1H), 4.37 (dd, J = 10.46, 4.66 Hz, 1H), 3.97-3.69 (m, 2H), 3.67-3.46 (m, 3H), 2.86-2.71 (m, 3H),
2.59 (d, J = 2.07 Hz, 1H), 1.34 (t, J = 7.44, 7.44 Hz, 3H). Consistent with the literature.11
(2R,4aR,6S,7R,8S,8aR)-6-(ethylthio)-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-7,8-diyl
diacetate 515
Compound 514a (1.50 g, 3.03 mmol) was dissolved in pyridine (85
mL) then acetic anhydride (12 mL) was added and stirred at room
temperature for 16 h, then diluted with CH2Cl2 (200 mL) and washed
with 5% HCl aq (2 x 100 mL), water (100 mL) and brine (100 mL). The organic phase was dried,
filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce 514, the title compound,
as a colourless liquid (1.16 g, 55% yield). On replication, yields varied between 45% and 55% for
scales between 50.0 mg and 5.00 g. Rf = 0.32. 7:3 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3)
ppm 7.49-7.40 (m, 2H), 7.40-7.31 (m, 3H), 5.50 (s, 1H), 5.34 (t, J = 9.33, 9.33 Hz, 1H), 5.04 (dd,
J = 9.98, 9.09 Hz, 1H), 4.58 (d, J = 10.05 Hz, 1H), 4.37 (dd, J = 10.41, 4.77 Hz, 1H), 3.73 (td, J =
19.01, 9.76, 9.76 Hz, 2H), 3.64-3.49 (m, 1H), 2.83-2.60 (m, 2H), 2.07 (s, 3H), 2.05 (s, 3H), 1.27
(t, J = 7.43, 7.43 Hz, 3H). Consistent with the literature.12
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(2R,4aR,6R,7R,8R,8aR)-7-hydroxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6,8-diyl
diacetate 516

Compound 515 (1.20 g, 3.03 mmol) was dissolved in CH2Cl2/H2O
(100:1) and cooled to 0°C and N-bromosuccinimide (540 mg, 3.03
mmol) and TMSOTf (0.06 mL, 0.30 mmol) were added and stirred at
0°C for 5 min. The reaction mixture poured into saturated aqueous NaHCO3 (50 mL) and extracted
with CH2Cl2 (3 x 50 mL). The combined organic phase was washed with brine (100 mL). The
organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was
dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce 516, the
title compound, as a light-yellow solid (426 mg, 40% yield). On replication, yields varied between
35% and 40% for scales between 50.0 mg and 5.00 g. Rf = 0.29. 7:3 hexanes/EtOAc. 1H NMR
(300 MHz, CDCl3) ppm 7.54-7.39 (m, 2H), 7.42-7.33 (m, 3H), 6.20 (d, J = 3.82 Hz, 1H), 5.52 (s,
1H), 5.35 (t, J = 9.78, 9.78 Hz, 1H), 4.32 (dd, J = 10.42, 4.69 Hz, 1H), 3.99-3.79 (m, 2H), 3.813.57 (m, 2H), 2.85 (s, 1H), 2.21 (s, 3H), 2.16 (s, 3H). Consistent with the literature.13

(2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl
2,2,2-trichloroacetimidate 519

Compound 487 (5.20 g, 9.62 mmol) was dissolved in CH2Cl2 (50 mL)
and Cl3CCN (5 mL, 49.9 mmol) and K2CO3 (5.00 g, 36.2 mmol) were
added. The reaction mixture was stirred for 5 h at room temperature.
The reaction mixture passed through Celite and concentrated under reduced pressure to produce
519, the title compound without purification (5.70 g, 86% yield). On replication, yields varied
between 81% and 86% for scales between 100 mg and 5.20 g. Rf = 0.12 only β-anomer 1:7
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EtOAc/hexanes. 1H NMR (300 MHz, CDCl3) ppm 8.63 (s, 1H), 7.37-7.27 (m, 20H), 5.75 (d, J =
8.03 Hz, 1H), 5.01-4.87 (m, 2H), 4.82 (d, J = 10.70 Hz, 1H), 4.74 (s, 2H), 4.64 (d, J = 11.53 Hz,
1H), 4.46 (d, J = 4.80 Hz, 2H), 4.10 (dd, J = 9.61, 8.05 Hz, 1H), 3.99 (d, J = 2.02 Hz, 1H), 3.76
(dd, J = 6.56, 6.04 Hz, 1H), 3.69-3.57 (m, 3H). Consistent with the literature.14
(3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl 2,2,2trichloroacetimidate 520
Compound 487 (325 mg, 0.60 mmol) was dissolved in CH2Cl2 (6
mL) and cooled to 0°C then Cl3CCN (0.6 mL, 6.00 mmol) and DBU
(0.01 mL, 0.06 mmol) were added. The reaction mixture was stirred
for 3 h before being concentrated under reduced pressure. The crude product was dissolved in
hexanes/ethyl acetate (7:1) and passed through a silica gel column to produce 520 the title compound as a colorless liquid (335 mg 82% yield α:β 1:0.5). On replication, yields varied between
78% and 82% for scales between 50.0 mg and 5.00 g. Rf = 0.31 α-anomer, 0.12 β-anomer 1:7
EtOAc/hexanes. α-Glycosyl donor: 1H NMR (300 MHz, CDCl3) ppm 8.51 (s, 1H), 7.39-7.21 (m,
20H), 6.51 (d, J = 3.44 Hz, 1H), 4.97-4.88 (m, 1H), 4.85-4.77 (m, 2H), 4.61 (t, J = 11.56, 11.56
Hz, 2H), 4.50-4.36 (m, 2H), 4.23 (dd, J = 9.87, 3.48 Hz, 1H), 4.07-3.98 (m, 3H), 3.69-3.48 (m,
3H). 13C NMR was not collected.
(2R,4aR,6R,7R,8S,8aR)-2-phenyl-7-(((2R,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexahydropyrano[3,2-d][1,3]dioxine-6,8-diyl
diacetate 521
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Acceptor 516 (3.00 g, 8.52 mmol) and donor 17 (9.70 g, 14.2 mmol)
were dissolved in CH2Cl2 (500 mL) and (10 g) activated 5Å MS was
added and stirred at room temperature for 30 min, and then cooled to
0°C. BF3.OEt2 (1.1 mL, 8.52 mmol) was then added dropwise and
stirred for 4 h at room temperature. The mixture passed through a pad of Celite and solvent concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (9:1)
and passed through a silica gel column to produce 521, title compound as a colourless liquid (3.80
g, 50% yield). On replication, yields varied between 42% and 50% for scales between 50.0 mg
and 10.0 g. Rf = 0.34. 3:7 EtOAc/hexanes. 1H NMR (500 MHz, CDCl3) ppm 7.47-7.39 (m, 2H),
7.40-7.27 (m, 21H), 7.26-7.24 (m, 2H), 6.35 (d, J = 3.73 Hz, 1H), 5.55 (t, J = 9.77, 9.77 Hz, 1H),
5.46 (s, 1H), 4.90 (dd, J = 17.93, 7.44 Hz, 1H), 4.80 (d, J = 11.78 Hz, 1H), 4.73 (dd, J = 11.65,
2.51 Hz, 2H), 4.62 (d, J = 11.83 Hz, 1H), 4.52 (d, J = 11.36 Hz, 1H), 4.47 (d, J = 11.77 Hz, 1H),
4.40 (d, J = 11.69 Hz, 1H), 4.32-4.27 (m, 1H), 4.03-3.89 (m, 5H), 3.85 (dd, J = 10.13, 2.69 Hz,
1H), 3.68 (t, J = 10.32, 10.32 Hz, 1H), 3.59-3.51 (m, 2H), 3.50 (dd, J = 8.89, 5.55 Hz, 1H), 1.99
(s, 3H), 1.94 (s, 3H). 13C NMR (125 MHz, CDCl3) ppm 169.9, 169.6, 138.9, 138.8, 138.7, 138.5,
138.0, 136.9, 129.6, 129.1, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.8, 127.6, 127.4, 127.4,
127.2, 126.1, 103.8, 101.5, 99.9, 97.5, 89.3, 79.2, 78.7, 75.4, 75.1, 74.9, 74.7, 74.1, 73.6, 73.5,
73.4, 73.3, 73.3, 73.2, 73.0, 72.7, 70.1, 70.0, 69.8, 68.8, 68.6, 68.5, 64.7, 21.0, 20.8. EI-MS m/z
calcd for C51H54O13 874.36. Found: [M+H2O]+ 892.39
(2R,4aR,7R,8S,8aR)-6-hydroxy-2-phenyl-7-(((2R,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexahydropyrano[3,2-d][1,3]dioxin-8-yl
acetate 522
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Compound 521 (8.00 g, 9.15 mmol) was dissolved in THF (550 mL)
and prepared salt of ethyleneamine and acetic acid (18.0 g) was added,
which was formed by mixing acetic acid (36 mL) with ethylene diamine (29 mL) at room temperature to 0°C for 15 minutes. The reaction
mixture was stirred at room temperature for 24 h. The mixture was
concentrated, then CH2Cl2 (300 mL) was added and the organic phase was washed with water (2
x 200 mL) and with brine (200 mL). The organic phase was dried, filtered, and concentrated under
reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (9:1) and passed
through a silica gel column to produce 522, the title compound as a white solid, mixtures of α and
β anomers (ratio: 1/1 determined by 1H NMR) (3.00 g, 40% yield). On replication, yields varied
between 32% and 40% for scales between 100 mg and 8.00 g. Rf = 0.31. 1:9 EtOAc/hexanes. 1H
NMR (500 MHz, CDCl3) ppm 7.44-7.20 (m, 25H), 5.45 (d, J = 4.52 Hz, 2H), 5.31 (t, J = 9.32, 9.32
Hz, 1H), 5.17 (d, J = 3.54 Hz, 1H), 4.97-4.82 (m, 3H), 4.78-4.65 (m, 4H), 4.53 (dd, J = 11.31, 6.53
Hz, 1H), 4.44 (dd, J = 24.09, 11.80 Hz, 2H), 4.38-4.30 (m, 2H), 4.08-3.87 (m, 5H), 3.82-3.71 (m,
1H), 3.63-3.47 (m, 3H), 3.46 (dd, J = 6.32, 5.10 Hz, 1H), 3.43-3.37 (m, 1H), 1.97 (s, 3H).

13

C

NMR (125 MHz, CDCl3) ppm 170.1, 138.6, 138.5, 138.4, 138.3, 137.9, 137.8, 137.6, 137.2, 137.2,
137.0, 128.7, 128.5, 128.3, 128.3, 128.0, 127.8, 127.6, 127.5, 126.3, 126.2, 101.5, 101.5, 97.5,
97.2, 91.2, 84.3, 79.5, 79.3, 79.1, 78.8, 75.2, 75.0, 74.4, 74.3, 73.6, 73.5, 72.9, 72.5, 71.8, 70.7,
70.3, 70.1, 69.0, 68.8, 68.7, 68.0, 66.9, 62.9, 60.5, 14.3. EI-MS m/z calcd for C49H52O12 832.34.
Found: [M+H2O]+ 850.38.
(2R,4aR,6S,7R,8S,8aR)-6-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-phenyl-7(((2R,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2yl)oxy)hexahydropyrano[3,2-d][1,3]dioxin-8-yl acetate 523
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Compound 522 (50.0 mg, 0.06 mmol) and diphenylsulfoxide
(36.0 mg, 0.17 mmol) were stirred over (130 mg) of activated 4Å
MS for 45 min in CH2Cl2 (4 mL), then the mixture was cooled to
–78°C, and triflic anhydride (14 μL, 0.08 mmol) and 2-chloropyridine (30 μL, 0.32 mmol) were added and warmed to –40°C
and stirred for 45 min, then compound 523 (25.0 mg, 0.19 mmol) in CH2Cl2 (1 mL) was added
and allowed to stir for 16 h. The reaction mixture was quenched with Et3N (0.5 mL). The mixture
passed through a pad of Celite and washed with CH2Cl2 (50 mL). The organic phase was washed
with water (2 x 30 mL), saturated aqueous NaHCO3 (30 mL) and brine (30 mL). The organic phase
was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in
hexanes/ethyl acetate (10:1) and passed through a silica gel column to produce 523, the title compound as a colorless liquid compound (25.0 mg, 46% yield). On replication, yields varied between
40% and 46% for scales between 50.0 mg and 1.00 g. Rf = 0.36. 1:9 EtOAc/hexanes. 1H NMR
(500 MHz, CDCl3) ppm 7.71-7.60 (m, 1H), 7.48-7.42 (m, 3H), 7.37-7.28 (m, 19H), 7.41-7.38 (m,
2H), 5.52 (t, J = 9.72, 9.72 Hz, 1H), 5.45 (s, 1H), 5.00 (d, J = 3.58 Hz, 1H), 4.94 (dd, J = 7.38,
3.88 Hz, 2H), 4.79 (dd, J = 21.55, 11.34 Hz, 3H), 4.68 (d, J = 11.53 Hz, 1H), 4.56 (d, J = 11.32
Hz, 1H), 4.45 (dd, J = 30.60, 11.78 Hz, 2H), 4.27 (dd, J = 10.27, 4.93 Hz, 1H), 4.17-4.11 (m, 1H),
4.06-3.97 (m, 3H), 3.96-3.88 (m, 3H), 3.79-3.63 (m, 3H), 3.61-3.55 (m, 2H), 3.52-3.45 (m, 2H),
3.41 (dd, J = 10.63, 5.01 Hz, 1H), 1.96 (s, 3H), 1.41 (s, 3H), 1.31 (s, 3H) ) 13C NMR (125 MHz,
CDCl3) ppm 169.8, 145.7, 138.7, 138.7, 138.6, 138.0, 137.1, 131.0, 129.3, 129.0, 128.4, 128.3,
128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 126. 2, 124.8, 109.4, 101.5, 98.7, 97.8, 79.7, 78.8,
77.1, 76.1, 74.9, 74.8, 74.4, 73.5, 73.4, 72.8, 70.1, 70.0, 69.0, 68.9, 68.3, 66.7, 62.6, 26.7, 25.6,
21.0. EI-MS m/z calcd for C55H62O14 946.41. Found: [M+Na]+ 969.40.
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(2R,3R,4S,5R,6R)-2-(((2S,3R,4S,5S,6R)-2-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 523a
To a solution of compound 523 (200 mg, 0.21 mmol) in MeOH (10
mL) Pd/C (1.27 g, 5.90 mmol) and ammonium formate (0.73 g, 11.6
mmol) were added and refluxed at 70°C for 7 h. After cooling to room
temperature, the reaction mixture passed through a pad of Celite and
washed with MeOH (50 mL). The solvent was evaporated and then
co-evaporated with toluene. The crude product was dissolved in ethyl acetate/methanol (9:1) and
passed through a silica gel column to produce 523a, the title compound as a colorless liquid (72.0
mg, 70% yield). On replication, yields varied between 62% and 70% for scales between 50.0 mg
and 500 mg. Rf = 0.29. EtOAc. 1H NMR (300 MHz, CDCl3) ppm 5.07 (dd, J = 32.12, 3.61 Hz,
2H), 4.47-4.29 (m, 1H), 4.20-4.00 (m, 2H), 4.00-3.86 (m, 1H), 3.86-3.65 (m, 9H), 3.64-3.45 (m,
4H), 1.92 (s, 3H), 1.41 (s, 3H), 1.35 (s, 3H). 13C NMR (125 MHz, CDCl3) ppm 177.9, 109.3, 96.7,
96.3, 76.1, 74.7, 72.3, 72.0, 71.0, 70.2, 70.0, 69.7, 68.9, 68.5, 66.1, 61.4, 25.6, 24.2, 22.1, 19.4.
EI-MS m/z calcd for C20H34O14: 498.19. Found: [M+ Na]+ 479.17, note: Ac removed in the process.
(2R,4aR,6S,7R,8S,8aS)-6-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-phenyl-7(((2R,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2yl)oxy)hexahydropyrano[3,2-d][1,3]dioxin-8-ol 523b
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To a solution of compound 523 (90.0 mg, 0.09 mmol) in methanol (50 mL), solution of sodium methoxide was added until a
pH of 12 was reached, then stirred for 16 h. Dowex 50WX8 was
added to neutralize solution. Mixture filtered and concentrated
under reduced pressure. The crude product was dissolved in
hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce 523b, title compound
as a colourless liquid (60.0 mg, 70% yield). On replication, yields varied between 65% and 70%
for scales between 50.0 mg and 500 mg. Rf = 0.36. 2:8 EtOAc/hexanes. 1H NMR (500 MHz,
CDCl3) ppm 7.56-7.49 (m, 2H), 7.43-7.34 (m, 19H), 7.34-7.25 (m, 4H), 5.53 (s, 1H), 5.05 (d, J =
3.75 Hz, 1H), 4.95 (dd, J = 7.59, 3.90 Hz, 2H), 4.84 (d, J = 11.55 Hz, 2H), 4.77 (d, J = 11.88 Hz,
1H), 4.69 (d, J = 11.74 Hz, 1H), 4.58 (d, J = 11.51 Hz, 1H), 4.51 (d, J = 11.75 Hz, 1H), 4.41 (d,
J = 11.75 Hz, 1H), 4.29 (dd, J = 10.22, 4.83 Hz, 1H), 4.26-4.19 (m, 2H), 4.13-4.07 (m, 2H), 4.023.87 (m, 4H), 3.83 (dd, J = 8.28, 6.29 Hz, 1H), 3.77-3.65 (m, 3H), 3.60-3.49 (m, 3H), 3.49-3.39
(m, 2H), 1.43 (s, 3H), 1.35 (s, 3H) 13C NMR (125 MHz, CDCl3) ppm 138.6, 138.5, 138.3, 137.8,
137.7, 137.2, 129.1, 128.5, 128.4, 128.4, 128.3, 128.2, 128.2, 127.8, 127.8, 127.7, 127.6, 127.5,
127.5, 126.4, 109.4, 102.0, 98.2, 98.1, 81.1, 81.1, 78.7, 76.3, 75.6, 75.3, 75.0, 74.7, 74.7, 74.5,
74.5, 74.3, 73.7, 73.6, 73.5, 73.4, 73.4, 73.0, 72.8, 70.3, 69.2, 69.2, 69.0, 68.9, 66.6, 62.4, 26.7,
25.5. EI-MS m/z calcd for C53H60O13 904.40. Found: [M+Na]+ 927.39.
(2R,3R,4S,5R,6R)-2-(((2S,3R,4S,5S,6R)-2-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 523c
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To a solution of acetyl deprotected of 523b (60.0 mg, 0.06 mmol) in
MeOH (3 mL), Pd/C (400 mg, 1.86 mmol) and ammonium formate
(230 mg, 3.65 mmol) were added and refluxed at 70°C for 7 h. After
cooling to room temperature, the reaction mixture was then passed
through a pad of Celite and washed with MeOH (20 mL). The solvent was concentrated under
reduced pressure and then co-evaporated with toluene. The crude product was dissolved in ethyl
acetate/methanol (9.5:0.5) and passed through a silica gel column to produce 523c, title compound
as a colourless liquid (23.0 mg, 73% yield). On replication, yields varied between 68% and 73%
for scales between 60.0 mg and 200 mg. Rf = 0.29. 95:5 EtOAc/MeOH. 1H NMR (500 MHz,
MeOD) ppm 5.12 (d, J = 3.55 Hz, 1H), 5.06 (d, J = 3.73 Hz, 1H), 4.69-4.51 (m, 2H), 4.44-4.30
(m, 1H), 4.19-4.02 (m, 2H), 3.92 (dd, J = 3.12, 1.08 Hz, 1H), 3.87-3.66 (m, 8H), 3.66-3.55 (m,
3H), 1.43 (s, 3H), 1.37 (s, 3H) 13C NMR (125 MHz, MeOD) ppm 109.3, 96.7, 76.2, 74.7, 73.0,
72.3, 72.0, 71.0, 70.2, 70.0, 69.7, 68.9, 68.5, 66.1, 61.4, 61.2, 25.6, 24.2. EI-MS m/z calcd for
C18H32O13 456.18. Found: [M+Na]+ 479.17.
(2R,3R,4S,5S,6R)-2-(((2S,3R,4S,5R,6R)-2-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)4,5-bis(2-methoxyacetoxy)-6-((2-methoxyacetoxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-6((2-methoxyacetoxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2-methoxyacetate) 526
Compound 523a (220 mg, 0.44 mmol) was dissolved in pyridine (6.4
mL), and cooled to 0°C, then acetic anhydride (3.2 mL) was added
dropwise and stirred for 16 h. The reaction mixture was diluted EtOAc
(100 mL), and the mixture was washed with 10% HCl aq (50 mL),
with water (50 mL) and with brine (50 mL). The organic phase was
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dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (2:8) and passed through a silica gel column to produce 526, the yellow liquid
compound (322 mg, 73% yield). On replication, yields varied between 70% and 73% for scales
between 50.0 mg and 220 mg. Rf = 0.27. 9:1 hexanes/ethyl acetate. 1H NMR (300 MHz, CDCl3)
ppm 5.51-5.39 (m, 1H), 5.31-5.22 (m, 2H), 5.18-5.11 (m, 1H), 5.11-5.04 (m, 1H), 5.03-4.93 (m,
1H), 4.36-4.22 (m, 3H), 4.23-4.15 (m, 1H), 4.16-4.05 (m, 4H), 3.98 (dd, J = 10.96, 6.19 Hz, 1H),
3.84-3.68 (m, 3H), 3.59 (dd, J = 10.72, 5.32 Hz, 1H), 2.09 (7s, 21H), 1.44 (s, 3H), 1.37 (s, 3H).
C NMR (125 MHz, CDCl3) ppm 170.7, 170.5, 170.4, 170.2, 170.1, 170.0, 169.9, 109.8, 96.2,

13

95.2, 74.8, 74.5, 71.3, 69.0, 68.6, 68.3, 67.9, 67.7, 67.4, 67.3, 66.6, 62.0, 61.3, 26.9, 25.5, 20.9,
20.9, 20.8, 20.8, 20.7, 20.7, 20.6. EI-MS m/z was not collected.
(2R,3R,4S,5S,6R)-2-(((2S,3R,4S,5R,6R)-2-((R)-2,3-dihydroxypropoxy)-4,5-bis(2-methoxyacetoxy)-6-((2-methoxyacetoxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-6-((2-methoxyacetoxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2-methoxyacetate) 526a
Compound 526 (130 mg, 0.17 mmol) was dissolved in acetonitrile
(6 mL) and Zn(NO3)2.6H2O (260 mg, 1.37 mmol) was added. The
mixture was stirred for 10 h at 50°C, and the solvent was then evaporated under reduced pressure, then CH2Cl2 (50 mL) was added and
the organic phase was washed with water (2 x 30 mL) and brine (30
mL). The organic phase was dried, filtered, and concentrated under reduced pressure. The crude
product was dissolved in methanol/ethyl acetate (1:9) and passed through a silica gel column to
produce 526a, title compound as a liquid (75.0 mg, 62% yield). On replication, yields varied between 57% and 62% for scales between 30.0 mg and 500 mg. Rf = 0.31. 7:3 hexanes/ethyl acetate.
1

H NMR (300 MHz, CDCl3) ppm 5.48-5.41 (m, 2H), 5.39-5.27 (m, 2H), 5.19-5.03 (m, 2H), 4.99
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(t, J = 9.80, 9.80 Hz, 1H), 4.34-4.21 (m, 2H), 4.18 (dd, J = 11.02, 7.04 Hz, 1H), 4.13-4.02 (m, 2H),
4.03-3.90 (m, 2H), 3.85 (dd, J = 10.57, 3.50 Hz, 1H), 3.82-3.68 (m, 2H), 3.66-3.53 (m, 2H), 2.99
(d, J = 4.48 Hz, 1H), 2.29 (t, J = 6.01, 6.01 Hz, 1H), 2.14 (s, 3H), 2.12 (s, 3H), 2.10 (s, 3H), 2.08
(s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 2.01 (s, 3H). 13C NMR (125 MHz, CDCl3) ppm 170.7, 170.6,
170.3, 170.2, 170.1, 170.0, 169.7, 128.4, 127.7, 96.9, 96.0, 71.3, 70.6, 70.4, 68.6, 68.4, 67.7, 67.6,
67.5, 67.2, 63.5, 61.9, 61.0, 20.8, 20.7, 20.7, 20.7, 20.6, 20.6. EI-MS m/z calcd for C29H42O20:
710.23. Found: [M+ Na]+ 733.22.
(2R,3R,4S,5S,6R)-2-(((2S,3R,4S,5R,6R)-2-((S)-2-hydroxy-3-(palmitoyloxy)propoxy)-4,5bis(2-methoxyacetoxy)-6-((2-methoxyacetoxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-6-((2methoxyacetoxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2-methoxyacetate) 526b
Compound 526a (250 mg, 0.35 mmol), was dissolved in anhydrous
CH2Cl2 (4 mL) under nitrogen and palmitic acid (90.0 mg, 0.35
mmol), EDC (67.0 mg, 0.35 mmol), and DMAP (2 pinches) were
added under nitrogen at 0°C and the reaction was stirred on ice for 6
h. CH2Cl2 (30 mL) and water (10 mL) were added to the reaction
mixture and the organic phase was washed water (2 x 10 mL) and once with brine (10 mL). The
organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was
dissolved in ethyl acetate and passed through a silica gel column to produce 526b, title compound
as a colourless liquid (210 mg, 63% yield). Rf = 0.55. EtOAc. 1H NMR (300 MHz, CDCl3) ppm
5.53-5.42 (m, 2H), 5.41-5.34 (m, 1H), 5.34-5.22 (m, 1H), 5.13 (d, J = 3.53 Hz, 1H), 5.08 (dd, J =
10.77, 3.59 Hz, 1H), 5.01 (t, J = 9.71, 9.71 Hz, 1H), 4.35-4.24 (m, 2H), 4.25-4.04 (m, 6H), 4.01
(dd, J = 11.03, 6.17 Hz, 1H), 3.85-3.77 (m, 2H), 3.53 (dd, J = 10.83, 7.58 Hz, 1H), 3.05 (d, J =
4.09 Hz, 1H), 2.38 (t, J = 7.61, 7.61 Hz, 2H), 2.13 (7s, 21H), 1.69-1.61 (m, 2H),1.33-1.25 (m,
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24H), 0.91 (t, J = 6.94, 6.94 Hz, 3H). 13C NMR (125 MHz, CDCl3) ppm 173.8, 173.7, 170.8, 170.5,
170.3, 170.0, 170.0, 169.7, 96.8, 95.3, 74.9, 71.1, 70.1, 69.2, 68.5, 68.5, 67.8, 67.6, 67.4, 67.2,
64.9, 61.9, 61.1, 34.1, 31.9, 29.7, 29.7, 29.6, 29.6, 29.5, 29.5, 29.3, 29.3, 29.2, 29.1, 27.2, 27.2,
24.9, 22.7, 20.8, 20.7, 20.6, 20.6, 20.6, 14.1. EI-MS m/z calcd for C45H72O21: 948.46. Found: [M]+
949.46.
(2R,3R,4S,5S,6R)-2-(((2S,3R,4S,5R,6R)-4,5-bis(2-methoxyacetoxy)-6-((2-methoxyacetoxy)methyl)-2-((S)-2-((Z)-octadec-6-enoyloxy)-3-(palmitoyloxy)propoxy)tetrahydro-2Hpyran-3-yl)oxy)-6-((2-methoxyacetoxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2-methoxyacetate) 527
Compound 526b (50.0 mg, 0.05 mmol) was dissolved in anhydrous
CH2Cl2 (2 mL) under nitrogen and cis-vaccenic acid (23.0 mg, 0.08
mmol), EDC (17.0 mg, 0.08 mmol), and DMAP (2 pinches) were
added under nitrogen at 0°C and the reaction was stirred on ice for
16 h. CH2Cl2 (30 mL) and water (10 mL) were added to the reaction mixture and the organic phase
was washed with water (2 x 10 mL) and once with brine (10 mL). The organic phase was dried,
filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (1:2) and passed through a silica gel column to produce 527, title compound as
a colourless liquid (62.0 mg, 64% yield). Rf = 0.29. 8:2 hexanes/EtOAc. 1H NMR (300 MHz,
CDCl3) ppm 5.48-5.43 (m, 1H), 5.41 (t, J = 9.65, 9.65 Hz, 1H), 5.37-5.33 (m, 2H), 5.29-5.18 (m,
3H), 5.07 (dd, J = 10.86, 3.58 Hz, 1H), 5.02-4.92 (m, 2H), 4.42 (dd, J = 12.00, 3.48 Hz, 1H), 4.324.14 (m, 4H), 4.08-3.94 (m, 3H), 3.83 (dd, J = 10.68, 5.53 Hz, 1H), 3.78 (dd, J = 9.98, 3.62 Hz,
1H), 3.67 (dd, J = 10.67, 4.82 Hz, 1H), 2.38-2.27 (m, 4H), 2.16-1.93 (m, 25H), 1.67-1.54 (m, 4H),
1.40-1.17 (m, 48H), 0.88 (dd, J = 7.81, 6.07 Hz, 6H)). 13C NMR (125 MHz, CDCl3) 168.7, 168.4,
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166.0, 165.9, 165.8, 165.5, 165.4, 165.2, 165.0, 125.4, 125.3, 92.0, 91.1, 70.6, 66.7, 65.0, 63.9,
63.8, 63.3, 63.3, 63.2, 62.9, 62.9, 62.7, 62.4, 57.7, 57.6, 57.3, 57.2, 56.7, 56.6, 29.7, 29.6, 29.5,
27.4, 27.3, 25.3, 25.2, 25.2, 25.2, 25.0, 25.0, 25.0, 24.9, 24.9, 24.8, 24.7, 24.6, 24.5, 22.7, 20.4,
20.4, 20.4, 20.3, 20.2, 18.2, 18.1, 18.1, 16.2, 16.2, 16.2, 16.1, 9.6. EI-MS m/z calcd for C63H104O22:
1213.70. Found: [M]+ 1214.70.
(2R,3R,4S,5S,6R)-2-(((2S,3R,4S,5R,6R)-2-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)4,5-bis(2-methoxyacetoxy)-6-((2-methoxyacetoxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-6((2-methoxyacetoxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2-methoxyacetate) 530
Compound 523c (40.0 mg, 0.09 mmol) was dissolved in pyridine (2
mL), and cooled to 0°C, then methoxyacetyl chloride (3 mL, 1.10
mmol) was added dropwise and stirred for 16 h. The reaction mixture
diluted with EtOAc (50 mL) and the organic phase was washed with
10% HCl aq (30 mL), water (30 mL) and brine (30 mL). The organic phase was dried, filtered,
and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (2:8) and passed through a silica gel column to produce 530, title compound as a yellow liquid
(60.0 mg, 72% yield). On replication, yields varied between 68% and 72% for scales between 20.0
mg and 100 mg. Rf = 0.3. 2:8 EtOAc/hexanes. 1H NMR (500 MHz, CDCl3) ppm 5.55-5.48 (m,
2H), 5.38-5.31 (m, 2H), 5.13 (dd, J = 10.77, 3.50 Hz, 1H), 5.10-5.04 (m, 2H), 4.40-4.34 (m, 2H),
4.33-4.26 (m, 2H), 4.25-3.93 (m, 17H), 3.86 (d, J = 16.51 Hz, 1H), 3.82 (dd, J = 9.95, 3.54 Hz,
1H), 3.73 (ddd, J = 15.34, 9.62, 5.30 Hz, 2H), 3.59 (dd, J = 10.96, 5.67 Hz, 1H), 3.46-3.39 (m,
21H), 1.43 (s, 3H), 1.36 (s, 3H)

13

C NMR (125 MHz, CDCl3) ppm 170.0, 169.8, 169.8, 169.7,

169.6, 169.4, 169.3, 109.8, 95.8, 94.8, 74.5, 74.5, 71.8, 69.7, 69.5, 69.3, 69.0, 68.6, 68.3, 68.2,
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68.1, 67.5, 67.3, 67.1, 66.2, 61.9, 61.0, 61.0, 59.5, 59.4, 38.8, 30.4, 29.0. 26.7, 25.4, 23.8, 23.0,
14.1, 11.0. EI-MS m/z calcd for C39H60O27 960.33. Found: [M+Na]+ 983.33.
(2R,3R,4S,5S,6R)-2-(((2S,3R,4S,5R,6R)-2-((R)-2,3-dihydroxypropoxy)-4,5-bis(2-methoxyacetoxy)-6-((2-methoxyacetoxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-6-((2-methoxyacetoxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2-methoxyacetate) 530a
Compound 530 (17.0 mg, 0.02 mmol) was dissolved in acetonitrile
(2 mL) and Zn(NO3)2.6H2O (32.0 mg, 0.11 mmol) was added. The
mixture was stirred for 6 h at 50°C, and the solvent was then evaporated under reduced pressure, then CH2Cl2 (30 mL) was added and
the organic phase was washed with water (20 mL) and brine (20
mL). The organic phase was dried, filtered, and concentrated under reduced pressure. The crude
product was dissolved in methanol/ethyl acetate (1:9) and passed through a silica gel column to
produce 530a, title compound as a colourless liquid (15.0 mg, 96% yield). On replication, yields
varied between 89% and 96% for scales between 17.0 mg and 100 mg. Rf = 0.38. 9:1
EtOAc/MeOH. 1H NMR (500 MHz, MeOD) ppm 5.59 (dd, J = 3.27, 1.21 Hz, 1H), 5.55 (t, J =
9.69, 9.69 Hz, 1H), 5.44 (d, J = 3.60 Hz, 1H), 5.38 (dd, J = 10.80, 3.42 Hz, 1H), 5.24 (dd, J =
10.76, 3.57 Hz, 1H), 5.20 (d, J = 3.52 Hz, 1H), 5.11 (dd, J = 10.20, 9.40 Hz, 1H), 4.47-4.39 (m,
2H), 4.36 (dd, J = 11.11, 6.25 Hz, 1H), 4.27-4.17 (m, 6H), 4.16-3.98 (m, 12H), 3.92 (d, J = 17.02
Hz, 1H), 3.89-3.81 (m, 2H), 3.67-3.59 (m, 2H), 3.57 (dd, J = 10.03, 6.05 Hz, 1H), 3.50-3.38 (m,
22H) 13C NMR (125 MHz, MeOD) ppm 171.94, 171.92, 171.82, 171.68, 171.47, 171.22, 171.14,
97.25, 95.97, 75.21, 73.18, 72.06, 70.97, 70.64, 70.57, 70.43, 70.36, 70.25, 70.20, 70.16, 70.14,
69.77, 69.28, 69.22, 68.56, 68.47, 64.25, 63.17, 62.77, 61.55, 59.81, 59.72, 59.68, 59.65, 59.61,
59.48. EI-MS m/z calcd for C36H56O27 920.30. Found: [M+H]+ 921.31.
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(2R,3R,4S,5S,6R)-2-(((2S,3R,4S,5R,6R)-2-((S)-2-hydroxy-3-(palmitoyloxy)propoxy)-4,5bis(2-methoxyacetoxy)-6-((2-methoxyacetoxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-6-((2methoxyacetoxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2-methoxyacetate) 530b
Compound 530a (12.0 mg, 0.01 mmol), was dissolved in anhydrous CH2Cl2 (2 mL) under nitrogen and palmitic acid (4.00 mg) ,
0.01 mmol), EDC (2.50 mg, 0.01 mmol), and DMAP (2 pinches)
were added under nitrogen at 0°C and the reaction was stirred on
ice for 6 h. then CH2Cl2 (20 mL) was added and the organic phase
was washed with water (10 mL) and brine (10 mL). The organic phase was dried, filtered, and
concentrated under reduced pressure. The crude product was dissolved in ethyl acetate and passed
through a silica gel column to produce 530b, title compound as a colourless liquid (8.00 mg, 53%
yield). On replication, yields varied between 48% and 53% for scales between 12.0 mg and 50.0
mg. Rf = 0.55 EtOAc. 1H NMR (500 MHz, CDCl3) ppm 5.62-5.45 (m, 2H), 5.41-5.29 (m, 2H)
5.18-5.02 (m, 3H), 4.43-4.34 (m, 2H), 4.34-4.25 (m, 1H), 4.21-3.95 (m, 19H), 3.90 (s, 1H), 3.883.82 (m, 1H), 3.77 (dd, J = 11.03, 3.09 Hz, 1H), 3.53 (dd, J = 10.97, 7.30 Hz, 1H), 3.49-3.33 (m,
21H), 3.06 (d, J = 4.27 Hz, 1H), 2.36-2.32 (m, 2H), 1.66-1.60 (m, 2H), 1.37-1.17 (m, 24H), 0.89
(t, J = 6.96, 6.96 Hz, 3H)

13

C NMR (125 MHz, CDCl3) ppm 171.94, 171.92, 171.82, 171.68,

171.47, 171.22, 171.14, 97.25, 95.97, 75.21, 73.18, 72.06, 70.97, 70.64, 70.57, 70.43, 70.36, 70.25,
70.20, 70.16, 70.14, 69.77, 69.28, 69.22, 68.56, 68.47, 64.25, 63.17, 62.77, 61.55, 59.81, 59.72,
59.68, 59.65, 59.61, 59.48. EI-MS m/z calcd for C70H118O29 1158.53. Found: [M]+ 1159.54.
(2R,3R,4S,5S,6R)-2-(((2S,3R,4S,5R,6R)-4,5-bis(2-methoxyacetoxy)-6-((2-methoxyacetoxy)methyl)-2-((S)-2-((Z)-octadec-6-enoyloxy)-3-(palmitoyloxy)propoxy)tetrahydro-2H-
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pyran-3-yl)oxy)-6-((2-methoxyacetoxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2-methoxyacetate) 531
Compound 530b (11.0 mg, 0.01 mmol) was dissolved in anhydrous CH2Cl2 (2 mL) under nitrogen and cis-vaccenic acid (4.00
mg, 0.01 mmol), EDC (3.00 mg, 0.01 mmol), and DMAP (2
pinches) were added under nitrogen at 0°C and the reaction was
stirred on ice for 16 h. then CH2Cl2 (20 mL) was added and the
organic phase was washed with water (10 mL) and brine (10 mL). The organic phase was dried,
filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (1:3) and passed through a silica gel column to produce 531, title compound as
a colourless liquid (7.00 mg, 50% yield). Rf = 0.4. 2.5:7.5 EtOAc/hexanes. 1H NMR (500 MHz,
CDCl3) ppm 5.57-5.50 (m, 1H), 5.47 (t, J = 9.56, 9.56 Hz, 1H), 5.39 (dd, J = 10.70, 3.27 Hz, 1H),
5.36-5.33 (m, 2H), 5.27 (d, J = 3.51 Hz, 1H), 5.25-5.18 (m, 1H), 5.15 (dd, J = 10.76, 3.54 Hz, 1H),
5.10-5.02 (m, 1H), 5.00 (d, J = 3.52 Hz, 1H), 4.46-4.33 (m, 3H), 4.29 (dd, J = 11.08, 7.13 Hz, 1H),
4.23 (dd, J = 12.01, 6.49 Hz, 1H), 4.19-3.94 (m, 16H), 3.90-3.77 (m, 3H), 3.71 (dd, J = 10.93, 4.75
Hz, 1H), 3.52-3.31 (m, 21H), 2.40-2.25 (m, 4H), 2.06-1.96 (m, 4H), 1.70-1.61 (m, 4H), 1.39-1.09
(m, 44H), 0.92-0.83 (m, 6H) 13C NMR (125 MHz, CDCl3) ppm 173.4, 173.1, 170.0, 169.9, 169.9,
169.8, 169.7, 169.4, 169.3, 130.1, 129.9, 96.8, 96.7, 96.1, 76.3, 76.2, 76.2, 76.1, 76.1, 76.0, 75.8,
75.8, 71.9, 71.9, 69.7, 69.7, 69.5, 69.5, 69.4, 69.4, 68.9, 68.6, 68.5, 68.3, 67.7, 67.6, 67.6, 67.5,
67.4, 62.3, 61.8, 61.0, 59.5, 59.5, 59.5, 34.3, 34.2, 34.1, 32.0, 31.9, 29.9, 29.9, 29.8, 29.8, 29.7,
29.7, 29.7, 29.5, 29.4, 29.3, 29.3, 29.3, 29.1, 27.3, 25.0, 25.0, 22.8, 22.8, 14.2, 14.2. EI-MS m/z
calcd for C70H118O29 1422.77. Found: [M+H]+ 1423.78.
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9.9 Experimental protocols for Chapter 6
(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-(phenylthio)tetrahydro-2H-pyran-3,4,5-triol 601
Compound 454a (20.7 g, 47 mmol) was dissolved in methanol (300 mL)
then NaOMe solution was added until a pH of 12 was reached. Upon stirring for 16 h, Dowex 50WX8 was added to neutralize the solution. The
solution was filtered and concentrated in reduced pressure, and co-evaporated with toluene. The crude product was dissolved in ethyl acetate /methanol (8:2) and passed
through a silica gel column to produce 601, the title compound, as a colourless liquid (10.7 g, 84%
yield). On replication, yields varied between 80% and 84% for scales between 100 mg and 40.0 g.
Rf = 0.30 (80% ethyl acetate, 20% methanol). 1H NMR (500 MHz, CDCl3) ppm 7.55 (dd, J = 8.1,
1.6 Hz, 2H), 7.35 – 7.18 (m, 3H), 4.59 (d, J = 9.7 Hz, 1H), 3.86 (dd, J = 12.07, 1.75 Hz, 1H), 3.743.47 (m, 2H), 3.44-3.33 (m, 1H), 3.26-3.15 (m, 2H). Consistent with the literature.1
(2R,3R,4S,5R,6S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-6-(phenylthio)tetrahydro-2H-pyran-3,4,5-triol 602
To a solution of compound 601 (4.95 g, 18 mmol) in anhydrous DMF (20
mL), tert-butyldimethylsilyl chloride (3.06 g, 20 mmol), imidazole (2.74 g,
40 mmol), and DMAP (0.45 g, 4 mmol) were added at 0°C. The ice bath
was then removed, and the reaction mixture stirred at ambient temperature for 12 h. The reaction
was diluted with saturated aqueous NaHCO3 (60 mL) and ethyl acetate (100 mL) was added, and
the organic phase was separated and organic phase was washed with saturated aqueous NaHCO3
(2 x 50 mL), water (50 mL), and brine (50 mL). The organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (8:2)
and passed through a silica gel column to produce 602, the title compound, as a colourless liquid
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(2.34 g, 76% yield). On replication, yields varied between 64% and 76% for scales between 50 mg
and 5.00 g. Rf = 0.30. 8:2 EtOAc/hexanes. 1H NMR (500 MHz, MeOD) ppm 7.51 (d, J = 7.2 Hz,
2H), 7.27 (t, J = 5.2 Hz, 3H), 5.23 (dd, J = 16.3, 5.3 Hz, 1H), 4.20 – 4.00 (m, 2H), 4.00 – 3.89 (m,
1H), 3.82 (s, 1H), 3.76 – 3.51 (m, 3H), 3.43 (s, 1H), 1.27 (d, J = 10.2 Hz, 1H), 0.97 – 0.76 (m,
9H), 0.21 – -0.08 (m, 6H). Consistent with the literature.2
(2R,3S,4S,5R,6S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-6-(phenylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 603
To a solution of compound 602 (1.53 g, 4.20 mmol) in pyridine (145 mL),
acetic anhydride (20 mL) was added. The reaction mixture was stirred at
room temperature for 12 h. The reaction was diluted with CH2Cl2 (50 mL)
and the mixture was washed with 5% HCl (2 x 30 mL), water (30 mL), and brine (30 mL). The
organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was
dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce 603, the
title compound, as a colourless liquid (1.61 g, 74%yield). On replication, yields varied between
68% and 74% for scales between 50.0 mg and 2.00 g. Rf = 0.40. 3:7 EtOAc/hexanes. 1H NMR
(500 MHz, CDCl3) ppm 7.50 (dd, J = 6.7, 2.9 Hz, 2H), 7.31 (dd, J = 5.1, 2.1 Hz, 3H), 5.50 (d, J =
3.3 Hz, 1H), 5.23 (t, J = 9.97, 9.97 Hz, 1H), 5.06 (dd, J = 9.91, 3.34 Hz, 1H), 4.72 (d, J = 10.06
Hz, 1H), 3.81-3.67 (m, 2H), 3.60 (dd, J = 9.18, 6.63 Hz, 1H), 2.10 (s, 3H), 2.07 (s, 3H), 1.96 (s,
3H), 0.84 (s, 9H), 0.00 (d, J = 4.94 Hz, 6H). Consistent with the literature.3
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(phenylthio)tetrahydro-2H-pyran-3,4,5-triyltriacetate 604
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Compound 603 (1.64 g, 3.20 mmol) was dissolved in THF (20 mL) and
TBAF (4 mL) was added and stirred at room temperature for 30 min. The
organic phase was dried, filtered, and concentrated under reduced pressure.
The crude product was dissolved in hexanes/ethyl acetate (6:4) and passed
through a silica gel column to produce 604, the title compound, as a colourless liquid (0.98 g, 77%
yield). On replication, yields varied between 68% and 77% for scales between 50.0 mg and 2.00
g. Rf = 0.30. 4:6 EtOAc/hexanes. 1H NMR (500 MHz, CDCl3) ppm 7.57-7.37 (m, 2H), 7.34-7.26
(m, 3H), 5.09-4.97 (m, 1H), 4.96-4.85 (m, 1H), 4.76-4.63 (m, 1H), 4.51-4.40 (m, 1H), 4.34 (d, J =
12.05 Hz, 1H), 3.58-3.48 (m, 2H), 2.10 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H). Consistent with the
literature.3
(2S,3R,4S,5S,6R)-2-(phenylthio)-6-((propionyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl
triacetate 605
To a solution of compound 604 (250 mg, 0.63 mmol) in C2H4Cl2 (5 mL),
propionyl chloride (0.16 mL, 1.83 mmol), pyridine (0.15 mL) and
DMAP (30.0 mg, 0.25 mmol) were added at 0°C and slowly warmed up
to the refluxed at 85°C for 4 h. The reaction was diluted with CH2Cl2 (50
mL) and the mixture was washed with 2M HCl (2 x 30 mL), water (30 mL), and brine (30 mL).
The organic phase was dried, filtered, and concentrated under reduced pressure. The crude product
was dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce
605, the title compound, as a colourless liquid (230 mg, 80% yield). Rf = 0.26 3:7 EtOAc/hexanes.
1

H NMR (500 MHz, CDCl3) ppm 7.47 – 7.37 (m, 2H), 7.31 – 7.18 (m, 3H), 5.17 (t, J = 9.3 Hz,

1H), 4.95 (dt, J = 22.7, 9.5 Hz, 2H), 4.65 (d, J = 10.1 Hz, 1H), 4.21 – 4.05 (m, 2H), 3.67 (ddd, J =
10.0, 4.8, 2.8 Hz, 1H), 2.39 – 2.13 (m, 2H), 2.09 – 1.86 (m, 9H), 1.12 – 0.94 (m, 3H). 13C NMR
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(76 MHz, MeOD) δ 170.48, 170.09, 169.30, 165.13, 133.70, 133.12, 129.85, 128.98, 128.63,
128.44, 85.86, 75.96, 73.72, 70.10, 69.10, 62.64, 20.79, 20.68, 20.54. EI-MS m/z was not collected.
(2R,3S,4S,5R,6S)-2-((isobutyryloxy)methyl)-6-(phenylthio)tetrahydro-2H-pyran-3,4,5-triyl
triacetate 606
To a solution of compound 604 (225 mg, 0.56 mmol) in C2H4Cl2 (5 mL),
iso-butyryl chloride (0.18 mL, 1.72 mmol), pyridine (0.14 mL), and DMAP
(30.0 mg, 0.25 mmol) were added to the reaction in 0°C and slowly
warmed up to the refluxed at 85°C for 4 h. The reaction was diluted with
CH2Cl2 (50 mL) and the mixture was washed with 2M HCl (2 x 30 mL), water (30 mL), and brine
(30 mL). The organic phase was dried, filtered, and concentrated under reduced pressure. The
crude product was dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column
to produce 606, the title compound, as a colourless liquid (260 mg, 97% yield). Rf = 0.27. 3:7
EtOAc/hexanes. 1H NMR (500 MHz, CDCl3) ppm 7.55 – 7.42 (m, 2H), 7.37 – 7.28 (m, 3H), 5.25
(t, J = 9.4 Hz, 1H), 5.15 – 4.88 (m, 2H), 4.71 (d, J = 10.1 Hz, 1H), 4.28 – 4.06 (m, 2H), 3.73 (ddd,
J = 10.0, 4.7, 2.9 Hz, 1H), 2.50 (p, J = 7.0 Hz, 1H), 2.14 – 1.91 (m, 9H), 1.10 (dd, J = 7.0, 5.3 Hz,
6H). 13C NMR (75 MHz, CDCl3) δ 175.4, 170.5, 170.0, 169.3, 133.0, 131.8, 128.9, 128.4, 85.8,
76.0, 73.8, 70.0, 67.8, 62.2, 33.9, 20.7, 20.5, 18.8, 18.7. EI-MS m/z was not collected.
(2R,3S,4S,5R,6S)-2-(((3-methylbutanoyl)oxy)methyl)-6-(phenylthio)tetrahydro-2H-pyran3,4,5-triyl triacetate 607
To a solution of compound 604 (212 mg, 0.53 mmol) in C2H4Cl2 (5 mL),
iso-pentanoyl chloride (0.19 mL, 1.56 mmol), pyridine (0.13 mL), and
DMAP (30.0 mg, 0.25 mmol) were added to the reaction in 0°C, and
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slowly warmed up to the refluxed at 85°C for 4 h. The reaction was diluted with CH2Cl2 (50 mL)
and the mixture was washed with 2M HCl (2 x 30 mL), water (30 mL), and brine (30 mL). The
organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was
dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce 607, the
title compound, as a colourless liquid (144 mg, 56% yield). Rf = 0.28. 3:7 EtOAc/hexanes. 1H
NMR (500 MHz, CDCl3) ppm 7.51 – 7.35 (m, 2H), 7.32 – 7.23 (m, 3H), 5.20 (t, J = 9.4 Hz, 1H),
5.09 – 4.85 (m, 2H), 4.67 (d, J = 10.1 Hz, 1H), 4.14 (d, J = 3.9 Hz, 2H), 3.67 (dt, J = 10.0, 3.9 Hz,
1H), 2.31 – 1.76 (m, 12H), 0.86 (dd, J = 6.5, 0.9 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ ppm 171.4,
170.5, 170.0, 169.2, 133.1, 131.7, 128.9, 128.4, 85.7, 76.0, 73.8, 70.1, 67.8, 62.2, 42.9, 25.4, 22.2,
20.7, 20.7, 20.6. EI-MS m/z was not collected.
(2R,3S,4S,5R,6S)-2-((benzoyloxy)methyl)-6-(phenylthio)tetrahydro-2H-pyran-3,4,5-triyl
triacetate 608
To a solution of compound 604 (130 mg, 0.33 mmol) in pyridine (5 mL),
benzoyl chloride (0.12 mL, 1.03 mmol), and DMAP (20.0 mg, 0.16
mmol) were added and stirred at 0°C and slowly warmed up to the refluxed at 85°C for 4 h. The reaction was diluted with CH2Cl2 (50 mL) and
the mixture was washed with 2M HCl (2 x 30 mL), water (30 mL), and brine (30 mL). The organic
phase was dried, filtered, and concentrated under reduced pressure and co-evaporated with toluene.
The crude product was dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel
column to produce 608, the title compound, as a colourless liquid (125 mg, 80% yield). Rf = 0.30.
2:8 EtOAc/hexanes. 1H NMR (500 MHz, CDCl3) ppm 7.89 (dd, J = 8.3, 1.4 Hz, 2H), 7.58 – 7.42
(m, 3H), 7.37 (dd, J = 8.4, 7.0 Hz, 2H), 7.32 – 7.17 (m, 3H), 5.38 (t, J = 9.4 Hz, 1H), 5.24 (t, J =
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9.7 Hz, 1H), 4.99 (dd, J = 10.0, 9.2 Hz, 1H), 4.73 (d, J = 10.1 Hz, 1H), 4.17 (d, J = 4.2 Hz, 2H),
3.82 (dt, J = 9.8, 4.2 Hz, 1H), 2.16 – 1.74 (m, 9H). 13C NMR and EI-MS m/z were not collected.
(2R,3S,4S,5R,6S)-2-((palmitoyloxy)methyl)-6-(phenylthio)tetrahydro-2H-pyran-3,4,5-triyl
triacetate 609
To a solution of compound 604 (125 mg, 0.31 mol) in CH2Cl2 (10 mL),
palmitic acid (121 mg, 0.47 mmol), EDC (94.0 mg, 0.49 mmol), and
DMAP (20.0 mg, 0.16 mmol) were added at 0°C and stirred at room temperature for 12 h. The reaction was diluted with CH2Cl2 (50 mL) and the
mixture was washed with 2M HCl (2 x 30 mL), water (30 mL), and brine (30 mL). The organic
phase was dried, filtered, and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (7:3) and passed through a silica gel column to produce 609, the
title compound, as a colourless liquid (160 mg, 74% yield). Rf = 0.41. 3:7 EtOAc/hexanes. 1H
NMR (500 MHz, CDCl3) ppm 7.53 – 7.46 (m, 2H), 7.31 (qd, J = 4.3, 1.6 Hz, 3H), 5.23 (t, J = 9.4
Hz, 1H), 5.06 (t, J = 9.8 Hz, 1H), 5.01 – 4.92 (m, 1H), 4.71 (d, J = 10.1 Hz, 1H), 4.24 – 4.11 (m,
2H), 3.72 (ddd, J = 10.1, 4.7, 3.1 Hz, 1H), 2.34 – 2.18 (m, 2H), 2.08 (d, J = 4.1 Hz, 6H), 1.97 (s,
3H), 1.66 – 1.43 (m, 2H), 1.38 – 1.09 (m, 24H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (125 MHz,
CDCl3) δ ppm 172.24, 170.57, 170.12, 169.32, 133.11, 131.75, 128.98, 128.44, 85.79, 75.94, 73.95,
70.06, 67.92, 62.24, 34.05, 31.97, 30.53, 29.81, 29.74, 29.64, 29.57, 29.54, 29.47, 29.41, 29.37,
29.24, 29.16, 29.10, 29.07, 24.84, 22.74, 20.81, 20.66, 14.18. EI-MS m/z was not collected.
Palmitoyl chloride 609a
Palmitic acid (5.00 g, 19.5 mmol) was dissolved in thionyl chloride (30 mL).
The reaction was stirred under reflex for 12 h. The product was dried, fil-
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tered, and concentrated under reduced pressure to produce palmitoyl chloride 609a, crude: (5.73
g, 106% yield)). Rf = 0.31. 1:1 EtOAc/hexanes. 1H NMR (300 MHz, CDCl3) δppm 2.88 (t, J = 7.3
Hz, 2H), 1.76 – 1.65 (m, 2H), 1.36 – 1.21 (m, 22H), 0.93 – 0.83 (m, 3H).4
(2S,3R,4S,5S,6R)-2-(phenylthio)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl
triacetate 610
To a solution of compound 601 (105 mg, 0.39 mmol) in pyridine (1 mL),
pivaloyl chloride (0.06 mL, 0.49 mmol) was added at 0°C and stirred for 12
h. The reaction was diluted with CH2Cl2 (50 mL) and the mixture was washed
with 2M HCl (2 x 30 mL), water (30 mL), and brine (30 mL). The organic
phase was dried, filtered, and concentrated under reduced pressure. Due to the sudden lab shutdown, purification was not completed. (crude: 381 mg). Rf = 0.29. 9:1 EtOAc/MeOH. 1H NMR
(301 MHz, CDCl3) δppm 7.94 – 7.78 (m, 2H), 7.63 – 7.52 (m, 3H), 4.88 (dd, J = 9.7, 3.3 Hz, 1H),
4.62 (d, J = 9.8 Hz, 1H), 4.40 – 4.20 (m, 2H), 4.01 (s, 1H), 3.94 – 3.73 (m, 2H), 1.34 – 1.11 (m,
18H).5
((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(phenylthio)tetrahydro-2H-pyran-2-yl)methyl palmitate 611
To solution of 609 (20.0 mg, 0.03 mmol) in CHCl3/MeOH (1 mL), tBuNH2 (5 μL, 0.04 mmol) was added at 0°C and stirred for 12 h, then
the same amount of reagent was added, as a sealed tube was not used in
this reaction and the reagent evaporated and stirred for 12 h. The solvent
concentrated under reduced pressure. The crude product was dissolved in ethyl acetate/methanol
(9.5:0.5) and passed through a silica gel column to produce 611 (3.20 mg, 21% yield). Rf = 0.32.
9.5:0.5 EtOAc/MeOH. 1H NMR (300 MHz, CDCl3) δppm 7.56 (dd, J = 6.56, 3.08 Hz, 2H), 7.35314

7.29 (m, 3H), 4.53 (q, J = 3.31, 3.31, 3.10 Hz, 1H), 4.29 (ddd, J = 9.06, 8.00, 2.26 Hz, 2H), 3.703.55 (m, 1H), 3.56-3.46 (m, 1H), 3.33 (t, J = 8.95, 8.95 Hz, 1H), 3.09-2.97 (m, 1H), 2.89-2.73 (m,
1H), 2.53 (s, 1H), 2.38 (t, J = 7.62, 7.62 Hz, 1H), 2.14-1.86 (m, 2H), 1.52-1.39 (m, 2H), 1.37-1.19
(m, 24H), 0.95 (t, J = 7.45, 7.45 Hz, 3H). Consistent with the literature.6
((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(phenylthio)tetrahydro-2H-pyran-2-yl)methyl isobutyrate 612
To a solution of Compound 606 (27.0 mg, 0.06 mmol) in CHCl3/MeOH (1
mL), t-BuNH2 (20 μL, 0.18 mmol) was added at 0°C and stirred for 6 h. The
solvent concentrated under reduced pressure. The crude product was dissolved in ethyl acetate/methanol (9:1) and passed through a silica gel column
to produce 612 (10.0 mg, 51% yield). Rf = 0.32. 9:1 EtOAc/MeOH. 1H NMR (301 MHz, CD3OD)
δppm 7.53 (dd, J = 7.5, 2.2 Hz, 2H), 7.34 – 7.20 (m, 3H), 4.58 (d, J = 9.8 Hz, 1H), 4.42 (dd, J =
11.9, 2.1 Hz, 1H), 4.15 (dd, J = 11.9, 6.5 Hz, 1H), 3.50 (ddd, J = 9.0, 6.5, 2.1 Hz, 1H), 3.38 (t, J =
8.8 Hz, 1H), 3.30 (p, J = 1.7 Hz, 2H), 3.27 – 3.12 (m, 2H), 2.57 (p, J = 7.0 Hz, 1H), 1.15 (dd, J =
7.0, 2.4 Hz, 6H). 13C NMR and EI-MS m/z were not collected.
((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(phenylthio)tetrahydro-2H-pyran-2-yl)methyl-3methylbutanoate 613
To a solution of compound 607 (18.0 mg, 0.04 mmol) in CHCl3/MeOH(1
mL), t-BuNH2 (15 μL, 0.13 mmol) was added at 0°C and stirred for 4 h. The
solvent concentrated under reduced pressure. The crude product was dissolved in ethyl acetate/methanol (9:1) and passed through a silica gel column to produce 613 (6.00 mg, 45% yield). Rf = 0.31. 9:1 EtOAc/MeOH. 1H NMR (301 MHz,
CDCl3) δppm 7.53 (dd, J = 7.24, 2.03 Hz, 2H), 7.39-7.19 (m, 3H), 4.57 (d, J = 9.74 Hz, 1H), 4.43
315

(dd, J = 11.85, 1.87 Hz, 1H), 4.15 (dd, J = 11.88, 6.54 Hz, 1H), 3.56-3.41 (m, 1H), 3.37 (t, J =
8.76, 8.76 Hz, 1H), 3.21 (dd, J = 19.19, 9.72 Hz, 2H), 2.21 (d, J = 7.10 Hz, 2H), 2.16-1.97 (m,
1H), 0.95 (d, J = 6.57 Hz, 6H). 13C NMR and EI-MS m/z were not collected.
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9.10 Experimental protocols for Chapter 7
(2S,3R,4S,5S,6R)-2-(((2R,3R,4S,5R,6S)-4,5-diacetoxy-2-(hydroxymethyl)-6-(phenylthio)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
702
Compound 708 (270 mg, 0.31 mmol) was dissolved in
THF (10 mL) and cooled to 0°C and 1M solution of
TBAF in THF (3 mL) was added and stirred for 4 h. The
reaction mixture concentrated in reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (1:2) and passed through a silica gel column to produce 702, the title compound,
as a colourless liquid (75.0 mg, 38% yield). Rf = 0.26. 1:2 hexanes/EtOAc. 1H NMR (300 MHz,
CDCl3) ppm 7.47 (dd, J = 6.38, 3.06 Hz, 2H), 7.40-7.28 (m, 3H), 5.34 (d, J = 3.29 Hz, 1H), 5.28
(t, J = 9.39, 9.39 Hz, 1H), 5.00-4.85 (m, 2H), 4.75 (d, J = 10.04 Hz, 1H), 4.52 (d, J = 7.62 Hz,
1H), 4.18-4.07 (m, 2H), 4.05-3.94 (m, 3H), 3.89 (t, J = 6.52, 6.52 Hz, 1H), 3.74 (dd, J = 10.27,
7.67 Hz, 1H), 3.53 (d, J = 9.89 Hz, 1H), 2.11 (s, 3H), 2.10 (s, 3H), 2.06 (s, 6H), 2.04 (s, 3H). 13C
NMR (125 MHz, CDCl3) ppm 170.43, 170.05, 170.01, 169.85, 169.53, 132.81, 131.98, 129.12,
128.41, 103.57, 86.13, 79.04, 77.25, 75.18, 74.56, 72.65, 70.88, 70.48, 69.76, 61.18, 31.97, 29.74,
29.70, 29.40, 22.73, 20.83, 20.61, 14.15. EI-MS m/z calcd for C28H36O15S: 644.18. Found: [M+
NH4]+ 662.21.
(2S,3R,4S,5R,6R)-6-(acetoxymethyl)-5-(((2S,3R,4S,5S,6R)-3,4,5-triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2,3,4-triyl triacetate 704
Lactose (10.0 g, 0.03 mol) was dissolved in acetic anhydride (32 mL) and sodium acetate (2.50 g ,0.03 mol) and
stirred at 100°C for 16 h. The reaction mixture was diluted
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with (200 mL) CH2Cl2 (200 mL) and washed with saturated aqueous NaHCO3 (150 mL), water
(150 mL) and brine (150 mL) and the crude compound was recrystallized with ethanol to produce
704, the title compound, as a white solid (15.0 g, 76%). On replication, yields varied between 70%
and 76% for scale in only 10.0 g each time. Rf = 0.37. 1:1 EtOAc/hexanes. 1H NMR (500 MHz,
CDCl3) ppm 5.67 (d, J = 8.21 Hz, 1H), 5.34 (d, J = 2.59 Hz, 1H), 5.30 (s, 1H), 5.25 (d, J = 9.24
Hz, 1H), 5.17-4.86 (m, 3H), 4.57-4.36 (m, 2H), 4.21-4.02 (m, 3H), 3.85 (dd, J = 16.55, 7.60 Hz,
2H), 2.06 (8 of s, 24H). Consistent with the literature.1
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(((2R,3R,4S,5R,6S)-4,5-diacetoxy-2-(acetoxymethyl)6-(phenylthio)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate 706
To a solution of fully acetylated lactose 704 (7.00 g, 0.10
mol) in CH2Cl2 (80 mL) was added thiophenol (2.73 mL,
0.03 mol) and BF3.OEt2 (3.3 mL ,0.03 mol) at 0°C and
the mixture was stirred for 16 h. Then trimethylamine was added and CH 2Cl2 were added (200
mL) and the organic phase was washed with (2M) NaOH (3 x 200 mL), water (3 x 200 mL) and
brine (200 mL). The crude product was dissolved in hexanes/ethyl acetate (7:3) and passed through
a silica gel column to produce 706, the title compound, as a colourless gel (5.50 g, 73% yield). On
replication, yields varied between 70% and 73% for scales between 70.0 mg and 15.0 g. Rf = 0.27.
8:2 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.47 (dd, J = 6.63, 2.99 Hz, 2H), 7.35-7.27
(m, 3H), 5.37-5.30 (m, 1H), 5.21 (t, J = 9.05, 9.05 Hz, 1H), 5.10 (dd, J = 10.44, 7.85 Hz, 1H), 5.004.84 (m, 2H), 4.67 (d, J = 10.07 Hz, 1H), 4.53 (dd, J = 11.91, 1.85 Hz, 1H), 4.46 (d, J = 7.86 Hz,
1H), 4.12-4.02 (m, 3H), 3.86 (t, J = 6.83, 6.83 Hz, 1H), 3.80-3.69 (m, 1H), 3.69-3.58 (m, 1H),
2.14, 2.10, 2.09, 2.04, 1.96 (7of s, 21H). Consistent with the literature.2
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(2R,3R,4S,5R,6S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-6-(((2R,3S,4R,5R,6S)-2-(((tertbutyldimethylsilyl)oxy)methyl)-4,5-dihydroxy-6-(phenylthio)tetrahydro-2H-pyran-3yl)oxy)tetrahydro-2H-pyran-3,4,5-triol 707
Compound 706 (5.00 g, 6.87 mmol) was dissolved in
methanol (50 mL) then NaOMe solution was added until
a pH of 12 was reached. The reaction was stirred at room
temperature for 5 h to produce a faint yellow coloured solution. DOWEX 50W X8 ion exchange
resin was added to the reaction mixture until a pH of 7 was reached. The solution was filtered and
concentrated under reduced pressure to obtain the desired product (2.25 g, 75%). Rf = 0.3 in 9:1
EtOAc/MeOH, then crude (1.23 g, 2.84 mmol) in DMF (7 mL) cooled to 0°C and DMAP (145
mg, 1.19 mmol), imidazole (870 mg, 12.8 mmol) and TBSCl (970 mg, 6.44 mmol) were added
and stirred for 16 h. The reaction mixture poured into NaHCO3 aq (50 mL) and stirred for 10 min.
The aqueous phase was extracted with ethyl acetate (3 x 50 mL) and the combined organic phase
was washed with water (2 x 100 mL) and brine (100 mL). The organic phase was dried, filtered,
and concentrated under reduced pressure. The crude product was dissolved in hexanes/ethyl acetate (1:9) and taken up through a silica gel column to produce 707, the title compound, as a colourless liquid (1.15 g, 61% yield in two steps). On replication, yields varied between 57% and
61% for scales between 5.00 g and 8.00 g. Rf = 0.27. 1:9 hexanes/EtOAc. 1H NMR (300 MHz,
CDCl3) ppm 7.65-7.41 (m, 2H), 7.33-7.26 (m, 3H), 4.53 (d, J = 9.71 Hz, 1H), 4.33 (d, J = 7.65
Hz, 1H), 4.06-3.99 (m, 1H), 3.97-3.91 (m, 2H), 3.87 (d, J = 5.79 Hz, 2H), 3.73-3.46 (m, 5H), 3.463.29 (m, 2H), 2.95 (s, 1H), 2.90-2.86 (m, 1H), 0.89 (s, 9H), 0.87 (s, 9H), 0.10 (d, J = 1.94 Hz, 6H),
0.07 (s, 6H). Consistent with the literature.3
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(2R,3S,4S,5R,6S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-6-(((2R,3R,4S,5R,6S)-4,5-diacetoxy-2-(((tert-butyldimethylsilyl)oxy)methyl)-6-(phenylthio)tetrahydro-2H-pyran-3yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate 708
Compound 707 (3.65 g, 5.50 mmol) was dissolved in
pyridine (16 mL) then acetic anhydride (8 mL) was
added and stirred at room temperature for 16 h then diluted with CH2Cl2 (100 mL) and the mixture was washed with 5% HCl aq (2 x 50 mL), water (50
mL) and brine (50 mL). The organic phase was dried, filtered, and concentrated under reduced
pressure. The crude product was dissolved in hexanes/ethyl acetate (8:2) and passed through a
silica gel column to produce 708, the title compound, as a colourless liquid (4.80 g, quantitative
yield). On replication, yields varied between 95% and 100% for scales between 250 mg and 3.65
g. Rf = 0.28. 8:2 hexanes/EtOAc. 1H NMR (300 MHz, CDCl3) ppm 7.49 (dd, J = 6.65, 2.96 Hz,
2H), 7.33-7.28 (m, 3H), 5.44 (d, J = 2.77 Hz, 1H), 5.16 (t, J = 9.37, 9.37 Hz, 1H), 5.05 (dd, J =
10.30, 7.80 Hz, 1H), 4.95 (d, J = 3.41 Hz, 1H), 4.86 (t, J = 9.64, 9.64 Hz, 1H), 4.65 (d, J = 2.12
Hz, 1H), 4.62 (s, 1H), 4.02-3.78 (m, 3H), 3.72 (dd, J = 8.30, 4.67 Hz, 1H), 3.65-3.47 (m, 2H),
3.41-3.29 (m, 1H), 2.12 (s, 3H), 2.08 (s, 3H), 2.01 (s, 6H), 1.96 (s, 3H), 0.94 (s, 9H), 0.88-0.84
(m, 9H), 0.13 (d, J = 5.00 Hz, 6H), 0.02 (d, J = 3.97 Hz, 6H). 13C NMR (125 MHz, CDCl3) ppm
170.22, 170.01, 169.65, 169.39, 168.97, 133.34, 132.51, 128.98, 128.28, 101.55, 100.40, 86.05,
85.61, 80.16, 79.77, 78.86, 74.67, 74.27, 74.06, 73.83, 73.41, 71.67, 71.63, 70.38, 69.83, 69.27,
66.88, 61.06, 60.26, 26.03, 25.89, 25.81, 20.88, 20.80, 20.73, 18.39, -4.90, -5.15, -5.47. EI-MS
m/z calcd for C40H64O15SSi: 872.35. Found: [M+ NH4]+ 890.38.

321

Reference
1.
Li, Z.; Zhang, Y.; Wu, L.; Yu, W.; Wilks, T. R.; Dove, A. P.; Ding, H.-m.; O’Reilly,
R. K.; Chen, G.; Jiang, M., Glyco-Platelets with Controlled Morphologies via CrystallizationDriven Self-Assembly and Their Shape-Dependent Interplay with Macrophages. ACS Macro Lett.
2019, 8, 596-602.
2.
Liu, B.; van Mechelen, J.; van den Berg, R. J.; van den Nieuwendijk, A. M.; Aerts, J.
M.; van der Marel, G. A.; Codée, J. D.; Overkleeft, H. S., Synthesis of Glycosylated 1‐
Deoxynojirimycins Starting from Natural and Synthetic Disaccharides. Eur. J. Org. Chem. 2019,
2019, 118-129.
3.
Lv, J.; Luo, T.; Zou, D.; Dong, H., Using DMF as both a catalyst and cosolvent for the
regioselective silylation of polyols and diols. Eur. J. Org. Chem. 2019, 2019, 6383-6395.

322

10 Supplementary Spectra Data

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

11 Vita Auctoris
NAME:

Seyed Iraj Sadraei

PLACE OF BIRTH:

Sari, Iran

YEAR OF BIRTH:

1980

EDUCATION:

Modares High school
1994-1998

Azad University of Tehran (North Branch),
Tehran, Iran. 1999-2004. B.Sc

Islamic Azad University (Saveh Branch),
Saveh, Iran 2007-2009. M.Sc

Brock University, St Catharines, Ontario, Canada
2012-2014. M.Sc

University of Windsor, Windsor, Ontario, Canada
2016-2020. PhD

415

